<SEC-DOCUMENT>0000950123-20-003936.txt : 20200522
<SEC-HEADER>0000950123-20-003936.hdr.sgml : 20200522
<ACCEPTANCE-DATETIME>20200505164223
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-20-003936
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		24
FILED AS OF DATE:		20200505
<PUBLIC-REL-DATE>20200522
DATE AS OF CHANGE:		20200505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avidity Biosciences, Inc.
		CENTRAL INDEX KEY:			0001599901
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461336960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03111
		FILM NUMBER:		20849585

	BUSINESS ADDRESS:	
		STREET 1:		10975 N. TORREY PINES RD.,
		STREET 2:		#150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-41-7900

	MAIL ADDRESS:	
		STREET 1:		10975 N. TORREY PINES RD.,
		STREET 2:		#150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avidity Biosciences LLC
		DATE OF NAME CHANGE:	20161227

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avidity NanoMedicines LLC
		DATE OF NAME CHANGE:	20140211
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on May&nbsp;5, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>as Amendment No.&nbsp;1 to the draft Registration Statement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:ARIAL" ALIGN="center"><B>AVIDITY BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">46-1336960</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>10975 N. Torrey Pines Road, Suite 150 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>La Jolla, California 92037 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT
STYLE="white-space:nowrap">401-7900</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Sarah Boyce </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>President and Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>10975 N. Torrey Pines Road, Suite 150 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>La
Jolla, California 92037 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">401-7900</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cheston J. Larson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Matthew T. Bush</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Alaina P. Ellis</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>12670 High Bluff
Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Diego, California 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858)
<FONT STYLE="white-space:nowrap">523-5400</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>John W. Wallen III, Ph.D.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>General Counsel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences,
Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>10975 N. Torrey Pines Road, Suite 150</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>La Jolla, California 92037</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT
STYLE="white-space:nowrap">401-7900</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Richard C. Segal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Charles S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Will H. Cai</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4401 Eastgate Mall<BR>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared effective.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is filed to
register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment
filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of Securities To Be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Aggregate Offering<BR>Price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of
1933, as amended. Includes shares of common stock that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a">The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in
any state or other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="96%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a"><B>PRELIMINARY PROSPECTUS (Subject To Completion) </B></FONT></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#cc062a"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020 </B></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g01z61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This is an
initial public offering of shares of common stock of Avidity Biosciences, Inc. We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on the Nasdaq Global Market under the symbol
&#147;RNA.&#148; We expect that the initial public offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; under
applicable Securities and Exchange Commission rules and have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#145;&#145;<A HREF="#toc897644_2">Risk Factors
</A>&#146;&#146; beginning on page 12 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Per&nbsp;share&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Initial public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Proceeds, before expenses, to Avidity Biosciences, Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock from us at the public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares of common stock to purchasers on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>SVB Leerink</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Credit Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Wells Fargo Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Page</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">71</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">72</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">73</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">75</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">76</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">78</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_9">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">81</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">83</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">98</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">143</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_13">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">150</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_14">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">169</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">173</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">175</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">181</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_18">Material United States Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">184</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">188</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">196</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">196</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">196</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc897644_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">F-1</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing
prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date,
regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially &#147;Risk Factors&#148; and our financial statements and related notes included elsewhere in this prospectus, before making an investment
decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company,&#148; &#147;Avidity Biosciences&#148; and &#147;Avidity&#148; refer to Avidity
Biosciences, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are pioneering a new
class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC
platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more
effectively target underlying genetic drivers of diseases. We are initially focused on muscle diseases to demonstrate the capabilities of our AOCs, and our muscle franchise consists of five programs. Our lead product candidate, AOC 1001, is designed
to treat myotonic dystrophy type 1 (DM1), a rare monogenic muscle disease. We expect to submit an investigational new drug application (IND) for AOC 1001 in 2021 and plan to initiate a Phase 1/2 clinical trial by the end of the same year. We also
intend to advance AOC product candidates in our four other muscle programs focused on the treatment of muscle atrophy, Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. In addition to our muscle
franchise, we have development efforts focused on immune and other cell types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our AOC Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Oligonucleotide therapeutics are designed based on genomic information to specifically inhibit or modify the expression of disease-related proteins and
RNAs. Considerable progress has been made toward harnessing the potential of oligonucleotides, and multiple oligonucleotide therapies have been approved for the treatment of several diseases. However, in light of their physical properties, effective
systemic delivery of oligonucleotides to a broad range of cells and organs has been one of the most significant factors limiting their utility. Our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering
and conjugation, and drug delivery techniques provide the foundation for our efforts to address some of the key limitations of oligonucleotide therapies. We collectively refer to the know-how and proprietary technology born out of this experience,
and their systematic application in the design and development of our product candidates, as our AOC platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Using our AOC platform, we have
established a framework for screening potential cell surface protein-mAb pairs to determine which pairs are well-suited to deliver oligonucleotides to specific cell types to induce pharmacologic changes. In addition to engineering optimized mAbs, we
are able to engineer and deploy various types of oligonucleotides whose specific mechanisms of action are designed to modify RNA function in different ways. This flexibility allows us to use oligonucleotides tailored to have the potential to
modulate a given disease process, and we further engineer our oligonucleotides to maximize their specificity, potency and stability. Beyond the specific mAb and oligonucleotide components of our engineered AOCs, we also optimize the antibody
conjugate design, including the linker, for stability and durability. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the product candidates derived from our AOC platform will have the potential to offer
the following distinct advantages: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expand scope of diseases addressable with oligonucleotides:</I> (i)&nbsp;utilize identified cell surface
protein-antibody pairs to design oligonucleotides in order to address various previously undruggable tissue and cell types to induce pharmacologic changes in those tissues and cells; (ii)&nbsp;flexibility to deploy an appropriate oligonucleotide
type for different diseases; and (iii)&nbsp;optimize all structural components of our AOCs for effective delivery&#151;the oligonucleotide, the mAb and the antibody conjugate design. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Potential to mitigate toxicity by limiting drug exposure:</I> (i)&nbsp;selection of the most potent oligonucleotide
type; (ii)&nbsp;targeted delivery to tissues and cells; and (iii)&nbsp;infrequent administration. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Less frequent dosing:</I> (i)&nbsp;ability to deliver oligonucleotides to tissues and cells at concentrations that
produce pronounced and prolonged pharmacodynamic effects as observed in our preclinical models; and (ii)&nbsp;ability to select appropriate oligonucleotide mechanisms to maximize durability. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Readily reproducible and scalable:</I> (i)&nbsp;AOCs synthesized using well-established and scalable methods for
manufacturing mAbs and oligonucleotides; and (ii)&nbsp;ability to use a single mAb across multiple programs provides significant leverage around development costs and timelines associated with each incremental muscle program. For example, we use the
same mAb targeting TfR1 across all our muscle programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Development Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have leveraged our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug
delivery techniques to build a pipeline of AOC development programs. Leveraging our access to extensive mAb libraries and our framework for screening potential cell surface protein-mAb pairs, we have studied over 100 different mAbs and dozens of
small interfering RNA (siRNA) sequences to form the basis of our growing pipeline. We are initially focused on muscle diseases based on our preclinical studies where we observed a 95% reduction of target gene expression in mouse skeletal muscle.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The chart below represents a summary of our wholly owned development programs, which are focused on muscle disease: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g43p29.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also have development efforts focused on immune and other cell types. For example, we are
collaborating with Eli Lilly and Company for the discovery, development and commercialization of AOCs directed to up to six messenger RNA (mRNA) targets initially in immunology and other select indications outside of muscle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The first program in our muscle franchise is focused on the treatment of DM1 and we are developing our lead product candidate, AOC 1001, as a
potentially disease modifying treatment. DM1 is a monogenic, autosomal dominant, progressive disease that primarily affects skeletal and cardiac muscle and is caused by a mutation in the dystrophy myotonic protein kinase (DMPK) gene product or DMPK
RNA. DM1 is estimated to affect over 40,000 people in the United States and there are similar prevalence estimates for Europe. However, we believe that, consistent with other rare diseases, the patient population is currently underdiagnosed due to
the lack of available therapies. AOC 1001 consists of a proprietary mAb that binds to a transporter protein, transferrin receptor 1 (TfR1), conjugated with an siRNA that is designed to address the underlying cause of DM1 by reducing the levels of
DMPK RNA. In preclinical studies, we observed the ability of our AOC to deliver siRNAs to muscle cells and reduce levels of mRNA for the DMPK gene, the molecular driver of the disease, in a durable, dose-dependent manner, meaning a long-lasting
effect that is proportional to the amount of the AOC administered. We expect to submit an IND for AOC 1001 in 2021 and we plan to initiate a Phase 1/2 clinical trial in DM1 patients by the end of the same year to assess the safety, tolerability,
pharmacokinetics, pharmacodynamics and exploratory clinical measures associated with AOC 1001. Due to the lack of available therapies in this rare disease, should our trial be successful, we plan to explore the potential to advance AOC 1001 into
registrational trials in order to expedite making AOC 1001 available for a patient population in severe need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The second program in our muscle
franchise is focused on muscle atrophy. Muscle atrophy is the loss of skeletal muscle mass that leads to muscle weakness and physical disability and can be caused by malnutrition, medications, injury or diseases such as sarcopenia, cachexia and many
rare genetic muscle disorders. Our AOC consists of our proprietary mAb targeting TfR1 conjugated with an siRNA designed to downregulate the levels of muscle RING-finger protein-1 (MuRF1) mRNA, a muscle-specific ubiquitin ligase (E3 ligase) that has
been shown to be upregulated upon induction of muscle atrophy. By targeting MuRF1, we have focused on an approach employing common effectors of both the catabolic and anabolic pathways associated with the degradation of protein in muscle cells,
unlike prior attempts to find therapeutics that primarily addressed either catabolic or anabolic pathways. In preclinical studies, we observed that a single 3 mg/kg dose of the siRNA in our AOC resulted in a greater than 50% reduction in MuRF1 mRNA
for over 20 weeks. We are in the process of selecting a product candidate for the treatment of muscle atrophy. Following regulatory clearance, in 2022, we plan to advance a product candidate into a Phase 1 clinical trial in healthy volunteers with a
limb temporarily immobilized to induce muscle atrophy. In this trial, we plan to assess <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment measurements of MuRF1 expression, biomarkers and histological changes, as well as certain
clinical measurements that we believe could demonstrate signals of activity. Our continued development activities will inform our view on the indications and development path to pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The third program in our muscle franchise is focused on DMD, which is the most common and severe form of muscular dystrophy and is progressive,
irreversible and ultimately fatal. DMD occurs in approximately one in every 3,500 to 5,000 live male births and is estimated to affect 10,000 to 15,000 people in the United States. DMD is caused by mutations in the DMD gene that encodes for the gene
product dystrophin, a protein critical for the normal function of muscle cells. These mutations lead to certain exons being misread resulting in the loss of function of the dystrophin protein. Our oligonucleotides are designed to promote the
skipping of those exons to restore a functional version of the dystrophin protein. We are focusing our initial efforts on the development of AOCs for mutations </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
amenable to skipping Exon 44, Exon 45 and Exon 51. We intend to conjugate the oligonucleotides to our proprietary mAb targeting TfR1. In a preclinical model of DMD, the mdx mouse model, we
observed that treatment of mdx mice with an AOC caused a greater than <FONT STYLE="white-space:nowrap">50-fold</FONT> increase in exon skipping compared to an equimolar dose of the unconjugated oligonucleotide. Following regulatory clearance, we
plan to commence a clinical trial for DMD in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also pursuing programs in FSHD and Pompe disease, both rare muscle diseases. FSHD is one
of the most common forms of muscular dystrophy with onset typically in teens and young adults. FSHD is caused by aberrant expression of a gene, double homeobox&nbsp;4 (DUX4), in adult skeletal muscle and is characterized by progressive skeletal
muscle loss. Our therapeutic strategy in FSHD is to use an AOC based on our proprietary mAb targeting TfR1 to deliver an siRNA targeted to the DUX4 mRNA. Pompe disease is a rare, autosomal recessive lysosomal storage disease caused by a mutation in
the gene that encodes for acid alpha-glucosidase (GAA) that results in the buildup of glycogen in the body&#146;s cells, causing impairment of normal tissue and organ function. Pompe disease is currently treated with enzyme replacement therapy
(ERT), which does not adequately address the breakdown of muscle tissue associated with the disease. Our program in Pompe disease also utilizes an AOC based on our proprietary mAb targeting TfR1 to deliver an siRNA targeting the glycogen synthetase
1 (GYS1) mRNA to diminish the toxic accumulation of glycogen in muscle. We are in the process of developing lead candidates for both FSHD and Pompe disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also intend to pursue the development of AOCs in cell types in addition to muscle. In preclinical models, we observed the ability of AOCs not only to
deliver to the liver, skeletal and cardiac muscle, but also to other tissue and cell types, including immune cells. For example, we have identified multiple receptor-antibody pairs that could be used in our AOCs in order to deliver siRNAs into
different immune cells, including those related to immuno-oncology. Observations around the specificity and selectivity of our AOCs are the basis for our interest in exploring the utility of our AOCs in immunology. We plan to continue to invest in
our AOC platform in order to explore the potential of our AOCs in previously inaccessible tissue and cell types in order to develop next generation oligonucleotide therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We hold worldwide development and commercialization rights to all our muscle programs. We have a disciplined strategy to maximize the value of our
pipeline whereby we plan to retain development and commercialization rights to those product candidates, indications and geographies that we believe we can ultimately commercialize successfully on our own. We plan to collaborate on product
candidates that we believe have promising utility in disease areas or patient populations that are better served by the resources or specific expertise of other biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to discover, develop and
commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options. Key elements of our strategy
to achieve this goal are to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Advance our lead product candidate AOC 1001 through clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> to approval. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Achieve clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for our
muscle atrophy program. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Progress our DMD program into clinical development and advance our other rare muscle disease programs.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Expand our pipeline into additional cell types and tissues. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Independently commercialize any approved products in indications and geographies where we believe we can maximize value and
pursue other options to realize the full potential of our platform. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have assembled a management team with deep experience in the discovery, development and commercialization of RNA therapeutics, including an extensive
knowledge of oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques. Our President and CEO, Sarah Boyce, has significant experience in the development and commercialization of
RNA therapeutics and in building global organizations, most recently having served as President of Akcea Therapeutics. Our Chief Scientific Officer, Arthur A. Levin, Ph.D., is a key opinion leader in the RNA therapeutics field who led teams
responsible for the development of many oligonucleotides including the first approved antisense drugs and the first <FONT STYLE="white-space:nowrap">micro-RNA</FONT> targeted therapeutic to enter clinical trials. Our Chief Operating Officer, Joseph
Baroldi, brings a depth of business development experience in RNA therapeutics having led more than twenty strategic transactions, most recently as Vice President, Business Development at Ionis Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our investors include leading life science institutions including RTW Investments, Alethea Capital, Alexandria Venture Investments, Boxer
Capital of Tavistock Group, Brace Pharma Capital, Cormorant Asset Management, LP, CureDuchenne, EcoR1 Capital, Logos Capital, Partner Fund Management, Perceptive Advisors LLC, ST Pharm and Takeda Ventures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to execute our
business strategy is subject to numerous risks, as more fully described in &#147;Risk Factors&#148; immediately following this Prospectus Summary. These risks include, among others: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur
significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when
needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are early in our development efforts and all of our development programs are in the preclinical or discovery stage. If
we are unable to successfully develop, obtain regulatory approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our approach to the discovery and development of product candidates based on our AOC platform is unproven, and we do not
know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our AOC platform obsolete. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the
results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in clinical trials and our product candidates may not have favorable results in clinical
trials, if any, or receive regulatory approval on a timely basis, if at all. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Any difficulties or delays in the commencement or completion, or termination or suspension, of our planned clinical trials
could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We rely on third parties to conduct our preclinical studies and clinical trials and to manufacture our product candidates,
and these third parties may not perform satisfactorily. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do
or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our business is subject to risks arising from the recent global outbreak of COVID-19. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were originally founded as a
Delaware limited liability company on November&nbsp;13, 2012, under the name Avidity NanoMedicines LLC. On June&nbsp;4, 2016, we changed our name to Avidity Biosciences LLC, and on April&nbsp;1, 2019, we converted into a Delaware corporation under
the name Avidity Biosciences, Inc. Our principal executive offices are located at 10975 N. Torrey Pines Road, Suite 150, La Jolla, California 92037, and our telephone number is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-401-7900.</FONT></FONT> Our website address is www.aviditybiosciences.com<I>. </I>The information contained in, or accessible through, our website does not constitute part of this
prospectus. We have included our website address as an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We use our pending trademark Avidity Biosciences in this
prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth
Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an
&#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies.
These provisions include, but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control of
financial reporting pursuant of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the U.S. Securities and Exchange Commission (SEC) determines the new rules are
necessary for protecting the public; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may take advantage of these provisions until the last day of our
fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the Securities Act), which such fifth anniversary
will occur in 2025. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities
Exchange Act of 1934 (the Exchange Act), our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an
emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure
obligations in this prospectus and in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this prospectus and that
we provide to our stockholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our
financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an
emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is
less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days after the date of this prospectus, to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock from us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise
their option to purchase additional shares of common stock in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds of this offering to fund the research and development of our development programs and for working capital and general corporate purposes, including <FONT STYLE="white-space:nowrap">pre-commercial</FONT>
activities. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page 12 and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;RNA&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering set forth above is based on
44,195,874 shares of our common stock outstanding as of March&nbsp;31, 2020, including 298,893 shares subject to forfeiture or our right of repurchase, after giving effect to the automatic conversion of all outstanding shares of our convertible
preferred stock into 37,804,563 shares of our common stock immediately prior to the closing of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,091,513 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2020, at a
weighted-average exercise price of $0.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">36,392 shares of common stock issuable upon the exercise of outstanding warrants as of March&nbsp;31, 2020, at a
weighted-average exercise price of $1.16 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2020 Incentive Plan (the 2020 Plan), which will become effective in connection with this offering (which number includes
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares remaining available for issuance under our existing 2013 Equity Incentive Plan (the 2013 Plan) as of March&nbsp;31, 2020 (which shares will
become available for issuance under the 2020 Plan upon its effectiveness), but does not include any potential evergreen increases pursuant to the terms of the 2020 Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
reserved for future issuance under our 2020 Employee Stock Purchase Plan (the ESPP), which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP).
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and
restated bylaws, each of which will occur immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into 37,804,563 shares of our common
stock immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the adjustment of outstanding warrants to purchase 16,474&nbsp;shares of our Series&nbsp;A convertible preferred stock into
warrants to purchase 16,474&nbsp;shares of our common stock immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="white-space:nowrap">-for-</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reverse stock split of our common stock to be effected prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the outstanding options or warrants described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. We have derived the
summary statements of operations data for the years ended December&nbsp;31, 2018 and 2019 from our audited financial statements included elsewhere in this prospectus. Our unaudited financial statements have been prepared on a basis consistent with
our audited financial statements included elsewhere in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our results of operations for the three
months ended March&nbsp;31, 2019 and 2020 and our financial position as of March&nbsp;31, 2020. We have derived the summary statements of operations data for the three months ended March&nbsp;31, 2019 and 2020 and the summary balance sheet data as
of March&nbsp;31, 2020 from our unaudited financial statements included elsewhere in this prospectus. You should read these data together with our financial statements and related notes included elsewhere in this prospectus and &#147;Selected
Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and contract research</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total interest and other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share/unit, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (4.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares/units outstanding, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,224,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,554,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,001,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares of common stock outstanding, basic&nbsp;and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,224,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,628,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note 2 to our financial statements included elsewhere in this prospectus for an explanation of the method used to
calculate the historical net loss per share/unit, basic and diluted, and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 88,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 88,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term debt, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Gives effect to the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of
37,804,563 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock and preferred stock warrant liabilities to permanent equity immediately prior to the closing of this offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above, and (ii)&nbsp;the issuance and
sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share would increase (decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the pro forma as adjusted amounts of each of our cash and cash equivalents, working capital, total assets and total
stockholders&#146; equity (deficit) by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual
initial public offering price and other terms of our initial public offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as total current assets less total current liabilities. See our financial statements included
elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together
with all of the other information in this prospectus, including our financial statements and related notes included elsewhere in this prospectus and in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price
of our common stock could decline and you could lose part or all of your investment. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial Position and
Capital Requirements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant
losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical-stage
biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. All of our development programs, including our lead product candidate, AOC 1001, are in preclinical development or in the drug
discovery stage. We commenced operations in 2012, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, developing our proprietary AOC technology platform, identifying product candidates,
establishing our intellectual property portfolio and conducting research and preclinical studies. Our approach to the discovery and development of product candidates based on our AOC platform is unproven, and we do not know whether we will be able
to develop any product candidates that succeed in clinical development or products of commercial value. As an organization, we have not yet completed any clinical trials, obtained regulatory approvals, manufactured a commercial-scale product, or
arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as
they could be if we had a history of successfully developing and commercializing biopharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred significant operating
losses since our inception. We do not have any products approved for sale and have not generated any product revenue since our inception. If our product candidates are not successfully developed and approved, we may never generate any significant
revenue. Our net losses were $11.2&nbsp;million and $24.7&nbsp;million for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2019, respectively, and $6.1 million for the three months ended March&nbsp;31, 2020. As of March&nbsp;31, 2020,
we had an accumulated deficit of $28.3&nbsp;million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our
operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue
to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will
require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, identifying lead product candidates, discovering additional product candidates, obtaining
regulatory approval for these product candidates and manufacturing, marketing and selling any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never
generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or
if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the
value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could
also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this
necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing
activities, particularly as we conduct our ongoing and planned preclinical studies of our development programs, initiate clinical trials for our product candidates and seek regulatory approval for our current product candidates and any future
product candidates we may develop. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the
outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, following the
completion of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to
raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, will enable us to fund
our operations for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. In particular, we expect that the net proceeds from this offering and our existing cash, cash equivalents and marketable securities will allow us to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we
currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt
financings or other capital sources, including potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we
believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities, which may adversely affect our ability to develop our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our future capital requirements will depend on many factors,
including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical
trials of our product candidates which we are pursuing or may choose to pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product candidate is
approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company,
including enhanced internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and amount of the milestone or other payments made to us under our Research Collaboration and License Agreement
(the Lilly Agreement) with Eli Lilly and Company (Lilly) or any future collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and
adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or
acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming,
expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved,
may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be
available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in
this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Until such time, if
ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential additional collaborations, licenses and other similar arrangements.
We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Our Loan and Security Agreement (as amended, the Loan Agreement) with Silicon Valley Bank (SVB) involves, and any future debt financing and preferred equity
financing, if available, may involve, agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring
dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our
future revenue streams, research programs, product candidates or AOC platform, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity
or debt financings or other arrangements when needed or on terms acceptable to us, we would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are early in our development efforts and all of our development programs are in the preclinical or discovery stage. If we are unable to successfully develop,
obtain regulatory approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are in the early stages of our development efforts and all of our development programs, including AOC 1001, are in the preclinical or drug discovery
stage. We have invested substantially all of our efforts in developing our AOC platform, identifying potential product candidates and conducting preclinical studies. We will need to progress AOC 1001 and our other product candidates through IND
enabling studies and receive authorization from the U.S. Food and Drug Administration (FDA) to proceed under an IND prior to initiating their clinical development. Our ability to generate product revenues, which we do not expect will occur for many
years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful completion of preclinical studies with favorable results, including those compliant with good laboratory
practices (GLP) toxicology studies, biodistribution studies and minimum effective dose studies in animals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of INDs by the FDA, or similar regulatory filing by comparable foreign regulatory authorities for the conduct of
clinical trials of AOC 1001 and our other product candidates and our proposed design of future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">successful enrollment in clinical trials and completion of clinical trials with favorable results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities, including new drug applications (NDAs) from the FDA
and maintaining such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining an acceptable safety profile of our products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining and growing an organization of people who can develop and commercialize our products and technology.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are unable to develop, obtain regulatory approval for, or, if approved, successfully commercialize our product candidates,
we may not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our approach to the discovery and development of product candidates based on our
AOC platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our product candidates or render our AOC platform obsolete.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our proprietary AOC
platform, which leverages a novel and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
unproven approach. While we have had favorable preclinical study results based on our technology platform, we have not yet succeeded and may not succeed in demonstrating efficacy and safety for
any product candidates in clinical trials or in obtaining marketing approval thereafter. Our lead product candidate, AOC 1001, is in late preclinical development and we have not yet completed any clinical trials for any product candidate. Our
research methodology and novel approach to oligonucleotide-based therapy may be unsuccessful in identifying additional product candidates, and any product candidates based on our technology platform may be shown to have harmful side effects or may
have other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. Further, because all of our product candidates and development programs are based on
our AOC platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in
part on our ability to maintain a competitive position with our AOC approach. If we fail to stay at the forefront of technological change in utilizing our AOC platform to create and develop product candidates, we may be unable to compete
effectively. Our competitors may render our AOC approach obsolete, or limit the commercial value of our product candidates, by advances in existing technological approaches or the development of new or different approaches (including, for example,
using different mAbs or transporter protein combinations with oligonucleotides than us), potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By
contrast, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our AOC platform and potential of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect
on our business and could potentially cause us to cease operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Preclinical and clinical development involves a lengthy and expensive process with an
uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. We have not tested any of our product candidates in clinical trials and our product candidates may not have
favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Preclinical and clinical
development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure
can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure
rate for product candidates in our industry is high. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The results from preclinical studies or clinical trials of a product candidate may not predict
the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show
the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain preclinical studies of AOC 1001 and other potential product candidates
targeting rare muscle disorders, we do not know whether AOC 1001 or the other potential product candidates will perform in future clinical trials as they have performed in these prior studies. The positive results we have observed for our product
candidates in preclinical animal models may not be predictive of our future clinical trials in humans. Furthermore, for some indications that are we are pursuing, including DM1, there are no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
animal models of the human disease and therefore the animal models may not be predictive for human disease outcomes. It is not uncommon to observe results in clinical trials that are unexpected
based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for AOC 1001.
If unexpected observations or toxicities are observed in these studies, or in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for any of our other development programs, this will delay clinical trials for AOC 1001 or our other
development programs. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical
development even after achieving promising results in earlier studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the foregoing reasons, we cannot be certain that our ongoing and planned
preclinical studies and planned clinical trials will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and
other indications, which could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any difficulties or delays in
the commencement or completion, or termination or suspension, of our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before we can initiate clinical trials for our product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign
regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND application or similar regulatory filing required
for authorization to proceed with clinical development. We are currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for AOC 1001, and expect to submit an IND in 2021. We expect to initiate a Phase 1/2 clinical trial of
AOC 1001 by the end of 2021. We will also need to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and submit INDs for our other development programs prior to initiating clinical development. The FDA or comparable foreign
regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND or similar regulatory filing, which may lead to delays and increase the costs of
our preclinical development programs. Any such delays in the commencement or completion of our planned clinical trials for AOC 1001 or any other product candidate could significantly affect our product development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials
can be delayed for a number of reasons, including delays related to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial
design; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any failure or delay in reaching an agreement with contract research organizations (CROs) and clinical trial sites, the
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining approval from one or more institutional review boards (IRBs); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of
additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> including subjects failing to remain in our trials due to movement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
restrictions, heath reasons or otherwise resulting from the novel strain of coronavirus, <FONT STYLE="white-space:nowrap">COVID-19;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or
participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign
regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the
manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing
our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory
authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or
delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being
conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the
clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold,
unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in
regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs,
timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, conducting clinical trials in foreign countries, as we may do for our product
candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or
cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive
compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a
conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the
clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of
marketing approval of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we experience delays in the completion of, or termination of, any clinical trial of
our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will
increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, many of the factors that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion of, clinical
trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge
our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be
able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical
development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials for our
product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant
factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the
clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians&#146; and
patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating as well as
any product candidates under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified
with the diseases which we are targeting or may not meet the entry criteria for such trials. We are initially developing product candidates targeting genetically defined, rare muscle disorders with limited patient pools from which to draw for
clinical trials. Genetically defined diseases generally, including those for which our current product candidates are targeted, have low incidence and prevalence. We also may encounter difficulties in identifying and enrolling subjects with a stage
of disease appropriate for our planned clinical trials and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects
to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to
participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants.
If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or we otherwise have difficulty enrolling a
sufficient number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future
clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials
and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot
assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval,
cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating
results and financial condition. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not evaluated any product candidates in human clinical trials. Although other oligonucleotide
therapeutics have received regulatory approval, our AOCs, which combine oligonucleotides with a mAb, are a novel approach to oligonucleotide therapies, which may present enhanced risk uncertainty associated with the safety profile of AOC 1001 and
other AOC therapeutics compared to more well-established classes of therapies, or oligonucleotide or <FONT STYLE="white-space:nowrap">mAb-based</FONT> therapies on their own. Moreover, there have been only a limited number of clinical trials
involving the use of oligonucleotide therapeutics and none involving the proprietary technology used in our AOC platform. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. As is the case with
biopharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates&#146; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side
effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial
of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.
Any of these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, if our product candidates are associated
with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on
findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities
may draw different conclusions or require additional testing to confirm these determinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It is possible that as we test our product candidates
in larger, longer and more extensive clinical trials, or as the use of these product candidates becomes more widespread if they receive regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be
reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Patients treated with our products, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or other
regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our products, if any, reach the market, we
may make the decision or be required by regulatory authorities to amend the labeling of our products, recall our products or even withdraw approval for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by
such product, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its
manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a medication guide outlining the
risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to change the way a product is distributed, conduct additional clinical trials or change the labeling of
a product or be required to conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of the product may decrease significantly or the product could become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could
significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>As an organization, we have never conducted any clinical trials or submitted an
application for regulatory approval, and may be unable to do so for any of our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are early in our development efforts
for our product candidates and we will need to successfully complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, Phase 1 clinical trials and later-stage and pivotal clinical trials, in order to obtain FDA or comparable foreign
regulatory approval to market AOC 1001 or any other product candidates. Carrying out clinical trials and the submission of a successful NDA is a complicated process. As an organization, we plan to commence our first Phase 1/2 clinical in 2021,
subject to receiving authorization to proceed under an IND. We have not previously conducted any clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an
IND or an NDA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of AOC 1001 or any other product candidates will be
required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates.
We may require more time and incur </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical
trials, could prevent us from or delay us in submitting NDAs for and commercializing our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our product candidates are subject to extensive
regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution
and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets.
In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical
trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial
discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is
never guaranteed. Neither we nor any current or future collaborator is permitted to market any of our product candidates in the United States until we receive approval from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with
substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from
preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable
foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval,
or may object to elements of our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA or comparable foreign regulatory authorities can delay, limit or deny
approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may disagree with the design or implementation of our or our current or future collaborators&#146;
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance
required by the FDA or comparable foreign regulatory agencies for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by
individuals using drugs similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where
the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or any of our current or future collaborators may be unable to demonstrate that a product candidate is safe and
effective, and that product candidate&#146;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or
sufficient to support the submission of an NDA or other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other
significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party
manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulations of such authorities may significantly change in a manner rendering our or any of our potential future
collaborators&#146; clinical data insufficient for approval; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve
additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and
comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain,
applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may expend our
limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because we have limited financial and managerial resources, we focus on specific product candidates and specific indications. As a result, we may forgo
or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market
for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights to such product candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to obtain or maintain orphan drug designations for any of our product candidates,
and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs or biologics for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000
individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United
States. In the European Union, the European Medicines Agency&#146;s (EMA&#146;s) Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. We have not received orphan drug designation in the United States for any product candidate. We may seek
orphan drug designation in the United States and the European Union for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
AOC&nbsp;1001 for patients with DM1, and we may seek orphan drug designation for certain of our other product candidates. There can be no assurance that the FDA or the EMA&#146;s Committee for
Orphan Medicinal Products will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs,
tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product
is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of
clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six
years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different
drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the
later drug is clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was
materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. In addition, if a subsequent drug is approved for
marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens
the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek
Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review
or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may seek
Breakthrough Therapy or Fast Track designation for some of our product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Drugs or biologics designated as Breakthrough Therapies
by the FDA may also be eligible for expedited review and approval. If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical
needs for this condition, the sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot
assure you that the FDA would decide to grant it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Even if we obtain Fast Track Designation for one or more of our product candidates, we may not experience a faster development process, review or approval compared to <FONT
STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures. In addition, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported. Fast Track Designation alone does not guarantee qualification
for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Whether to grant Breakthrough Therapy or Fast Track Designation is within the discretion of the FDA.
Accordingly, even if we believe one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a product
candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate
approval by the FDA. In addition, even if one or more of our product candidates qualify for either of these designations, the FDA may later decide that the product candidate no longer meet the conditions for qualification.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not
accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may conduct
one or more of our clinical trials for our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by
the FDA. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S.
population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA or,
if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. For studies that are conducted only at sites outside of
the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection if it deems such inspection necessary. For such studies not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore
there is an additional potential risk that the FDA could determine that the study design or protocol for a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which could require us to conduct additional clinical trials.
There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional
clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Conducting
clinical trials outside the United States also exposes us to additional risks, including risks associated with: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient
data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From
time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.&nbsp;As a result, the interim, preliminary or topline results that we report may differ from
future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.&nbsp;Topline data also remain subject to audit and verification procedures that may
result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim,
preliminary or topline data from our clinical studies. Interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment
continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In
addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product,
product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our
product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Disruptions at the&nbsp;FDA&nbsp;and
other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or
commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ability of the&nbsp;FDA&nbsp;to review and
approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and
other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund
research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the&nbsp;FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to
approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&nbsp;For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the
U.S. government has shut down several times and certain regulatory agencies, such as the&nbsp;FDA, have had to furlough critical FDA employees and stop critical activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020 the FDA announced its intention to
postpone most inspections of foreign manufacturing facilities and products and subsequently, on March&nbsp;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities.
Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health
concerns continue to prevent the FDA or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to
timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Reliance on Third Parties
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on third parties to conduct our preclinical studies and will rely on third parties to conduct our future clinical trials. If these third parties
do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product
candidates may be delayed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are dependent on third parties to conduct our preclinical studies and expect to rely on such third parties for
our future clinical trials, including our planned Phase 1/2 clinical trial of AOC 1001. Specifically, we have used and relied on, and intend to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our
preclinical studies and planned clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent
collection and analysis of data. While we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our
clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are
required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs
through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and
the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with products produced under cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is
no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our
clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships
with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials
are expected to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual
conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the
clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on
commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural transition period when a
new CRO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs,
investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and
prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties
increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely,
and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive
marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit an
NDA to the FDA or any comparable filing to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of products.
If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or
maintain regulatory approval for their manufacturing facilities. Our AOCs, including AOC 1001, consist of a proprietary mAb conjugated with the oligonucleotide therapy. All of our mAbs are manufactured by starting with cells which are stored in a
cell bank. We have multiple working cell banks and one master cell bank for our mAbs manufactured in accordance with cGMP and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we
could lose multiple cell banks and have our manufacturing impacted by the need to replace the cell banks. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and
qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative
manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions
and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our or a third party&#146;s failure to
execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an inability to initiate clinical trials of our product candidates under development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for
our product candidates or any other future product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we may be unable to establish any agreements with third-party manufacturers or to do so
on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our product candidates and any products that we may develop may compete with other product candidates and products for access to
manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related
remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing
or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future
profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our reliance on third parties
requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary
technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would
impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are dependent on the Lilly Agreement for the discovery, development and commercialization of AOCs directed
against certain targets in immunology and other select indications. Under certain circumstances, Lilly may unilaterally terminate the agreement for convenience, which could materially and adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, we entered into the Lilly Agreement for the discovery, development and commercialization of AOCs directed against certain targets in
immunology and other select indications (Lilly AOCs). Under the Lilly Agreement, Lilly will be solely responsible for funding the cost of preclinical research and discovery activities, clinical development, regulatory approval and commercialization
for the Lilly AOCs. Lilly primarily controls the research and development activities, pursuant to the terms of the Lilly Agreement, and our lack of control over such activities could result in delays or other difficulties in the development and
commercialization of the Lilly AOCs. Any dispute with Lilly may result in the delay or termination of the research, development or commercialization of the Lilly AOCs, and may result in costly litigation that diverts our management&#146;s attention
and resources away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and which may adversely affect our business, financial condition, results of operation and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, Lilly can terminate the Lilly Agreement (including for convenience), and in the event Lilly terminates the Lilly Agreement, we would be
prevented from receiving any research and development funding, milestone payments, royalty payments and other benefits under the agreement. In addition, any decision by Lilly to terminate the Lilly Agreement may negatively impact public perception
of our AOC product candidates, which could adversely affect the market price of our common stock. We cannot provide any assurance with respect to the success of the collaboration with Lilly. Any of the foregoing events could have a materially
adverse effect on our on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may seek to enter into additional collaborations, licenses
and other similar arrangements and may not be successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product
candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. We may not be successful in our efforts to establish such collaborations for our product candidates because our research and
development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to
demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. We may have to relinquish
valuable rights to our future revenue streams, research programs, product candidates or AOC platform, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering
into additional agreements with other potential collaborators. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be
able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights
under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development
and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Commercialization of Our Product Candidates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if
we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved,
could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product
candidates, when and if any of them are approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following potential approval of any our product candidates, the FDA may impose significant
restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the
product. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events
of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or
mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could
require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, if any of our product
candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In
particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless, in their independent
medical judgment, prescribe it to their patients in a manner that is inconsistent with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#146;s communications on the subject of <FONT
STYLE="white-space:nowrap">off-label</FONT> use of their products. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit
or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and
industry. Namely, the current U.S. administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage
in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive
Orders, will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we are slow or unable to adapt to changes in existing requirements or
the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our
business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The commercial success of our product candidates will depend upon the degree of market
acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our product candidates
may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our
current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of
factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">demonstration of clinical efficacy and safety compared to other more-established products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the indications for which our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to
alternative treatments and therapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare
programs, including Medicare and Medicaid, private health insurers and other third-party payors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the willingness of patients to pay all, or a portion of,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of market introduction of our products as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effectiveness of our or any of our current or potential future collaborators&#146; sales and marketing strategies; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unfavorable publicity relating to the product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we
may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never
be successful. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses. If we are found or alleged to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product candidates
would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. If we are found to have promoted such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies
from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also required companies to enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot
successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers
establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to
generate revenue. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and
Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of
reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Moreover, we are initially developing product candidates targeting rare muscle disorders with small patient
populations. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will
need to implement a coverage and reimbursement strategy for any approved product candidate with a smaller patient population that accounts for the smaller potential market size. Even if we obtain coverage for a given product by a third-party payor,
the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. For products administered under the supervision of a physician, obtaining coverage
and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be
available, which may impact physician utilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may
become available may be decreased or eliminated in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third-party payors increasingly are challenging prices charged for biopharmaceutical
products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider
our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs
may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize
an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory
financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is significant uncertainty related to third-party payor coverage and reimbursement of newly
approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party
payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what
third-party payors will decide with respect to the coverage and reimbursement for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Obtaining and maintaining reimbursement status is
time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for
coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying
price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to
generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, increasing efforts by governmental and third-party payors in the United States and
abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to
experience pricing pressures in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on
healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more
effective, our business and our ability to develop and successfully commercialize products may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The biotechnology and
biopharmaceutical industries are characterized by rapid advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop
products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is
intense competition amongst RNA targeted therapies. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research
institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively
affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to face competition from existing products and products in development for each of our product candidates. With respect to AOC&nbsp;1001,
there are currently no approved therapies to treat the underlying cause of DM1. Products currently in development to treat DM1 include: tideglusib, a <FONT STYLE="white-space:nowrap">GSK3-&szlig;</FONT> inhibitor in late-stage clinical development
by AMO Pharma for the congenital phenotype of DM1; <FONT STYLE="white-space:nowrap">ERX-963,</FONT> which is in early clinical development by Expansion Therapeutics, Inc. for the treatment of excessive daytime sleepiness in DM1; AT466, which is an <FONT
STYLE="white-space:nowrap">AAV-antisense</FONT> candidate in preclinical development by Audentes Therapeutics, Inc.; an antibody linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; gene editing treatments in preclinical
development by Vertex Pharmaceuticals, Inc.; an RNA-targeting gene therapy in preclinical development by Locana, Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Current treatments for muscle atrophy are primarily focused on nutritional intake and physical exercise. Other products in developments for muscle
atrophy in cachexia include: adlumiz and <FONT STYLE="white-space:nowrap">AEZS-130,</FONT> which are ghrelin agonists in a Phase&nbsp;3 clinical trial by Helsinn Healthcare SA and a Phase&nbsp;2 trial by Aeterna Zentaris Inc., respectively;
GSK2881078, an androgen receptor modulator in Phase&nbsp;2 clinical in development by GlaxoSmithKline plc; NGM120, a GSF15 inhibitor by NGM Biopharmaceuticals Inc.; and <FONT STYLE="white-space:nowrap">PF-06946860</FONT> in Phase&nbsp;1 clinical
development by Pfizer Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease.
Deflazacort is an FDA approved corticosteroid marketed by PTC Therapeutics, Inc. In addition, there are two FDA approved exon skipping drugs marketed by Sarepta Therapeutics, Inc.: Eteplirsen, an unconjugated PMO approved for DMD patients amenable
to skipping Exon 51; and Vyondys 53 for the treatment of DMD patients amenable to skipping Exon 53. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta Therapeutics with <FONT
STYLE="white-space:nowrap">SRP-5051,</FONT> a PPMO currently being evaluated in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a Phase 2 clinical trial for patients amenable to Exon 51 skipping 51, and PTC Therapeutics with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial. In addition,
several companies are developing gene therapies, including Milo Biotechnology (AAV1-FS344), Pfizer <FONT STYLE="white-space:nowrap">(PF-06939926),Sarepta</FONT> Therapeutics <FONT STYLE="white-space:nowrap">(SRP-9001</FONT> and Galgt2 gene therapy
program), and Solid Biosciences Inc. <FONT STYLE="white-space:nowrap">(SGT-001).</FONT> We are also aware of several companies targeting <FONT STYLE="white-space:nowrap">non-dystrophin</FONT> mechanisms for the treatment of DMD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are currently no therapies to treat the underlying cause of FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a
supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children&#146;s Research Institute, and losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a
Phase 2 clinical trial by Fulcrum Therapeutics Inc. The only approved therapy for Pompe disease is Lumizyme (known as Myozyme outside of the United States), an ERT delivered by <FONT STYLE="white-space:nowrap">bi-weekly</FONT> intravenous infusion,
and marketed by Sanofi Genzyme. We are aware of multiple ERT therapies in clinical development, including <FONT STYLE="white-space:nowrap">AT-GAA,</FONT> which uses a pharmacological chaperone, in a Phase 3 clinical trial by Amicus Therapeutics,
Inc., and neoGAA in a Phase 3 clinical trial by Sanofi Genzyme. In addition, several companies are developing gene therapies, including Actus Therapeutics, Inc. (ACTUS101), Asklepios BioPharmaceutical, Inc.
<FONT STYLE="white-space:nowrap">(AAV2/8-LSPhGAA),</FONT> Audentes Therapeutics (AT845) and Spark Therapeutics, Inc. <FONT STYLE="white-space:nowrap">(SPK-3006).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies
working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Dyne Therapeutics, Ionis Pharmaceuticals and Sarepta Therapeutics, as well as gene
therapy and CRISPR approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply
resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can
be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price,
reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may
develop. Competitive products or technological approaches may make any products we develop, or our AOC platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to
compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If the market
opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the
potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or
market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other
things, the diagnosis criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product
candidates relative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and
elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results
of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant
market share. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest
significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates
ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time
consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no
prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize
qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal
sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and
distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any
products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in
commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and
uncertainties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets.
We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product
candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing
and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including
earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall
below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our quarterly and annual operating results may fluctuate significantly, which makes it
difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization
activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that
compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of
our agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and amount of the milestone or other payments we may receive under the Lilly Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of demand for any approved products, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product
candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a
result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or
investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of
analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are dependent on the services of our management and other clinical and scientific personnel, and if we are
not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly Arthur Levin, Ph.D., our Chief
Scientific Officer, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of
our preclinical studies and clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will
with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. This lack of insurance means
that we may not have adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will need to expand and effectively manage our
managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain
qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has
experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will
significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may encounter difficulties in managing our growth and expanding our operations successfully. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We had 36 full-time employees as of April&nbsp;30, 2020. As we continue development and pursue the potential commercialization of our product candidates,
as well as function as a public company, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we
expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete
effectively will depend, in part, on our ability to manage any future growth effectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The terms of our Loan Agreement place restrictions on our operating
and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, we have an outstanding term loan in the principal amount of $3.5&nbsp;million under our Loan Agreement with SVB. The term loan
is secured by a lien covering substantially all of our personal property, rights and assets, excluding intellectual property, which is subject to a negative pledge. The Loan Agreement contains customary affirmative and negative covenants and events
of default applicable to us. The affirmative covenants include, among others, covenants requiring us to maintain governmental approvals, deliver certain financial reports, maintain insurance coverage and protect material intellectual property. The
negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying cash dividends or making other distributions, making investments, creating liens,
selling assets and making any payment on subordinated debt, in each case subject to certain exceptions. The restrictive covenants of the Loan Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may
consider beneficial. In addition, SVB could declare a default upon the occurrence of any event that it interprets as a material adverse change as defined under the Loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Agreement. If we default under the Loan Agreement, SVB may accelerate all of our repayment obligations and take control of our pledged assets, potentially requiring us to renegotiate our
agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, SVB&#146;s right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation.
Any declaration by SVB of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further
restrict our operating and financial flexibility. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to various federal, state and foreign healthcare and privacy laws and regulations, which
could increase compliance costs, and our failure to comply with these laws and regulations could harm our results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers
expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare and privacy laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our
operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully
soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase,
lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or
entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit,
among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false
record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability
for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false
statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical
supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), information related to
payments and other &#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by such healthcare
professionals and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
such information regarding payments and transfers of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners,
clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; some state laws require biotechnology companies to comply
with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of
value to physicians and other healthcare providers or marketing expenditures; some state laws that require biotechnology companies to report information on the pricing of certain drug products; and some state and local laws require the registration
or pharmaceutical sales representatives; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">foreign, federal and state data privacy, data security, and data breach notification laws, regulations, standards, and
codes of conduct that may govern the collection, use, disclosure and protection of health-related and other personal information. HIPAA imposes requirements relating to the privacy, security and transmission of individually identifiable health
information. HIPAA requires covered entities to limit the use and disclosure of protected health information. The U.S. federal government may impose civil, criminal and administrative fines and penalties and/or additional reporting or oversight
obligations for a violation of HIPAA&#146;s requirements. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, makes HIPAA&#146;s privacy and security standards directly
applicable to business associates, independent contractors or agents of covered entities, created tiers of civil monetary penalties, makes civil or criminal penalties directly applicable to business associates, and gave state attorneys general new
authority to file civil actions for damages or injunctions to enforce HIPAA and seek attorneys&#146; fees and costs. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ
from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by federal law, and may have a more prohibitive effect than federal law, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws and
regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages,
reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business
is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and
cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United
States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and
reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state
levels that seek to reduce healthcare costs and improve the quality of healthcare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, in March 2010, the Patient Protection and
Affordable Care Act (as amended by the Health Care and Education Reconciliation Act, collectively, the ACA) was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our potential product candidates, the
Affordable Care Act: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to
individuals who are enrolled in Medicaid managed care organizations; expands eligibility criteria for Medicaid programs; expands the entities eligible for discounts under the Public Health program; increases the statutory minimum rebates a
manufacturer must pay under the Medicaid Drug Rebate Program; creates a new Medicare Part D coverage gap discount program; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the current U.S. administration to repeal or
replace certain aspects of the ACA. For example, H.R. 1, &#147;An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018&#148;, informally titled the Tax Cuts and Jobs Act (the
Tax Act), includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying
health coverage for all or part of a year (commonly referred to as the individual mandate.). On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable
feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court&#146;s
decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the United States Supreme Court granted
the petitions for writs of certiorari to review this case and has allotted one hour for oral arguments, which are expected to occur in the fall.<U> </U>It is unclear how such litigation and other efforts to challenge, repeal or replace the ACA will
impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.
On August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to
subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) will suspend these Medicare sequester reductions
from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced
Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical
pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the current U.S. administration&#146;s budget proposal for
the fiscal year 2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. Although a number of these and other measures may require additional authorization to become effective, Congress and the current U.S. administration have
each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private
payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in
Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates, if approved. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous
materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and
any of our third-party manufacturers or suppliers and current or potential future collaborators will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could
be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use,
generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product
development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general
liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with
fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance for certain costs and expenses we may incur
due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that
may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research,
development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We face an inherent risk of product liability as a result of the clinical trials of our product
candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing,
marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties.
Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the
commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a diversion of our management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant negative financial impact; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a decline in our stock price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently do not hold product liability insurance coverage, but will need to obtain this insurance coverage prior to commencing clinical trials of
our product candidates. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain
sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we will maintain such insurance, any claim that may
be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various
exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property,
general liability, employment benefits liability, business automobile, workers&#146; compensation, products liability, malicious invasion of our electronic systems, and clinical trials, and directors&#146; and officers&#146;, employment practices
and fiduciary liability insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our
financial position and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We and any of our current and potential future collaborators will be required to report to regulatory
authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we or any of our current and potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities
would require that we and such collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we
become aware of the adverse event as well as the nature of the event. We and any of our current or potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our current or potential
future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in
approval or clearance of future products. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or
current or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use,
security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of such
data. In the ordinary course of business, we collect, store, transmit and otherwise process large amounts of data including, without limitation, proprietary business information and personal information. Despite the implementation of security
measures, our internal technology systems (including infrastructure) and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats (such as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks), unauthorized access or use, natural
disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or
individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar
disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches
experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any security breach or other
incident, whether real or perceived, could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays
in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a
material adverse effect on our business. To the extent that any real or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a
loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and
security laws. For further discussion on the potential liability related to the violation of these laws, see &#147;Risk Factors&#151;We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and
contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our business is subject to risks arising from the recent global outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and other epidemic diseases.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The recent outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has been declared by the World Health Organization to be a
pandemic has spread across the globe and is impacting worldwide economic activity. A pandemic, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> or other public health epidemic, poses the risk that we or our employees, contractors,
including our CROs, suppliers, collaborators and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be
requested or mandated by governmental authorities. International and U.S. governmental authorities in impacted regions are taking actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#147;stay-at-home&#148;
orders, and restricting business functions outside of one&#146;s home. In response, we have closed our executive offices with our administrative employees continuing their work remotely and limited the number of staff in our research and development
laboratories. To date we have not experienced material disruptions in our business operations. However, while it is not possible at this time to estimate the impact that <FONT STYLE="white-space:nowrap">COVID-19</FONT> could have on our business in
the future, particularly as we advance our product candidates to clinical development, the continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the measures taken by the governmental authorities could disrupt the supply chain and
the manufacture or shipment of drug substances and finished drug products or mAbs for our product candidates for use in our research, preclinical studies and clinical trials, delay, limit or prevent our employees and CROs from continuing research
and development activities, impede our clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, impede testing, monitoring, data collection and analysis and other related activities, any of which could
delay our preclinical studies and clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak
could also potentially affect the business of the FDA, EMA or other regulatory authorities, which could result in delays in meetings related to planned clinical trials. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and mitigation
measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus
and the actions to contain its impact. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and
expenses. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes,
typhoons, fires, extreme weather conditions, medical epidemics </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our product candidates. Our ability
to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. In addition, our
corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area
is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our business could be affected by litigation, government investigations and enforcement actions. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation, government investigation and
enforcement actions on a variety of matters in the United States. or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback,
anti-bribery, securities, commercial, employment and other claims and legal proceedings which may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could
result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Legal proceedings, government investigations and enforcement actions can be expensive and time consuming. An adverse outcome resulting
from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, reputational
damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our employees and
independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in
misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i)&nbsp;the laws and regulations of the FDA and other
similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (ii)&nbsp;manufacturing standards, including cGMP requirements, (iii)&nbsp;federal and state data
privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws
also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could
result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to
the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could
have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation
in Medicare, Medicaid and other federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a
corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our
business and our results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and
anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could
harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations,
U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the
U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the
countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing,
soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad
once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or
government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly
authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax
reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may engage in strategic transactions that could impact
our liquidity, increase our expenses and present significant distractions to our management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we may consider strategic
transactions, such as acquisitions of companies, asset purchases and <FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies. Additional
potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future
transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may
not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt
our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional
transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial
condition and stock price. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The global credit and financial markets have recently experienced extreme volatility and disruptions, including
severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in
credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market
conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms
could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers,
manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in U.S. tax law may materially adversely affect our financial condition, results of operations and cash flows. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On March&nbsp;27, 2020, the CARES Act was signed into law to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> crisis. The CARES Act is an
approximately $2&nbsp;trillion emergency economic stimulus package that includes numerous U.S. federal income tax provisions, including the modification of: (i)&nbsp;net operating loss (NOL) rules (as discussed below), (ii) the alternative minimum
tax refund and (iii)&nbsp;business interest deduction limitations under Section&nbsp;163(j) of the Internal Revenue Code of 1986, as amended (the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Tax Act also significantly changed the U.S. federal income taxation of U.S. corporations. The Tax Act remains unclear in many respects and has been,
and may continue to be, the subject of amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and Internal Revenue Service (IRS), which have lessened or increased certain adverse impacts of the
Tax Act and may continue to do so in the future. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax
liabilities. We continue to work with our tax advisors and auditors to determine the full impact the Tax Act and the CARES Act will have on us. We urge our investors to consult with their legal and tax advisors with respect to both the Tax Act and
the CARES Act and the potential tax consequences of investing in our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our ability to use net operating loss carryforwards and other tax
attributes may be limited in connection with this offering or other ownership changes. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred substantial losses during our
history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such
unused losses expire (if at all). At December&nbsp;31, 2019, we had federal and state NOL carryforwards of approximately $15.3&nbsp;million and $15.0&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Tax Act, federal NOL carryforwards generated in periods after December&nbsp;31, 2017, may be carried forward indefinitely. Under the CARES
Act, NOL carryforwards arising in tax years beginning after December&nbsp;31, 2017 and before January&nbsp;1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss. Because we had no taxable income in our tax
year ended December&nbsp;31, 2019, which was our first corporate tax year, we do not anticipate that such provision of the CARES Act will be relevant to us. The deductibility of federal NOL carryforwards, particularly for tax years beginning after
December&nbsp;31, 2020, may be limited. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our NOL carryforwards are subject to review and possible adjustment by the IRS, and state
tax authorities. Under Section&nbsp;382 of the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An &#147;ownership change&#148; pursuant to
Section&nbsp;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#146;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage
within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection
with this offering. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations on our ability to
utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future income tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation
allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to obtain
and maintain patent protection for our therapeutic programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and
technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our
therapeutic programs and other proprietary technologies we may develop. We seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to our therapeutic programs and other proprietary
technologies we may develop. If we are unable to obtain or maintain patent protection with respect to our therapeutic programs and other proprietary technologies we may develop, our business, financial condition, results of operations and prospects
could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our
ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent
applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection against competitors or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all
necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter
into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators,
outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our
ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art.
Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in
some cases not at all. Therefore, we cannot be certain that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for
patent protection of such inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves
complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patent applications may
not result in patents being issued which protect our therapeutic programs and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if our patent applications issue as
patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents issuing from our patent
applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our therapeutic programs and other proprietary technology will be protectable or remain protected by valid and enforceable
patents. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which
could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and regulatory review of our therapeutic programs and eventual
product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or
enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the United States
Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and&nbsp;inter partes&nbsp;review, or other similar proceedings challenging our patent rights. An adverse determination in any
such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our therapeutic programs and other proprietary technologies we may develop and
compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from
our scientists and management, even if the eventual outcome is favorable to us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and proprietary rights
throughout the world. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Filing, prosecuting and defending patents on our therapeutic programs and other proprietary technologies we may
develop in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third
parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United
States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property
rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to
biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, some jurisdictions, such
as Europe, Japan and China, may have a higher standard for patentability than in the United States, including, for example, the requirement of claims having literal support in the original patent filing and the limitation on using supporting data
that is not in the original patent filing. Under those heightened patentability requirements, we may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in U.S.
and other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and
proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many
countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant
a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by
government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO
and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with several procedural, documentary, fee payment and other similar provisions
during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by
payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application,
resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse
effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general,
thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in either the patent laws or interpretation of the patent laws in the United
States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&nbsp;a patent application was
entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for
patentability are met, the first inventor to file&nbsp;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent
application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward
of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first
to either (i)&nbsp;file any patent application related to our therapeutic programs and other proprietary technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect
patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant
review,&nbsp;inter partes&nbsp;review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party
could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third
party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the patent positions of companies in the development and
commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations
governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Issued patents covering our therapeutic programs and other proprietary technologies we may develop could be found invalid or unenforceable if challenged in court
or before administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we initiated legal proceedings against a third party to enforce a patent
covering our therapeutic programs and other proprietary technologies we may develop, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review,&nbsp;inter partes&nbsp;review, derivation proceedings, and
equivalent proceedings in foreign jurisdictions (e.g.,&nbsp;opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our therapeutic programs and
other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior
art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on our therapeutic programs and other proprietary technologies we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension for our product candidate, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidate we may develop, one or more of patents issuing
from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent extension term
(PTE) of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval, only one
patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by
regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate (SPC). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to
claims challenging the inventorship of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our patent rights, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship disputes arise
from conflicting obligations of consultants or others who are involved in developing our therapeutic programs and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging
inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or
right to use, intellectual property that is important to our therapeutic programs and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a
distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to seeking patent protection for our therapeutic programs and other proprietary technologies we may develop, we also rely on trade secrets
and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information and to maintain our competitive position. With respect to our AOC platform and development
programs, we consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be one of our important sources of intellectual property, including our extensive knowledge of the modulation of RNA processes using oligonucleotides and
siRNA, oligonucleotide drug delivery techniques and antibody conjugation. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. In particular, the trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> in connection with our AOC platform, development programs and other proprietary technology we may develop may over time be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel with scientific positions in
academic and industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants,
advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or
have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to
obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and
outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from
using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting
obligations of our employees, consultants or others who are involved in developing our product candidate. Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade secrets that are important to our therapeutic programs and other proprietary technologies we may
develop. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in obtaining necessary rights to any product candidate we may develop through acquisitions and
<FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently solely own intellectual property rights covering our therapeutic programs.
Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or
prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of
use, processes or other intellectual property rights from third parties that we identify as necessary for our therapeutic programs and other proprietary technologies we may develop. The licensing or acquisition of third-party intellectual property
rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a
competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We
also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party
intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed
alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work
for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. Litigation may be
necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, while it is our policy to require our employees
and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact,
conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third
parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay
the development and commercialization of our therapeutic programs and other proprietary technologies we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success
depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other
intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and
other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have also been implemented. As stated
above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Numerous U.S. and foreign issued patents and
pending patent applications owned by third parties exist in the fields in which we are commercializing or plan to commercialize our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and
pharmaceutical industries expand and more patents are issued, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our
therapeutic programs and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a
competitor in the fields in which we are developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe
we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party
patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to our planned products. As such, we monitor third-party patents in the relevant pharmaceutical markets. In addition, because
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that we may infringe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without
authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents
may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a
license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive,
which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing
products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of
management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or
technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or
technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidate or technologies, which could harm our business significantly.
Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our product
candidate and commercialize our product, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us
might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a
result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Engaging in litigation
defending against third parties alleging infringement of patent and other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of
litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is
unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common
stock. Such proceedings could substantially increase our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources
to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. If we do not prevail in the patent proceedings the
third parties may assert a claim of patent infringement directed at our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our
patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third parties, such as a
competitor, may infringe our patent rights. In an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the
patent does not cover the technology in question. In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. An adverse result in
any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk
that some of our confidential information could be compromised by disclosure during this type of litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the
results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may
be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to those
rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our product candidate in the United States must be approved by
the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion
with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a
suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not
provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may not be able to protect our rights to these trademarks and trade names, which we need to build
name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly
leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or
trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our
proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may
not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make products that are similar to our product candidate or utilize similar technology but that are
not covered by the claims of the patents that we license or may own;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we might not have been the first to make the inventions covered by our current or future patent applications;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we might not have been the first to file patent applications covering our inventions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our current or future patent applications will not lead to issued patents;</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any patent issuing from our current or future patent applications may be held invalid or unenforceable, including as a
result of legal challenges by our competitors or other third parties;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do not have
patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies that are patentable;</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may harm our business; and</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may choose not to file&nbsp;for patent protection in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file&nbsp;a patent application covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We partially depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our
obligations under our intellectual property licenses, if the licenses are terminated or if disputes regarding these licenses arise, we could lose significant rights that are important to our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are dependent, in part, on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology licensed from others. Our licenses to
such patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the
future. The agreements under which we license patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology from others are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, we are a party to an exclusive option agreement to obtain an exclusive worldwide license with the University of Alberta, pursuant to
which we have the option to <FONT STYLE="white-space:nowrap">in-license</FONT> key patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
applications for our Exon 51 skipping AOC for DMD and future product candidates. If we decide to exercise this option, this agreement imposes various diligence, milestone payment, royalty,
insurance and other obligations on us and any future license agreements we enter into may do the same. If we fail to comply with obligations under any license agreements, our licensors may have the right to terminate our license, in which event we
would not be able to develop or market technology or product candidates covered by the intellectual property licensed under these agreements. In addition, we may need to obtain additional licenses from our existing licensors and others to advance
our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to
expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we
are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we or our licensors fail to
adequately protect our licensed intellectual property, our ability to commercialize product candidates could suffer. We do not have complete control over the maintenance, prosecution and litigation of our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications and may have limited control over future intellectual property that may be <FONT STYLE="white-space:nowrap">in-licensed.</FONT> For example, we cannot be certain
that activities such as the maintenance and prosecution by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is
possible that our licensors&#146; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves, or may not be conducted in accordance with our best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the
relevant patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Disputes that may arise between us and our licensors
regarding intellectual property subject to a license agreement could include disputes regarding: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If disputes over intellectual property that we have licensed prevent or impair
our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates. As a result, any termination of or disputes over our
intellectual property licenses could result in the loss of our ability to develop and commercialize our AOC platform, or AOC products, or we could lose other significant rights, any of which could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, our agreements with certain of our third-party research partners provide
that improvements developed in the course of our relationship may be owned solely by either us or our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
third-party research partner, or jointly between us and the third party. If we determine that rights to such improvements owned solely by a research partner or other third party with whom we
collaborate are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our
product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to
access technology that is important to our business. We also may need the cooperation of any <FONT STYLE="white-space:nowrap">co-owners</FONT> of our intellectual property in order to enforce such intellectual property against third parties, and
such cooperation may not be provided to us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our
development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The growth of our business may depend in
part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use third-party proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may develop
product candidates containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT> pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or
tests with our product candidates, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we may <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties,
we may require licenses to such <FONT STYLE="white-space:nowrap">co-owners</FONT> interest to such patents. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were
that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights,
which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which
means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with
these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to
negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to
pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more
established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More
established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to
assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we
may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and
our business financial condition, results of operations and prospects could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We, our collaborators and our service providers may be subject to a variety of privacy and data security laws
and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical
studies, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations
in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal data. Guidance on
implementation and compliance practices are often updated or otherwise revised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, there are numerous federal and state privacy
and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and
state consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually
identifiable health information upon &#147;covered entities&#148; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or
transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the U.S. Department of Health and Human Services (HHS),
affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may
be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of
HIPAA <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Even when HIPAA does not apply, according to the FTC failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or
affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act (the FTCA), 15 U.S.C &#167; 45(a). The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and
volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits
stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which
are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the California Consumer Privacy Act (CCPA), which went into effect
on January&nbsp;1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The
CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have
noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the European Union, in May 2018, a new privacy regime, the General Data Protection Regulation, the GDPR, took effect in the European Economic Area,
the EEA. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
other things, the GDPR imposes new requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities,
changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In
addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#147;adequate&#148; data
protection laws, and imposes substantial fines for breaches and violations (up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of our consolidated annual worldwide gross revenue). The GDPR also confers
a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Moreover, the United Kingdom
leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from
the EU will be regulated, especially following the United Kingdom&#146;s departure from the EU on January&nbsp;31, 2020. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force
following the United Kingdom&#146;s departure from the EU. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional
mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our use of open source software could impose limitations on our ability to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our use of open source software could impose limitations on our ability to commercialize our product candidates. As a result, as we seek to use our
platform in connection with commercially available products, we may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software
components on terms that permit its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do
not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we make available source code for modifications or derivative works we
create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open source licenses, be required to release the source code of our
proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open source
software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to
commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to <FONT STYLE="white-space:nowrap">re-engineer</FONT> our product candidates or to discontinue the
sale of our product candidates in the event <FONT STYLE="white-space:nowrap">re-engineering</FONT> cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of
operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>There has been no public market for our common stock and an active, liquid and orderly market for our common stock may not develop, and you may not be able to
resell your common stock at or above the public offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common
stock. Although we have applied to list our common stock on the Nasdaq Global Market (Nasdaq), an active trading market for our common stock may never develop or be sustained following this offering. We and the representatives of the underwriters
will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In
addition, an active trading market may not develop following the consummation of this offering or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them
or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn,
could materially adversely affect our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our common
stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our stock price is likely to be volatile. The stock market in general and the market for stock of
biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at
or above the initial public offering price. The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of our preclinical studies and clinical trials, and the results of trials of our competitors or those of other
companies in our market sector; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to enroll subjects in our future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its
use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success or failure of our efforts to develop, acquire or license additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">innovations, clinical trial results, product approvals and other developments regarding our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital
commitments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing, supply or distribution delays or shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">achievement of expected product sales and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or recommendations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an inability to obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our stock by insiders and stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additions or departures of key personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">intellectual property, product liability or other litigation against us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the
market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management&#146;s attention and resources, which could have a material adverse effect on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes
described in &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our
management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds
from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable return to
our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>You will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share of our
outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this offering will experience immediate dilution of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover of this prospectus. In the past, we issued options to acquire common stock at
prices significantly below the initial public offering price. To the extent these outstanding options are ultimately exercised, investors purchasing common stock in this offering will sustain further dilution. For a further description of the
dilution that you will experience immediately after this offering, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>After this offering, our executive officers, directors and
principal stockholders, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of
outstanding options). As a result, such persons, acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management,
the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding
a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a
return on your investment will depend on appreciation, if any, in the price of our common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid any cash
dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In
addition, under the terms of our Loan Agreement, we are prohibited from paying any cash dividends without the consent of the lenders and any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be
limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly
reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on shares of common stock outstanding as of March&nbsp;31, 2020, upon the closing of this offering, we will have outstanding a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of
outstanding options. Of these shares, only the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock sold in this offering by us, plus any shares sold upon exercise of the
underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market immediately following this offering, unless they are purchased by one of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our directors and executive officers and holders of substantially all of our outstanding securities have entered into
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any
of our securities, without the prior written consent of Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC. The underwriters may permit our officers, directors and other securityholders who
are subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion. See
&#147;Underwriting.&#148; Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be eligible for sale in the public market, of
which&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, as of March&nbsp;31, 2020, up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become
eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. If these additional
shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After this offering, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
outstanding common stock, or approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our total outstanding common stock as of March&nbsp;31, 2020, will be entitled to rights with respect to
the registration of their shares under the Securities Act, subject to vesting and the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See &#147;Description of Capital
Stock&#151;Registration Rights.&#148; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller
reporting companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act,
and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a
&#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an
emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public
companies that are not emerging growth companies. These exemptions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting pursuant to Sarbanes-Oxley; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval
of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have taken advantage of reduced reporting burdens in this
prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth
company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an
emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also a smaller reporting company as defined in the
Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take
advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last
business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will
be required to devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a public company, we will incur significant legal, accounting and
other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to
our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring
establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional
rules and regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high
level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot
currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or reports or publish
unfavorable research or reports about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading market for our common
stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry
analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers
us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume
to decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial
statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial
reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2021. When we lose our status as an &#147;emerging growth company&#148; and reach an accelerated filer threshold, our independent registered public accounting
firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and
require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over
financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the
future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control
over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its
Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other
regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the
capital markets. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead
to entrenchment of management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect
immediately prior to the consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of
our board of directors. The provisions in our charter documents will include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the
membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to
elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to remove
a director for cause, and the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and
other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to adopt,
amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for
certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the
ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or
to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain
control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also subject to the anti-takeover provisions contained in Section&nbsp;203 of the Delaware General
Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the
board of directors has approved the transaction. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the
Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that
the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the
Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision
would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative
forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder&#146;s
ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to
this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions
in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and
financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This
risk is especially relevant for us, because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of our
management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical studies and planned clinical
trials for our product candidates, our plans to use our AOC product platform to expand our pipeline of product candidates and develop marketable products, the timing and likelihood of regulatory filings and approvals for our product candidates, the
impact of COVID-19 on our business, our ability to commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the potential to develop future product candidates, the potential benefits of
strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are
forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terms such as
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus are only predictions. We have based these
forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak
only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on
these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by
applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the
factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as well as
from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from
publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which
we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of
this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in &#147;Risk Factors.&#148; These and other factors could cause
results to differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately $<B>
</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>million (or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of $<B>
</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each $1.00 increase (decrease) in the
assumed initial public offering price of $<B> </B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, which is the midpoint of the estimated price range set
forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $<B>
</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same and after deducting the estimated underwriting discounts and commissions. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the
assumed initial public offering price stays the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital to support our
operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to use the
net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance the development of AOC 1001 for DM1 through the completion of our planned Phase 1/2 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance the development of our AOC for muscle atrophy through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
advance the development of our AOC for DMD through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for other development work associated with advancing our AOC platform and for working capital and general
corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also use a portion of the remaining net proceeds and our existing cash and cash equivalents to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe, based on our current operating plan, that the net proceeds from this offering together with our existing cash and cash equivalents, will be
sufficient to fund our operations for at least the next&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months from the date of this prospectus. However, our expected use of proceeds from this offering described above represents our current intentions based on our
present plans and business condition. We cannot predict with certainty all of the particular uses of the net proceeds from this offering or the actual amounts that we will spend on the uses set forth above. The net proceeds from this offering,
together with our cash and cash equivalents, will not be sufficient for us to fund all of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of each of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to
conduct our ongoing and planned preclinical studies and planned clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
trials, the results of such studies and trials, and other factors described in &#147;Risk Factors,&#148; as well as the amount of cash used in our operations and any unforeseen cash needs.
Therefore, our actual expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, investment grade
interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our
business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of
operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, under the terms of our Loan Agreement, we are
prohibited from paying any cash dividends without the consent of SVB. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of March&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to reflect (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred
stock into 37,804,563 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock and preferred stock warrant liabilities to permanent equity immediately prior to the closing of this offering,
and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of
<B></B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;</B> shares of our common stock in this offering at an assumed initial public offering price of $<B>
</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The pro forma as
adjusted information below is illustrative only, and our cash and cash equivalents and capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering
determined at pricing. You should read this information in conjunction with our financial statements and related notes included elsewhere in this prospectus and in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and other financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:8pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:8pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:8pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>As of March&nbsp;31, 2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; "><B>(in thousands, except share and par value data)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>Pro Forma</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>Pro Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL; "><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">88,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; "> 88,751</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred stock, $0.0001 par value; 38,054,628 shares authorized, 37,804,563 shares issued and
outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">136,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; "> &#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">3,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">3,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; 52,042,016 shares authorized, 6,391,311 shares issued and outstanding,
including 298,893 shares subject to forfeiture or a right of repurchase, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, 44,195,874 shares issued and outstanding, including 298,893 shares
subject to forfeiture or a right of repurchase, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding, including 298,893&nbsp;shares subject to forfeiture or a right of repurchase, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">(42,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">94,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">(28,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">(28,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">(70,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">66,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">69,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; "> 69,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of our cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by approximately
$&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the
same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the pro forma as adjusted amount of each of our cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting
the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our
common stock to be outstanding after this offering set forth above is based on 44,195,874 shares of our common stock outstanding as of March&nbsp;31, 2020, including 298,893 shares subject to forfeiture or our right of repurchase, after giving
effect to the automatic conversion of all outstanding shares of our convertible preferred stock into 37,804,563 shares of our common stock immediately prior to the closing of this offering, and excludes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,091,513 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2020, at a
weighted-average exercise price of $0.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">36,392 shares of common stock issuable upon the exercise of outstanding warrants as of March&nbsp;31, 2020, at a
weighted-average exercise price of $1.16 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our the 2020 Plan, which will become effective in connection with this offering (which number includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares remaining available for issuance under
our 2013 Plan as of March&nbsp;31, 2020 (which shares will become available for issuance under the 2020 Plan upon its effectiveness), but does not include any potential evergreen increases pursuant to the terms of the 2020 Plan); and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our ESPP, which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As
of March&nbsp;31, 2020, our historical net tangible book value (deficit) was $(71.0) million, or $(11.10) per share of our common stock, based on 6,391,311 shares of common stock issued and outstanding as of such date, including 298,893 shares
subject to forfeiture or our right of repurchase as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities and convertible preferred stock, divided by the number of shares of common
stock outstanding at March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On a pro forma basis, after giving effect to the automatic conversion of all outstanding shares of our
convertible preferred stock into 37,804,563 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock and preferred stock warrant liabilities to permanent equity immediately prior to the
closing of this offering, our pro forma net tangible book value as of March&nbsp;31, 2020 would have been approximately $66.0&nbsp;million, or approximately $1.49 per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock in this offering at an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover
page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2020 would have been
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
This amount represents an immediate increase in pro forma net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an
immediate dilution in pro forma net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing shares of common stock in this offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from
the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma increase in historical net tangible book value per share as of March&nbsp;31, 2020 attributable to
the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma as adjusted net tangible book value per share to new
investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Each
increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and decrease (increase) the dilution to investors participating in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net
tangible book value after the offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma as adjusted net tangible book value per share to
existing stockholders would be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution per share to new investors would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes on the pro forma as adjusted basis described above, as of March&nbsp;31, 2020, the differences between the number of
shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The which is
calculations below are based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover
page of the prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares of our common stock in full: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the percentage of shares of common stock held by existing stockholders before this offering will decrease to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of shares of our common stock outstanding after this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares held by new investors participating in this offering will increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of shares of
our common stock outstanding after this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The foregoing tables and calculations on a pro forma and pro forma as adjusted
basis are based on 44,195,874 shares of our common stock outstanding as of March&nbsp;31, 2020, including 298,893 shares subject to forfeiture or our right of repurchase, after giving effect to the automatic conversion of all outstanding shares of
our convertible preferred stock into 37,804,563 shares of our common stock immediately prior to the closing of this offering, and exclude: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,091,513 shares of common stock issuable upon the exercise of outstanding stock options as of March&nbsp;31, 2020, at a
weighted-average exercise price of $0.55 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">36,392 shares of common stock issuable upon the exercise of outstanding warrants as of March&nbsp;31, 2020, at a
weighted-average exercise price of $1.16 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our the 2020 Plan, which will become effective in connection with this offering (which number includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares remaining available for issuance under
our 2013 Plan as of March&nbsp;31, 2020 (which shares will become available for issuance under the 2020 Plan upon its effectiveness), but does not include any potential evergreen increases pursuant to the terms of the 2020 Plan); and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance
under our ESPP, which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent any outstanding options, warrants or other rights are exercised, or we issue additional equity or convertible securities in the future,
there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following tables set forth our selected historical financial data as of, and for the periods ended on, the dates indicated. We have derived the
selected statements of operations data for the years ended December&nbsp;31, 2018 and 2019 and the selected balance sheet data as of December&nbsp;31, 2018 and 2019 from our audited financial statements included elsewhere in this prospectus. We have
derived the selected statements of operations data for the three months ended March&nbsp;31, 2019 and 2020 and the selected balance sheet data as of March&nbsp;31, 2020 from our unaudited financial statements included elsewhere in this prospectus.
Our unaudited financial statements have been prepared on a basis consistent with our audited financial statements included elsewhere in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring
adjustments, necessary to fairly state our results of operations for the three months ended March&nbsp;31, 2019 and 2020 and our financial position as of March&nbsp;31, 2020. You should read these data together with our financial statements and
related notes included elsewhere in this prospectus and in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our
future results. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="8"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and contract research</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total interest and other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share/unit, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares/units outstanding, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,224,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,554,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,001,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares of common stock outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,224,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,628,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See Note&nbsp;2 to our financial statements included elsewhere in this prospectus for an explanation of the method used to
calculate the historical net loss per share/unit, basic and diluted, and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital (deficit)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible notes (including accrued interest)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term debt, including current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Convertible preferred units/stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Predecessor&#146;s/accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total members&#146;/stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital (deficit) as total current assets less total current liabilities. See our financial statements
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>You should
read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and
analysis are set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, and includes forward looking statements that involve risks and uncertainties. As a result of
many factors, including those factors set forth in &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are pioneering a new class of
oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC platform to design, engineer and develop
therapeutics that combine the tissue selectivity of mAbs and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. We are
initially focused on muscle diseases to demonstrate the capabilities of our AOCs, and our muscle franchise consists of five programs. Our lead product candidate, AOC 1001, is designed to treat DM1, a rare monogenic muscle disease. We expect to
submit an IND for AOC 1001 in 2021 and plan to initiate a Phase 1/2 clinical trial by the end of the same year. We also intend to advance AOC product candidates in our four other muscle programs focused on the treatment of muscle atrophy, DMD, FSHD
and Pompe disease. In addition to our muscle franchise, we have development efforts focused on immune and other cell types. <B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our
inception in 2012, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our proprietary AOC platform, identifying potential product candidates, establishing our
intellectual property portfolio and conducting research and preclinical studies, and providing other general and administrative support for these operations. We have not generated any revenue from product sales and, as of March&nbsp;31, 2020, we
have raised a total of $166.2&nbsp;million to fund our operations, comprised of aggregate gross proceeds of $131.6&nbsp;million from the sale and issuance of convertible preferred units and stock and convertible notes, $27.6&nbsp;million from
funding under collaboration and research services agreements, and $7.0&nbsp;million from loans under our credit facility with SVB. As of March&nbsp;31, 2020, we had cash and cash equivalents of $88.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have incurred operating losses in each year since inception. Our net losses were $11.2&nbsp;million and $24.7&nbsp;million for the years ended
December&nbsp;31, 2018 and 2019, respectively, and $6.1&nbsp;million for the three&nbsp;months ended March&nbsp;31, 2020. As of March&nbsp;31, 2020, we had an accumulated deficit of $28.3&nbsp;million. We expect our expenses and operating losses
will increase substantially as we conduct our ongoing and planned preclinical studies and clinical trials, continue our research and development activities, utilize third parties to manufacture our product candidates and related raw materials, hire
additional personnel, protect our intellectual property and incur additional costs associated with being a public company, including audit, legal, regulatory, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with
maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs. Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our preclinical studies
and clinical trials and our expenditures on other research and development activities, as well as the generation of any collaboration and services revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based upon our current operating plans, we believe that the estimated net proceeds from this offering,
together with our existing cash and cash equivalents, will be sufficient to fund our operations for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months from the date of this offering. While we may generate revenue under our
current and/or future collaboration agreements, we do not expect to generate any revenues from product sales until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will
take a number of years and may never occur. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.
Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential
collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other
arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Agreement and Plan of Conversion </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, we entered into an Agreement and Plan of Conversion, pursuant to which we converted from Avidity Biosciences LLC, a Delaware limited
liability company (Avidity LLC), into Avidity Biosciences, Inc., a Delaware corporation (Avidity Inc.). All of the membership interests of Avidity LLC were converted into securities of Avidity Inc., as follows: (i)&nbsp;each outstanding common unit
of Avidity LLC converted into one share of Avidity Inc.&#146;s common stock; (ii)&nbsp;each outstanding Series A convertible preferred unit of Avidity LLC converted into one share of Avidity Inc.&#146;s Series A convertible preferred stock; and
(iii)&nbsp;each outstanding Series B convertible preferred unit of Avidity LLC converted into one share of Avidity Inc.&#146;s Series B convertible preferred stock. Outstanding convertible notes, warrants and stock awards under Avidity LLC&#146;s
employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity Inc. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Research
Collaboration and License Agreement with Lilly </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, we entered into the Lilly Agreement with Lilly for the discovery, development
and commercialization of AOC products in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, we and Lilly will collaborate on preclinical research and discovery activities for such products, with Lilly being
responsible for funding the cost of such activities by both parties. Lilly will also lead the clinical development, regulatory approval and commercialization of all such products, at its sole cost. We granted Lilly an exclusive, worldwide,
royalty-bearing license, with the right to sublicense, under our technology to research, develop, manufacture, and sell products containing AOCs that are directed to up to six mRNA targets. We retain the right to use our technology to perform our
obligations under the agreement and for all purposes not granted to Lilly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Lilly paid us an upfront license fee of $20.0&nbsp;million in 2019, and
we are eligible to receive up to $60.0&nbsp;million in development milestone payments, up to $140.0&nbsp;million in regulatory milestone payments and up to $205.0&nbsp;million in commercialization milestone payments per target. We are eligible to
receive a tiered royalty ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> to <FONT STYLE="white-space:nowrap">low-double</FONT> digits from Lilly on worldwide annual net sales of licensed products, subject to specified and capped
reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrently with the Lilly Agreement, we issued a convertible promissory note to Lilly (the Lilly Note) and received cash proceeds of
$15.0&nbsp;million in 2019. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. In connection with the sale of our Series C convertible preferred stock in November 2019, all outstanding
principal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
interest accrued under the Lilly Note converted into 4,576,342 shares of our Series&nbsp;C convertible preferred stock, at a conversion price equal to 80% of the per share cash price paid by the
investors in the Series C convertible preferred stock financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our revenue to date has been
derived from payments received under the Lilly Agreement and payments for research services under other research services agreements. Our services under these other research services agreements were substantially completed in early 2018, and
therefore no related revenue was recognized in 2019 or is expected in future periods. For the foreseeable future, we may generate revenue from reimbursements of services under the Lilly Agreement, as well as a combination of upfront payments and
milestone payments under our current and/or future collaboration agreements. We do not expect to generate any revenue from the sale of products unless and until such time that our product candidates have advanced through clinical development and
regulatory approval, if ever. We expect that any revenue we generate, if at all, will fluctuate from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> as a result of the timing and amount of payments
relating to such services and milestones and the extent to which any of our products are approved and successfully commercialized. If we fail to complete preclinical and clinical development of product candidates or obtain regulatory approval for
them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Operating
Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Research and Development </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses consist of external and internal costs associated with our research and development activities, including our discovery
and research efforts, and the preclinical and clinical development of our product candidates. Our research and development expenses include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external costs, including expenses incurred under arrangements with third parties, such as CROs, contract manufacturers,
consultants and our scientific advisors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">internal costs, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">employee-related expenses, including salaries, benefits, and stock-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">facilities, information technology and depreciation, which include direct and allocated expenses for rent and maintenance
of facilities and depreciation of leasehold improvements and equipment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development costs, including third-party
costs reimbursed under our collaboration with Lilly, are expensed as incurred, with reimbursements of such amounts being recognized as revenue. We account for nonrefundable advance payments for goods and services that will be used in future research
and development activities as expenses when the service has been performed or when the goods have been received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At any one time, we are working on multiple programs. Our internal resources, employees and
infrastructure are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs. As such, we do not track internal costs on a specific program basis. The following table summarizes our external
costs and internal costs for the periods presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Arial MT; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>Year&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL; "><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>Three&nbsp;Months&nbsp;Ended<BR>March 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:ARIAL; "><B>2020</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL; "><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">External costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">1,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">6,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">3,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Internal costs:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Salaries and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">3,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">5,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">1,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Facilities and other unallocated costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">3,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">2,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">956</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">6,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">7,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">1,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">2,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Arial MT; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&nbsp;&nbsp;8,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">14,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&nbsp;&nbsp;1,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL; ">&nbsp;&nbsp;5,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect our research and development expenses to increase for the foreseeable future as we continue to conduct our
ongoing research and development activities, advance our preclinical research programs toward clinical development, including conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and conduct clinical trials. The process of
conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The timelines and costs with research and development activities are uncertain can vary significantly for each product candidate and development program
and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to preclinical and clinical results, regulatory developments,
ongoing assessments as to each program&#146;s commercial potential, and our ability to maintain or enter into new collaborations, to the extent we determine the resources or expertise of a collaborator would be beneficial for a given program. We
will need to raise substantial additional capital in the future. In addition, we cannot forecast which development programs may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such
arrangements would affect our development plans and capital requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our development costs may vary significantly based on factors such as:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and scope of preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the cost and timing of manufacturing our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the phase of development of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the efficacy and safety profile of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>General and Administrative </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and
administrative expenses consist primarily of employee-related expenses, including salaries, benefits and stock-based compensation, for employees in our finance, accounting, legal, business development and support functions. Other general and
administrative expenses include allocated facility, information technology and depreciation related costs not otherwise included in research and development expenses and professional fees for auditing, tax, intellectual property and legal services.
Costs related to filing and pursuing patent applications are recognized as general and administrative expenses as incurred since recoverability of such expenditures is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities
and increased costs of operating as a public company. These increased costs will likely include increased expenses related to audit, legal, regulatory and tax services associated with maintaining compliance with exchange listing and SEC
requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Interest and
Other Income (Expense) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Interest income </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest income consists primarily of interest earned on our cash and cash equivalents. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Interest expense </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest expense consists of
cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense associated with our financing arrangements, which include borrowings under our Loan Agreement with SVB and convertible notes with certain of our investors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Other expense </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We classify our outstanding
warrants to purchase shares of our Series A convertible preferred stock as liabilities on our balance sheets at their estimated fair value since the underlying convertible preferred stock is classified as temporary equity. At the end of each
reporting period, changes in the estimated fair value during the period are recorded as a component of interest and other expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Three Months Ended March 31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the three months ended March 31, 2019 and 2020 (in thousands): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Revenue </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Revenue was $0 for the three months ended March 31, 2019 compared to $1.4 million for the three months ended March 31, 2020. Revenue during the three
months ended March 31, 2020 was derived from the Lilly Agreement, which was entered into in April 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses were $1.3 million for the three months ended March 31, 2019 compared to $5.5 million for the three months ended March
31, 2020. The increase of $4.2&nbsp;million was primarily driven by a $3.6 million increase in expenses incurred in connection with research and preclinical studies, including manufacturing activities, related to AOC 1001 and our other development
programs, as well as a $0.6 million increase in personnel costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and administrative expenses were $0.9 million for the three months ended March 31, 2019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">compared to $2.0 million for the three months ended March 31, 2020. The increase of $1.1 million was primarily driven by increases of $0.7 million in personnel costs and
$0.4&nbsp;million in intellectual property patent filing costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Interest and Other Income (Expense) </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest and other expense was $0.4 million for the three months ended March&nbsp;31, 2019 compared to interest and other income of $0.1 million for the
three months ended March 31, 2020. The decrease of expense was primarily related to reduced interest expense as a result of the conversion in November 2019 of all outstanding convertible notes issued to certain of our investors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2019 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2018 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Revenue </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Revenue was $0.4&nbsp;million for the year ended December&nbsp;31, 2018 compared to $2.3&nbsp;million for the year ended December&nbsp;31, 2019. Revenue
during the year ended December&nbsp;31, 2019 was derived from the Lilly Agreement, which was entered into in April 2019. Revenue during the year ended December&nbsp;31, 2018 was derived from the performance of research and development activities
pursuant to agreements with other parties, which were substantially completed in early 2018. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses were $8.4&nbsp;million for the year ended December&nbsp;31, 2018 compared to $14.5&nbsp;million for the year ended
December&nbsp;31, 2019. The increase of $6.1&nbsp;million was primarily driven by a $4.7&nbsp;million increase in expenses incurred in connection with research and preclinical studies, including manufacturing activities, related to AOC 1001 and our
other development programs, as well as a $1.4&nbsp;million increase in personnel costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and administrative expenses were $2.4&nbsp;million for the year ended December&nbsp;31, 2018 compared to $5.1&nbsp;million for the year ended
December&nbsp;31, 2019. The increase of $2.7&nbsp;million in 2019 was primarily driven by increases of $1.1&nbsp;million in personnel costs, $0.4&nbsp;million in professional services, $0.3&nbsp;million in legal costs incurred in connection with the
Lilly Agreement and $0.2&nbsp;million in intellectual property patent filing costs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Interest and Other Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest and other expense was $0.7&nbsp;million for the year ended December&nbsp;31, 2018 compared to $7.4&nbsp;million for the year ended
December&nbsp;31, 2019. The increase of $6.7&nbsp;million was primarily related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to interest expense incurred in 2019 in connection with our outstanding convertible notes issued to certain of our investors, including $5.7&nbsp;million of noncash interest expense representing
the accretion of debt premium and issuance costs, and additional interest in connection with the Loan Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From our
inception through March&nbsp;31, 2020, we have received aggregate gross proceeds of $131.6&nbsp;million from the sale of convertible preferred units and stock and convertible notes, $27.6&nbsp;million from research funding under the Lilly Agreement
and other research services agreements and $7.0&nbsp;million from loans under the Loan Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Convertible Promissory Notes </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2018 and February 2019, we issued convertible promissory notes to certain of our existing investors and received proceeds of $3.0&nbsp;million
and $4.5&nbsp;million, respectively (the 2018 Notes and 2019 Notes, respectively). The 2018 Notes and 2019 Notes accrued simple interest at a rate of 8% and 10% per annum, respectively, and had a maturity date in December 2020, subject to earlier
conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in April 2019, as described above, in connection with the Lilly Agreement, we issued the Lilly Note and received cash
proceeds of $15.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2019, in connection with our Series C financing transaction, all outstanding amounts of principal and
accrued interest from the 2018 Notes, 2019 Notes and Lilly Note, which totaled $23.8&nbsp;million, were converted into an aggregate of 6,893,036 shares of our Series C convertible preferred stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>SVB Loan and Security Agreement </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2017,
we entered into an amendment to our Loan Agreement with SVB, which provided up to $7.0&nbsp;million in available borrowings in two tranches. In 2017, we drew the first tranche of $5.0&nbsp;million, of which $4.6&nbsp;million was used to repay our
existing debt obligations to SVB. In August 2018, we drew the second tranche of $2.0&nbsp;million. Interest accrues on the unpaid principal balance at an adjustable annual rate of the prime rate per the Wall Street Journal plus 0.20%. In addition to
our monthly payments of principal and interest, our repayment obligations include a final payment of 6.5% of the original principal advanced which is due upon final maturity of the loan in June 2021. As of March&nbsp;31, 2020, $3.5&nbsp;million of
principal was outstanding under the Loan Agreement and no amounts remained available for us to borrow thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Loan Agreement is
collateralized by substantially all of our assets, excluding intellectual property, which is subject to a negative pledge. The Loan Agreement contains customary affirmative and negative covenants and events of default applicable to us. The
affirmative covenants include, among others, covenants requiring us to maintain governmental approvals, deliver certain financial reports, maintain insurance coverage and protect material intellectual property. The negative covenants include, among
others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying cash dividends or making other distributions, making investments, creating liens, selling assets and making any
payment on subordinated debt, in each case subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with execution of the Loan Agreement, we issued SVB a
warrant to purchase 16,474 shares of our Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following issuance. The preferred stock warrant has a term of ten years. The warrant will become
exercisable for an aggregate of 16,474&nbsp;shares of our common stock upon the completion of this offering at an exercise price of $2.2615&nbsp;per share. In connection with the First </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Amendment in June 2017, we issued SVB an additional warrant to purchase 19,918 shares of common stock at an exercise price of $0.25 per share, exercisable at any time following issuance. The
common stock warrant has a term of seven years. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Future Capital Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, we had cash and cash equivalents in the amount of $88.8&nbsp;million. Based upon our current operating plans, we believe that
the estimated net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operations for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months from the date of this prospectus. However, our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this
estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the
timing of progress and expenses in these studies and trials is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our future capital requirements are difficult to forecast and will depend
on many factors, including but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical
trials of our product candidates which we are pursuing or may choose to pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product candidate is
approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company,
including enhanced internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and amount of the milestone or other payments made to us under the Lilly Agreement Lilly or any future
collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and
adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or
acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently have no additional borrowing available under our Loan Agreement with SVB or other committed sources of
capital. Until we can generate a sufficient amount of product revenue to finance our cash requirements, if ever, we expect to finance our future cash needs primarily through equity offerings, debt financings or other capital sources, including
potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital
through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to
delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table shows a
summary of our cash flows for the periods presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;5,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net (decrease) increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;1,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Operating Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cash used in operating activities was $2.1&nbsp;million during the three months ended March&nbsp;31, 2019 as compared to $7.2&nbsp;million during the
three months ended March 31, 2020. The increase of $5.1&nbsp;million was the result of an increase in our net loss adjusted for increases in non-cash items totaling $3.5&nbsp;million and an increase in the net changes in working capital totaling
$1.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cash provided by operating activities was $2.5&nbsp;million during the year ended December&nbsp;31, 2019 as compared to cash
used in operating activities of $9.7&nbsp;million during the year ended December&nbsp;31, 2018. The increase of $12.1&nbsp;million was the result of an increase in deferred revenue of $18.9&nbsp;million, partially offset by a $13.5&nbsp;million
increase in net loss adjusted for increases in <FONT STYLE="white-space:nowrap">non-cash</FONT> items totaling $7.2&nbsp;million and a decrease in the net changes in working capital totaling $0.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Investing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in
investing activities was $10,000 during the three months ended March&nbsp;31, 2020 as compared to $0 during the three months ended March&nbsp;31, 2019. This change primarily was the result of additional purchases of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash used in investing activities was $0.2&nbsp;million during the year ended December&nbsp;31, 2019 as compared to $49,000 during the year ended
December&nbsp;31, 2018. This change primarily was the result of additional purchases of property and equipment in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Financing Activities
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities was $3.8&nbsp;million during the three months ended March&nbsp;31, 2019 as compared to
$1.3&nbsp;million during the three months ended March&nbsp;31, 2020. During the three months ended March&nbsp;31, 2019, we received $4.5&nbsp;million from the issuance of convertible notes and made principal payments on our Loan Agreement of $0.7
million. During the three months ended March&nbsp;31, 2020, we received $2.2&nbsp;million from the sale of shares of our Series&nbsp;C convertible preferred stock, made principal payments on our Loan Agreement of $0.7&nbsp;million and paid
$0.2&nbsp;million of deferred financing costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net cash provided by financing activities was $89.2&nbsp;million during the year ended
December&nbsp;31, 2019 as compared to $5.1&nbsp;million during the year ended December&nbsp;31, 2018. During 2019, we received $92.1&nbsp;million from the sale of shares of our Series C convertible preferred stock, net of issuance costs, and the
issuance of convertible notes. During 2018, we received $3.0&nbsp;million from the issuance of convertible notes and $2.0&nbsp;million from a draw under the Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
summarizes our contractual obligations and commitments at December&nbsp;31, 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments&nbsp;Due&nbsp;by&nbsp;Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less<BR>than</B><br><B>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More<BR>than</B><br><B>5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Long-term debt obligations, including interest&nbsp;and final payment<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cancellable</FONT> purchase obligations<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;9,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;2,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We will make principal and interest payments to SVB in accordance with the required payment schedule.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents monthly payments under our operating lease obligations which relate to our corporate headquarters in San Diego,
California. We lease 8,561 square feet of office space under an operating lease that expires in December 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents purchase commitments with two contract manufacturing organizations for the manufacture of materials used in our
preclinical and planned clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, we had $8.4 million of outstanding non-cancellable purchase
commitments with two contract manufacturing organizations for the manufacture of materials for use in our preclinical and planned clinical trials. Approximately $8.2&nbsp;million of the purchase commitments are expected to be paid within the next
twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We enter into contracts in the normal course of business for contract research services, contract manufacturing services,
professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined under rules and regulations of the SEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Polices and Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This
management discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these
financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities revenue and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical
experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and
expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While our significant
accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this prospectus, we believe that the following accounting policies are the most critical to understanding and evaluating our historical and
future performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, all of our revenue has been derived from our collaboration and research agreements entered into with Lilly and other various parties. The terms
of these arrangements include payments to us for the following: <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> license fees; development, regulatory and commercial milestone
payments;&nbsp;payments for research and development services provided by us or for manufacturing supply services we may provide through our contract manufacturers; and royalties on net sales of licensed products.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective January&nbsp;1, 2019, we began recognizing revenue in accordance with the provisions of Accounting Standards Codification (ASC) Topic 606,
<I>Revenue from Contracts with Customers</I> <I>(Topic</I>&nbsp;<I>606). </I>The adoption of Topic 606 using the modified retrospective approach did not have a material impact on our financial position, results of operations or cash flows as we did
not have any revenue-generating arrangements in effect at January&nbsp;1, 2019. In accordance with Topic 606, we perform the following five steps in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under
each of these agreements: (i)&nbsp;identification of the contract(s) with a customer; (ii)&nbsp;determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii)&nbsp;measurement of the transaction price, including any constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations; and (v)&nbsp;recognition of revenue when, or as, we satisfy each
performance obligation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an agreement includes a license to our intellectual property and that license is determined to be distinct from the other
performance obligations identified in the arrangement, we recognize revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&nbsp;For licenses that are bundled
with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees.&nbsp;We evaluate the measure of progress each reporting period and, if
necessary, adjust the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to our assessment of the Lilly Agreement, we identified
multiple promises to deliver goods and services, which include at inception of the agreement: (i)&nbsp;a license to technology and patents, information and know-how; and (ii)&nbsp;collaboration, including research services, technical and regulatory
support provided by the Company. The Company has identified one performance obligation for all the deliverables under the agreement since the delivered elements are either not capable of being distinct or are not distinct within the context of the
contract. Accordingly, the Company will recognize revenue for the fixed or determinable collaboration in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expense over the five-year period over which
it expects to deliver its performance obligations. We periodically review and update the estimated collaboration expenses, when appropriate, which adjusts the percentage of revenue that is recognized for the period. While such changes to our
estimates have no impact on our reported cash flows, the amount of revenue recorded in the period could be materially impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through
December&nbsp;31, 2018, we recognized revenue from upfront payments for licenses or options to obtain licenses in the future, milestone payments that were generated from defined research or development events, as well as amounts for other research
and development services under strategic alliance and collaboration agreements. We recognized revenue when all four of the following criteria were met: (i)&nbsp;persuasive evidence of an arrangement exists; (ii)&nbsp;products have been delivered or
services rendered; (iii)&nbsp;the selling price is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For all periods presented, amounts received prior to satisfying the above revenue recognition criteria
were recognized as deferred revenue until all applicable revenue recognition criteria were met. Deferred revenue represented the portion of payments received that have not been earned. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Stock-based
compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of stock option
awards using the Black-Scholes option pricing model and recognize forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Black-Scholes option pricing model requires the
use of subjective assumptions, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant.
Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require judgment to develop. See Note&nbsp;8 to our financial
statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted in the
years ended December&nbsp;31, 2018 and 2019 and the three months ended March&nbsp;31, 2020. Stock-based compensation totaled approximately $0.1&nbsp;million, $0.4&nbsp;million and $4,000 for the years ended December&nbsp;31, 2018 and 2019 and the
three months ended March&nbsp;31, 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, the unrecognized stock-based compensation expense related to stock
options was $7.6&nbsp;million which is expected to be recognized as expense over a weighted-average period of approximately 3.6&nbsp;years. The intrinsic value of all outstanding stock options as of March&nbsp;31, 2020 was approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the
estimated offering price range set forth on the cover page of this prospectus, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million related to vested options and approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million related to unvested options. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><I>Common Stock Valuations
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are required to estimate the fair value of the common stock underlying our equity awards when performing fair value calculations. The fair
value of the common stock underlying our equity awards was determined on each grant date by our board of directors, taking into account input from management and independent third-party valuation analyses. All options to purchase shares of our
common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. In the
absence of a public trading market for our common stock, on each grant date we develop an estimate of the fair value of our common stock in order to determine an exercise price for the option grants. Our determinations of the fair value of our
common stock were made using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as
Compensation </I>(the Practice Aid). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors considered various objective and subjective factors, along with input from </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">management, to determine the fair value of our common stock, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">valuations of our common stock performed with the assistance of independent third-party valuation specialists;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy, including the status of research and development efforts of our product
candidates, and the material risks related to our business and industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a
sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trends and developments in our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and
various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic
obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our future operations, discounting to the present value with an appropriate risk
adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in our
valuations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Historically, we estimated the enterprise value of our business and underlying stock option grants using the back-solve method and used
the Option Pricing Method (OPM) to allocate enterprise value. The back-solve method is a market approach that assigns an implied enterprise value based on the most recent round of funding or investment and allows for the incorporation of the implied
future benefits and risks of the investment decision assigned by an outside investor. Under OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity
class. The values of the preferred and common stock are inferred by analyzing these options. We believed the OPM was the most appropriate method at that time given the expectation of various potential liquidity outcomes and the difficulty of
selecting and supporting appropriate enterprise values given our early stage of development. In March 2020, we changed to a hybrid of the OPM and Probability-Weighted Expected Return Method (PWERM). The PWERM is a scenario-based analysis that
estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. Under
this hybrid method, we considered the expected initial public offering liquidity scenario, but also used the OPM to capture all other scenarios in the event a near-term initial public offering does not occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include
assumptions regarding our future operating performance, the time to complete an initial public offering or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions, our stock-based
compensation expense, net loss and net loss per common share could have been significantly different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the completion of this offering,
the fair value of our common stock will be based on the closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Accrued Research and Development Costs </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are required to make estimates of our accrued expenses resulting from our obligations under contracts with CROs, manufacturers, vendors and
consultants, in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are
provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of
the preclinical study as measured by the timing of various aspects of the study or related activities. In accruing for these activities, we obtain information from various sources and estimates level of effort or expense allocated to each period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of
services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates
of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Company Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Net Operating Loss and Research and Development Carryforwards and Other Income Tax Information </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we had federal and state net operating loss (NOL) carryforwards of $15.3&nbsp;million and $15.0&nbsp;million, respectively.
The net loss generated in 2019 will carryforward indefinitely but the federal NOL carryforwards generated in tax years beginning after December&nbsp;31, 2020 will only be available to offset up to 80% of future tax income. The state NOL
carryforwards will begin to expire in 2039, unless previously utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, we also had federal and state research credit
carryforwards of $0.3&nbsp;million. The federal research and development tax credit carryforwards expire beginning in 2039 unless previously utilized, and the state research and development tax credit carryforwards do not expire. We have not
completed a Section&nbsp;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study and the fact that there may
be additional such ownership changes in the future. Pursuant to Sections 382 and 383 of the Code, annual use of our NOL and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than
50% occurs within a three-year period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">See Note 2 to our financial statements included elsewhere in this prospectus for recently adopted accounting pronouncements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our cash and cash equivalents consist of cash in readily available checking accounts and money market accounts. We do not hold any short-term
investments. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. Due to the nature of our cash and cash equivalents, an immediate hypothetical 10% change in interest rates would not have a material effect
on the fair value of our cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to market risk related to changes in foreign currency exchange rates. We
contract with vendors that are located outside the United States and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. To date, these fluctuations
have not been significant and based on our expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
volumes with these vendors in fiscal year 2020, a movement of 10% in the exchange rates would not have a material effect on our results of operations or financial condition </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a
material effect on our results of operations during the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As an emerging growth company under the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised
accounting standards and, therefore, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. We also intend to rely on other exemptions provided by
the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of Sarbanes-Oxley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of the
consummation of this offering; (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion; (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large accelerated
filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded
$700.0&nbsp;million as of the last business day of the second fiscal quarter of such year; or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt securities during the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current
limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and
the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. We are initially focused on muscle diseases to demonstrate the
capabilities of our AOCs, and our muscle franchise consists of five programs. Our lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1), a rare monogenic muscle disease. We expect to submit an investigational new
drug application (IND) for AOC 1001 in 2021 and plan to initiate a Phase 1/2 clinical trial by the end of the same year. We also intend to advance AOC product candidates in our four other muscle programs focused on the treatment of muscle atrophy,
Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. In addition to our muscle franchise, we have development efforts focused on immune and other cell types. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Our AOC Platform </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Oligonucleotide
therapeutics are designed based on genomic information to specifically inhibit or modify the expression of disease-related proteins and RNAs. Considerable progress has been made toward harnessing the potential of oligonucleotides, and multiple
oligonucleotide therapies have been approved for the treatment of several diseases. However, in light of their physical properties, effective systemic delivery of oligonucleotides to a broad range of cells and organs has been one of the most
significant factors limiting their utility. Our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques provide the foundation for our efforts to address some
of the key limitations of oligonucleotide therapies. We collectively refer to the <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology born out of this experience, and their systematic application in the design and development
of our product candidates, as our AOC platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Using our AOC platform, we have established a framework for screening potential cell surface <FONT
STYLE="white-space:nowrap">protein-mAb</FONT> pairs to determine which pairs are well-suited to deliver oligonucleotides to specific cell types to induce pharmacologic changes. In addition to engineering optimized mAbs, we are able to engineer and
deploy various types of oligonucleotides whose specific mechanisms of action are designed to modify RNA function in different ways. This flexibility allows us to use oligonucleotides tailored to have the potential to modulate a given disease
process, and we further engineer our oligonucleotides to maximize their specificity, potency and stability. Beyond the specific mAb and oligonucleotide components of our engineered AOCs, we also optimize the antibody conjugate design, including the
linker, for stability and durability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the product candidates derived from our AOC platform will have the potential to offer the
following distinct advantages: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expand scope of diseases addressable with oligonucleotides</I>: (i)&nbsp;utilize identified cell surface
protein-antibody pairs to design oligonucleotides in order to address various previously undruggable tissue and cell types to induce pharmacologic changes in those tissues and cells; (ii)&nbsp;flexibility to deploy an appropriate oligonucleotide
type for different diseases; and (iii)&nbsp;optimize all structural components of our AOCs for effective delivery&#151;the oligonucleotide, the mAb and the antibody conjugate design. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Potential to mitigate toxicity by limiting drug exposure: </I>(i)<I></I>&nbsp;selection of the most potent
oligonucleotide type; (ii)&nbsp;targeted delivery to tissues and cells; and (iii)&nbsp;infrequent administration. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Less frequent dosing: </I>(i)&nbsp;ability to deliver oligonucleotides to tissues and cells at concentrations that
produce pronounced and prolonged pharmacodynamic effects as observed in our preclinical models; and (ii)&nbsp;ability to select appropriate oligonucleotide mechanisms to maximize durability. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Readily reproducible and scalable</I>: (i)&nbsp;AOCs synthesized using well-established and scalable methods for
manufacturing mAbs and oligonucleotides; and (ii)&nbsp;ability to use a single mAb across multiple programs provides significant leverage around development costs and timelines associated with each incremental muscle program. For example, we use the
same mAb targeting TfR1 across all our muscle programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are initially focused on muscle diseases for which we believe our AOC
approach can overcome the limitations of current oligonucleotide therapies. For example, a single dose of an AOC administered to mice demonstrated a 95% reduction of target gene expression in mouse skeletal muscle, which in part led us to focus on
developing a pipeline of AOCs in muscle diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The first program in our muscle franchise is focused on the treatment of DM1 and we are
developing our lead product candidate, AOC 1001, as a potentially disease modifying treatment. DM1 is a monogenic, autosomal dominant, progressive disease that primarily affects skeletal and cardiac muscle and is caused by a mutation in the
dystrophy myotonic protein kinase (DMPK) gene product or DMPK RNA. DM1 is estimated to affect over 40,000 people in the United States and there are similar prevalence estimates for Europe. However, we believe that, consistent with other rare
diseases, the patient population is currently underdiagnosed due to the lack of available therapies. AOC&nbsp;1001 consists of a proprietary mAb that binds to a transporter protein, transferrin receptor 1 (TfR1), conjugated with a small interfering
RNA (siRNA) that is designed to address the underlying cause of DM1 by reducing the levels of DMPK RNA. In preclinical studies, we observed the ability of our AOC to deliver siRNAs to muscle cells, and reduce levels of messenger RNA (mRNA) for the
DMPK gene, the molecular driver of the disease, in a durable, dose-dependent manner, meaning a long-lasting effect that is proportional to the amount of the AOC administered. We expect to submit an IND for AOC&nbsp;1001 in 2021 and we plan to
initiate a Phase&nbsp;1/2 clinical trial in DM1 patients by the end of the same year to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory clinical measures associated with AOC&nbsp;1001. Due to the lack of available
therapies in this rare disease, should our trial be successful, we plan to explore the potential to advance AOC&nbsp;1001 into registrational trials in order to expedite making AOC&nbsp;1001 available for a patient population in severe need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The second program in our muscle franchise is focused on muscle atrophy. Muscle atrophy is the loss of skeletal muscle mass that leads to muscle
weakness and physical disability and can be caused by malnutrition, medications, injury or diseases such as sarcopenia, cachexia and many rare genetic muscle disorders. Our AOC consists of our proprietary mAb targeting TfR1 conjugated with an siRNA
designed to downregulate the levels of muscle RING-finger protein-1 (MuRF1) mRNA, a muscle-specific ubiquitin ligase (E3 ligase) that has been shown to be upregulated upon induction of muscle atrophy. By targeting MuRF1, we have focused on an
approach employing common effectors of both the catabolic and anabolic pathways associated with the degradation of protein in muscle cells, unlike prior attempts to find therapeutics that primarily addressed either catabolic or anabolic pathways. In
preclinical studies, we observed that a single 3 mg/kg dose of the siRNA in our AOC resulted in a greater than 50% reduction in MuRF1 mRNA for over 20 weeks. We are in the process of selecting a product candidate for the treatment of muscle atrophy.
Following regulatory clearance, in 2022, we plan to advance a product candidate into a Phase 1 clinical trial in healthy volunteers with a limb temporarily immobilized to induce muscle atrophy. In this trial, we plan to assess <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-treatment measurements of MuRF1 expression, biomarkers and histological changes, as well as certain clinical measurements that we believe could demonstrate signals of activity. Our continued
development activities will inform our view on the indications and development path to pursue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The third program in our muscle franchise is focused on DMD, which is the most common and severe form
of muscular dystrophy and is progressive, irreversible and ultimately fatal. DMD occurs in approximately one in every 3,500 to 5,000 live male births and is estimated to affect 10,000 to 15,000 people in the United States. DMD is caused by mutations
in the DMD gene that encodes for the gene product dystrophin, a protein critical for the normal function of muscle cells. These mutations lead to certain exons being misread resulting in the loss of function of the dystrophin protein. Our
oligonucleotides are designed to promote the skipping of those exons to restore a functional version of the dystrophin protein. We are focusing our initial efforts on the development of AOCs for mutations amenable to skipping Exon 44, Exon 45 and
Exon 51. We intend to conjugate the oligonucleotides to our proprietary mAb targeting TfR1. In a preclinical model of DMD, the mdx mouse model, we observed that treatment of mdx mice with an AOC caused a greater than
<FONT STYLE="white-space:nowrap">50-fold</FONT> increase in exon skipping compared to an equimolar dose of the unconjugated oligonucleotide. Following regulatory clearance, we plan to commence a clinical trial for DMD in 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also pursuing programs in FSHD and Pompe disease, both rare muscle diseases. FSHD is one of the most common forms of muscular dystrophy, with
onset typically in teens and young adults. FSHD is caused by aberrant expression of a gene, double homeobox 4 (DUX4),&nbsp;in adult skeletal muscle and is characterized by progressive skeletal muscle loss. Our therapeutic strategy in FSHD is to use
an AOC based on our proprietary mAb targeting TfR1 to deliver an siRNA targeted to the DUX4 mRNA. Pompe disease is a rare, autosomal recessive lysosomal storage disease caused by a mutation in the gene that encodes for acid alpha-glucosidase (GAA)
that results in the buildup of glycogen in the body&#146;s cells, causing impairment of normal tissue and organ function. Pompe disease is currently treated with enzyme replacement therapy (ERT), which does not adequately address the breakdown of
muscle tissue associated with the disease. Our program in Pompe disease also utilizes an AOC based on our proprietary mAb targeting TfR1 to deliver an siRNA targeting the glycogen synthetase 1 (GYS1) mRNA to diminish the toxic accumulation of
glycogen in muscle. We are in the process of developing lead candidates for both FSHD and Pompe disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also intend to pursue the development
of AOCs in cell types in addition to muscle. In preclinical models, we observed the ability of AOCs not only to deliver to the liver, skeletal and cardiac muscle, but also to other tissue and cell types, including immune cells. For example, we have
identified multiple receptor-antibody pairs that could be used in our AOCs in order to deliver siRNAs into different immune cells, including those related to immuno-oncology. In preclinical studies, we observed significant <FONT
STYLE="white-space:nowrap">AOC-mediated</FONT> mRNA knockdown in CD8+ and CD4+ tumor infiltrating lymphocytes and <FONT STYLE="white-space:nowrap">T-regs</FONT> <I>in vivo</I>, while also observing no effect on mRNA levels in T or B cells in the
spleen. These observations around the specificity and selectivity of our AOCs are the basis for our interest in exploring the utility of our AOCs in immunology. We plan to continue to invest in our AOC platform in order to explore the potential of
our AOCs in previously inaccessible tissue and cell types in order to develop next generation oligonucleotide therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We hold worldwide
development and commercialization rights to all our muscle programs. We have a disciplined strategy to maximize the value of our pipeline whereby we plan to retain development and commercialization rights to those product candidates, indications and
geographies that we believe we can ultimately commercialize successfully on our own. We plan to collaborate on product candidates that we believe have promising utility in disease areas or patient populations that are better served by the resources
or specific expertise of other biopharmaceutical companies. For example, in April 2019, we entered into a Research Collaboration and License Agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) for the discovery, development and
commercialization of AOCs directed to up to six mRNA targets initially in immunology and other select indications on a worldwide basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have
assembled a management team with deep experience in the discovery, development and commercialization of RNA therapeutics, including an extensive knowledge of oligonucleotide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques. Our President and CEO, Sarah Boyce, has significant experience in the development
and commercialization of RNA therapeutics and in building global organizations, most recently having served as President of Akcea Therapeutics. Our Chief Scientific Officer, Arthur A. Levin, Ph.D., is a key opinion leader in the RNA therapeutics
field who led teams responsible for the development of many oligonucleotides including the first approved antisense drugs and the first <FONT STYLE="white-space:nowrap">micro-RNA</FONT> targeted therapeutic to enter clinical trials. Our Chief
Operating Officer, Joseph Baroldi, brings a depth of business development experience in RNA therapeutics having led more than twenty strategic transactions, most recently as Vice President, Business Development at Ionis Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our investors include leading life science institutions including RTW Investments, Alethea Capital, Alexandria Venture Investments, Boxer
Capital of Tavistock Group, Brace Pharma Capital, Cormorant Asset Management, LP, CureDuchenne, EcoR1 Capital, Logos Capital, Partner Fund Management, Perceptive Advisors LLC, ST Pharm and Takeda Ventures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to discover, develop and
commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options. Key elements of our strategy
to achieve this goal are to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Advance our lead product candidate AOC 1001 through clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> to approval.</B>&nbsp;&nbsp;We are developing AOC 1001 for the treatment of DM1, a serious rare monogenic disease for which there are no available therapies. Therefore, we are highly focused
on a development path that could enable us to deliver a therapy to patients in need as soon as possible. AOC 1001 is specifically designed to reduce levels of DMPK mRNA, the gene product that when mutated causes DM1. In preclinical studies, we
observed the ability of our AOC to deliver siRNAs to muscle cells, and reduce levels of mRNA for the DMPK gene, the molecular driver of the disease, in a durable, dose-dependent manner. We expect to submit an IND for AOC 1001 in 2021 and plan to
initiate a Phase 1/2 clinical trial by the end of the same year. Assuming that the results of our Phase 1/2 clinical trial are positive, we plan to meet with regulatory authorities to discuss potential expedited regulatory pathways.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Achieve clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for
our muscle atrophy program.</B>&nbsp;&nbsp;We are in the process of selecting a lead candidate for the treatment of muscle atrophy, a condition associated with several diseases including sarcopenia, cachexia and rare genetic muscle diseases. By
targeting MuRF1, a muscle-specific E3 ligase that has been shown to be upregulated upon induction of muscle atrophy, we are developing a solution employing common effectors of both the catabolic and anabolic pathways associated with the degradation
of protein in muscle cells, unlike prior attempts to find a solution by addressing only one of these pathways. Following regulatory clearance, in 2022, we plan to advance a product candidate into a Phase 1 clinical trial in healthy volunteers with a
limb temporarily immobilized to induce muscle atrophy. In this trial, we plan to assess <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment measurements of MuRF1 expression, biomarkers and histological changes, as well as certain
clinical measurements that we believe could demonstrate signals of activity. Our continued development activities will inform our view on the indications and development path to pursue. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Progress our DMD program into clinical development and advance our other rare muscle disease programs.</B>&nbsp;&nbsp;We
are developing AOCs to treat the underlying cause of DMD. We employ oligonucleotides to promote the skipping of specific exons in order to address a number of specific mutations in the dystrophin gene. Our initial development efforts are expected to
be in boys with DMD mutations amenable to skipping Exon 44, Exon 45 and Exon 51. In preclinical studies, we observed that treatment with an AOC caused an approximately </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
<FONT STYLE="white-space:nowrap">50-fold</FONT> increase in exon skipping compared to the unconjugated oligonucleotide. In 2022, following regulatory clearance, we plan to commence a clinical
trial. Our deep muscle pipeline is further supplemented by our efforts to explore the utility of AOCs in both FSHD and Pompe disease on the premise that our AOCs are well-suited to address muscle diseases caused by aberrant expression of a single
gene. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Expand our pipeline into additional tissue and cell types.</B>&nbsp;&nbsp;In preclinical models, we have observed the
ability to deliver AOCs not only to the liver, skeletal and cardiac muscle, but also to immune cells and other tissue and cell types. In regards to potential in immuno-oncology, in preclinical studies we observed significant <FONT
STYLE="white-space:nowrap">AOC-mediated</FONT> mRNA reduction in CD8+ and CD4+ tumor infiltrating lymphocytes and <FONT STYLE="white-space:nowrap">T-regs</FONT> <I>in vivo</I>. These observations with respect to the specificity and selectivity of
our AOCs are the basis for our interest in exploring the utility of our AOCs in immunology and also serve as the basis for our collaboration with Lilly. We plan to continue to invest in our AOC platform to explore the full potential of our AOCs in
additional previously inaccessible tissue and cell types.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Independently commercialize any approved products in indications and geographies where we believe we can maximize value
and pursue other options to realize the full potential of our platform.&nbsp;&nbsp;</B>We have a disciplined strategy to maximize the value of our pipeline by retaining development and commercialization rights to those product candidates,
indications and geographies that we believe we can ultimately commercialize successfully on our own if they are approved. We plan to collaborate on product candidates that we believe have promising utility in disease areas or patient populations
that are better served by the resources or specific expertise of other biopharmaceutical companies.<B> </B>Our collaboration with Lilly is an example of where we believe that the development of certain immunology targets is well served by a
strategic collaboration. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our AOC Product Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Overview </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are pioneering a new
class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC
platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more
effectively target underlying genetic drivers of diseases. All of our oligonucleotides target disease-related RNA. RNA is a polymeric molecule essential in the coding, decoding, regulation and expression of genes. We have accumulated deep experience
regarding oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug delivery techniques. We collectively refer to the <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology born
out of this experience, and their systematic application in the design and development of our product candidates, as our AOC Platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Evolution of Oligonucleotide Therapeutics </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Oligonucleotide therapeutics are typically short strands of modified RNA or DNA that are manufactured by chemical synthesis. They are designed, based on
genomic information using Watson and Crick base pairing rules, to inhibit or modify the expression of specific disease-related proteins and RNAs. Because messenger RNA (mRNA) serves as the template for synthesis of all proteins, modulating the
levels or function of a disease-related RNA alters the production of disease-associated proteins in a highly specific fashion which, in turn, alters disease processes. When delivered to the cells where the functional change is needed,
oligonucleotides have been shown to be effective at modifying the molecular basis of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Considerable progress has been made toward
harnessing the potential of oligonucleotides, and multiple oligonucleotide therapies have been approved for the treatment of several diseases. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
in light of their physical properties, such as their size and water solubility, effective systemic delivery of oligonucleotides to a broad range of cells and organs has been one of the most
significant factors limiting their utility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Single-stranded phosphorothioate oligonucleotides (often referred to as antisense oligonucleotides
(ASOs)) bind nonspecifically to plasma and cell surface proteins. As a result, ASOs accumulate in the liver and the kidney as part of the natural filtering function of those organs. However, even when the liver is the target organ for delivery, the
ASO&#146;s <FONT STYLE="white-space:nowrap">non-specific</FONT> binding and uptake results in most of the drug being delivered to <FONT STYLE="white-space:nowrap">non-parenchymal</FONT> cells rather than the true target for therapeutic activity,
hepatic parenchymal cells. As a result, many early <FONT STYLE="white-space:nowrap">ASO-based</FONT> therapeutics were limited to organs where site-specific delivery to cells was an effective therapeutic approach, for example by intrathecal
administration to the central nervous system (CNS) or by intravitreal administration to the retina. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unlike ASOs, the physical properties of small
interfering RNA (siRNA) and phosphorodiamidate morpholino oligomers (PMOs) render them so they can only weakly bind to either plasma or cell surface proteins. Thus, they are ultimately cleared rapidly from plasma by renal filtration, with fractional
reabsorption in the kidney. If unconjugated, or unformulated, these oligonucleotides have minimal uptake into target organs. Therefore, they require high doses to be administered frequently that increase the potential for toxicity, while yielding
limited activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Despite the limitations of these early unconjugated oligonucleotide technologies, companies have employed these approaches to
commercialize oligonucleotide drugs that generated an aggregate of over two billion dollars of sales in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following these early approaches, the
field turned towards finding appropriate conjugates to aid in delivery of oligonucleotides in order to increase uptake. Third parties have conjugated <FONT STYLE="white-space:nowrap">PMO-based</FONT> oligonucleotides to charged peptides in order to
penetrate cells. These peptide PMOs (PPMOs) help increase uptake into cells such as muscle, but clearance remains relatively rapid and the accumulation of these highly-charged, cell penetrating peptides has been associated with renal functional
changes. In clinical trials, these compounds have not yet demonstrated an improvement in efficacy over unconjugated PMOs or established a long-term safety profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">More recently, researchers have begun to engage proteins on cell surfaces to enhance the delivery of oligonucleotides using a process called
receptor-mediated uptake. Conjugating sugar molecules (GalNAc) to oligonucleotides in order to engage asiaglycoprotein (ASGPR), a transporter protein expressed primarily on the surface of hepatic parenchymal cells, facilitates intracellular delivery
of oligonucleotide therapeutics, resulting in increased efficiency as compared to unconjugated oligonucleotides. The emerging preclinical and clinical data around the GalNAc-ASGPR approach and recent FDA approval of givosiran, which uses this
approach, supports the thesis that receptor-mediated uptake is a viable delivery strategy for oligonucleotides therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to increase the
uptake of oligonucleotides, efforts have also been made to use antibody conjugates as a means of delivering oligonucleotides into cells. Antibodies are&nbsp;naturally occurring&nbsp;proteins&nbsp;produced by the immune system that first identify and
then neutralize or clear antigens, such as bacteria, viruses and other substances, by selectively binding to these foreign substances.&nbsp;A mAb&nbsp;is a single, homogeneous&nbsp;entity&nbsp;that recognizes a specific molecular entity,&nbsp;for
example&nbsp;a cell surface protein.&nbsp;Today, mAbs are&nbsp;frequently engineered&nbsp;for desired characteristics, such as&nbsp;high selectivity and high affinity for their target cell surface proteins and, therefore, theoretically could
facilitate the trafficking of oligonucleotide therapeutics into those cells. However, we believe that others have tried and failed to make viable antibody conjugated oligonucleotides because of the failure to optimize each of the mAb, the
oligonucleotide and the antibody conjugate design. Finding the right transport protein and the right mAb requires an understanding of whether there is sufficient density of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the targeted cell surface receptor to move the required number of therapeutic molecules into the cell and how to traffic the therapeutic molecules appropriately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Overall, we believe the advancements in the oligonucleotide field support the hypothesis that delivery of oligonucleotides can be greatly enhanced by
using appropriate conjugates that are recognized by specific proteins on the surface of cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Our Approach </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our AOC platform was developed out of our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and
conjugation, and drug delivery techniques. Based on the data-driven hypothesis that the delivery of oligonucleotides can be greatly enhanced by using antibodies as conjugates, our scientists have established a framework for screening potential cell
surface <FONT STYLE="white-space:nowrap">protein-mAb</FONT> pairs to determine which pairs we believe are well suited to deliver active oligonucleotides to specific cell types. We have identified multiple cell surface
<FONT STYLE="white-space:nowrap">protein-mAb</FONT> pairs that can deliver oligonucleotides into various tissue and cell types to induce pharmacologic changes. For example, we have employed AOCs built on a scaffold of a mAb or mAb fragment that
binds with high selectivity and affinity to transferrin receptor 1 (TfR1) to deliver oligonucleotides to cell types outside of the liver, in particular to muscle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our AOC platform also affords us the option to deploy various types of oligonucleotides, including siRNAs and PMOs, whose specific mechanisms of action
modify RNA function in different ways. This flexibility allows us to use oligonucleotides that are tailored to modulate a given disease process. Mechanisms of these oligonucleotides can range from reducing the expression of a disease-related RNA
with siRNAs, to correction of aberrant processing of RNAs with splice modifying oligonucleotides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In preclinical studies, our AOCs have
demonstrated pharmacologic responses as measured by mRNA reduction in liver, skeletal muscle, cardiac muscle, <FONT STYLE="white-space:nowrap">B-</FONT> and <FONT STYLE="white-space:nowrap">T-cells</FONT> and lymphocyte subsets, as well as
macrophages (see Figure 1 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 1: Percent Reduction of Target Gene Expression </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g20b40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>Different AOCs and controls were used in each cell type, which were studied independently. The mAb/siRNA for each tissue are as
follows: Liver: ASGPR/Factor VII; Muscle/Heart: TfR1/myostatin; B Cells: TfR1/HPRT; Tregs: mAbx/HPRT; CD8+TILs: TfR1/SHP2; and Macrophages: Aby/HPRT. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Our AOC Platform Proprietary Chemistry </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Successfully engineering an active AOC requires a sophisticated understanding of the precise characteristics of each of the components of the AOC, as
well as their behavior when acting in concert. We have deployed significant <FONT STYLE="white-space:nowrap">know-how</FONT> towards optimizing our AOCs, beginning with their individual oligonucleotide and mAb components. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Optimization of the oligonucleotide. </I>We have engineered our oligonucleotides to maximize their
stability, potency and specificity. For many of our applications, the oligonucleotide we employ is a double-stranded siRNA, comprised of a passenger and guide strand. Modifications to the passenger strand are designed to reduce loading into the RNA
Induced Silencing Complex (RISC), decreasing inadvertent RNA interference (RNAi) activity. In comparison, modifications to the guide strand, also known as the active strand, are designed to enhance RISC loading, increasing the potential for matching
sequences in newly transcribed RNA. Following a match, enzymes in the RISC will cleave the targeted mRNA, thereby effectively destroying it and reducing disease-related RNA levels (see Figure 2 below). Our siRNAs have been stabilized to withstand
the nucleases in lysosomes, enhancing their ability to escape the lysosome after AOC internalization and antibody degradation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 2:
Mechanisms of Action of Oligonucleotides Used in our AOCs </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g96w97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In preclinical studies, we observed that AOCs in circulation were stable for at least seven days. The biologic
activity of the AOC was independent of plasma circulation times because the AOCs were cleared from plasma more rapidly than tissues. Once delivered into cells, our oligonucleotide therapeutics were stabilized and, particularly when loaded into the
RISC, had prolonged activity. In mice treated with our AOC, the half-life of siRNA in muscle tissue was approximately 12 days (see left panel of Figure 3 below). In comparison, the half-life of siRNA in RISC had a projected half-life of
approximately 80 days, suggesting that, once in tissues, the siRNA is stabilized in RISC, prolonging the duration of action (see right panel of Figure 3 below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 3: Half-life of siRNA in Mice Muscle Tissue and RISC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g05r92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:8pt; font-family:ARIAL"><I>Ln represents the logarithm of tissue concentration. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that chemical modifications to the siRNA drive their long-lived pharmacologic activity. We
observed that a single dose of 3 mg/kg of an siRNA in an AOC administered to mice reduced the level of muscle RING-finger protein-1 (MuRF1), the targeted mRNA in muscle, for more than five months (see Figure 4 below). We believe that these results
suggest that AOCs for muscle diseases may be given as infrequent intravenous doses similar to those that are being used with other siRNA therapeutics in the liver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 4: Duration of Response to Single 3 mg/kg Dose </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g33h06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Data are expressed as mean (SE) compared to saline controls. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Optimization of the mAb. </I>Because the mAb is the key delivery agent for our oligonucleotides, we are focused on identifying and tailoring mAbs to
enhance their selectivity and minimize toxicity. For example,<I> </I>all our muscle programs employ our proprietary, effector function null, fully humanized IgG1 mAb targeting human TfR1. This antibody was selected to minimize interference with
transferrin binding, minimizing alterations of iron uptake by the targeted cells. Further, our antibody is selective to TfR1 and does not cross-react with TfR2, which is widely expressed in the liver. Selectivity of our anti-transferrin receptor
antibody for human and cynomolgus monkey TfR1 can be attributed to our antibody binding domain, to an epitope that is conserved between human TfR1 and cynomolgus monkey TfR1. To minimize antibody-dependent cell-mediated cytotoxicity (ADCC) and
complement fixation, we introduced mutations to eliminate effector functions. Reduction of ADCC has been shown for the lead clones. The final clone-expressing cell was selected based on high production yields and optimized physical and chemical
properties. The selected mAb demonstrated good delivery into human skeletal muscle cells <I>in vitro</I> and favorable bioconjugation with an siRNA, and polyclonal versions of the mAb showed favorable delivery and pharmacodynamics in studies in
cynomolgus monkeys. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Optimization of the </I><I>antibody </I><I>conjugate design. </I>In addition to the oligonucleotide
and the mAb, we have also optimized the conjugation of the two, including the linker. Our linkers are optimized for stability and durability, as evidenced by preclinical studies in which we observed enhanced stability of some linkers over others
(see Figure 5 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 5: AOCs with Different Linkers at 0.5 mg/kg </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g18y97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to optimizing our linker, we optimize several other key aspects including sites of conjugation and the
ratio of oligonucleotides to antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Advantages of our AOC Product Platform </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the product candidates derived from our AOC platform will have the potential to offer the following distinct advantages: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Expand scope of diseases addressable with oligonucleotides</I>: (i)&nbsp;utilize identified cell surface
protein-antibody pairs to design oligonucleotides in order to address various previously undruggable tissue and cell types to induce pharmacologic changes in those tissues and cells; (ii)&nbsp;flexibility to deploy an appropriate oligonucleotide
type for different diseases; and (iii)&nbsp;optimize all structural components of our AOCs for effective delivery&#151;the oligonucleotide, the mAb and the antibody conjugate design. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Potential to mitigate toxicity by limiting drug exposure: </I>(i)<I></I>&nbsp;selection of the most potent
oligonucleotide type; (ii)&nbsp;targeted delivery to tissues and cells; and (iii)&nbsp;infrequent administration. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Less</I><I> frequent dosing: </I>(i)&nbsp;ability to deliver oligonucleotides to tissues and cells at concentrations
that produce pronounced and prolonged pharmacodynamic effects as observed in our preclinical models; and (ii)&nbsp;ability to select appropriate oligonucleotide mechanisms to maximize durability. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Readily reproducible and scalable</I>: (i)&nbsp;AOCs synthesized using well-established and scalable methods for
manufacturing mAbs and oligonucleotides; and (ii)&nbsp;ability to use a single mAb across multiple programs provides significant leverage around development costs and timelines associated with each incremental muscle program. For example, we use the
same mAb targeting TfR1 across all our muscle programs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Development Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have leveraged our deep experience with oligonucleotide therapeutics, modulation of RNA processes, antibody engineering and conjugation, and drug
delivery techniques to build a pipeline of AOC development programs. Leveraging our access to extensive mAb libraries and our framework for screening potential cell surface <FONT STYLE="white-space:nowrap">protein-mAb</FONT> pairs, we have studied
over 100 different mAbs and dozens of siRNA sequences to form the basis of our growing pipeline. The chart below represents a summary of our wholly owned development programs, which are focused on muscle disease: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g43p29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to our wholly owned programs in muscle disease, we also have development efforts focused on immune and
other cell types. Under the Lilly Agreement, we are collaborating with Lilly for the discovery, development and commercialization of AOCs directed to up to six selected mRNA targets, in immunology and other select indications outside of muscle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Our Muscle Disease Franchise </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have
selected muscle as the first tissue type in which to explore the potential of our AOCs. In our early screening efforts, we observed a 95% reduction of target gene expression in mouse skeletal muscle with the AOC we tested, which in part led us to
focus on developing a deep pipeline of AOCs that are designed to address five muscle diseases&#151;DM1, muscle atrophy, DMD, FSHD and Pompe disease. We use the same proprietary mAb targeting TfR1 across our muscle programs, which we believe gives us
significant leverage of development costs and timelines associated with each incremental muscle program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>AOC 1001 for the Treatment of Myotonic
Dystrophy Type 1 (DM1) </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead product candidate, AOC 1001, is a potentially disease-modifying treatment for DM1. AOC 1001 consists of a
proprietary mAb targeting TfR1 conjugated with an siRNA that is designed to reduce levels of dystrophy myotonic protein kinase (DMPK) RNA, the gene product that when mutated causes DM1. In preclinical studies in mice and cynomolgus monkeys, we
observed the ability of AOC 1001 to deliver siRNAs to muscle cells and reduce the levels of DMPK RNA. We expect to submit an IND for AOC 1001 in 2021 and plan to initiate a Phase 1/2 clinical trial by the end of the same year. Due to the lack of
available therapies for this rare disease, should our trial be successful, we plan to explore the potential to advance AOC 1001 into registrational trials in order to expedite availability of AOC 1001 to patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Disease Overview</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">DM1 is a monogenic, autosomal dominant, progressive disease that primarily affects skeletal and cardiac muscle. DM1 patients can suffer from various
manifestations of the disease including myotonia and muscle weakness, respiratory problems, fatigue, hypersomnia, cardiac abnormalities, severe gastrointestinal (GI) complications, and cognitive and behavioral impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">DM1 is caused by an increase in the number of CUG triplet repeats found in the 3&#146; <FONT STYLE="white-space:nowrap">non-coding</FONT> region of the
DMPK gene product. The number of repeats ranges from up to approximately 35 in healthy individuals to many thousands in DM1 patients. The higher than normal number of CUG repeats form large hairpin loops that entrap the DMPK <FONT
STYLE="white-space:nowrap">pre-mRNA</FONT> in the nucleus and impart toxic activity, referred to as a toxic gain-of-function. Specifically, mutant DMPK <FONT STYLE="white-space:nowrap">pre-mRNA</FONT> sequesters a critical CUG-binding protein,
muscle blind-like protein (MBNL), forming nuclear foci and inhibiting its ability to perform its normal function of guiding <FONT STYLE="white-space:nowrap">pre-mRNA</FONT> processing of gene transcripts from many other genes. As a result, multiple <FONT
STYLE="white-space:nowrap">pre-mRNAs</FONT> that encode key proteins are <FONT STYLE="white-space:nowrap">mis-processed.</FONT> The resulting atypical proteins that are translated ultimately cause DM1. When DMPK and CUG levels are reduced as result
of DPMK mRNA level reductions, nuclear foci are diminished and MBNL can perform its normal function. This disease process is illustrated in Figure 6 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 6: DM1 Disease Process </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g86v25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">DM1 is estimated to affect over 40,000 people in the United States and there are similar prevalence estimates for
Europe. However, we believe that, consistent with other rare diseases, the patient population is currently underdiagnosed due to lack of available therapies. DM1 is highly variable with respect to disease severity, presentation, and age of onset. As
we advance our own efforts to better characterize the actual DM1 patient population and as the diagnoses rate improves with the advent of new therapies, we believe that the overall prevalence estimates will increase. Based on age of onset and
severity of symptoms, DM1 is typically categorized into four overlapping phenotypes: late-onset; classical (adult-onset); childhood; and congenital (cDM1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All forms of DM1, except the late-onset form, are associated with high levels of disease burden and premature mortality. Excluding neonatal cDM1 deaths,
life expectancy ranges from 45 years to 60 years. Seventy percent of early mortality is caused by cardiorespiratory complications. Respiratory failure due to muscle weakness (especially diaphragmatic weakness), causes at least 40% of early
mortality, and cardiac abnormalities, including sudden death, account for approximately 30%. The clinical course of DM1 is usually slowly progressive, but may become extremely disabling, especially when more generalized limb weakness and respiratory
muscle involvement develops. Systemic manifestations such as fatigue, GI complications, incontinence and excessive daytime sleepiness greatly impact a patient&#146;s quality of life. As a result, DM1 leads to physical impairment, activity
limitations and decreased participation in social activities and work. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Table 2: DM1 Phenotypes </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>Phenotype</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Principal Clinical Signs</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Estimated % of<BR>DM1 Patients<BR>(Approx.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Age of Onset</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Late-onset</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Myotonia</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Mild muscle weakness</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Cataracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&lt;10%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">20-70</FONT> years</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Classical</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">(Adult-onset)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Muscle weakness and wasting</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Myotonia</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Cardiac conduction abnormalities</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Respiratory insufficiency</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Fatigue/Excessive daytime sleepiness</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">GI disturbance</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Cataracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">75%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">10-30</FONT> years</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Childhood</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Psychosocial problems</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Low IQ</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Incontinence</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&lt;10%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">1 to 10 years</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">Congenital (cDM1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Infantile hypotonia</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Severe generalized weakness</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Respiratory deficits</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Intellectual disability</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Classic signs present in adults</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Birth</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Current Treatment Landscape and Limitations </U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are currently no approved therapies to treat DM1, and treatment is focused largely on symptom management. Due to the well-known challenges of
delivery, a previous attempt at treating DM1 with an unconjugated antisense oligonucleotide was discontinued. Therefore, there remains a high unmet medical need for new disease modifying therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Tideglusib, an inhibitor of glycogen synthase kinase 3 (GSK3-&szlig;), is in late-stage clinical development for the cDM1. Another product candidate, <FONT
STYLE="white-space:nowrap">ERX-963,</FONT> is in a Phase&nbsp;1 clinical trial for the treatment of excessive daytime sleepiness in DM1 patients. However, neither product candidate addresses the underlying genetic cause of the DM1. We are also aware
of preclinical efforts in gene therapy for the treatment of DM1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Our Solution</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">AOC 1001 consists of a proprietary mAb that binds to TfR1 conjugated with an siRNA, siDMPK.19, targeted to DMPK RNA, and is designed to be administered
to the patient as an intravenous infusion. We believe that the following specific characteristics of AOC 1001 position it to have advantages over historical and current efforts to develop an effective therapy for DM1 patients: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Addresses the underlying cause of the disease</I>&#151;DM1 is caused by an increase in the number of CUG triplet repeats
occurring in the DMPK gene product. AOC 1001 is designed to inhibit the level of toxic DMPK RNA, thereby reducing the CUG burden in the nucleus and thereby releasing MBNL to allow for normal mRNA processing (see Figures 7 and 8 below).
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Efficient delivery of drug substance to diseased cells</I>&#151;In an effort to solve for challenges identified in prior
unsuccessful efforts to deliver an unconjugated oligonucleotide into muscle cells, the TfR1 antibody component of AOC 1001 facilitates efficient delivery of AOC 1001 to skeletal and cardiac
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
muscle cells. Once inside the muscle cells, the siRNA component of AOC 1001, siDMPK.19, acts to reduce levels of DMPK mRNA in both the nucleus and the cytoplasm. In preclinical studies in
cynomolgus monkeys, we observed that treatment with an AOC containing siDMPK.19 produced a greater than 50% reduction of DMPK mRNA across a wide range of skeletal muscles at a concentration of 1 nM or less, approximately 1,000 fold more potent than
has been reported for an unconjugated antisense oligonucleotide. We also observed reductions in DMPK mRNA in the GI tract. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Reproducible and scalable therapeutic</I>&#151;As with all our AOCs, AOC 1001 is readily synthesized using
well-established and scalable methods for manufacturing mAbs and oligonucleotides. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our preclinical studies to date support our
hypotheses on the potential advantages of AOC 1001. In <I>in vitro</I> experiments in cells from patients with DM1, after treatment with siDMPK.19, we observed reductions in nuclear foci, and a return to more normal splicing patterns for key genes.
Additionally, marked and prolonged reduction in DMPK mRNA levels was observed in cynomolgus monkeys after administration of a single intravenous dose of an AOC consisting of the lead <FONT STYLE="white-space:nowrap">TfR1-Ab</FONT> conjugated to
siDMPK.19. Treatment in these monkeys was well-tolerated and no clinically meaningful changes in hematology, serum biochemistry or histology were observed at a dose of 6 mg/kg. Taken together, we believe these data suggest that AOC 1001 has
potential to be a disease modifying therapy for the treatment of DM1, and has the potential advantage of infrequent administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Preclinical
Data and Next Steps</U> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have observed dose-dependent and long-lasting reductions in the levels of DMPK in cynomolgus monkeys. We observed that a
single dose of 2 mg/kg of siDMPK.19 included in AOC 1001 produced an approximately 75% reduction of DMPK mRNA in skeletal muscles from cynomolgus monkeys (see Figure 7 below). Similar effects were observed in cardiac muscle and the diaphragm, where
we observed between a 50% to greater than 75% reduction in DMPK levels with single doses of 1 to 5 mg/kg of siDMPK.19 measured six weeks after administration (see left panel of Figure 8 below). Durability of response in the heart and diaphragm was
observed in monkeys administered a single dose of 2 mg/kg where there were approximately 50% and 65% reductions in DMPK mRNA levels in cardiac muscle and diaphragm, respectively, 12 weeks after administration (see right panel of Figure 8 below).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 7: DMPK mRNA Levels in Skeletal Muscle from Cynomolgus Monkey </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>After a Single Dose of 2mg/kg of siDMPK.19 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g91l87.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 8: DMPK mRNA Levels in Heart and Diaphragm </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g22y30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In preclinical studies in cynomolgus monkeys, we observed that treatment with an AOC containing siDMPK.19 produced a
greater than 50% reduction of DMPK mRNA across a wide range of skeletal muscles at a concentration of 1 nM or less and we also observed reductions in DMPK mRNA in the jejunum and ileum (see Figure 9 below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 9: DMPK mRNA Expression in Skeletal Muscle and GI Tissue </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g14p88.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g20k45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is substantial evidence that siRNA is active in the nucleus of cells and we believe that our RISC-based
mechanism is preferable over other strategies. In preclinical studies, we observed that DM1 patient cells have approximately <FONT STYLE="white-space:nowrap">30-times</FONT> more metastasis associated lung adenocarcinoma transcript 1 (Malat1), a
long <FONT STYLE="white-space:nowrap">non-coding</FONT> RNA in the nucleus than in the cytoplasm. In incubation of DM1 patient cells with an siRNA targeting two different concentrations of Malat1, we observed reductions in the levels of Malat1,
consistent with the literature. We also observed that incubating DM1 patient cells with siDMPK.19 for seven hours reduced levels of the DMPK mRNA in both the nucleus and the cytoplasm as compared to a control (see Figure 10 below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 10: Nuclear and Cytoplasmic DMPK mRNA Levels in DM1 Patient-Derived Muscle Cells </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:4%" ALIGN="center">


<IMG SRC="g897644g45w62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because siRNA is active in the nucleus, we observed in preclinical studies that it is possible to reduce the number
of MBNL-associated nuclear foci after incubation with siDMPK.19. Using fluorescence microscopy, we observed that incubation of DM1 patient cells with siDMPK.19 resulted in a release of the MBNL and quantifiable reductions in nuclear foci. In
addition, we observed substantial improvements in disease-related biomarkers as measured by the splice score in the cells of DM1 patients following treatment with siDMPK.19. We used <FONT STYLE="white-space:nowrap">RNA-sequence</FONT> (RNA-seq)
analysis of the myotubes from DM1 patients to create a splice score for control human subjects&#146; cells treated with siDMPK.19 or the inactive siRNA, siDMPK.29. When patient myotubes were analyzed, there was a marked improvement in the splice
score of the myotubes treated with the siDMPK.19 compared to the inactive siDMPK.29 (see Figure&nbsp;11 below). The splice signature approached that of control myotubes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 11: Correction of Treatment Signature in DM1 Myotubes as Determined by <FONT
STYLE="white-space:nowrap">RNA-seq</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g93u47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:19%; margin-right:19%; font-size:8pt; font-family:ARIAL"><I>Splice score of treated DM1 myotubes was observed to be improved towards normal by incubation
with siDMPK.19 (blue open circles). Mock treated DM1 myotubes (open black diamonds) show the full splice derangement. The filled circles represent the splice scores in myotubes from normal subjects treated with siDMPK. The filled black diamonds
represent mock transfected myotubes from healthy individuals. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These data above demonstrating marked and prolonged reductions in levels of DMPK
mRNA expression, nM potency, along with reductions in nuclear foci and a return to more normal splicing patterns for key genes, suggest that AOC&nbsp;1001 has potential to be a potent, infrequently dosed, disease modifying therapy in DM1. The mAb
targeting TfR1 conjugated with siDMPK.19 dosed in monkeys has been well tolerated and no clinically meaningful changes in hematology, serum biochemistry or histology have been observed after administration of a dose of 6 mg/kg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently conducting toxicity studies in preparation for clinical development. We plan to submit an IND in 2021 and expect to initiate a Phase
1/2 clinical trial by the end of the same year. Initially we plan to evaluate multiple dose levels of AOC 1001 in adult-onset patients with genetically confirmed DM1 who have measurable muscle strength deficits. We will assess several measures
including safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory clinical measures associated with AOC 1001. We also plan to explore the potential of AOC 1001 in the cDM1 and childhood onset patient populations. Because AOC 1001
targets the underlying cause of DM1 by reducing the level of mutant DMPK mRNA in muscle and heart tissue regardless of the number of CUG repeats, we believe it has the potential to clinically benefit all phenotypes of DM1 patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Our Muscle Atrophy Program </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are in the
process of selecting a product candidate for the treatment of muscle atrophy. Our product candidate will consist of our proprietary mAb targeting TfR1 conjugated with an siRNA designed to downregulate the expression of MuRF1 RNA. By targeting MuRF1,
a muscle-specific ubiquitin ligase (E3 ligase) that has been shown by third parties to be upregulated upon induction of muscle atrophy, we are developing a solution employing common effectors of both the catabolic and anabolic pathways associated
with the degradation of protein in muscle cells. While several historical attempts at developing a therapy to treat muscle atrophy have failed, those attempts followed a different approach than we are taking. In preclinical studies, we observed that
a single 3 mg/kg dose of the siRNA in our AOC resulted in a greater than 50% reduction of MuRF1 in gastrocnemius skeletal muscle for over 20 weeks. Following regulatory clearance, we plan to advance our product candidate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
into a Phase 1 clinical trial in 2022. The strength and scope of emerging data over this period will inform our view on ideal indications to pursue for advanced development and therefore, also
our decision on the most appropriate future development path for our muscle atrophy product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Disease Overview</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Muscle atrophy is the loss of skeletal muscle mass that leads to muscle weakness and physical disability. Muscle atrophy can be caused by immobility,
aging, malnutrition, medications, or a wide range of injuries or diseases that impact the musculoskeletal or nervous system. Examples of diseases that cause muscle atrophy include those characterized by large patient populations such as sarcopenia
and cachexia, as well as many rare genetic muscle diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Muscle atrophy is caused by a change in the balance between catabolic (protein
breakdown) and anabolic (protein synthesis) signals that activate <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokine pathways that induce protein degradation or inhibit growth factor pathways that promote protein synthesis,
respectively (see Figure 12 below). Genetic profiling of atrophic muscles has identified a group of E3 ligases that are upregulated upon induction of muscle atrophy. Of these, the muscle-specific E3 ligase MuRF1 has been shown to be upregulated in
most <I>in vivo</I> models, as well as in clinical trials. Inhibiting MuRF1 expression diminishes the impact from the pro inflammatory factor side of the pathway and diminishes the growth-inhibiting effects of the growth factor pathway (see Figure
12 below). Furthermore, genetic ablation of MuRF1 in mice has been shown by third parties to render muscles partially resistant to muscle atrophy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 12: Pathways for the Induction of Muscle Atrophy </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g55g31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The prevalence of muscle atrophy is widespread, spanning multiple diseases and conditions. Cachexia, a muscle wasting
syndrome caused by an underlying disease such as cancer, is estimated to affect 50% to 80% of all cancer patients, and contributes to a significant portion of all cancer deaths. Sarcopenia is another disease characterized by the involuntary loss of
muscle, typically associated with the aging process. In the United States, sarcopenia is estimated to affect 5% to 13% of people aged 60 years to 70&nbsp;years and up to 50% of people aged over 80 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Current Treatment Landscape and Limitations </U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Current treatments for muscle atrophy primarily focus on nutritional intake and physical exercise. Historically, attempts to develop a therapy addressing
the underlying disease have included anti-inflammatory agents and drugs that either activate protein synthesis (including myostatin inhibitors) or inhibit protein degradation. None of these approaches have been successful in clinical trials. We
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
believe that these approaches failed in clinical trials because they focused on single pathways and on the regulation of either catabolic or anabolic mechanisms. Muscle atrophy involves multiple
pathways and the simultaneous activation and inhibition of catabolic and anabolic mechanisms, respectively. Contrary to previous attempts, by targeting E3 ligases such as MuRF1, we are regulating common effectors of both the catabolic and anabolic
pathways involved in the induction of muscle atrophy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Preclinical Data and Next Steps </U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In a commonly used model of muscle atrophy (denervation), <FONT STYLE="white-space:nowrap">pre-treatment</FONT> of mice with an AOC comprised of the
mouse mAb targeting TfR1 conjugated with an siRNA targeted against MuRF1 (at 6 mg/kg) showed a 54% sparing of muscle cross sectional area (CSA) on Day 28 after dosing (see left panel of Figure 13 below) and 35% sparing of weight (see right panel of
Figure 13 below) on Day 17 compared to mice treated with an AOC with a control siRNA. The results of this study replicate data from the same model in mice with MuRF1 genetically ablated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 13: Impact of Downregulation of MuRF1 on Denervation-Induced Muscle Atrophy in Mice </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g79k49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The duration of action of an siRNA against MuRF1 delivered as an AOC was observed to be prolonged in preclinical
studies. After a single dose of 3 mg/kg of siRNA against MuRF1, we observed a greater than 50% reduction of MuRF1 mRNA in gastrocnemius skeletal muscle compared to control, which lasted longer than 20&nbsp;weeks in the heart and even longer in
skeletal muscle (see Figure&nbsp;14 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 14: Single 3 mg/kg Dose of siRNA Against MuRF1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g32y50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:8pt; font-family:ARIAL"><I>Data are expressed as mean (SE) compared to saline controls. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently in the process of selecting a product candidate to advance into clinical development. Following additional preparatory preclinical
studies and regulatory clearance, we plan to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
advance our product candidate into a Phase 1 clinical trial in 2022. We plan to conduct our first clinical trial in healthy volunteers with a limb temporarily immobilized to induce muscle
atrophy. In this trial, we plan to assess <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment measurements of MuRF1 expression, biomarkers and histological changes, and certain clinical measurements. We expect this trial to be of short
duration as we believe that changes in MuRF1 expression can be observed within days of immobilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The strength and scope of emerging data over
this period will inform our view on ideal indications to pursue and the most appropriate future development path for our muscle atrophy product candidate. Should we determine that our product candidate is best used for muscle atrophy associated with
certain rare diseases, we will likely retain rights for later stage development and potential commercialization. Should we find that its utility is best served in diseases underpinned by large patient populations, we may elect to leverage the
resources or specific expertise of another biopharmaceutical company via a strategic collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Our Duchenne Muscular Dystrophy (DMD)
Programs </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are developing AOCs to treat the underlying cause of DMD. DMD is caused by mutations in the gene that encodes for dystrophin, a
protein critical for the normal function of muscle cells. The oligonucleotides in our AOCs are designed to promote the skipping of specific exons to allow the production of the dystrophin gene product. We are focusing our initial efforts on the
development of AOCs for mutations amenable to skipping Exon 44, Exon 45 and Exon 51 and we intend to conjugate these individual oligonucleotides to our proprietary mAb targeting TfR1. In preclinical studies, we observed that treatment of an mdx
mouse with an AOC caused a greater than <FONT STYLE="white-space:nowrap">50-fold</FONT> increase in exon skipping compared to an equimolar dose of the unconjugated oligonucleotide. In 2022, following regulatory clearance, we plan to commence a
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Disease Overview</U> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">DMD
is a monogenic, <FONT STYLE="white-space:nowrap">X-linked,</FONT> recessive disease caused by mutations in the gene that encodes for dystrophin. DMD almost exclusively occurs in boys and is progressive, irreversible and ultimately fatal. In DMD
patients, mutations in the affected gene hinder the production of normal levels of dystrophin protein, which is needed to maintain the integrity of muscle fibers. Dystrophin protein acts as a shock absorber through its role as the foundation of the
dystrophin associated glycoprotein complex (DAPC), a group of proteins that connects the inner and outer elements of muscle cells to ensure proper muscle function. The absence of functional dystrophin leads to stresses and tears of muscle cell
membranes, resulting in muscle cell death and the progressive loss of muscle function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For patients suffering from DMD, symptoms usually begin to
manifest between three and five years of age. Affected boys fail to reach developmental milestones or experience motor function challenges, such as difficulty walking or climbing stairs. Muscle wasting initially presents in the legs and pelvic area
and later affects the muscles of the shoulders, neck and arms. As the disease progresses, patients with DMD fall frequently, can no longer run, play sports or perform most daily functions, and are further weakened by physical activity. By their
early teens, DMD patients typically lose their ability to walk and become dependent on a wheelchair for mobility. By their twenties, patients essentially become paralyzed from the neck down and require a ventilator to breathe. Though disease
severity and life expectancy vary, a patient&#146;s quality of life dramatically decreases over time, and death typically occurs by early adulthood from either cardiac or respiratory complications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">DMD occurs in approximately one in every 3,500 to 5,000 live male births and is estimated to affect 10,000 to 15,000 people in the United States. The
estimated prevalence of DMD in the European Union is similar to or higher than that in the United States. A global database analysis characterized over 7,000 genetic mutations that cause DMD. Exons 44, 45 and 51 represent approximately 30% of the
total mutations observed in DMD that are amenable to skipping (see Figure 15 below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 15: Overview of DMD Exons Amenable to Skipping </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g20v85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:12%; font-size:10pt; font-family:ARIAL"><U>Current Treatment Landscape and Limitations </U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. There are two approved unconjugated
phosphorodiamidate morpholino oligomer <FONT STYLE="white-space:nowrap">(PMO)-based</FONT> oligonucleotide therapies, each addressing a specific mutation&#151;eteplirsen approved for DMD patients amenable to Exon 51 skipping and golodirsen for the
treatment of DMD patients amenable to Exon 53 skipping. However, both drugs, in addition to requiring weekly intravenous infusions, have demonstrated a less than 1% mean increase in dystrophin in clinical trials. The FDA approved labels for both
drugs state that a clinical benefit has not yet been established and continued approval may be contingent upon the verification of such clinical benefit in confirmatory clinical trials. Ataluren is a small molecule drug, conditionally approved in
the European Union, Iceland and South Korea for <FONT STYLE="white-space:nowrap">non-sense</FONT> mutations in DMD in ambulatory patients aged five years and older. However, in multiple clinical trials, ataluren failed to meet the both the primary
endpoint of improvements in the <FONT STYLE="white-space:nowrap">six-minute</FONT> walk test, as well as additional secondary outcome measures. The FDA issued a complete response letter for ataluren in October 2017, requesting additional evidence of
effectiveness. Additional approaches currently in clinical development include peptide-conjugated <FONT STYLE="white-space:nowrap">PMO-based</FONT> oligonucleotides (PPMOs) and gene therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:ARIAL"><U>Our Solution</U> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our initial development
efforts in DMD are focused on AOCs based on PMOs that can induce exon skipping specifically for Exons 44, 45 and 51 conjugated to our proprietary mAb targeting TfR1. We believe that our AOCs have the potential to increase the production of
dystrophin in DMD patients for two reasons. First, because of recent advances in the understanding of the splicing process and placement of skipping agents on <FONT STYLE="white-space:nowrap">pre-mRNA</FONT> described in published literature and
based on these advances, we have screened for and identified PMOs with optimized skipping activity. Second, the mAb targeting TfR1 allows for more efficient delivery to muscle cells, therefore allowing for better uptake of the PMO. In preclinical
studies, we also observed that our TfR1-based AOCs induced exon skipping in cardiac muscle, which we believe may address some of the cardiomyopathies in patients with DMD, a key complication of the disease. Based on their mechanism of action, we
believe that our AOCs could have utility in several additional DMD mutations beyond these first three. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:ARIAL"><U>Preclinical Data and Next Steps </U>
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In an mdx mouse model of DMD, a widely accepted mouse model in DMD, we observed that conjugating an oligonucleotide designed to bind to a specific
exon can induce exon skipping and production of dystrophin protein more efficiently than unconjugated oligonucleotides. Fourteen days following treatment with a single 8mg/kg dose of a mouse Exon 23-targeting PMO conjugated to a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">mouse-specific-mAb</FONT> targeting TfR1, we observed an approximately <FONT STYLE="white-space:nowrap">50-fold</FONT> increase in the degree of splice switching
as compared to an equimolar dose of the unconjugated PMO (see Figure 16 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 16: AOC Treatment Exon Skipping </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Compared to an Unconjugated Oligonucleotide in Mouse DMD Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g36p25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the gastrocnemius of mdx mice treated with varying doses of the AOC, we observed near-maximum benefit at
concentrations of approximately <FONT STYLE="white-space:nowrap">50-100</FONT> nM, providing us with a framework for establishing target concentration in clinical trials (see Figure 17 below). We further observed that administering the PMO
conjugated to a control <FONT STYLE="white-space:nowrap">non-binding</FONT> mAb failed to increase splice skipping to the same degree as conjugating the same oligonucleotide to the mAb targeting TfR1 (see Figure 17 below), despite achieving
concentrations of PMO in the muscle in the active range of <FONT STYLE="white-space:nowrap">50-100</FONT> nM. The absence of meaningful skipping with a <FONT STYLE="white-space:nowrap">non-targeting</FONT> mAb demonstrated that <FONT
STYLE="white-space:nowrap">non-specific</FONT> uptake is inefficient compared to receptor-mediated uptake associated with the mAb targeting TfR1. We have also observed that TfR1-based AOCs induce exon skipping in cardiac muscle, which we believe may
address some of the cardiomyopathies in patients with DMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 17: Exon Skipping versus Concentration After Treatment </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>with a TfR1 mAb AOC or Control mAb AOC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g63w26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; margin-right:16%; font-size:8pt; font-family:ARIAL"><I>The PMO conjugated to a <FONT STYLE="white-space:nowrap">non-targeting</FONT> mAb (black square)
allowed for uptake into muscle, but skipping was substantially less compared to the TfR1 targeted AOC. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In a preclinical study of human primary myocytes incubated with two different unconjugated PMOs (44
Seq 5 and 44 Seq 7), we observed substantial skipping of Exon 44 of dystrophin (see Figure&nbsp;18 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 18: Dystrophin Skipping with
Lead Candidates for Exon 44 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g49a97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Our Facioscapulohumeral Muscular Dystrophy (FSHD) Program </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">FSHD is one of the most common forms of muscular dystrophy and affects both sexes equally, with onset typically in teenage and young adult years. FSHD is
characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk and progresses to weakness in muscles in lower extremities and the pelvic girdle. FSHD is caused by aberrant
expression of a gene, double homeobox 4 (DUX4), in adult skeletal muscle. DUX4 is the major molecular signature that distinguishes muscle tissue affected by FSHD from healthy muscle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FSH Society estimated FSHD affects approximately one in 20,000 people in the United States. A recent study conducted in the Netherlands reported a
more frequent prevalence of one in 8,333 people. We believe that the patient population is between 16,000 to 38,000 in the United States. As is typical in diseases with no approved therapies, we believe that these patient population estimates are
conservative. Losmapimod is a p38 MAPK inhibitor, which may modulate DUX4 expression, and is being evaluated in a Phase 2 clinical trial by a third party. Creatine monohydrate, a supplement that enhances muscle performance, is also being evaluated
in a Phase 2 clinical trial by a third party. Our therapeutic strategy in FSHD is to use an AOC based on our proprietary mAb that targets TfR1 to deliver an siRNA targeted to the DUX4 mRNA. In preclinical models, we observed siRNA-mediated DUX4
silencing in FSHD patient-derived muscle cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:ARIAL"><I>Our Pompe Disease Program </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pompe disease is a rare, autosomal recessive lysosomal storage disease caused by a mutation in the gene that encodes for glucosidase alpha acid (GAA)
that results in the buildup of glycogen in the body&#146;s cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs normal tissue and organ function. Patients with Pompe disease experience serious muscle-related
problems, including progressive muscle weakness, especially in the legs, trunk and diaphragm. As the disorder progresses, breathing problems can lead to respiratory failure. To date, more than 300 mutations have been identified in GAA that are
pathogenic in nature. In general, GAA enzyme activity correlates with the age of onset and rate of progression. Pompe disease affects an estimated one in 40,000 people in the United States, ranging from one in 14,000 in African Americans to one in
100,000 in individuals of European decent. Pompe disease is estimated to affect between 5,000 and 10,000 patients worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The only approved
therapy for Pompe disease is Lumizyme, a form of enzyme replacement therapy (ERT), known as Myozyme outside of the United States, which is delivered by bi-weekly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
intravenous infusion. However, ERT does not adequately address the breakdown of muscle tissue associated with the disease. We are also aware of gene therapies in clinical development designed to
increase GAA levels in patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our program in Pompe disease utilizes an AOC based on our mAb that targets TfR1 to deliver an siRNA targeting the
mRNA encoding glycogen synthetase 1 (GYS1), a protein required for the synthesis of glycogen in muscle. Reducing glycogen synthesis in muscle will reduce the toxic accumulation of glycogen in the disease. We believe that an siRNA-based approach is
well suited to the treatment of Pompe disease because of the ability to specifically inhibit GYS1 and not the closely related liver form of the enzyme, glycogen synthetase 2, the latter being critical to glucose regulation in the body. We believe
that our approach to address the breakdown of muscle tissue associated with Pompe disease may be complementary to ERT, as well as future gene therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Opportunities in Immunology and Other Areas </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend
to pursue the development of AOCs in other tissue and cell types, including immune cells. In the field of immunology, we believe AOCs have the potential to target a broader set of cell types and diseases than traditional oligonucleotide therapies.
We believe oligonucleotide therapies have the potential to address the challenges of immune responses at the RNA level; however, the ability to modulate immune responses has been hampered by the inappropriate delivery of these agents to immune
cells. By identifying and optimizing antibodies for specific immune cells, our goal is to leverage our AOC platform to develop product candidates that can deliver siRNAs to disease-driving subsets of immune cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In studies designed to explore AOCs in immuno-oncology, we observed significant <FONT STYLE="white-space:nowrap">AOC-mediated</FONT> mRNA reduction in
CD8+ tumor infiltrating lymphocytes (TILs) <I>in </I><I>vivo</I> in the syngeneic <FONT STYLE="white-space:nowrap">CT-26</FONT> tumor model with an intravenous dose of 6 mg/kg siRNA. However, we observed that the AOCs had no effect on the mRNA
levels in T or B cells in the spleen (see Figure 19 below), suggesting that activity can be limited to only the cell populations involved in immune-responses to tumors without affecting lymphocytes outside the tumor. We believe this specificity was
driven by the fact that the AOC employed our mAb targeting TfR1, and TfR1 is over expressed only on activated lymphocytes. We also observed significant AOC-mediated mRNA reduction in CD4+ TILs and T-regs from mice treated with an AOC comprised of a
mAb targeting TfR1 and an siRNA targeting SHP2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 19: Target mRNA Levels in CD8+ TILs, Splenic T Cells and Splenic&nbsp;B Cells from Mice
Treated </B><B><I>in vivo</I></B><B> with an AOC </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g47w24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have also identified a mAb that binds to macrophages specifically, and when conjugated with an siRNA, produces
reduction in levels of the target mRNA in that cell both <I>in vitro</I> and <I>in vivo</I>. We believe this finding supports the development of AOCs for diseases where macrophages play a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
significant role, like autoimmune disorders. We are in the process of generating data to demonstrate the pharmacologic effects of siRNA reduction in animal models of immune disorders, which will
help inform our future development plans. Our internal efforts are focused on finding additional surface <FONT STYLE="white-space:nowrap">protein-mAb</FONT> pairs and demonstrating reduction in the expression of key targets in subsets of immune
cells. As we identify appropriate product candidates in immunology, we may choose to advance these on our own or seek a strategic collaborator based on the nature of potential indications. Our findings in immunology served as one of the key bases of
our collaboration with Lilly who has access to a defined set of up to six mRNA targets initially in immunology and other select indications on a worldwide basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beyond immune cells, we plan to continue to invest in our AOC platform to explore the full potential of our AOCs in cardiomyopathies, as well as in
additional previously inaccessible tissue and cell types.<B> </B>Our goal is to discover, develop and commercialize novel AOC therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide
range of serious diseases currently lacking adequate treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not own or operate manufacturing facilities. We currently rely on third-party manufacturers and suppliers for the antibodies, oligonucleotides and
linkers used to make our AOCs, and we expect to continue to do so to meet our preclinical, clinical and commercial activities. Our third-party manufacturers are required to manufacture our product candidates under current Good Manufacturing Practice
(cGMP) requirements and other applicable laws and regulations. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The biotechnology and biopharmaceutical
industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical
and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that
may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to AOC 1001, there are currently no approved therapies to treat the underlying cause of DM1.
Products currently in development to treat DM1 include: tideglusib, a GSK3-&szlig; inhibitor in late-stage clinical development by AMO Pharma for the congenital phenotype of DM1; <FONT STYLE="white-space:nowrap">ERX-963,</FONT> which is in early
clinical development by Expansion Therapeutics, Inc. for the treatment of excessive daytime sleepiness in DM1; AT466, which is an <FONT STYLE="white-space:nowrap">AAV-antisense</FONT> candidate in preclinical development by Audentes Therapeutics,
Inc.; an antibody linked oligonucleotide in preclinical development by Dyne Therapeutics Inc.; gene editing treatments in preclinical development by Vertex Pharmaceuticals, Inc.; an RNA-targeting gene therapy in preclinical development by Locana,
Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Current treatments for muscle atrophy are
primarily focused on nutritional intake and physical exercise. Other products in developments for muscle atrophy in cachexia include: adlumiz and <FONT STYLE="white-space:nowrap">AEZS-130,</FONT> which are ghrelin agonists in a Phase 3 clinical
trial by Helsinn Healthcare SA and a Phase&nbsp;2 trial by Aeterna Zentaris Inc., respectively; GSK2881078, an androgen receptor modulator in Phase&nbsp;2 clinical in development by GlaxoSmithKline plc; NGM120, a GSF15 inhibitor by NGM
Biopharmaceuticals Inc.; and <FONT STYLE="white-space:nowrap">PF-06946860</FONT> in Phase 1 clinical development by Pfizer Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently patients
with DMD are treated with corticosteroids to manage the inflammatory component of the disease. Deflazacort is an FDA approved corticosteroid marketed by PTC Therapeutics, Inc. In addition, there are two FDA approved exon skipping drugs marketed by
Sarepta </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Therapeutics, Inc.: Eteplirsen, an unconjugated PMO approved for DMD patients amenable to skipping Exon&nbsp;51; and golodirsen for the treatment of DMD patients amenable to skipping
Exon&nbsp;53. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta Therapeutics with <FONT STYLE="white-space:nowrap">SRP-5051,</FONT> a PPMO currently being evaluated in a
Phase&nbsp;2 clinical trial for patients amenable to Exon&nbsp;51 skipping&nbsp;51, and PTC Therapeutics with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial. In addition, several companies are developing gene
therapies, including Milo Biotechnology (AAV1-FS344), Pfizer <FONT STYLE="white-space:nowrap">(PF-06939926),</FONT> Sarepta Therapeutics <FONT STYLE="white-space:nowrap">(SRP-9001</FONT> and Galgt2 gene therapy program), and Solid Biosciences Inc. <FONT
STYLE="white-space:nowrap">(SGT-001).</FONT> We are also aware of several companies targeting <FONT STYLE="white-space:nowrap">non-dystrophin</FONT> mechanisms for the treatment of DMD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are currently no therapies to treat the underlying cause of FSHD. Products currently in development to treat FSHD include: creatine monohydrate, a
supplement that enhances muscle performance, which is being evaluated in a Phase 2 clinical trial by Murdoch Children&#146;s Research Institute, and losmapimod, a p38 MAPK inhibitor that may modulate DUX4 expression, which is being evaluated in a
Phase 2 clinical trial by Fulcrum Therapeutics Inc. The only approved therapy for Pompe disease is Lumizyme (known as Myozyme outside of the United States), an ERT delivered by <FONT STYLE="white-space:nowrap">bi-weekly</FONT> intravenous infusion,
and marketed by Sanofi Genzyme. We are aware of multiple ERT therapies in clinical development, including <FONT STYLE="white-space:nowrap">AT-GAA,</FONT> which uses a pharmacological chaperone, in a Phase 3 clinical trial by Amicus Therapeutics,
Inc., and neoGAA in a Phase 3 clinical trial by Sanofi Genzyme. In addition, several companies are developing gene therapies, including Actus Therapeutics, Inc. (ACTUS101), Asklepios BioPharmaceutical, Inc.
<FONT STYLE="white-space:nowrap">(AAV2/8-LSPhGAA),</FONT> Audentes Therapeutics (AT845) and Spark Therapeutics, Inc. <FONT STYLE="white-space:nowrap">(SPK-3006).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies
working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Aro Biotherapeutics, Arrowhead Therapeutics, Dyne Therapeutics, Ionis Pharmaceuticals and Sarepta Therapeutics, as well as gene
therapy and CRISPR approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical
and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread
market acceptance, rendering our treatments obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being
concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials
and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our
commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical
to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in
many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the success of our programs are likely to be their efficacy, safety profile, convenience, level of promotional
activity, intellectual property protection and availability of reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We strive to protect our product candidates and our AOC product platform through a variety of methods, including seeking and maintaining patents intended
to cover our AOC product platform, our products and compositions, their methods of use and processes for their manufacture, and any other inventions that are commercially important to the development of our business. We also rely on <FONT
STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our proprietary position. We also rely on trade secrets and know-how that
may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file patent applications for new commercially valuable inventions to expand our intellectual property
portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that we have a significant global intellectual property position and substantial
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to our AOC product candidates and our technology platform. As of April&nbsp;30, 2020, our intellectual property portfolio consisted of two issued U.S. patents and over 20 pending U.S. patent
applications that we own. Collectively, these patent rights relate to various aspects of our AOC product candidates and technology platform. In addition, we have an exclusive option to an exclusive license to certain patent rights from the
University of Alberta. In addition to filing and prosecuting patent applications in the United States, we often file counterpart patent applications in additional countries where we believe such foreign filing is likely to be beneficial, including
Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, and South Korea. We also file patent applications pursuant to the Patent Cooperation Treaty (PCT). Our PCT patent applications are in the first phase of the PCT process,
which is the international phase, in which patent protection is pending under a single patent application filed with the United States Patent and Trademark Office (USPTO) as a contracting state of the PCT. These PCT patent applications have not yet
entered the second phase of the PCT process, which is the national and regional phase, in which rights are continued by filing necessary documents with the patent offices of separate contracting states of the PCT.&nbsp;The national phase of the PCT
patent application process occurs 30 months after the earliest priority date of the PCT patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We continually assess and refine our
intellectual property strategy as we develop new product candidates and platform technologies. To that end, we are prepared to file additional patent applications in any appropriate fields if our intellectual property strategy requires such filings,
or where we seek to adapt to competition or seize business opportunities. Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may
own or license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. Please see &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property&#148; for additional information on the risks associated with our intellectual property strategy and portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual Property Relating to
AOC 1001 </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With regard to AOC 1001, as of April&nbsp;30, 2020, we owned two pending U.S. patent applications and one pending patent
application filed pursuant to the Patent Cooperation Treaty (PCT). These patent rights relate to AOC 1001 composition of matter, formulations containing AOC 1001, methods of manufacturing, and methods of treating diseases, using AOC 1001. Any
patents issued from these applications are expected to expire in 2038-2041, however, a patent term extension may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual Property Relating
to Our DMD AOC Product Candidates </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With regard to our DMD AOC product candidates, as of April&nbsp;30, 2020, we owned three pending U.S.
patent applications and 19 pending patent applications in various countries and regions including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Singapore, and South Korea. These patent rights relate to the DMD AOCs composition of matter, formulations containing the DMD
AOCs, methods of manufacturing, and methods of treating diseases, using our DMD AOCs. Any patents issued from these applications are expected to expire in 2038; however, a patent term extension may be available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual Property Relating to Our Muscle Atrophy AOC Product Candidate </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With regard to our muscle atrophy AOC product candidate, as of April&nbsp;30, 2020 we owned one pending U.S. patent application and one pending PCT
patent application. These patent rights relate to the muscle atrophy AOC composition of matter, formulations containing the muscle atrophy AOC, methods of manufacturing, and methods of treating diseases, using our muscle atrophy AOC. Any patents
issued from these applications are expected to expire in 2038; however, a patent term extension may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual Property Relating to Our FSHD
AOC Product Candidate </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With regard to our FSHD AOC product candidate, as of April&nbsp;30, 2020 we owned one pending U.S. patent application.
These patent rights relate to the FSHD AOC composition of matter, formulations containing the FSHD AOC, methods of manufacturing, and methods of treating diseases, using our FSHD AOC. Any patents issued from these applications are expected to expire
in 2041; however, a patent term extension may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Intellectual Property Relating to Our AOC Product Platform </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of April&nbsp;30, 2020, we owned 14 families of U.S. and foreign patents and patent applications generally covering our AOC product platform. These
families include two issued U.S. patents, 14&nbsp;pending U.S. patent applications, four PCT patent applications and 23 foreign patent applications in the European Patent Office, Australia, Canada, China, Israel, Hong Kong, Japan, South Korea,
Mexico, Singapore, and Taiwan, relating to key aspects and components of our AOC product platform systems. Our patent applications contain claims covering (i)&nbsp;proprietary antibodies; (ii)&nbsp;proprietary oligonucleotide chemical structures;
(iii)&nbsp;proprietary oligonucleotide sequences; (iv)&nbsp;proprietary AOC structures; and (v)&nbsp;methods for manufacturing and using our AOC technologies. Some of these AOC platform cases generically cover our various product candidates. The
issued U.S. patents and any U.S. patents issuing from our pending U.S. patent applications are expected to expire between 2037 and 2040. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The term
of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20&nbsp;years from the earliest date of filing of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that
are caused by the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent. In
the future, if and when our biopharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. We intend to seek patent term extensions to any of our issued patents
in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length
of such extensions. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2038 to 2041, unless we receive patent term extension or patent term adjustment, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">However, the actual protection afforded by a patent varies on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors,
including the type of patent, the scope of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the
scope of claims allowable in patents in the field of oligonucleotide therapy has emerged in the United States. The patent situation outside of the United States is even more uncertain. Changes in the patent laws and rules, either by legislation,
judicial decisions, or regulatory interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual
property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in
obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of
our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in
protecting our platform and product candidates and the methods used to manufacture them. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the
commercialization of our platform&#146;s product candidates. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be
used to prevent us from commercializing our AOC product platform and product candidates and practicing our proprietary technology. Our issued patents and those that may issue in the future may be challenged, narrowed, circumvented or invalidated,
which could limit our ability to stop competitors from marketing related platforms or product candidates or limit the length of the term of patent protection that we may have for our AOC product platform and product candidates. In addition, the
rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these reasons, we may
have competition for our AOC product platform and product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any product candidate can be
commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. For this and other risks related to our proprietary technology, inventions,
improvements, platforms and product candidates, please see the section entitled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to file applications for trademark registrations in connection with our product candidates in various jurisdictions, including the United
States. We have filed for trademark protection of the Avidity Biosciences mark with the United States Patent and Trademark Office and foreign patent and trademark organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential and
proprietary information as trade secrets, including through contractual means with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, third parties may independently develop substantially
equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants,
outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements under the commencement of employment or consulting relationships with us. These agreements provide that all confidential information
concerning our business or financial affairs developed or made known to the individual during the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and
development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific
collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use
such inventions. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain
adequate remedies for such breaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by
maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached,
and we may not have adequate remedies for any breach. To the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in
relation to the resulting <FONT STYLE="white-space:nowrap">know-how</FONT> or inventions. For more information, please see the section entitled &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research Collaboration and License Agreement with Lilly </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, we entered into the Lilly Agreement with Lilly for the discovery, development and commercialization of antibody-oligonucleotide conjugate
products (Products) in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the parties will collaborate on preclinical research and discovery activities for Products and Lilly will be responsible for funding the
cost of preclinical research and discovery activities of both parties for all Products. Lilly will lead the clinical development, regulatory approval and commercialization of all Products, at Lilly&#146;s sole cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Lilly Agreement, we granted Lilly an exclusive, worldwide, royalty-bearing license under our technology to research, develop, manufacture, and
sell Products directed to up to six mRNA targets. Lilly has the right to sublicense its rights under the Lilly Agreement subject to certain conditions. Lilly granted us a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under certain
Lilly technology solely to conduct research under the Lilly Agreement. We retain the right to use our technology to perform our obligations under the Lilly Agreement and for all purposes not granted to Lilly. We agreed that we will not, ourselves or
with a third party, research, develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Lilly paid us an upfront license fee of $20.0&nbsp;million, and we are eligible to receive up to $60.0&nbsp;million in development milestone payments,
up to $140.0&nbsp;million in regulatory milestone payments and up to $205.0&nbsp;million in commercialization milestone payments per target. In addition, Lilly is obligated to pay us a tiered royalty ranging from the
<FONT STYLE="white-space:nowrap">mid-single</FONT> to <FONT STYLE="white-space:nowrap">low-double</FONT> digits on worldwide annual net sales of licensed Products, subject to specified and capped reductions for the market entry of biosimilar
products, loss of patent coverage of licensed Products and for payments owed to third parties for additional rights necessary to commercialize licensed Products in the territory. Lilly&#146;s royalty obligations and the Lilly Agreement will expire
on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the later of
ten years from the date of the first commercial sale or when there is no longer a valid patent claim covering such licensed Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Lilly Agreement may be terminated either by us or Lilly in the event of an uncured material breach by the other party. Lilly may terminate the Lilly
Agreement on a <FONT STYLE="white-space:nowrap">target-by-target</FONT> basis or in its entirety without cause, subject to certain limitations, including that Lilly may not terminate the Lilly Agreement on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis within the first three years of the effective date of the Lilly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Agreement if doing so would reduce the number of Products subject to the collaboration to fewer than a certain number. In the event either party commences a legal action challenging the validity
or enforceability of any licensed patents, the other party will have the right to terminate the Lilly Agreement with respect to the challenged patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Lilly Agreement includes various representations, warranties, covenants, dispute resolution mechanisms, indemnities and other provisions customary
for transactions of this nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrently with the Lilly Agreement, we issued a convertible promissory note to Lilly (the Lilly Note), and
received cash proceeds of $15.0&nbsp;million. The Lilly Note accrued simple interest of 8.0% per annum and converted into shares of our Series&nbsp;C convertible preferred stock in November 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Government authorities in the United
States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion,
advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application (NDA) process before it may be legally marketed in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe our AOC product candidates may be subject to regulation in the United States as combination products. If marketed individually, each
component of our product candidates would be subject to different regulatory pathways and would require approval of independent marketing applications by the FDA. A combination product, however, is assigned to an FDA center that will have primary
jurisdiction over its regulation based on a determination of the combination product&#146;s primary mode of action, which is the single mode of action that provides the most important therapeutic effect. In the case of our AOC product candidates, we
believe that the primary mode of action is attributable to the drug component of the product. Accordingly, we believe the FDA&#146;s Center for Drug Evaluation and Research (CDER), will have primary jurisdiction over premarket development of our
product candidates. We expect to seek approval of AOC 1001 and each of our other AOC product candidates through submission of a single NDA reviewed by CDER, and we do not expect that the FDA will require a separate marketing authorization for each
constituent of AOC 1001 or our other AOC product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (the FDCA) and its implementing regulations. The process of
obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#146;s refusal to approve pending
applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement
or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process required by the
FDA before a drug may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory
Practice (GLP) regulations and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice (GCP)
requirements to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">submission to the FDA of an NDA after completion of all pivotal trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to
assess compliance with current GMP (cGMP) requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity, and of selected clinical investigation sites to assess
compliance with GCP; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the
United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage.
Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data,
to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase
of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted.
An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the clinical
trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety
concerns about ongoing or proposed clinical trials or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.
Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration of
the investigational product to human subjects under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for
their participation in any clinical trial. They must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be
evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at
each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to
each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Human clinical
trials are typically conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Phase 1</I></B>:&nbsp;&nbsp;The product candidate is initially introduced into healthy human volunteers and tested
for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially
when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Phase 2</I></B>:&nbsp;&nbsp;The product candidate is administered to a limited patient population with a specified
disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. Multiple Phase 2 trials may be
conducted to obtain information prior to beginning larger and more expensive Phase 3 trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B><I>Phase 3</I></B>:&nbsp;&nbsp;The product candidate is administered to an expanded patient population to further
evaluate dosage, to provide statistically significant evidence of clinical efficacy, and to further test for safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to
establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product approval and labeling. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain
additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being
exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been
associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its
charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission
of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide
advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical
trials that they believe will support approval of the new drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal
studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the
last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a
significant risk to humans exposed to the same or similar drugs, findings from animal or <I>in vitro </I>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction
compared to that listed in the protocol or investigator brochure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are also requirements governing the reporting of ongoing clinical trials and completed trial
results to public registries. Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose specified clinical trial information, which is publicly available at
www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also
obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>NDA Review and Approval Process </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Assuming successful
completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, along with
descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission
of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also
includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA reviews an NDA to determine, among other things, whether a
product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (PDUFA) guidelines that are
currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted
to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for
filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The
resubmitted application also is subject to review before the FDA accepts it for filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may refer an application for a novel drug to an
advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are
not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application
does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response
Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be
approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response
Letter is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the
criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the
indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#146;s
safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement
for a risk evaluation and mitigation strategy (REMS) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if
required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or
marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or if problems occur
following initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the Pediatric Research Equity Act (PREA) requires a sponsor to conduct pediatric clinical trials for most
drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or
waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the
product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for
approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a
<FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A sponsor
may seek approval of its product candidate under programs designed to expedite FDA&#146;s review and approval of new drugs and biological products that meet certain criteria. The FDA has a fast track designation program that is intended to expedite
or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate
the potential to address unmet medical needs for the disease or condition. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor
provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the
NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it treats a serious condition and, if approved, would provide a significant improvement in safety or
effectiveness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to
review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may
be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a
condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication
approved under accelerated approval on an expedited basis if, for example, the sponsor fails to conduct the required confirmatory trial or if such confirmatory trial fails to verify the predicted clinical benefit of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#147;breakthrough therapies&#148; that may be
eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to treat a
serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. If the FDA designates a product as breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the
sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical
and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA
review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may
result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. The breakthrough therapy designation also includes all of the fast
track program features, which means that the sponsor may file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the
application and the payment of applicable user fees before the FDA may initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if
relevant criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval
but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA
review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their
establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and
our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and
quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA may withdraw approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or
with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or
imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical holds on clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing
warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims
relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may
prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by the manufacturer and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common
across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s
communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Orphan Drug Designation and Exclusivity
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease
or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in
the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and
its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. However, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same
product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our product candidates for seven years if a competitor obtains approval of the same drug as defined by
the FDA or if our product candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. In addition, if an orphan designated product receives marketing approval for an indication broader than what
is designated, it may not be entitled to orphan exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year
period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously
approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug
application (ANDA) or an NDA submitted under Section&nbsp;505(b)(2)(505(b)(2) NDA) submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original
innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent
invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA
to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical
investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is
another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in
response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of
marketing exclusivity, except in certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to FDA regulation of pharmaceutical products, U.S. federal and state healthcare laws and regulations restrict business practices in the
pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the business or financial arrangements and relationships with healthcare
providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, and physician payment transparency laws. In addition to the federal laws summarized below, we may also be subject to similar state
and local laws and regulations that may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT
STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The federal
Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return
for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual
knowledge of this statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The federal civil and criminal false claims
laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government,
knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money
to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims
Act and the civil monetary penalties statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created additional
federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up
a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does
not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is
available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the Centers for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Medicare&nbsp;&amp; Medicaid Services (CMS) information related to payments or other transfers of value made during the previous year to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors), certain other health care providers beginning in 2022, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and
investment interests held during the previous year by such health care providers as defined under statute and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false
claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by
<FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require
drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that
require the registration of pharmaceutical sales representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Violation of any of such laws or any other governmental regulations that apply
may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement
to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare
programs and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in
the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as
well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors. For products administered under
the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the
reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the extent of coverage and amount of
reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit sales of any product that receives approval. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to
secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party
reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>U.S. Healthcare Reform </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, there
has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and
affect the profitable sale of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Among policy makers and payors in the United States, there is significant interest in promoting
changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly
affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) was passed, which substantially changed the way
healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%;
required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered
under Medicare Part D; imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified federal government programs,
implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs;
creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS
to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There remain judicial and political challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act of 2017 (Tax Act) includes a
provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a
year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and
inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District
Court&#146;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&nbsp;2, 2020, the United States Supreme
Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to occur in the fall. It is unclear how such litigation, and other efforts to repeal and replace the ACA will impact the ACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare
payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2029 unless additional
Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law on March&nbsp;27, 2020 and will suspend these Medicare sequester reductions from May&nbsp;1, 2020 through December&nbsp;31, 2020
due to the COVID-19 pandemic. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, there has recently been heightened
governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, the current U.S.
administration&#146;s budget proposal for the fiscal year 2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part
D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. The Trump Administration previously released a &#147;Blueprint&#148; to
lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of
their products and reduce the out of pocket costs of pharmaceutical products paid by consumers. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each
indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there
has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Foreign Regulation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to market any product
outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing
authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical
trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union (EU) the approval process varies between
countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory
approval in one country or jurisdiction may negatively impact the regulatory process in others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To market a medicinal product in the European
Economic Area (EEA) (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization (MA). There are two types of marketing authorizations: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the
Committee for Medicinal Products for Human Use of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal
products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes,
<FONT STYLE="white-space:nowrap">auto-immune</FONT> and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
scientific or technical innovation or which are in the interest of public health in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective
territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member
State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the
EEA make an assessment of the <FONT STYLE="white-space:nowrap">risk-benefit</FONT> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Data and marketing exclusivity </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the EEA, new products
authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years
from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&nbsp;years have elapsed from the
initial authorization of the reference product in the EU. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&nbsp;years, the
marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pediatric investigation plan </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the EEA,
marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan (PIP) agreed with the EMA&#146;s Pediatric
Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some
or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is
likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for
pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product is eligible for six months&#146; supplementary protection
certificate extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical trials </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Clinical trials
of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization (ICH) guidelines on GCPs. Additional GCP guidelines from the European
Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European
Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#145;no fault&#146; compensation to any study subject injured in the clinical trial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion
from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and
quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new Regulation on
Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only a limited
involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical
trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Data Privacy and Security
Laws </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to laws and regulations governing data privacy and the protection of health-related and other personal information. In
the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, impose certain requirements relating to the privacy, security and transmission of protected health
information on HIPAA covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates who conduct certain activities for or on their behalf involving protected health
information. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have
the same effect, thus complicating compliance efforts. For example, the California Consumer Privacy Act (CCPA), which went into effect on January&nbsp;1, 2020, gives California residents expanded rights to access and delete their personal
information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches
that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">EU member states and other
jurisdictions have also adopted data protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
broadly to the collection, use, storage, disclosure, processing and security of personal information that identifies or may be used to identify an individual, such as names, contact information,
and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations, and have generally become more stringent over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of May&nbsp;25, 2018, Regulation 2016/676, known as the General Data Protection Regulation (GDPR) replaced the Data Protection Directive with respect
to the processing of personal data in the European Union. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal
data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health
data and pseudonymised (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data and additional obligations when we contract third-party processors in connection with the processing of the personal data. The GDPR allows EU member states to make
additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up
to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Additionally, following the United
Kingdom&#146;s withdrawal from the European Union, we will have to comply with the GDPR and the United Kingdom GDPR, each regime having the ability to fine up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20 million/
&pound;17.5&nbsp;million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred
between each jurisdiction, which exposes us to further compliance risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The challenges we could face under the GDPR may also apply to other
jurisdictions outside the EU that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity. For example, the CCPA has been characterized as the first &#147;GDPR-like&#148; privacy statute to be enacted in the
United States because it mirrors a number of the key provisions in the GDPR. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of April&nbsp;30, 2020, we had 36 full-time
employees, 18 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently occupy approximately 8,561 square
feet of office and laboratory space in La Jolla, California, under a lease that expires in 2021. We also have a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> sublease for an additional 450 square feet
within the same building. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are in the process of negotiating a new lease to replace our current space for additional office and laboratory space
with an expected occupancy in 2021. We believe that this new facility will meet our current and near-term needs and that suitable additional space will be available as and when needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we may be involved in
legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can
have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets
forth the name, age and position of each of our executive officers and directors as of April&nbsp;30, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">President and Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Joseph Baroldi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Operating Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arthur A. Levin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Scientific Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Troy Wilson, Ph.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Carsten Boess<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Todd Brady<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Noreen Henig, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Edward Kaye, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Michael Martin, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Roderick Wong, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the compensation committee </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Member of the nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Sarah Boyce</I>
has served as our President and Chief Executive Officer and as a member of our board of directors since October 2019. Prior to joining Avidity, she served as President and a member of the board of directors of Akcea Therapeutics, Inc. from April
2018 through September 2019, where she led the commercialization of the company&#146;s rare disease products. Ms.&nbsp;Boyce served as Chief Business Officer of Ionis Pharmaceuticals, Inc. from January 2015 to April 2018, and Vice President, Head of
International Business Strategy and Operations at Forest Laboratories, Inc. from 2012 to 2014. She previously held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG, Bayer AG and
<FONT STYLE="white-space:nowrap">F.&nbsp;Hoffmann-La&nbsp;Roche</FONT> AG. Ms.&nbsp;Boyce currently serves on the board of directors of Ligand Pharmaceuticals Incorporated. Ms.&nbsp;Boyce holds a B.S. in Microbiology from the University of
Manchester, England. Ms.&nbsp;Boyce&#146;s knowledge of our business, as well as her extensive development, commercial and executive management experience, contributed to our board of directors&#146; conclusion that she should serve as a director of
our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Joseph Baroldi</I> has served as our Chief Operating Officer since February 2020. Mr.&nbsp;Baroldi has over twenty years of
experience in the life sciences industry. Most recently, Mr.&nbsp;Baroldi was Vice President of Business Development at Ionis Pharmaceuticals, Inc. from February 2009 to January 2020, where he held several roles of increasing responsibility over the
last decade. Previously, Mr.&nbsp;Baroldi held several roles in strategic planning and scientific research at Hologic, Inc. (formerly <FONT STYLE="white-space:nowrap">Gen-Probe</FONT> Inc.) from April 2005 to January 2009. Mr.&nbsp;Baroldi holds an
M.B.A. from the Rady School of Management at the University of California, San Diego and a B.S. in Biological Sciences from the University of California, Irvine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Arthur A. Levin, Ph.D.</I>, has served as our Chief Scientific Officer since October 2019, and prior to that as our Executive Vice President of
Research and Development since January 2014. Dr.&nbsp;Levin has a combined three decades of experience in all aspects of drug development from discovery through drug registration and has played key roles in the development of numerous
oligonucleotides. From April 2012 to January 2014, he served as Executive Vice President at miRagen Therapeutics, Inc. Prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to that, Dr.&nbsp;Levin held various senior management positions at Santaris Pharma A/S Corp. and Ionis Pharmaceuticals, Inc. Since September 2015, Dr.&nbsp;Levin has served as a member of the
board of directors of Stoke Therapeutics, Inc. Dr.&nbsp;Levin holds a Ph.D. in Toxicology from the University of Rochester and a B.S. in Biology from Muhlenberg College. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Troy Wilson, Ph.D., J.D.</I>,&nbsp;is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as a member of our board of directors
since November 2012 and as Chairman since February 2019. Dr.&nbsp;Wilson served as our President and Chief Executive Officer from November 2012 to February 2019. He has been President and Chief Executive Officer and a member of the board of
directors of Kura Oncology, Inc. since August 2014 and has served as a member of the board of directors of Puma Biotechnology, Inc. since October 2013. He has also served as Executive Chairman of the board of directors of Wellspring Biosciences,
Inc., a privately-held biopharmaceutical company, since July 2012, and has served as the sole managing member of Wellspring Biosciences&#146; parent company, Araxes Pharma LLC, since May 2012. Previously, Dr.&nbsp;Wilson served as a director of
Zosano Pharma Corporation from June 2014 to October 2019. He also served as President and Chief Executive Officer of Wellspring Biosciences and Araxes Pharma from July 2012 to March 2019, and as President and Chief Executive Officer and a member of
the board of directors of Intellikine, Inc. Dr.&nbsp;Wilson holds a J.D. from New York University and a Ph.D. in Bioorganic Chemistry and a B.A. in Biophysics from the University of California, Berkeley. Dr.&nbsp;Wilson&#146;s knowledge of our
business and his senior executive and board-level experience at biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as Chairman of our company.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Carsten Boess</I> has served on our board of directors since April 2020. Mr.&nbsp;Boess has also served on the board of directors of Rocket
Pharmaceuticals, Inc. since January 2016. Previously, Mr.&nbsp;Boess was the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, Ltd. from August 2015 until February 2020. Before Kiniksa, Mr.&nbsp;Boess was the Chief Financial
Officer at Alexion Pharmaceuticals from 2004 to 2005 and the Senior Vice President and Chief Financial Officer at Synageva BioPharma Corp. from 2011 until the company&#146;s acquisition by Alexion Pharmaceuticals in 2015. Previously, Mr.&nbsp;Boess
served in multiple roles with increasing responsibility at Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice
President of Finance at Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva-based World Wide Executive Finance Management Team while at Serono. Mr.&nbsp;Boess also held several financial executive roles at Novozymes of North
America and Novo Nordisk in France, Switzerland and China. During his tenure at Novo Nordisk, he served on Novo Nordisk&#146;s Global Finance Board. Mr.&nbsp;Boess received a Bachelor&#146;s degree and Master&#146;s degree in Economics and Finance,
specializing in Accounting and Finance from the University of Odense, Denmark. Mr.&nbsp;Boess&#146; business, financial and corporate governance experience in the biotechnology industry contributed to our board of directors&#146; conclusion that he
should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Todd</I><I></I><I>&nbsp;Brady</I>&nbsp;has served on our board of directors since December&nbsp;2016.
Mr.&nbsp;Brady&nbsp;has served as the Director of Finance and Investments at Brace Pharma Capital, Inc., a healthcare-focused investment firm, since April 2014. He also serves as a director for Vero Biotech, LLC, Pipeline Therapeutics, Inc., and
Tyrogenex, Inc., and formerly served as a director for Cocrystal Pharma, Inc. and as a board observer for Precision Biosciences Inc. and miRagen Therapeutics, Inc. Mr.&nbsp;Brady&nbsp;has an extensive and diverse background in capital markets,
working in equity research, asset management, private equity and corporate banking. He holds an M.B.A. from the Schulich School of Business (York University) and is a Chartered Financial Analyst (CFA). Mr.&nbsp;Brady&#146;s extensive financial
experience and service as a director of other biotechnology companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Noreen Henig, M.D.</I>, has served on our board of directors since August 2019. Since May 2020,
Dr.&nbsp;Henig has served as the Chief Medical Officer of Kezar Life Sciences, Inc. Previously, from July 2018 to March 2020, Dr.&nbsp;Henig served as the Chief Medical Officer of Breath Therapeutics GmbH, which is now Zambon SpA following an
acquisition in July 2019. Previously, Dr.&nbsp;Henig served as the Chief Development Officer of ProQR Therapeutics N.V. where she oversaw preclinical and clinical drug development from March 2014 to November 2017. Before joining ProQR,
Dr.&nbsp;Henig was Senior Director, Global Respiratory, from 2011 to 2014, and Director, Respiratory Therapeutics, from 2008 to 2011, at Gilead Sciences, Inc. Dr.&nbsp;Henig&#146;s specialties as a physician include pulmonary, critical care, allergy
and immunology. Dr.&nbsp;Henig holds an M.D. with a distinction in immunology from the Albert Einstein College of Medicine of Yeshiva University and a B.A. from Yale University. She also completed training in internal medicine at the University of
California, San Francisco and in pulmonary and critical care medicine at the University of Washington. Dr.&nbsp;Henig&#146;s drug development and clinical trial experience contributed to our board of directors&#146; conclusion that she should serve
as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Edward M. Kaye, M.D.</I>, has served on our board of directors since August 2019. Dr.&nbsp;Kaye has served as the
Chief Executive Officer and a member of the board of directors of Stoke Therapeutics Inc. since October 2017. Dr.&nbsp;Kaye joined Stoke from Sarepta Therapeutics, Inc. where he served as a member of the board of directors from September 2016 to
August 2017, President and Chief Executive Officer from September 2016 to July 2017, Interim Chief Executive Officer from April 2015 to September 2016 and Chief Medical Officer from June 2011 to March 2017. From 2001 to 2007, Dr.&nbsp;Kaye served in
various positions at Genzyme Corporation, including most recently as Group Vice President of Clinical Development. Previously, Dr.&nbsp;Kaye served as Chief of Biochemical Genetics at Children&#146;s Hospital of Philadelphia, Chief of Neurology at
St. Christopher&#146;s Hospital for Children and as a member of the research staff at Massachusetts General Hospital and Tufts University Medical Center. Dr.&nbsp;Kaye currently serves as a Neurological Consultant at the Children&#146;s Hospital of
Boston. Dr.&nbsp;Kaye is also a member of the board of directors of Cytokinetics, Inc. Dr.&nbsp;Kaye holds an M.D. from the Loyola University Stritch School of Medicine and a B.S. in Biology/Chemistry from Loyola University. Dr.&nbsp;Kaye&#146;s
extensive leadership and clinical experience in the medical and biotechnology fields contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Michael Martin, Ph.D.</I>, has served on our board of directors since December&nbsp;2016 and has been the President of Takeda Ventures, Inc., the
corporate venture arm of Takeda Pharmaceutical Company Limited, since January 2017. He previously served as Senior Investment Director of Takeda Ventures from April 2015 to January 2017. Prior to joining Takeda Ventures, Dr.&nbsp;Martin was a member
of Global Licensing and Business Development at Takeda Pharmaceutical Company Limited from October 2012 to April 2015, where he led efforts for sourcing and transacting technologies and early stage pipeline programs. He has also held executive and
scientific roles with Intellikine Inc. (acquired by Takeda), TargeGen, Inc. (acquired by Sanofi-Aventis), Arena Pharmaceuticals, Inc. and Monsanto Corporation. Dr.&nbsp;Martin holds a Ph.D. in Medicinal Chemistry from University of Illinois, a M.S.
in Analytical Chemistry from Saint Louis University and B.S. degrees in Chemistry and Mathematics from Saint Louis University. Dr.&nbsp;Martin&#146;s extensive biotechnology investment and industry experience contributed to our board of
directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Roderick Wong, M.D.</I>, has served on our board of directors
since November&nbsp;2019. Dr.&nbsp;Wong has over fifteen years of healthcare investment experience. Since 2010, he has served as Managing Partner and Chief Investment Officer of RTW Investments, LP, a healthcare-centered investment firm. Prior to
RTW Investments, Dr.&nbsp;Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Previously, Dr.&nbsp;Wong held various healthcare investment and healthcare research roles at SAC Capital Advisors and
Cowen&nbsp;&amp; Company. Since July 2015, Dr.&nbsp;Wong has served as Chairman of the board of directors of Rocket Pharmaceuticals, Inc. Dr.&nbsp;Wong also previously served on the board of directors of Penwest Pharmaceuticals Co. He holds an M.D.
from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
University of Pennsylvania Medical School, an M.B.A. from Harvard Business School and a B.S. in Economics from Duke University. Dr.&nbsp;Wong&#146;s years of experience investing in the
biopharmaceutical industry contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and
Election of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors currently consists of eight members. Our board of directors has determined that all of our directors, other than Ms.&nbsp;Boyce
and Dr.&nbsp;Wilson, are independent directors in accordance with the listing requirements of the Nasdaq Global Market (Nasdaq). Nasdaq&#146;s independence definition includes a series of objective tests, including that the director is not, and has
not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors
has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the
director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and
our management. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately prior to the closing of this
offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until the third annual meeting
following reelection. Effective upon the closing of this offering, our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;I directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual meeting of stockholders following this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;II directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the Class&nbsp;III directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our third annual meeting of stockholders following this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation that will go into effect immediately prior to the closing of this offering will provide that the
authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as
possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our board of
directors or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock then entitled to vote
in an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors is currently led by our Chairman, Dr.&nbsp;Wilson. Our board of directors recognizes that it is important to determine an optimal
board leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of chief executive officer and chairman of the board of directors in recognition of the differences between
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over
meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to managing the board of directors and overseeing our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has concluded that our current leadership structure is appropriate at this time. However, our board of directors will continue to
periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through its committees, regularly
discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior management to
enable our board of directors to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit
committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with management
regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation policies or programs has the potential to
encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board of directors, corporate disclosure practices and potential conflicts of interest. While each committee is
responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by our board
of directors as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This
committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent
registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical
accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit and the
review of our quarterly unaudited financial statements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory
requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board of directors any
changes to such investment policy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results
of operations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and
ethics; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of
the audit committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The members of our audit committee are Mr. Boess, Mr. Brady and Dr. Martin. Mr. Boess
serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Mr. Boess is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has determined each of Mr. Boess, Mr.
Brady and Dr. Martin is independent under the applicable rules of the SEC and Nasdaq. Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and
Nasdaq. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee approves
corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these
officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the performance of the
compensation committee and its members, including compliance by the compensation committee with its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The members of our compensation
committee are Dr. Kaye, Dr. Henig and Dr. Martin. Dr.&nbsp;Kaye serves as the chairperson of the committee. Our board of directors has determined that each of Dr.&nbsp;Kaye, Dr. Henig and Dr. Martin is independent under the applicable Nasdaq listing
standards, is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the
compensation committee will operate under a written charter, which the compensation committee will review and evaluate at least annually. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board of directors&#146;
responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to
be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies,
reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The members of our nominating and corporate governance committee are Dr. Henig, Dr. Kaye and
Dr.&nbsp;Wong. Dr. Henig serves as the chairperson of the committee. Our board of directors has determined that each of Dr. Henig, Dr. Kaye and Dr. Wong is independent under the applicable Nasdaq listing standards.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Upon the listing of our common stock on Nasdaq, the nominating and corporate governance committee will operate under a written charter, which the nominating and corporate governance committee
will review and evaluate at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">None of the members of our compensation committee is currently, or has at any time been, one of our officers or employees. None of our executive officers
currently serves, or has served during the past fiscal year, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of
directors) of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Diversity
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of
directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current
members) for election or appointment, the nominating and corporate governance committee and the board of directors will take into account many factors, including the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personal and professional integrity, ethics and values; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">strong finance experience; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of
residence and specialized experience; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience relevant to our business industry and with relevant social policy concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the board of
directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to adopt a
written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions, which will be effective upon the closing of this offering. Upon the closing of this offering, our code of business conduct and ethics will be available under the Corporate Governance section of our website at www.aviditybiosciences.com.
In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not
constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This section&nbsp;discusses the material components of the executive compensation program for our executive officers who are named in the &#147;Summary
Compensation Table&#148; below, whom we refer to as our NEOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion may contain forward-looking statements that are based on our current
plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ materially from the currently planned programs summarized in
this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our NEOs for services rendered during the year ended December&nbsp;31, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Name and principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:ARIAL; "><B>position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>incentive plan<BR>compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All other<BR>compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,295,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,449,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Troy Wilson, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><I>Former Chief Executive Officer; Chairman</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Arthur A. Levin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">P. Kent Hawryluk<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><I>Former Chief Business Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents the grant date fair value of stock options to purchase shares of our common stock computed in accordance with
Financial Accounting Standards Board (FASB) ASC 718. See Note 8 to our financial statements included elsewhere in this prospectus for a description of the assumptions used in valuing our stock options. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents annual bonuses for 2019 paid in early 2020 under our annual bonus plan, as described below.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes life insurance premiums for all of our NEOs. For Mr.&nbsp;Hawryluk, also includes (i) $380,792 in severance paid
to him in early 2020 pursuant to his release agreement and (ii) $39,430 representing accrued but unused vacation payout. For Dr.&nbsp;Wilson, also includes (a)&nbsp;a $10,175 car allowance, (b) $23,045 representing accrued but unused vacation payout
and (c)&nbsp;and $30,866 paid as a retainer for his service as Chairman following his termination of employment. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Wilson ceased serving as our Chief Executive Officer on October&nbsp;7, 2019, at which time he transitioned to
the role of <FONT STYLE="white-space:nowrap">non-employee</FONT> Chairman. Dr.&nbsp;Wilson&#146;s salary reflects his salary as Chief Executive Officer from January&nbsp;1, 2019 through October&nbsp;6, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Mr.&nbsp;Hawryluk&#146;s employment terminated on December&nbsp;19, 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative Disclosure to Compensation Tables </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The primary
elements of compensation for our NEOs are base salary, annual performance bonuses and equity awards. The NEOs also participate in employee benefit plans and programs that we offer to our other employees, as described below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Annual Base Salary </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We pay our NEOs a
base salary to compensate them for the satisfactory performance of services rendered to us. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and
responsibilities. Base salaries for our NEOs have generally been set at levels deemed necessary to attract and retain individuals with superior talent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;Wilson&#146;s base salary during 2019 was $360,600 for the portion of such year he served as
our Chief Executive Officer. Following his transition to <FONT STYLE="white-space:nowrap">non-employee</FONT> Chairman in October 2019, he received an annual retainer of $132,000 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ms.&nbsp;Boyce&#146;s annual base salary of $440,000 was established in connection with her commencement of employment in October 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dr.&nbsp;Levin&#146;s annual base salary for 2019 was $394,000, which was increased for 2020 to $414,000. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Bonus Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time
our board of directors or compensation committee may approve bonuses for our NEOs based on individual performance, company performance or as otherwise determined appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For 2019, annual bonuses were based on such factors as the board and the compensation committee deemed appropriate, including the achievement of certain
corporate performance goals, and each individual NEO&#146;s performance as it relates to his or her area of responsibility. The annual bonuses paid to our NEOs for 2019 are reflected in the Summary Compensation Table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each NEO has an established target annual bonus amount. The 2020 target annual bonus amounts for each NEO, expressed as a percentage of annual base
salary, are 40% for Ms.&nbsp;Boyce and 30% for Dr.&nbsp;Levin. Dr.&nbsp;Wilson is not eligible for an annual bonus in his capacity as Chairman. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Equity-Based Incentive Awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of our employees and consultants, including our named executive officers. The board of directors is responsible for approving equity
grants. We typically grant equity awards to new hires upon their commencing employment with us. Generally, our equity awards vest over four years, subject to the employee&#146;s continued employment with us on each vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2019, in connection with her commencement of employment, we granted Ms.&nbsp;Boyce an option to purchase 2,525,105 shares of our common stock
under our 2013 Equity Incentive Plan, as amended (the 2013 Plan). Twenty-five percent of the options vest on the first anniversary of her employment commencement date and 1/48th of the options vest monthly thereafter, subject to
Ms.&nbsp;Boyce&#146;s continuous service through each such vesting date. The options were granted at an exercise price of $0.59 per share, which was the fair market value of a share on the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2019, we granted Mr.&nbsp;Hawryluk an option to purchase 50,000 shares of our common stock at an exercise price of $0.25 per share, which was
the fair market value of a share on the grant date. The options were eligible to vest in 24 equal monthly installments following the grant date, subject to his continuous service through each such vesting date. Mr.&nbsp;Hawryluk early exercised
these options for restricted shares subject to the same vesting schedule, which restricted shares were subject to repurchase by us at the original purchase price per share of $0.16 pursuant to the terms of the award agreements. Mr.&nbsp;Hawryluk
held 33,334 restricted shares from such award at the time of his termination in December 2019, which we repurchased from him in February 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with
Our NEOs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Employment Letter Agreement with Ms.&nbsp;Boyce </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into an employment letter agreement with Ms.&nbsp;Boyce on September&nbsp;19, 2019, which governs the terms of her employment with us.
Pursuant to her agreement, Ms.&nbsp;Boyce is entitled to an annual base salary of $440,000 and, commencing in 2020, is eligible to receive an annual performance bonus with a target amount of 40% of her base salary. Ms.&nbsp;Boyce&#146;s employment
is at will. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regardless of the manner in which Ms.&nbsp;Boyce&#146;s employment terminates, she is entitled to
receive amounts previously earned during her employment, including unpaid salary and cash out of unused vacation. In addition, Ms.&nbsp;Boyce is entitled to certain severance benefits under her employment letter agreement, subject to her execution
of a release of claims and compliance with post-termination obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ms.&nbsp;Boyce&#146;s employment letter agreement provides for severance
benefits for certain terminations that arise during and outside a change in control period. Upon a termination without cause or resignation for good reason outside of a change in control period (as such terms are defined below), Ms.&nbsp;Boyce is
entitled to: (i)&nbsp;continuation of her base salary for 12 months (such applicable period, the severance period), and (ii)&nbsp;payment of the COBRA premiums for her and her eligible dependents until the earliest of (a)&nbsp;the end the severance
period, (b)&nbsp;expiration of her eligibility for continuation coverage under COBRA, or (c)&nbsp;the date she becomes eligible for health insurance coverage in connection with her new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon a termination without cause or resignation for good reason within 30 days prior to or 12 months after a change in control (such period, the change
in control period), Ms.&nbsp;Boyce is entitled to all of the same severance benefits described above and accelerated vesting of the unvested portion of her <FONT STYLE="white-space:nowrap">sign-on</FONT> option grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For purposes of Ms.&nbsp;Boyce&#146;s employment letter agreement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;cause&#148; means (i)&nbsp;executive&#146;s willful failure substantially to perform executive&#146;s duties and
responsibilities to us or deliberate violation of our policy; (ii)&nbsp;executive&#146;s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury
to us; (iii)&nbsp;executive&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of ours or any other party to whom executive owes an obligation of nondisclosure as a result of executive&#146;s relationship with us;
or (iv)&nbsp;executive&#146;s willful breach of any of executive&#146;s obligations under any written agreement or covenant with us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;change in control&#148; has the same meaning given to &#147;company transaction&#148; in our 2013 Plan, as described
below; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;good reason&#148; means executive&#146;s resignation form employment with us if we take any of the following actions
without executive&#146;s prior written consent: (i)&nbsp;a material reduction in executive&#146;s base salary, unless pursuant to a salary reduction program applicable generally to our similarly situated employees; (ii)&nbsp;a material reduction in
executive&#146;s duties, including responsibilities and/or authorities, provided that it shall not constitute good reason if such reduction is a mere change of title alone or change in reporting relationship; (iii)&nbsp;relocation of
executive&#146;s principal place of employment to a place that increases executive&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than 50 miles as compared to executive&#146;s then-current principal place of employment
immediately prior to such relocation; or (iv)&nbsp;any other action or inaction that constitutes a material breach by us of this Agreement or any agreement under which executive provides services. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Chairman Agreement with Dr. Wilson </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
connection with his transition from Chief Executive Officer to Chairman in October 2019, we entered into a letter agreement with Dr.&nbsp;Wilson. Pursuant to his letter agreement, Dr.&nbsp;Wilson will receive an annual retainer of $132,000. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Executive Employment Agreement with Dr.&nbsp;Levin </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2013, we entered into an employment agreement with Dr.&nbsp;Levin setting forth the terms of his employment. Dr.&nbsp;Levin serves as our
Chief Scientific Officer. He receives an annual base salary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of $394,000. Dr.&nbsp;Levin is eligible to receive an annual bonus with a target amount equal to 30% of his then-current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regardless of the manner in which his service terminates, Dr.&nbsp;Levin is entitled to receive amounts previously earned during his term of service,
including unpaid salary and cash out of unused vacation. In addition, Dr.&nbsp;Levin is entitled to certain severance benefits under his employment agreement, subject to his execution of a release of claims and compliance with post-termination
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to his employment agreement, upon a termination without cause or resignation for good reason not in connection with a company
transaction (as such term is defined in his employment agreement), Dr.&nbsp;Levin is entitled to payment equal to 12 months (such applicable period, the &#147;severance period&#148;) of his then-current base salary, payable in a lump sum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, Dr.&nbsp;Levin&#146;s employment agreement provides for severance benefits for certain terminations that arise in connection with a company
transaction. Upon a termination without cause or resignation for good reason in connection with a company transaction, Dr.&nbsp;Levin is entitled to: (i)&nbsp;payment equal to 12 months of his then-current base salary, payable in a lump sum,
(ii)&nbsp;payment equal to his full target annual bonus for the year in which the company transaction occurs, payable in a lump sum, (iii)&nbsp;payment of the COBRA premiums for him and his eligible dependents until the earliest of (a)&nbsp;the end
of the severance period, (b)&nbsp;expiration of the executive&#146;s eligibility for continuation coverage under COBRA, or (c)&nbsp;the date the executive becomes eligible for health insurance coverage in connection with the executive&#146;s new
employment, and (iv)&nbsp;all accelerated vesting of any unvested and outstanding equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For purposes of Dr.&nbsp;Levin&#146;s employment
agreement, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;cause&#148; means executive has (i)&nbsp;been convicted of or pled guilty or nolo contendere to a felony or any crime
involving moral turpitude or dishonesty; (ii)&nbsp;participated in a fraud or act of dishonesty against us; (iii)&nbsp;materially breached any agreement between such executive and us or any written policy of ours; (iv)&nbsp;engaged in conduct that
demonstrates gross unfitness to serve; or (v)&nbsp;engaged in willful misconduct or (vi)&nbsp;refused to comply with any lawful directive of ours and, with respect to clauses (iii)&nbsp;and (vi), executive has not cured such noncompliance or breach
within 30 days of receipt of our written notice of such noncompliance or breach; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;good reason&#148; means executive&#146;s resignation from employment with us if we take any of the following actions
without executive&#146;s prior written consent: (i)&nbsp;a material reduction in executive&#146;s base salary, unless pursuant to a salary reduction program applicable generally to our similarly situated employees; (ii)&nbsp;a material reduction in
executive&#146;s duties, including responsibilities and/or authorities; (iii)&nbsp;a material reduction in the authority, duties, or responsibilities of the supervisor to whom executive is required to report, including a requirement that executive
report to an officer or employee instead of reporting directly to the board of directors or similar governing body; (iv)&nbsp;relocation of executive&#146;s principal place of employment to a place that increases executive&#146;s <FONT
STYLE="white-space:nowrap">one-way</FONT> commute by more than 50 miles as compared to executive&#146;s then-current principal place of employment immediately prior to such relocation; or (v)&nbsp;any other action or inaction that constitutes a
material breach by us of this Agreement or any agreement under which executive provides services. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Release Agreement with
Mr.&nbsp;Hawryluk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On December&nbsp;19, 2019, P. Kent Hawryluk&#146;s employment as our Chief Business Officer terminated. In connection with
his separation, we entered into a release agreement with Mr.&nbsp;Hawryluk, pursuant to which we agreed to pay him the following severance benefits: (i)&nbsp;cash severance in the amount of $292,917, payable in a lump sum following the effectiveness
of his release; (ii)&nbsp;his annual bonus for 2019 in the amount of $87,875, payable in a lump sum following the effectiveness of his release; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
(iii)&nbsp;continued health insurance coverage at Company&#146;s expense for 12 months following his termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to outstanding equity awards for each of our NEOs as of December&nbsp;31, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of</B><br><B>Shares</B><br><B>or</B><br><B>Units of<BR>Stock<BR>That</B><br><B>Have</B><br><B>Not<BR>Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares<BR>or<BR>Units&nbsp;
of<BR>Stock<BR>That<BR>Have<BR>Not<BR>Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,525,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Troy Wilson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,667</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arthur Levin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/29/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/28/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">P. Kent Hawryluk</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/29/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,625</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,334</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Stock option award granted to Ms.&nbsp;Boyce vests as to 25% of such grant on the one year anniversary of the vesting
commencement date (October 7, 2019) and monthly thereafter in equal installments until fully vested at the fourth anniversary of the vesting commencement date, subject to accelerated vesting in certain circumstances as described above under
&#147;Employment Letter Agreements with our NEOs.&#148; Stock option award granted to Dr.&nbsp;Levin vests in 48 equal monthly installments following the grant date until fully vested at the fourth anniversary of the grant date, subject to
accelerated vesting in certain circumstances as described above under &#147;Agreements with our NEOs.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Since we have not yet completed our initial public offering, the market value was computed using
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is the midpoint of the price range set forth on the cover page of this prospectus. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents shares of restricted stock issued upon early exercise of a stock option award granted on August&nbsp;29, 2017.
The award vests in 48 equal monthly installments following the vesting commencement date until fully vested at the fourth anniversary of the grant date. Unvested shares are subject to repurchase by us at the original purchase price per share of
$0.25 pursuant to the terms of the award agreements in the event of Dr.&nbsp;Wilson&#146;s termination of service prior to the final vesting date. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents shares of restricted stock issued upon early exercise of a stock option award granted on August&nbsp;29, 2017.
The award was scheduled to vest in accordance with the standard vesting schedule described in footnote (1) above, with a vesting commencement date of August&nbsp;29, 2017. These awards ceased vesting upon Mr.&nbsp;Hawryluk&#146;s termination of
employment on December&nbsp;31, 2019, and were repurchased by us at the original purchase price per share of $0.25 pursuant to the terms of the award agreements in February 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents shares of restricted stock issued upon early exercise of a stock option award granted on March&nbsp;29, 2019.
The award was scheduled to vest in accordance with the standard vesting schedule described in footnote (1) above, with a vesting commencement date of March&nbsp;29, 2019. These awards ceased vesting upon Mr.&nbsp;Hawryluk&#146;s termination of
employment on December&nbsp;19, 2019, and were repurchased by us at the original purchase price per share of $0.16 pursuant to the terms of the award agreements in February 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Elements of Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Perquisites, Health,
Welfare and Retirement Benefits </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our named executive officers are eligible to participate in our employee benefit plans, including our
medical, dental, vision, group life, disability and accidental death and dismemberment insurance plans, in each case on the generally on same basis as all of our other employees. We provide a 401(k) plan to our employees, including our current named
executive officers, as discussed in the section&nbsp;below entitled &#147;401(k) Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We generally do not provide perquisites or personal
benefits to our named executive officers, except in limited circumstances. Our board of directors may elect to adopt qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> benefit plans in the future if it determines that doing so is in
our best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officers are eligible to participate
in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under Section&nbsp;401(k) of the U.S. Internal Revenue Code of 1986, as amended (the
Code). The 401(k) plan provides that each participant may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> deferrals from his or her compensation up to the statutory limit, which is $19,500 for calendar year 2020, and other testing limits.
Participants that are 50 years or older can also make <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> contributions, which in calendar year 2020 may be up to an additional $6,500 above the statutory limit. Although the 401(k) plan
provides for discretionary matching and profit sharing contributions, we currently do not make either type of contribution to the 401(k) plan. Participant contributions are held and invested, pursuant to the participant&#146;s instructions, by the
plan&#146;s trustee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Nonqualified Deferred Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide
our officers and other employees with <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Termination or Change in Control Benefits </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our executive officers may become entitled to certain benefits or enhanced benefits in connection with a qualifying termination and/or a change in
control of our company. Each of our executive officers&#146; employment agreements entitles them to certain benefits, upon a qualifying termination and in connection with a change in control of our company. For additional discussion, please see
&#147;Agreements with Our NEOs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Incentive Award Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2020 Incentive Award Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to
this offering, we intend to adopt and ask our stockholders to approve the 2020 Plan, which would become effective in connection with this offering. Under the 2020 Plan, we may grant cash and equity incentive awards to eligible service providers in
order to attract, motivate and retain the talent for which we compete. The material terms of the 2020 Plan, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and
implementing the 2020 Plan and, accordingly, this summary is subject to change. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Eligibility and Administration </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2020 Plan.
Following our initial public offering, the 2020 Plan will generally be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to
other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under the
2020 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the
administration of, the 2020 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2020 Plan, including any vesting and vesting acceleration conditions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Limitation on Awards and Shares Available </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares initially available for issuance under awards granted pursuant to the 2020 Plan will be the sum of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, plus (ii)&nbsp;any shares subject to outstanding awards under the 2013 Plan as of the effective date of the 2020 Plan that
become available for issuance under the 2020 Plan thereafter in accordance with its terms. The number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
shares initially available for issuance will be increased by an annual increase on January&nbsp;1 of each calendar year beginning in 2021 and ending in 2030, equal to the lesser of (a)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of shares as
determined by our board of directors. No more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock may be issued upon the exercise of incentive stock options under the 2020 Plan.
Shares issued under the 2020 Plan may be authorized but unissued shares, shares purchased in the open market or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an award under
the 2020 Plan or the 2013 Plan expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, any shares subject to such award will, as applicable, become or again be
available for new grants under the 2020 Plan. Awards granted under the 2020 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a
merger or similar corporate transaction will not reduce the shares available for grant under the 2020 Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan provides for the grant of stock options, including incentive stock options (ISOs), and nonqualified stock options (NSOs), restricted stock,
dividend equivalents, restricted stock units (RSUs), stock appreciation rights (SARs), and other stock or cash-based awards. Certain awards under the 2020 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of
the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2020 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable
vesting and payment terms and post-termination exercise limitations. A brief description of each award type follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stock
options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock in the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable
capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. The exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of
grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or
five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally
may be granted only to our employees and employees of our parent or subsidiary corporations, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;SARs
entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market
value of the underlying share on the date of grant (except with respect to certain substitute SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan
administrator may apply to SARs and may include continued service, performance and/or other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Restricted stock and
RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of nontransferable shares of our common stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual
promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our
common stock prior to the delivery of the underlying shares. Delivery of the shares underlying RSUs may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on
continuing service, the attainment of performance goals and/or such other conditions as the plan administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Other stock or
cash-based awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash-based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common
stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash
compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service,
performance and/or other conditions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Performance Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified
performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan administrator may include: net earnings or
losses (either before or after one or more of interest, taxes, depreciation, amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income
(either before or after taxes) or adjusted net income; profits (including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating
earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested
capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per
share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development,
regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction;
recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or
leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms
or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our performance or the performance of a subsidiary, division, business segment or business unit, or based upon performance
relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Provisions of the 2020 Plan Relating to Director Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan provides that the plan administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors from
time to time subject to the 2020 Plan&#146;s limitations. Prior to commencing this offering, our stockholders will approve the initial terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, which is
described below under the heading &#147;Director Compensation.&#148; Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the
exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value (as
determined in accordance with ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
director during any fiscal year may not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, increased to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director. The plan administrator may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the plan
administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such compensation or in other
contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Certain Transactions
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with certain transactions and events affecting our common stock, including a change in control, or change in any applicable
laws or accounting principles, the plan administrator has broad discretion to take action under the 2020 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in
applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of
such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of
shares available, replacing awards with other rights or property or terminating awards under the 2020 Plan. In the event of a change in control where the acquirer does not assume awards granted under the 2020 Plan, awards issued under the 2020 Plan
may be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our
stockholders, or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2020 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Foreign Participants, Claw-back Provisions, Transferability and Participant Payments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of
awards, subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy or in the applicable award agreement. With limited
exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2020 Plan are generally <FONT STYLE="white-space:nowrap">non-transferable</FONT> prior to vesting
and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2020 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2020
Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions, a &#147;market sell order&#148; or such other consideration as it deems suitable or any combination
of the foregoing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Plan Amendment and Termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may amend or terminate the 2020 Plan at any time; however, except in connection with certain changes in our capital structure,
stockholder approval will be required for any amendment that increases the number of shares available under the 2020 Plan. The plan administrator will have the authority, without the approval of our stockholders, to amend any outstanding stock
option or SAR to reduce its price per share. No award may be granted pursuant to the 2020 Plan after the tenth anniversary of the date on which our board of directors adopts the 2020 Plan. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Securities Laws </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan is
intended to conform to all provisions of the Securities Act, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> The 2020
Plan will be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Federal Income Tax Consequences </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
material federal income tax consequences of the 2020 Plan under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to the 2020 Plan. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and
employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stock options and SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2020 Plan participant generally will not recognize taxable income and we generally will not be
entitled to a tax deduction upon the grant of a stock option or SAR. The tax consequences of exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option qualifies as an ISO or an
NSO. Upon exercising an NSO when the fair market value of our stock is higher than the exercise price of the option, a 2020 Plan participant generally will recognize taxable income at ordinary income tax rates equal to the excess of the fair market
value of the stock on the date of exercise over the purchase price, and we (or our subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal to the amount by which the fair market
value of the shares purchased exceeds the purchase price for the shares. Upon a subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference
between the sales price of the shares and the participant&#146;s tax basis in the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon exercising an ISO, a 2020 Plan participant generally
will not recognize taxable income, and we will not be entitled to a tax deduction for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of
adjustment for alternative minimum tax purposes. The participant will recognize taxable income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying
and disqualifying. A qualifying disposition generally occurs if the sale or other disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the
sale or disposition occurs before these two periods are satisfied, then a disqualifying disposition generally will result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon a qualifying
disposition of ISO shares, the participant will recognize long-term capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying
disposition of the shares, then the excess of the fair market value of the shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is
a disqualifying disposition in the same year of exercise, it eliminates the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the
participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes
a disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon exercising or settling an SAR, a 2020 Plan participant will recognize taxable income at ordinary income tax rates, and we should be entitled to a
corresponding tax deduction for compensation expense, in the amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the
subsequent disposition of the shares the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Restricted stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2020 Plan participant generally will not recognize taxable income at ordinary income tax
rates and we generally will not be entitled to a tax deduction upon the grant of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
restricted stock or RSUs. Upon the termination of restrictions on restricted stock or the payment of RSUs, the participant will recognize taxable income at ordinary income tax rates, and we
should be entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for
them. Upon the subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the
shares. However, a 2020 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in Section&nbsp;83 of the Code) may make
an election under Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount
paid, if any, for such shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made, the participant will not recognize
any additional ordinary income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Other stock or cash-based awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2020 Plan participant will not recognize taxable income and we will not be entitled to
a tax deduction upon the grant of other stock or cash-based awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that the participant receives will be taxable to
the participant at ordinary income tax rates and we should be entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the
subsequent disposition of the shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2013 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board
of directors adopted our 2013 Plan in January 2013, and our members approved our 2013 Plan in January 2013. Our 2013 Plan was most recently amended by our board of directors in November 2019 and approved by our stockholders in November 2019. As of
March&nbsp;31, 2020, there were 1,715,553 shares remaining available for the future grant of stock awards under our 2013 Plan. As of March&nbsp;31, 2020, there were outstanding stock options covering a total of 5,091,513&nbsp;shares of our common
stock that were granted under our 2013 Plan. We expect that any shares remaining available for issuance under the 2013 Plan will become available for issuance under the 2020 Plan in connection with this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock Awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our 2013 Plan provides
for the grant of NSOs and restricted stock awards to employees, directors and consultants, including employees and consultants of our affiliates. To date, we have only granted stock options (and restricted stock awards issued upon early exercise of
stock options) under the 2013 Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Authorized Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to certain capitalization adjustments, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2013
Plan will not exceed 10,065,722 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Shares subject to stock awards granted under our 2013 Plan that expire or otherwise terminate without being
exercised in full or that are settled in cash rather than in shares do not reduce or otherwise offset the number of shares available for issuance under our 2013 Plan. Additionally, if any shares issued pursuant to a stock award are forfeited back to
or repurchased because of the failure to meet a contingency or condition required to vest, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the 2013 Plan. This includes shares used to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Plan Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of
directors, or a duly authorized committee of our board of directors to which the board delegates its administrative authority, will administer our 2013 Plan and is referred to as the &#147;plan administrator&#148; herein. The plan administrator may
also delegate to one or more of our officers the authority to (i)&nbsp;designate employees (who are not officers) to receive specified options (and to the extent permitted by applicable law, other stock awards) and to the extent permitted by
applicable law, the terms of such stock awards and (ii)&nbsp;determine the number of shares subject to such stock awards; provided, however, that the board resolutions regarding such delegation must specify the total number of shares that may be
subject to awards granted by such officer, and provided further, that no officer may grant an award under the 2013 Plan to himself or herself. Under our 2013 Plan, the plan administrator has the authority to, among other things, determine award
recipients, dates of grant, the numbers and types of stock awards to be granted, the applicable fair market value and the provisions of each stock award, including the period of their exercisability and the vesting schedule applicable to a stock
award, to construe and interpret the 2013 Plan and awards granted thereunder (and to establish, amend and revoke any rules and regulations for the administration of the 2013 Plan), and to accelerate awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the 2013 Plan, the plan administrator also generally has the authority to effect, with the consent of any adversely affected participant,
(i)&nbsp;the reduction of the exercise, purchase or strike price of any outstanding stock award; (ii)&nbsp;the cancellation of any outstanding stock award and the grant in substitution therefore of other awards, cash, or other consideration; or
(iii)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options,
within the terms and conditions of the 2013 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2013 Plan vest at
the rate specified in the stock option agreement as determined by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The plan administrator determines the term of stock
options granted under the 2013 Plan, up to a maximum of ten years. If an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise
any vested options for a period of up to three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider trading policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period
following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of up to 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates
ceases due to disability, the optionholder may generally exercise any vested options for a period of up to 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date.
In no event may an option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Acceptable consideration for the purchase of common stock issued upon the
exercise of a stock option will be determined by the plan administrator and may include (i)&nbsp;cash, check, bank draft or money order payable to us, (ii)&nbsp;the tender of shares of our common stock previously owned by the optionholder,
(iii)&nbsp;a net exercise of the option, (iv)&nbsp;a deferred payment arrangement, or (v)&nbsp;other legal consideration approved by the plan administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless the plan administrator provides otherwise, options generally are not transferable except by
will or the laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized designee in each case, (i)&nbsp;an option may be transferred pursuant to a domestic relations order and (ii)&nbsp;an optionholder may
designate a beneficiary who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A stock option may include provisions for the early
exercise of options by the optionholder, the right of repurchase by us of vested shares acquired by the optionholder upon the exercise of the option, and the right of first refusal by us following receipt of notice from the optionholder of the
intent to transfer shares upon the exercise of the option. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Restricted Stock Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in
consideration for cash or cash equivalents, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms
and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have
not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. Additionally, rights to acquire shares of common stock under the restricted stock award agreement will be transferrable by the
participant only upon the terms and conditions as set forth in such agreement. A restricted stock award may include a provision for the right of first refusal by us following receipt of notice from the participant of the intent to transfer shares
pursuant to the restricted stock award agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Changes to Capital Structure </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of a capitalization adjustment, the board of directors, in its discretion, will make appropriate and proportionate adjustments to
(i)&nbsp;the class and maximum number of shares reserved for issuance under the 2013 Plan, and (ii)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. For purposes
of the 2013 Plan, capitalization adjustment generally means any change that is made in (or other events occurring with respect to) our common stock subject to the 2013 Plan or any award without the receipt of consideration by us through merger,
consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large <FONT STYLE="white-space:nowrap">non-recurring</FONT> cash dividend, stock split, reverse stock split, liquidating
dividend, combination or exchange of shares, change in corporate structure, or other similar equity restructuring transaction (within the meaning of FASB ASC Topic 718). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Dissolution or Liquidation</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2013 Plan provides that in the event of a dissolution or liquidation, unless otherwise
provided in an award agreement, all outstanding stock awards (other than those not subject to forfeiture or repurchase) will be terminated, and shares subject to repurchase or forfeiture may be repurchased or reacquired, provided the board of
directors may cause some or all stock awards to become vested, exercisable, and no longer subject to repurchase or forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Company
Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2013 Plan provides that in the event of a company transaction, unless otherwise provided in an award agreement or other written agreement between us and the award holder, the plan administrator may take
one or more of the following actions with respect to the stock awards: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring corporation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring corporation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if
applicable) at or before the effective time of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us with respect to the stock
award; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cancel or arrange for the cancellation of the stock award, to the extent not vested or exercised before the effective time
of the transaction, in exchange for such cash consideration, if any, as the board of directors may consider appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make a payment equal to the excess, if any, of (i)&nbsp;the value of the property the participant would have received on
exercise of the award, over (ii)&nbsp;any exercise price payable by the participant in connection with the exercise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The plan
administrator is not obligated to treat all stock awards, including the vested and unvested portions of a stock award, in the same manner and is not obligated to treat all participants in the same manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the 2013 Plan, a company transaction is generally defined as the consummation, in a single transaction or in a series of related transactions, of:
(i)&nbsp;a sale or other disposition of all or substantially all of our assets, (ii)&nbsp;the sale or disposition of at least 90% of our outstanding securities, (iii)&nbsp;a merger, consolidation or similar transaction where we do not survive the
transaction, or (iv)&nbsp;a merger, consolidation or similar transaction where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue
of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Change in Control</I>.&nbsp;&nbsp;&nbsp;&nbsp;A stock award may be subject to additional acceleration of vesting and
exercisability upon or after a change in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. Under the 2013 Plan, a change in control is
generally defined as (i)&nbsp;the acquisition by a person or entity of more than 50% of the combined voting power of our then outstanding stock other than by merger, consolidation or similar transaction, (ii)&nbsp;a consummated merger, consolidation
or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the
same proportions as their ownership immediately prior to such transaction, (iii)&nbsp;a consummated sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined
voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction, or (iv)&nbsp;individuals who, on the date the 2013 Plan is
adopted by the board of directors, are members of the board of directors ceasing for any reason to constitute at least a majority of the members of our board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Plan Amendment or Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
board of directors has the authority to amend, suspend, or terminate our 2013 Plan, provided that such action does not impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also
require the approval of our stockholders. Unless terminated sooner, the 2013 Plan will automatically terminate on the day before the 10th anniversary of the earlier of (i)&nbsp;the date the 2013 Plan was adopted by our board of directors, or
(ii)&nbsp;the date the 2013 Plan was approved by our stockholders. No stock awards may be granted under our 2013 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>2020 Employee Stock Purchase Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
connection with this offering, we intend to adopt and ask our stockholders to approve a 2020 Employee Stock Purchase Plan (the ESPP), which would become effective in connection with this offering. The material terms of the ESPP, as it is currently
contemplated, are summarized below. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
board of directors is still in the process of considering the ESPP and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Shares available; administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP
will be annually increased on January&nbsp;1 of each calendar year beginning in 2021 and ending in 2030, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and
(ii)&nbsp;such smaller number of shares as is determined by our board of directors. In no event will more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock be available
for issuance under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors or its committee will have authority to interpret the terms of the ESPP and determine
eligibility of participants. We expect that the compensation committee will be the initial administrator of the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Eligibility.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our employees are eligible to participate in the ESPP if they meet the eligibility requirements under the
ESPP established from time to time by the plan administrator. However, an employee may not be granted rights to purchase stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing
5% or more of the total combined voting power or value of all classes of our common or other class of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Grant of
rights.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP is intended to qualify under Section&nbsp;423 of the Code and stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan
administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The number of purchase periods within, and purchase dates during each offering period will be
established by the plan administrator prior to the commencement of each offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of
future offering periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ESPP permits participants to purchase common stock through payroll deductions of up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of their eligible compensation, which includes a participant&#146;s gross base compensation for services to us, including overtime payments and
excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any
offering period, which, in the absence of a contrary designation, will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. In addition, no employee will be permitted to accrue the right to
purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our
common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. The purchase price of the shares, in the absence of
a contrary determination by the plan administrator, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the
applicable purchase period. Participants may voluntarily end their participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such shorter or longer period specified by the plan administrator), and
will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A participant may not transfer rights granted under the ESPP other than by will, the laws of descent
and distribution or as otherwise provided under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Certain Transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the event of certain transactions
or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and
outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights
with other rights or property or termination of outstanding rights in exchange for cash, (ii)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (iii)&nbsp;the
adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and
termination of any rights under ongoing offering periods or (v)&nbsp;the termination of all outstanding rights. Under the ESPP, a change in control has the same definition as given to such term in the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Plan amendment; Termination.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may amend, suspend or terminate the ESPP at any time. However,
stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of
corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will
terminate on the tenth anniversary of the date it is initially approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Securities
Laws.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP has been designed to comply with various securities laws in the same manner as described above in the description of the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Federal Income Taxes.&nbsp;&nbsp;&nbsp;&nbsp;</I>The material federal income tax consequences of the ESPP under current federal income tax law are
summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign,
state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify under the provisions of Section&nbsp;423 of the Code. Under
the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee will not recognize taxable income on the date the employee is
granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or disposition, the participant will generally be subject to tax
in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the first day of the offering period during which the shares were
purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of: (i)&nbsp;the excess of the fair market
value of the shares at the time of such sale or disposition over the purchase price; or (ii)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of the offering period. Any additional gain will be treated as
long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the participating employee has a long-term capital loss for the
difference between the sale price and the purchase price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the shares are sold or otherwise disposed of before the expiration of the holding periods described
above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price and we will be entitled to a tax deduction for compensation
expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they
were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described above but are sold for a price that is less than the purchase price, the participant
will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled to a corresponding deduction), but the participant generally will be able to report a
capital loss equal to the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director
Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, we have not paid any cash compensation to&nbsp;the <FONT STYLE="white-space:nowrap">non-employee</FONT> members&nbsp;of
our board of directors for their services as directors, with the exception of Dr.&nbsp;Wilson, whose 2019 compensation for his service as our <FONT STYLE="white-space:nowrap">non-employee</FONT> Chairman during 2019 is disclosed in the Summary
Compensation Table and other executive compensation disclosure above due to his service as an executive officer for a portion of 2019.&nbsp;We have provided stock-based compensation to certain of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. We have reimbursed, and will continue to reimburse, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&nbsp;for their&nbsp;actual <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs&nbsp;and expenses incurred in connection with attending board meetings. Sarah Boyce, our President and Chief Executive Officer, is also a member of our board of directors, but does not
receive any additional compensation for her service as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective August&nbsp;28, 2019, we granted each of Dr.&nbsp;Henig and
Dr.&nbsp;Kaye options to purchase 20,114 shares of our common stock in connection with their appointment to our board of directors under our 2013 Plan. The stock options have a <FONT STYLE="white-space:nowrap">ten-year</FONT> term and an exercise
price of $0.20 per share, which our board of directors determined was equal to the fair market value per share of our common stock on the date of grant. The options will vest monthly over a <FONT STYLE="white-space:nowrap">one-year</FONT> period,
subject to continued service with us on each vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes compensation received by our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2019. Dr.&nbsp;Wilson and Ms.&nbsp;Boyce are not included in the following table as they served as executive officers during 2019 and their compensation
is included in the Summary Compensation Table in the &#147;Executive Compensation and Other Information&#148; section below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid in Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Todd Brady</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Noreen Henig, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Edward Kaye, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Michael Martin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Roderick Wong, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents the grant date fair value of stock options to purchase shares of our common stock computed in accordance with
FASB ASC 718. See Note 8 to our financial statements included with this prospectus for a description of the assumptions used in valuing our stock options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The aggregate number of shares subject to stock options outstanding at December&nbsp;31, 2019 for the
individuals who served as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during 2019 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities</B><br><B>Underlying Options</B><br><B>Outstanding at</B><br><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Todd Brady</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Noreen Henig, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Edward Kaye, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Michael Martin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Roderick Wong, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt and ask our stockholders to approve the initial terms of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, as it is currently contemplated, are summarized below. Our
board of directors is still in the process of considering the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide for annual retainer fees and/or long-term equity
awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. We expect each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with a <FONT STYLE="white-space:nowrap">non-employee</FONT> director serving as Chairman of the board of directors or lead independent director
receiving an additional annual retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as the chairs of the audit,
compensation and nominating and corporate governance committees will receive additional annual retainers of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively.
<FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also receive initial grants of options to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, vesting in equal monthly installments over three years, upon initial election or appointment to the board of directors, and
thereafter annual grants of options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock on the date of each annual meeting of stockholders following the completion
of this offering, vesting on the first to occur of (i)&nbsp;the first anniversary of the grant date or (ii)&nbsp;the next occurring annual meeting of our stockholders. In addition, equity awards granted to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors will vest upon a change in control of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compensation under our <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be subject to the annual limits on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2020 Plan, as described above. Our board
of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances
and considerations as it shall deem relevant from time to time, subject to the annual limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2020 Plan. As provided in the 2020 Plan, our board of
directors or its authorized committee may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the board of directors or its authorized committee may determine
in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers to
the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize
corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability
does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to indemnify our
employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this
capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our
amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts
incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and
amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and
our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may
discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit
us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for
liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened
litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_14"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following includes a summary of transactions since January&nbsp;1, 2017 to which we have been a party in which the amount involved exceeded or will
exceed the lesser of $120,000 and one percent of the average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge,
beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in
control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain other transactions with our directors, executive officers and stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion from Limited Liability Company to Corporation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
April 2019, we converted from a Delaware limited liability company named Avidity Biosciences, LLC (formerly known as Avidity NanoMedicines LLC) (Avidity LLC), to Avidity Biosciences, Inc., a Delaware corporation. We refer to this activity as the
Conversion. As a result, the members of Avidity LLC became our stockholders in the same ownership proportions as immediately prior to the Conversion, and all 6,159,933 common units, 4,350,299 Series A preferred units and 8,108,471 Series&nbsp;B
preferred units of Avidity LLC outstanding at the time of the Conversion were converted into 6,159,933 shares of common stock, 4,350,299 shares of Series A convertible preferred stock and 8,108,471 shares of Series B convertible preferred stock,
respectively, of Avidity Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Convertible Promissory Note Financings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>2018 Notes.&nbsp;&nbsp;&nbsp;&nbsp;</I>In July 2018, we issued and sold in a private placement to certain investors an aggregate principal amount of
$3.0&nbsp;million in convertible promissory notes (the 2018 Notes). The 2018 Notes accrued interest at a rate of 8% per annum. The 2018 Notes, including an aggregate of approximately $307,000 in accrued interest thereon, were automatically converted
into shares of our Series C convertible preferred stock in the Series C convertible preferred stock financing described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>2019
Notes.&nbsp;&nbsp;&nbsp;&nbsp;</I>In February 2019, we issued and sold in a private placement to certain investors an aggregate principal amount of $4.5&nbsp;million in convertible promissory notes (the 2019 Notes, and together with the 2018 Notes,
the Notes). The 2019 Notes accrued interest at a rate of 10% per annum. The 2019 Notes, including an aggregate of approximately $322,000 in accrued interest thereon, were automatically converted into shares of our Series C convertible preferred
stock in the Series C convertible preferred stock financing described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Lilly </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, we and Lilly entered into a research collaboration and license agreement, as described in &#147;Business&#151;Research and Collaboration
License Agreement with Lilly and Company.&#148; In connection with our entry into the research collaboration and license agreement, we entered into a convertible note purchase agreement with Lilly pursuant to which we issued and sold in a private
placement to Lilly a convertible promissory note in the principal amount of $15.0&nbsp;million (the Lilly Note). The Lilly Note accrued interest at a rate of 8% per annum. The Lilly Note, including approximately $674,000 in accrued interest thereon,
was automatically converted into shares of our Series C convertible preferred stock in the Series C convertible preferred stock financing described below. Lilly is a beneficial owner of more than 5% of our capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Convertible Preferred Unit and Preferred Stock Financings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Series B Convertible Preferred Unit Financings.&nbsp;&nbsp;&nbsp;&nbsp;</I>In December 2016, we entered into a Series B preferred unit purchase
agreement, pursuant to which we sold to investors in an initial closing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
subsequent closings from December 2016 to October 2017 in private placements an aggregate of 8,108,471 Series B preferred units. The per unit purchase price was $2.8269, and we received gross
proceeds of approximately $21.3&nbsp;million, which included the conversion of previously outstanding convertible promissory notes at a discounted price of $2.2615 per unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Series C Convertible Preferred Stock Financings.&nbsp;&nbsp;&nbsp;&nbsp;</I>In November 2019, we entered into a Series C preferred stock purchase
agreement, pursuant to which we sold to investors in an initial closing and a subsequent closing in November 2019 and January 2020, respectively, in private placements, an aggregate of 25,345,793 shares of Series C convertible preferred stock. The
per share purchase price was $4.2812, and we received gross proceeds of approximately $102.8&nbsp;million, which included the conversion of the 2018 Notes, the 2019 Notes and the Lilly Note at a discounted purchase price of $3.639, $3.425 and
$3.425, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth the aggregate number of these securities acquired by the listed directors, executive officers
or holders of more than 5% of our capital stock, or their affiliates. Each outstanding Series B preferred unit, including the Series B preferred units identified in the following table, was converted into one share of Series B convertible preferred
stock in connection with the Conversion. Each outstanding share of convertible preferred stock, including the shares identified in the tables above, will convert into shares of common stock at a ratio of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> immediately prior to the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2018&nbsp;Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2019 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Convertible<BR>Preferred<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Convertible<BR>Preferred<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% or Greater Stockholders<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with ALETHEA Capital
Management<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,144,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,517,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Brace Pharmaceuticals LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Cormorant Asset
Management<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with EcoR1 Capital<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,335,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Eli Lilly and Company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,576,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RTW Investments<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,423,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Takeda Ventures, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">479,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Troy Wilson, Ph.D., J.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">P. Kent Hawryluk<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are provided in &#147;Principal
Stockholders.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by ALETHEA Biotech Fund, LP and ALETHEA Fulcrum Fund, LP. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Todd Brady, a member of our board of directors, is the Director of Finance and Investments at Brace Pharma Capital, which
is an affiliate of Brace Pharmaceuticals. At the time of our 2018 and 2019 convertible note financings and our Series B convertible preferred unit financing, Mr.&nbsp;Brady served as one of our Managers. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by Cormorant Private Healthcare Fund II, LP, Cormorant Global Healthcare Master Fund, LP
and CRMA SPV, LP. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. and EcoR1 Venture
Opportunity Fund, L.P, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited
(collectively, RTW). Roderick Wong, M.D., a member of our board of directors, is Managing Partner and Chief Investment Officer of RTW Investments, LP, an affiliate of RTW. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Michael Martin, Ph.D., a member of our board of directors, is the President of Takeda Ventures. At the time of our 2018
and 2019 convertible note financings and our Series B convertible preferred unit financing, Mr.&nbsp;Martin served as one of our Managers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by a family trust. Troy Wilson, Ph.D., J.D., is a trustee of the family trust.
Dr.&nbsp;Wilson is currently, and was at the time of the Series C convertible preferred stock financing, our Chairman. At the time of our 2018 and 2019 convertible note financings and our Series B convertible preferred unit financing,
Dr.&nbsp;Wilson served as one of our Managers and as our Chief Executive Officer. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Represents securities acquired by an IRA and family trust. Mr.&nbsp;Hawryluk is the beneficiary of the IRA and the trustee
of the family trust. At the time of our 2018 and 2019 convertible note financings, our Series B convertible preferred unit financing and the first closing of our Series C convertible preferred stock financing, Mr.&nbsp;Hawryluk served as our Chief
Business Officer. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Takeda Evaluation Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2017, we and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, an affiliate of Takeda
Ventures, entered into an evaluation agreement. Michael Martin, Ph.D., a member of our board of directors, is the President of Takeda Ventures and, at the time we entered into the evaluation agreement, was one of our Managers. Pursuant to the
evaluation agreement, we conducted certain work in exchange for payment of approximately $605,000. The evaluation agreement terminated in June 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into an amended and
restated registration rights agreement in April 2019, as amended and restated in November 2019, with the holders of our convertible preferred stock, including entities with which certain of our directors are affiliated. The registration rights
agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their convertible preferred stock and certain additional covenants made by us. Except for the registration rights
(including the related provisions pursuant to which we have agreed to indemnify the parties to the registration rights agreement), all rights under this agreement will terminate upon closing of this offering. The registration rights will continue
following this offering and will terminate three years after the closing of this offering. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for more information regarding these registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into an amended and restated
voting agreement in April 2019, as amended and restated in November 2019 and as amended in April 2020, with the holders of our convertible preferred stock, including entities with which certain of our directors are affiliated, pursuant to which the
following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Carsten Boess, Sarah Boyce, Todd Brady, Noreen Henig, M.D., Edward Kaye, M.D., Michael Martin, Ph.D.,
Troy Wilson, Ph.D., J.D. and Roderick Wong, M.D. Pursuant to the voting agreement, Ms.&nbsp;Boyce, as our Chief Executive Officer, serves on our board of directors as the CEO director. Mr.&nbsp;Brady, Dr.&nbsp;Martin and Dr.&nbsp;Wong were initially
selected to serve on our board of directors as representatives of the holders of our convertible preferred stock, as designated by Brace Pharmaceuticals, Takeda Ventures and RTW Investments LP and its affiliates (RTW), respectively. Mr. Boess and
Dr.&nbsp;Wilson were initially selected to serve on our board of directors as representatives of the holders of our common stock and preferred stock, as designated by a majority of our common and preferred stockholders, voting together as a single
class. Dr.&nbsp;Henig and Dr.&nbsp;Kaye were initially selected to serve on our board of directors by our existing directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The voting agreement
will terminate upon the closing of this offering, and members previously elected to our board of directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by holders
of our common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board Composition and Election of Directors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Public Offering Participation Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We entered into a letter agreement in November 2019 with RTW, a beneficial owner of more than 5% of our capital stock. The letter agreement grants RTW a
participation right to purchase a specified percentage of shares of common stock in this offering at the public offering price, subject to compliance with applicable securities laws. The letter agreement further provides that, under certain
circumstances in which RTW is unable to participate in this offering, we are required to offer RTW shares of our common stock through a separate private placement to be concurrent with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Grants to Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have
granted restricted stock and stock options to certain of our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, as more fully described in &#147;Executive and Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into employment
letter agreements with our executive officers. For more information regarding these letter agreements, see &#147;Executive and Director Compensation&#151; Agreements with Our NEOs.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director and Officer Indemnification </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into
indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive
officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including
any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and
restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have purchased a policy
of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further information, see &#147;Executive and Director
Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this offering, setting forth the
policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities
Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds the lesser of $120,000 or one percent of the
average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods
or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit
committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related
person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our common stock as of April&nbsp;30, 2020, and as adjusted to
reflect the sale of shares of common stock in this offering, by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our named executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person<B> </B>or group of affiliated persons known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules,
beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 44,195,874 shares of common stock outstanding on April&nbsp;30, 2020, which gives effect
to the automatic conversion of all outstanding shares of our convertible preferred stock into 37,804,563 shares of our common stock immediately prior to the closing of this offering and includes 284,092 shares subject to forfeiture or a right of
repurchase. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to warrants, options or other rights held by such person that are currently exercisable or will
become exercisable within 60 days of April&nbsp;30, 2020 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Avidity Biosciences, Inc., 10975 N. Torrey Pines Road, Suite 150,
La Jolla, California 92037. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise,
subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RTW Investments<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,423,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Cormorant Asset
Management<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Eli Lilly and Company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,576,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with ALETHEA Capital
Management<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,635,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with EcoR1 Capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,733,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><I>Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">P. Kent Hawryluk<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Arthur Levin, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Troy Wilson, Ph.D., J.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,098,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Carsten Boess</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Todd Brady</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Noreen Henig, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Edward Kaye, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Michael Martin, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,540,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Roderick Wong, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,423,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,015,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;985,938 shares of common stock held by RTW Innovation Master Fund, Ltd., (ii)&nbsp;4,269,597 shares
of common stock held by RTW Master Fund, Ltd. and (ii)&nbsp;1,167,896 shares of common stock held by RTW Venture Fund Limited. RTW Investments, LP is the manager of RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund.
Dr.&nbsp;Wong is the Managing Partner and Chief Investment Officer of RTW Investments, and as such has sole voting and investment control over such shares. Dr.&nbsp;Wong disclaims beneficial ownership of such shares except to the extent of any
pecuniary interest therein. The address of RTW Investments and Dr.&nbsp;Wong is 412 West 15th&nbsp;Street, Floor 9, New York, New York, 10011. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;3,717,182 shares of common stock held by Cormorant Private Healthcare Fund II, LP (Cormorant Fund
II), (ii)&nbsp;885,732 shares of common stock held by Cormorant Global Healthcare Master Fund, LP (Cormorant Master Fund), and (iii)&nbsp;68,672 shares held by CRMA SPV, L.P. (CRMA, and, together with Cormorant Fund II and Cormorant Master Fund, the
Cormorant Funds). Cormorant Global Healthcare GP, LLC (Global GP) is the general partner of Cormorant Master Fund and Cormorant Private Healthcare II&nbsp;GP, LLC (Private GP) is the general partner of Cormorant II. Bihua Chen serves as the managing
member of both Global GP and Private GP. Cormorant Asset Management LP serves as the investment manager to Cormorant Fund II, Cormorant Master Fund and CRMA, and Ms.&nbsp;Chen serves as the managing member of Cormorant Asset Management GP, LLC.
Ms.&nbsp;Chen has sole voting and investment control over the shares held by the Cormorant Funds. Ms.&nbsp;Chen disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address of the Cormorant Funds,
Global GP, Private GP, Cormorant Asset Management LP, and Ms.&nbsp;Chen is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;3,051,343 shares of common stock held by ALETHEA Biotech Fund, LP (ALETHEA Biotech) and
(ii)&nbsp;583,948 shares of common stock held by ALETHEA Fulcrum Fund, LP. (ALETHEA Fulcrum). ALETHEA Capital Management, LLC is the general partner of ALETHEA Biotech and ALETHEA Fulcrum. Tony Hsu is the Managing Member of ALETHEA Capital
Management. By virtue of such relationships, Mr.&nbsp;Hsu has voting and investment power over the shares held by ALETHEA Biotech and ALETHEA Fulcrum. Mr.&nbsp;Hsu disclaims beneficial ownership of the shares held by ALETHEA Biotech and ALETHEA
Fulcrum, except to the extent of his actual pecuniary interest therein if any. The address for ALETHEA Capital Management is 18029 Calle Ambiente, Suite 509, Rancho Santa Fe, California 92067. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;1,360,776 shares of common stock held by EcoR1 Capital Fund Qualified, L.P. (EcoR1 Qualified),
(ii)&nbsp;317,471 shares of common stock held by EcoR1 Capital Fund, L.P. (EcoR1 Fund), and (iii)&nbsp;1,055,508 shares of common stock held by EcoR1 Venture Opportunity Fund, L.P. (EcoR1 Venture). EcoR1 Capital LLC is the general partner of EcoR1
Qualified and EcoR1 Fund. Biotech Opportunity GP, LLC is the general partner of EcoR1 Venture. Oleg Nodelman owns and controls EcoR1 Capital and Biotech Opportunity GP, LLC and as such may be deemed to beneficially own such shares. Mr.&nbsp;Nodelman
disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address of EcoR1 and Mr.&nbsp;Nodelman is 357 Tehama Street, Suite 3, San Francisco, California 94103. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes (i)&nbsp;1,181,774 shares held by a trust and (ii)&nbsp;30,292 shares held in an IRA account. Mr.&nbsp;Hawryluk
is the trustee of the trust and the beneficiary of the IRA account, and in such capacity has the power to vote and dispose of such shares. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes (i)&nbsp;41,666 shares of common stock underlying options held by Dr.&nbsp;Levin that are exercisable as of
April&nbsp;30, 2020 or that will become exercisable within 60 days after such date, and (ii)&nbsp;655,837 shares of common stock held by a family trust. Dr.&nbsp;Levin and his spouse, Madeline Butler, are
<FONT STYLE="white-space:nowrap">co-trustees</FONT> of the family trust and in such capacity have joint power to vote and dispose of such shares. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes (i)&nbsp;133,334 shares subject to repurchase and (ii)&nbsp;1,698,785 shares of common stock held by a family
trust. Dr.&nbsp;Wilson and his spouse, Lemoure Eliasson, are <FONT STYLE="white-space:nowrap">co-trustees</FONT> of the trust and in such capacity have joint power to vote and dispose of such shares. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 16,761 shares of common stock underlying options held by Dr.&nbsp;Henig that are exercisable as of April&nbsp;30,
2020 or that will become exercisable within 60 days after such date. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 16,761 shares of common stock underlying options held by Dr.&nbsp;Kaye that are exercisable as of April&nbsp;30,
2020 or that will become exercisable within 60 days after such date. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Consists of 1,540,691 shares held by Takeda Ventures, Inc., a wholly owned indirect subsidiary of Takeda Pharmaceutical
Company Limited. Takeda Ventures is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals
International AG is a wholly owned direct subsidiary of Takeda Pharmaceutical Company Limited. Dr.&nbsp;Martin is the President of Takeda Ventures, and as such may be deemed to beneficially own such shares. Dr.&nbsp;Martin disclaims beneficial
ownership of such shares except to the extent of any pecuniary interest therein. </P></TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">(11) Consists of the shares described in footnotes 1 and 5 through
11 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following description summarizes some of the
terms of our amended and restated certificate of incorporation and amended and restated bylaws, the registration rights agreement and of the Delaware General Corporation Law. Because it is only a summary, it does not contain all the information that
may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and registration rights agreement, copies of which have been filed as exhibits to the
registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, our authorized capital stock will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.0001 par value per share,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock, $0.0001 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, there were
44,195,874 shares of our common stock outstanding and held of record by 108 stockholders, including 298,893 shares of restricted common stock which are subject to forfeiture or our right of repurchase, after giving effect to the automatic conversion
of all outstanding shares of our convertible preferred stock into 37,804,563 shares of common stock, which will automatically occur immediately prior to the closing of this offering. Based on the number of shares of common stock outstanding as of
March 31, 2020, and further assuming the issuance by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering, there will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding upon the closing of this offering. Holders of our common stock are entitled to one vote for each share held on all
matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of
directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters
shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended
and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital
stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend
or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and
Bylaws&#151;Amendment of Charter Provisions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to preferences that may be applicable to any then outstanding preferred stock, holders
of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be
entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of
common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be
outstanding upon the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the
holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, all of our previously outstanding shares of convertible preferred stock will have been converted into common stock,
there will be no authorized shares of our previously outstanding convertible preferred stock, and we will have no shares of preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which will become
effective immediately prior to the closing of this offering, our board of directors has the authority, without further action by our stockholders, to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such
series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such
series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may authorize the issuance of preferred stock
with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other
corporate purposes, could, among other things, have the effect of delaying, deterring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock.
We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On August&nbsp;7, 2015, in connection with the Loan Agreement, we issued SVB a warrant to purchase 16,474 Series A preferred units at an exercise price
of $2.2615 per unit (the SVB Series A Warrant). On June&nbsp;9, 2017, in connection with the first amendment to the Loan Agreement, we issued SVB a warrant to purchase 19,918 common units at an exercise price of $0.25 per unit (the SVB Common
Warrant and, together with the SVB Series A Warrant, the SVB Warrants). The SVB Series A Warrant and the SVB Common Warrant were converted into warrants to purchase 16,747 shares of Series A convertible preferred stock and 19,918 shares of common
stock, respectively, in connection with our conversion into a corporation in April 2019, and the SVB Series A Warrant will become a warrant to purchase 16,474 shares common stock at an exercise price of $2.2615 per share in connection with this
offering. The SVB Warrants contain a net exercise provision under which SVB may, in lieu of payment of the exercise price in cash, surrender the warrant and receive, a net amount of shares of our common stock based on the fair market value of our
common stock at the time of the net exercise of the warrant after deduction of the aggregate exercise price. The SVB Series A Warrant expires ten years from its date of issuance and the SVB Common Warrant expires seven years from its date of
issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March 31, 2020, options to
purchase 5,091,513 shares of our common stock were outstanding, of which 234,252 were vested and exercisable as of that date. For additional information regarding the terms of our 2013 Plan, see &#147;Executive and Director
Compensation&#151;Incentive Award Plans&#151;2013 Equity Incentive Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March 31, 2020, upon the closing of this offering holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion convertible preferred stock
immediately prior to the closing of this offering, will be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to registration rights agreement by and among us and
certain investors. The registration of shares of common stock as a result of the following rights being exercised would enable holders to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Form <FONT
STYLE="white-space:nowrap">S-1.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></I>If at any time beginning six months following the effective date of the registration statement of which this prospectus forms a part, the holders of at least 30% of the registrable
securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the aggregate price to the public of the offering is $10.0&nbsp;million or more, we may be required to
provide notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, among other things, within the
preceding 12 months, we have already effected two registrations for the holders of registrable securities in response to these demand registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Form S-</I>3.&nbsp;&nbsp;&nbsp;&nbsp;If at any time we become entitled under the Securities Act to register our shares on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> the holders of the registrable securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the public of the
offering is $1.0&nbsp;million or more, we may be required to provide notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect
such a registration if, among other things, within the preceding 12&nbsp;months, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the holders requesting registration intend to distribute their shares by means of an underwriting, the underwriter of such offering will have the
right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If at any time following the closing of this offering we propose to register any shares of our common stock under the Securities Act,
subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the
managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our registration
rights agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in a registration statement attributable to us, and
they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration
effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling
securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Termination of Registration
Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The registration rights terminate three years after the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could
make the following transactions more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible
that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a
premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These provisions, summarized below, are intended to discourage coercive takeover practices and
inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The ability of our board
of directors, without action by the stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede
the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholder Meetings </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws
provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and
the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent
without a meeting. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board of Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, with one class being elected each
year by our stockholders. For more information on the classified board of directors, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing directors may tend to discourage a third party from attempting
to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Removal of Directors
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except
for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any
election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested stockholders&#148; from
engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person
became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years
prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a
financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate
of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under
Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to
us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended and restated certificate of
incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action asserting a claim governed by the internal affairs
doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the
selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In any case, stockholders will not be
deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in
legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise
acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment of Charter Provisions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amendment of any
of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of
discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions
may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in
their best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
transfer agent and registrar for our common stock will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar&#146;s address
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nasdaq Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to have our common stock listed on Nasdaq under the symbol &#147;RNA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For a
discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the public
market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on Nasdaq, we cannot assure you that there will be an active public market for
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the number of shares of our common stock outstanding as of March 31, 2020, and assuming (i)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in this offering, (ii) the automatic conversion of all of our outstanding shares of convertible preferred stock into
37,804,563 shares of common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity upon the closing of this offering, (iii)&nbsp;no exercise of the underwriters&#146; option to purchase
additional shares of common stock and (iv)&nbsp;no exercise or vesting of outstanding options, warrants or other rights, we will have outstanding an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Of these shares, all
shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act.
Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be
&#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from
registration under Rule 144 or 701 under the Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, our officers, directors and holders of substantially all of our securities, have agreed
with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file
a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC
may, in their sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, in certain cases without public notice, release all or any portion of the securities subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of
shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these
<FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director
or stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I>Affiliate Resales of Restricted Securities
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an
affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain
&#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume in our common stock on Nasdaq during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Affiliate resales under Rule 144 are also subject to the availability of current
public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form
144 with the SEC and Nasdaq concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate
of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares
subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of
Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, under Rule 701, any of
an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement
under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement,
and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all shares
of common stock subject to outstanding stock options and common stock issued or issuable under our equity incentive plans and employee stock purchase plan. We expect to file the registration statement covering shares offered pursuant to these stock
plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the
public market subject to compliance with the resale provisions of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March 31, 2020, upon the closing of this offering holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our convertible preferred stock
into 37,804,563 shares of our common stock immediately prior to the closing of this offering, will be entitled to various rights with respect to the registration of these shares under the Securities Act upon the closing of this offering.
Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchase by our
affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_18"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences
to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax
effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the Internal Revenue
Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the IRS), in each case in effect as of the date
hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax
consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is limited to
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all
U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income or the alternative minimum
tax. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock
being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If an entity treated as a partnership for U.S. federal income tax
purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding
our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>THIS
DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>
OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL
ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that
is neither a &#147;U.S. person&#148; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation created or organized in or under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United
States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As described in &#147;Dividend Policy,&#148;
we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal
income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of
capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described
below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussion below on effectively connected income, dividends paid to
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other
applicable documentation) certifying qualification for the lower treaty rate). If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, who then will be required to provide certification
to the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits
under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected
with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
maintains a permanent establishment or fixed base in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To
claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively
connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income
basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such
effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment or fixed base in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our common stock constitutes a U.S. real property interest (USRPI), by reason of our status as a U.S. real property holding
corporation (USRPHC), for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Gain described in the first bullet point above generally will be
subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified
by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Gain described in the second bullet point
above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
(even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with
respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC.
Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business
assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established
securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable
disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. If we are a USRPHC and either our common stock is not regularly traded on an established securities market or a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds, or is treated as holding, more than 5% of our outstanding common stock, directly or indirectly, during the applicable testing period, such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not
apply. If we are a USRPHC and our common stock is not regularly traded on an established securities market, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s proceeds received on the disposition of shares will also generally be
subject to withholding at a rate of 15%. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to become, a USRPHC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially applicable income tax treaties that may
provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual
knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in
connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common
stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does
not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the
tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Backup withholding
is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the
required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign Account Tax Compliance
Act (FATCA)) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed
on dividends on, or subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in clause (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United
States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to
<FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing
FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally
applies to payments of dividends on our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, proposed Treasury Regulations
eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC, as the representatives of the
several underwriters for the offering named below, have entered into an underwriting agreement with respect to the common stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally, and not
jointly, agreed to purchase from us the number of shares of our common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent
and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares
described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to
contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters are offering the shares, subject to prior
sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the
public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Option to Purchase Additional Shares.&nbsp;&nbsp;&nbsp;&nbsp;</I>We have granted to the
underwriters an option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at the public offering price, less the underwriting discounts and
commissions. This option is exercisable for a period of 30 days. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discounts and Commissions.&nbsp;&nbsp;&nbsp;&nbsp;</I>The following table shows the public offering price, underwriting discounts and
commissions and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With Full<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of the offering payable by us, excluding underwriting discounts
and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We also have agreed to reimburse the underwriters for up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for their FINRA counsel fee. In accordance with FINRA Rule&nbsp;5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters propose to offer the shares of our common stock to the public at the public offering price set forth on the cover page of this
prospectus. The underwriters may offer the shares of our common stock to securities dealers at the public offering price less a concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discretionary Accounts.&nbsp;&nbsp;&nbsp;&nbsp;</I>The underwriters do not intend to confirm sales of the shares to any accounts over which they have
discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Market Information.&nbsp;&nbsp;&nbsp;&nbsp;</I>Prior to this offering, there has been no public market for shares of
our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will
include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the history of, and prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our past and present financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future
revenues; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in activities
similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An active trading market for the shares may not develop. It is also possible that after the offering the shares
will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied for the quotation of our common stock on the
Nasdaq Global Market under the symbol &#147;RNA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stabilization.&nbsp;&nbsp;&nbsp;&nbsp;</I>In connection with this offering, the
underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stabilizing transactions permit bids to purchase shares of our common stock so long as the stabilizing bids do not exceed a
specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Overallotment transactions involve sales by the underwriters of shares of our common stock in excess of the number of
shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is
not greater than the number of shares that they may purchase pursuant to the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares that the underwriters have the option to
purchase. The underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been
completed in order to cover syndicate short positions. In determining </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price
at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short
position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares
in the open market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock
originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Passive Market
Making.&nbsp;&nbsp;&nbsp;&nbsp;</I>In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on Nasdaq in accordance with Rule 103 of Regulation M under the Exchange
Act, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid
of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, such bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements.&nbsp;&nbsp;&nbsp;&nbsp;</I>Pursuant to certain
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, we and our executive officers, directors and substantially all of our other securityholders, have agreed, subject to certain exceptions, not to offer, sell, assign, transfer,
pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic consequence of ownership of,
directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or
exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC for a period of 180 days after the date of the pricing
of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or
exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The exceptions
permit us, among other things and subject to restrictions, to: (i)&nbsp;issue common stock or options pursuant to employee benefit plans, (ii)&nbsp;issue common stock upon exercise of outstanding options or warrants (iii)&nbsp;issue securities in
connection with acquisitions or similar transactions, or (iv)&nbsp;file registration statements on Form <FONT STYLE="white-space:nowrap">S-8.</FONT> The exceptions permit parties to the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT>
agreements, among other things and subject to restrictions, to: (a)&nbsp;make certain gifts, (b)&nbsp;if the party is a corporation, partnership, limited liability company or other business entity, make transfers to any stockholders, partners,
members of, or owners of similar equity interests in, the party, or to an affiliate of the party, if such transfer is not for value, (c)&nbsp;if the party is a corporation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
partnership, limited liability company or other business entity, make transfers in connection with the sale or transfer of all of the party&#146;s capital stock, partnership interests, membership
interests or other similar equity interests, as the case may be, or all or substantially all of the party&#146;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by the
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement, (d)&nbsp;enter into transactions relating to shares of our common stock acquired in open market transactions after completion of the offering, provided that no public
announcement or filing is required to be made regarding such transaction during the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period, (e)&nbsp;enter into a
<FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan, provided that such plan does not permit the sale of any common stock during the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period and
no public announcement or filing is made regarding such plan during the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period, (f)&nbsp;make transfers to us to satisfy tax withholding obligations
pursuant to our equity incentive plans disclosed in this prospectus, (g)&nbsp;make transfers pursuant to court or regulatory agency order, a qualified domestic order or in connection with a divorce settlement, (h)&nbsp;make transfers pursuant to
agreements that provide for the repurchase by us or the forfeiture of securities, (i)&nbsp;transfers pursuant to third-party tender offer, merger, consolidation or other similar transaction, (j)&nbsp;the conversion of the outstanding shares of our
convertible preferred stock into shares of our common stock in connection with the consummation of the offering. In addition, the <FONT STYLE="white-space:nowrap">lock-up</FONT> provision will not restrict broker-dealers from engaging in market
making and similar activities conducted in the ordinary course of their business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities
(USA) LLC and Wells Fargo Securities, LLC, in their sole discretion, may release our common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. When
determining whether or not to release our common stock and other securities from <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC
will consider, among other factors, the holder&#146;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time of the request. In the event of such a release or waiver for
one of our directors or officers, Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC shall provide us with notice of the impending release or waiver at least three business days before the
effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Electronic Offer, Sale and Distribution of Shares.&nbsp;&nbsp;&nbsp;&nbsp;</I>A prospectus in electronic format may be made available on the websites
maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. Cowen and Company, LLC, SVB
Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be
allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or
the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Other Relationships.&nbsp;&nbsp;&nbsp;&nbsp;</I>Certain of the underwriters and their affiliates have provided, and may in the future provide,
various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees. SVB, an affiliate of SVB Leerink LLC, is a lender under our debt
facility and holds warrants to purchase shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Canada</I>.&nbsp;&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with
remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>United Kingdom.&nbsp;&nbsp;&nbsp;&nbsp;</I>In addition, in the United Kingdom, this document is being distributed only to, and is
directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling
within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as relevant persons) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United
Kingdom within the meaning of the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any person in the United Kingdom that is not a relevant person should
not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Switzerland.&nbsp;&nbsp;&nbsp;&nbsp;</I>This document is not intended to constitute an offer or solicitation to purchase or invest in the
shares. The shares may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (FinSA) and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated
trading venue (exchange or multilateral trading facility) in Switzerland. Neither this document nor any other offering or marketing material relating to the shares of our common stock constitutes a prospectus within the meaning of, and has been
prepared without regard to, the FinSA, the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules
or the listing rules of any other stock exchange or regulated trading venue (exchange or multilateral trading facility in Switzerland). Neither this document nor any other offering or marketing material relating to the shares or the offering may be
publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neither this document nor any other offering or marketing material
relating to the offering, the Company or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss
Financial Market Supervisory Authority FINMA, and the offer of shares has not been and will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does
not extend to acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>European Economic Area.&nbsp;&nbsp;&nbsp;&nbsp;</I>In relation to each Member State of the European Economic
Area and the United Kingdom (each, a Relevant State), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been
approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except it may make
an offer to the public in that Relevant State of any shares at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation),
subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus
Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Hong Kong.</I>&nbsp;&nbsp;&nbsp;&nbsp;The shares have not been offered or sold and will not be
offered or sold in Hong Kong, by means of any document, other than (i)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the SFO) of Hong Kong and any rules made
thereunder; or (ii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies ((Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the CO) or which do not
constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in
Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or
are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Singapore</I>.&nbsp;&nbsp;&nbsp;&nbsp;Each representative has acknowledged that this prospectus has not been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, each representative has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or
sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection
with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore,
as modified or amended from time to time (the SFA)) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any
person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">securities or securities-based derivatives contracts (each term as defined in
Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an
offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments)(Securities and Securities-based
Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the
SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets
products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT
STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Israel.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the State of
Israel this prospectus shall not be regarded as an offer to the public to purchase shares of our common stock under the Israeli Securities Law, 5728-1968, which requires a prospectus to be published and authorized by the Israel Securities Authority,
if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728-1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the
Addressed Investors); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728-1968, subject to certain conditions (the Qualified Investors). The
Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it
to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728-1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the
State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Qualified Investors may have to submit written evidence that
they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728-1968. In particular, we may request, as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within
one of the categories listed in the First Addendum to the Israeli Securities Law, 5728-1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728-1968 regarding Qualified Investors is applicable to it;
(iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728-1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of our common stock that
it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728-1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than
in accordance with the provisions of the Israeli Securities Law, 5728-1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their
identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers
made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further
offer of shares on our behalf or on behalf of the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California. The
underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The financial statements as of December 31, 2018 and 2019 and for the years then ended included in this Prospectus and in the Registration Statement
have been so included in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, appearing elsewhere herein and in the Registration Statement, given on the authority of said firm as experts in auditing and
accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and our common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the closing of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports,
proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance
therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available at the website of the SEC referred to above. We maintain a website at
www.aviditybiosciences.com. Upon the closing of this offering, you may access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is
electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making
an investment decision with respect to our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc897644_23"></A>AVIDITY BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_4">Statements of Convertible Preferred Stock/Units and Stockholders&#146;/Members&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin897644_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><A NAME="fin897644_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Avidity Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, California </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have audited the accompanying balance sheets of Avidity Biosciences, Inc. (the &#147;Company&#148;) as of December&nbsp;31, 2018 and 2019, the related statements of
operations, convertible preferred stock/units and stockholders&#146;/members&#146; deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2018 and 2019, and the results of its operations and its cash flows for the years then ended<B>,</B> in conformity with
accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Change in Accounting Principle </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As discussed in Note&nbsp;2 to the financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards
Codification Topic&nbsp;842, Leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emphasis of a Matter - Coronavirus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">As more fully described in Note&nbsp;10 to the financial statements, the Company may be impacted by the outbreak of a novel coronavirus (COVID-19), which was declared a
global pandemic by the World Health Organization in March 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We conducted our audits in
accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are
required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such
opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">/s/ BDO USA, LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2016. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">April 3, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_2"></A>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in
thousands, except share data and par value) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma</B><br><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL"><B>Liabilities, Convertible Preferred Stock/Units and Stockholders&#146;/Members&#146; Equity
(Deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Long-term debt, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Lease liability, long term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Long-term debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Convertible preferred units&#151;12,828,990 units authorized at December&nbsp;31, 2018 and no units
authorized at December&nbsp;31, 2019 and March 31, 2020; 12,458,770 units issued at December&nbsp;31, 2018 and no units issued at December 31, 2019 and March 31, 2020; liquidation preferences of $32.8&nbsp;million, $0 and $0 at December&nbsp;31,
2018 and 2019 and March&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Convertible preferred stock&#151;$0.0001 par value; no shares authorized at December 31, 2018 and
38,054,628 shares authorized at December&nbsp;31, 2019 and March 31, 2020; no shares, 37,267,331 and 37,804,563 shares issued at December&nbsp;31, 2018 and 2019 and March&nbsp;31, 2020, respectively; liquidation preferences of $0,
$139.0&nbsp;million and $141.3 million at December&nbsp;31, 2018 and 2019 and March 31, 2020, respectively; no shares issued and outstanding, pro&nbsp;forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Stockholders&#146;/members&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Common units&#151;21,500,000 units authorized at December&nbsp;31, 2018, no units authorized at December
31, 2019 and March&nbsp;31, 2020; 5,994,758 units issued and outstanding at December&nbsp;31, 2018, no units issued and outstanding at December 31, 2019 and March 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Common stock&#151;$0.0001 par value; no shares authorized at December 31, 2018, 52,042,016 shares
authorized at December 31, 2019 and March&nbsp;31, 2020, respectively; no shares, 6,304,898 and 6,391,311&nbsp;shares issued and outstanding at December&nbsp;31, 2018, December&nbsp;31, 2019 and March 31, 2020, respectively; 44,195,874 shares issued
and outstanding at March&nbsp;31, 2020, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Additional-paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Predecessor&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Total stockholders&#146;/members&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 66,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:ARIAL">Total liabilities, convertible preferred stock/units and stockholders&#146;/members&#146; equity
(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_3"></A>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share/unit and per share/unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and contract research</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of preferred warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total interest and other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share/unit, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares/units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,224,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,554,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,001,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted (unaudited) (Note 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted-average shares outstanding, basic and diluted (unaudited) (Note&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,224,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,628,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_4"></A>Statements of Convertible Preferred Stock/Units and Stockholders&#146;/Members&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except shares/units and per share/unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Predecessor&#146;s<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;/<BR>Members&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,339,686</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,072</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common units upon exercise of unit options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655,072</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of early exercise options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,994,758</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Distribution to members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common units upon exercise of unit options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,175</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss to date of conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Conversion from LLC to C corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,458,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,587</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,159,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,159,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,104</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series C convertible preferred stock, net of issuance costs of $4.1&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,915,525</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series C convertible preferred stock upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,893,036</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,965</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of early exercise options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Statements of Convertible Preferred Stock/Units and Stockholders&#146;/Members&#146; Deficit&#151;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except shares/units and per share/unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Predecessor&#146;s<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;/<BR>Members&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,267,331</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,304,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,173</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,185</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,357</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common stock upon exercise of stock options (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Vesting of early exercise options (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of Series C convertible preferred stock, net of issuance costs of $0.1&nbsp;million
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at March&nbsp;31, 2020 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,804,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,391,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_4"></A>Statements of Convertible Preferred Stock/Units and Stockholders&#146;/Members&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except shares/units and per share/unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Predecessor&#146;s<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;/<BR>Members&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Units</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,994,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Distribution to members (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Issuance of common units upon exercise of unit options (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Balance at March&nbsp;31, 2019 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,159,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,549</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stock-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Amortization of discounts and loan issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#150;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued compensation related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Change in lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from the issuance of common stock/units, net of repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from long-term debt, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Payment on long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Distributions to members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of convertible notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Payment of deferred financing cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Supplemental schedule of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series C convertible preferred stock upon conversion of outstanding convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Costs incurred, but not paid, in connection with capital expenditures included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Costs incurred, but not paid, in connection with deferred financing costs included in accounts payable and
accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#150;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin897644_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information as of March 31, 2020 and thereafter and for the three months ended </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Business and
Business Organization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Description of Business </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Avidity Biosciences, Inc. (the Company or Avidity) is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called
Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide-based therapies in order to treat a wide range of serious diseases. The Company utilizes its proprietary AOC platform to design, engineer and
develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Formation and
Conversion </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company was formed under the laws of the State of Delaware as Avidity Biosciences LLC in November 2012, and in April 2019,
pursuant to an Agreement and Plan of Conversion, Avidity Biosciences LLC a Delaware limited liability company (Avidity LLC), was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were
converted into securities of Avidity Biosciences, Inc. as follows: (i)&nbsp;each outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.&#146;s common stock; (ii)&nbsp;each outstanding Series A convertible
preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.&#146;s Series A preferred stock; and (iii)&nbsp;each outstanding Series B preferred unit of Avidity Biosciences LLC converted into one share of Avidity Biosciences,
Inc.&#146;s Series B convertible preferred stock. All the property, rights, privileges, powers and franchises of Avidity LLC vested in Avidity Biosciences, Inc., and all debts, liabilities and duties of Avidity LLC became debts, liabilities and
duties of Avidity Biosciences, Inc. Outstanding convertible notes, warrants and stock awards under Avidity LLC&#146;s employee benefit and incentive compensation plans continued on the same terms and conditions and became binding upon Avidity
Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March&nbsp;31, 2020, the Company has devoted substantially all of its resources to organizing and staffing the company, business planning, raising
capital, developing its proprietary AOC platform, identifying potential product candidates, establishing its intellectual property and conducting research and preclinical studies, and providing other general and administrative support for these
operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it&nbsp;continues the development of its product
candidates and development programs. As of March&nbsp;31, 2020, the Company had an accumulated deficit of $28.3&nbsp;million and cash and cash equivalents of $88.8&nbsp;million. Based on the Company&#146;s current business plan, management believes
that existing cash and cash equivalents will be sufficient to fund the Company&#146;s obligations for at least 12 months after these financial statements are issued.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential
collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or
delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company&#146;s business, results of operations and future prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The preparation of financial
statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the
disclosure of contingent assets and liabilities in the Company&#146;s financial statements and accompanying notes. Although these estimates are based on the Company&#146;s knowledge of current events and actions it may undertake in the future,
actual results may materially differ from these estimates and assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On an ongoing basis, management evaluates its estimates, primarily
related to revenue recognition, stock-based compensation, fair value of common stock, and accrued research and development costs. These estimates are based on historical data and experience, as well as various other factors that management believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Estimates relating to the valuation of stock
require the selection of appropriate valuation methodologies and models, and significant judgment in evaluating ranges of assumptions and financial inputs.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Interim Financial Information </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
accompanying interim balance sheet as of March 31, 2020, the statements of operations and cash flows for the three months ended March 31, 2019 and 2020 and the statements of convertible preferred stock/units and stockholders&#146;/members&#146;
deficit for the three months ended March 31, 2019 and 2020 and the related footnote disclosures are unaudited. In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial
statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position as of March 31, 2020 and its results of operations and cash flows for the three
months ended March 31, 2019 and 2020 in accordance with GAAP. The results for the three months ended March 31, 2020 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Information </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The unaudited pro
forma information as of March&nbsp;31, 2020 has been prepared to give effect to (i)&nbsp;the automatic conversion of all of the outstanding shares of the Company&#146; convertible preferred stock into 37,804,563 shares of the Company&#146;s common
stock and (ii)&nbsp;the related reclassification of the carrying value of the convertible preferred stock and preferred stock warrant liabilities to permanent equity, all of which will occur immediately prior to the completion of the Company&#146;s
planned initial public offering (IPO). The unaudited pro forma information does not reflect any pro forma adjustments for common stock to be issued in conjunction with the IPO or any related estimated net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unaudited pro forma net loss per common share is computed using the weighted-average number of common shares outstanding after giving effect to the
conversion of all the outstanding convertible preferred stock and convertible notes into shares of common stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. The cash and
cash equivalents balance at December&nbsp;31, 2018 and 2019 and March 31, 2020 represents cash in readily available checking and money market accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentration of Credit Risk </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Financial instruments,
which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the
Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Deferred
Offering Costs </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to its
planned IPO. The deferred offering costs will be offset against the proceeds received upon the completion of the planned IPO. In the event the planned IPO is terminated, all of the deferred offering costs will be expensed within the Company&#146;s
statements of operations. As of December 31, 2019 and March 31, 2020, $0 and $1.3 million, respectively, of deferred offering costs were recorded within other assets in the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Preferred Stock Warrant Liabilities </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has
outstanding freestanding warrants to purchase shares of its Series&nbsp;A convertible preferred stock. Since the underlying Series&nbsp;A convertible preferred stock is classified outside of permanent equity, these preferred stock warrants are
classified as other long-term liabilities in the accompanying balance sheets. The Company adjusts the carrying value of such preferred stock warrants to their estimated fair value at each reporting date, with any related increases or decreases in
the fair value recorded as an increase or decrease to other income (expense) in the statements of operations. The preferred stock warrant liabilities will continue to be adjusted to fair value until such time as the preferred stock warrants are no
longer outstanding or the underlying securities are no longer redeemable outside the control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or
paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must
maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which
the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;1&#151;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Quoted prices in active markets for identical assets or liabilities </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;2&#151;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Observable inputs, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets
that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Level&nbsp;3&#151;Unobservable</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">inputs that are supported by little or no market activity and that are significant to determining the fair value of the
assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The asset&#146;s or
liability&#146;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">None of the <FONT STYLE="white-space:nowrap">Company&#146;s&nbsp;non-financial&nbsp;assets</FONT> are recorded at fair value on <FONT
STYLE="white-space:nowrap">a&nbsp;non-recurring&nbsp;basis.</FONT> Financial liabilities that are measured at fair value on a recurring basis include the preferred stock warrant liabilities. No transfers between levels have occurred during the
periods presented. The carrying amounts reflected in the Company&#146;s balance sheets for prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The carrying
value of the Company&#146;s debt approximates fair value due to the interest being reflective of current market rates for debt with similar terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The preferred stock warrant liabilities are recorded at fair value utilizing the Black-Scholes option pricing model using significant unobservable
inputs adjusted for the preferred stock warrant&#146;s expected life and the fair value of the underlying preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table
provides a reconciliation of the preferred stock warrant liabilities measured at fair value using Level&nbsp;3 unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2017 and 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2019 and March 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment, including leasehold improvements, are stated at cost less accumulated depreciation and amortization. Depreciation and
amortization are recorded using the straight-line method over the estimated useful lives of the related assets, which ranges from three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of the estimated
useful lives of the assets or the remaining lease term. Repairs and maintenance charges that do not increase the useful life of the assets are charged to operating expenses as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Long-lived assets
consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount
of those assets. The Company has not recognized any impairment losses in any of the periods presented in these financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segment Information
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company manages its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
operations as a single operating segment in the United States for the purposes of assessing performance and making operating decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, all the Company&#146;s
revenues has been derived from collaboration and research agreements (Note 3). The terms of these arrangements include the following types of payments to the Company: <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">up-front</FONT> license fees; development, regulatory and commercial milestone payments;&nbsp;payments for research and development services provided by the Company or for manufacturing supply services the Company provides
through its contract manufacturers; and royalties on net sales of licensed products.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective January&nbsp;1, 2019, the Company
adopted&nbsp;Accounting Standards Update (ASU) No. <FONT STYLE="white-space:nowrap">2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers</I> (ASU <FONT STYLE="white-space:nowrap">2014-09),</FONT> which supersedes all existing revenue
recognition requirements,&nbsp;using the modified retrospective approach. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company
expects to receive for those goods or services. An adjustment to retained earnings was not required upon adoption as the Company had no revenue generating agreements in effect on the date of adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> the Company performs the following steps in determining the appropriate amount
of revenue to be recognized as it fulfills its obligations under each of these agreements: (i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the promised goods or services are performance
obligations including whether they are distinct in the context of the contract; (iii)&nbsp;measurement of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance
obligations; and (v)&nbsp;recognition of revenue when, or as, the Company satisfies each performance obligation. See Note 3 for further discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to January&nbsp;1, 2019, the Company recognized revenues when all four of the following criteria were met: (i)&nbsp;persuasive evidence that an
arrangement exists, (ii)&nbsp;delivery of the products and/or services has occurred, (iii)&nbsp;the selling price is fixed or determinable, and (iv)&nbsp;collectability is reasonably assured. The Company&#146;s research evaluation agreement contains
multiple elements, including payments for reimbursement of internal and third parties&#146; development costs. The Company considers a variety of factors in determining the appropriate method of revenue recognition under these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company receives payments from its collaborators based on billing schedules established in each
<FONT STYLE="white-space:nowrap">contract.&nbsp;Up-front</FONT> and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its research and collaboration
arrangements.&nbsp;Amounts are recorded as accounts receivable when the Company&#146;s right to consideration is unconditional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development
Costs </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred and include salaries, benefits and stock-based compensation associated with
research and development personnel, third-party research and development expenses, license fees, laboratory supplies, facilities, overhead costs, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
consultants. Nonrefundable advance payments for goods and services that will be used in future research and development activities are capitalized and recorded as expense in the period that the
Company receives the goods or when services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upfront and milestone payments to acquire contractual rights to licensed technology are
recorded when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent Costs
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since
recoverability of such expenditures is uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Income taxes are recorded using the asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax
consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using
enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will
not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for uncertain tax positions in accordance with the provisions of Accounting Standards Codification
(ASC)&nbsp;740, <I>Income Taxes</I>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The
determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities reflect the future tax consequences of the differences between the financial reporting and tax bases of assets and
liabilities using current enacted tax rates. Valuation allowances are recorded when the realizability of such deferred tax assets does not meet a <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold. For tax benefits to be
recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company is subject to taxation in the United States and state jurisdictions. As of December&nbsp;31, 2019 and March 31, 2020, the
Company&#146;s tax years since inception are subject to examination by taxing authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company expenses stock-based compensation to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> over the requisite service period
(usually the vesting period) on a straight-line basis, net of actual forfeitures during the period, based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes
option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management&#146;s best estimates and involve inherent uncertainties and the application of management&#146;s judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss Per Share/Unit </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share/unit
is calculated by dividing the net loss attributable to common stock/units by the weighted-average number of common stock/units outstanding for the period. Diluted net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
loss per stock/unit attributable to common stock/units is computed dividing the diluted net loss attributable to common stock/units by the weighted-average number of common stock/units
outstanding for the period, including potential dilutive common stock/units. The Company has excluded 488,998 and 458,868 weighted-average shares/units subject to repurchase or forfeiture from the weighted-average number of common shares/units
outstanding for the years ended December&nbsp;31, 2018 and 2019, respectively, and 526,743 and 373,677 weighted-average share/units subject to repurchase or forfeiture for the three months ended March 31, 2019 and 2020, respectively. For purpose of
this calculation, outstanding stock/unit options, warrants to purchase convertible preferred stock/units, convertible promissory notes, and convertible preferred stock/units are only included in the calculation of diluted net loss per share/unit
when their effect is dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic and diluted net loss attributable to common holders per share/unit is presented in conformity with the two
class method required for participating securities as the convertible preferred stock/units and warrants to purchase Series A convertible stock/units are considered participating securities. The Company&#146;s participating securities do not have a
contractual obligation to share in the Company&#146;s losses. As such, the net loss was attributed entirely to common holders.&nbsp;Accordingly, for the years ended December&nbsp;31, 2018 and 2019 and for the three months ended March 31, 2019 and
2020, there is no difference in the number of shares/units used to calculate basic and diluted shares outstanding. In addition to the convertible promissory notes that were outstanding at December&nbsp;31, 2018, the following securities that could
potentially decrease net loss per share/unit in the future are not included in the determination of diluted loss per share/unit as their effect is anti-dilutive (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding convertible preferred stock/units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding warrants to purchase convertible preferred stock/units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding warrants to purchase common stock/units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding common stock/units options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#146;s unaudited pro forma net loss per share (in thousands, except share and per share data): </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Numerator</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months<BR>Ended<BR>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Add:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value of preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,724,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,001,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Add pro forma adjustments to reflect:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,129,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,627,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares used to compute pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,224,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,628,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I>, which
requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The Company early adopted the new standard beginning January&nbsp;1,
2019 using a modified retrospective approach. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-02&nbsp;provides</FONT> a number of optional practical expedients and accounting policy elections. The Company elected the package of practical expedients
requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or initial direct costs for any existing leases. As a result of these decisions, financial
information will not be updated, and the disclosures required under this guidance will not be provided for dates and periods prior to January&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company currently has one operating lease for office and laboratory spaces in San Diego, California. The operating lease was impacted by the new
accounting standard and resulted in the present values of the future lease payments being presented as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;right-to-use&nbsp;asset,</FONT></FONT> with a corresponding lease
liability at the date of adoption. The financial impact from the adoption of this standard is discussed in Note 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2014, the FASB issued <FONT
STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers</I>, which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new standard
requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services.
<FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09</FONT> defines a five-step approach for recognizing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new standard allows for two methods of adoption: (i)&nbsp;full retrospective
adoption, meaning the standard is applied to all periods presented, or (ii)&nbsp;modified retrospective adoption, meaning the cumulative effect of applying the new standard is recognized as an adjustment to the opening retained earnings balance.
Additionally, in November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-18,</FONT> Clarifying the Interaction between Topic&nbsp;808 and Topic&nbsp;606, which clarifies the effect of the revenue standard on the accounting
for collaborative arrangements. The update clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic&nbsp;606 when the collaborative arrangement participant is a customer in the
context of a unit of account. In those situations, Topic 606 should be applied. The Company adopted the new standards on January&nbsp;1, 2019 using the modified retrospective method. The adoption of these standards did not have a material impact on
the Company&#146;s financial position, results of operations or cash flows as the Company did not have any revenue-generating arrangements in effect at January&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation &#150; Stock Compensation (Topic&nbsp;718):
Improvements to Nonemployee Share-Based Payment Accounting</I>. ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> expanded the scope of Topic&nbsp;718 to include share-based payment transactions for acquiring goods and services from nonemployees.
An entity should apply the requirements of Topic&nbsp;718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> specifics that
Topic&nbsp;718 applies to all share-based payment awards, and that Topic&nbsp;718 does not apply to share-based payments used to effectively provide (1)&nbsp;financing to the issuer or (2)&nbsp;awards granted in conjunction with selling goods or
services to customers as part of a contract accounted for under Topic&nbsp;606 Revenue from Contracts with Customers. The Company adopted this standard on January&nbsp;1, 2019 and its adoption had no impact on the Company&#146;s financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Significant Agreements and Contracts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Collaboration and License Agreements and Research Agreement </I></B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research Collaboration and License Agreement with Eli Lilly and Company </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2019, the Company entered into a Research Collaboration and License Agreement (the Lilly Agreement) with Eli Lilly and Company (Lilly) for the
discovery, development and commercialization of antibody-oligonucleotide conjugate products directed against certain targets in immunology and other select indications on a worldwide basis. Under the Lilly Agreement, the Company granted Lilly an
exclusive, worldwide, royalty-bearing license, with the right to sublicense (subject to certain conditions), under the Company&#146;s technology to research, develop, manufacture, and sell products containing antibody-oligonucleotide conjugates that
are directed up to six mRNA targets. The Company retains the right to use its technology to perform its obligations under the agreement and for all purposes not granted to Lilly. The Company that it will not, itself or with a third party, research,
develop, manufacture or commercialize or otherwise exploit any compound or product directed against targets subject to the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
consideration of the rights granted to Lilly under the agreement, the Company received a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront fee of $20.0&nbsp;million and is eligible to receive up to $60.0&nbsp;million in development
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
milestone payments, up to $140.0&nbsp;million in regulatory milestone payments and up to $205.0&nbsp;million in commercialization milestone payments per target. In addition, Lilly is obligated to
reimburse the Company for research expenses, as defined, incurred under the agreement. Lilly is obligated to pay the Company a tiered royalty ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> to
<FONT STYLE="white-space:nowrap">low-double</FONT> digits on worldwide annual net sales of licensed products, subject to specified and capped reductions for the market entry of biosimilar products, loss of patent coverage of licensed products and
for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Lilly&#146;s royalty obligations and the Lilly Agreement will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the later of ten years from the date of the first commercial sale or
when there is no longer a valid patent claim covering such licensed product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has identified multiple promises to
deliver goods and services, which include at inception of the agreement: (i)&nbsp;a license to technology and patents, information and <FONT STYLE="white-space:nowrap">know-how;</FONT> and (ii)&nbsp;collaboration, including research services,
technical and regulatory support provided by the Company. At inception and through December&nbsp;31, 2019, the Company has identified one performance obligation for all the deliverables under the agreement since the delivered elements are either not
capable of being distinct or are not distinct within the context of the contract. Accordingly, the Company will recognize revenue for the fixed or determinable collaboration in an amount proportional to the collaboration expenses incurred and the
total estimated collaboration expenses over the five-year period over which it expects to deliver its performance obligations. In connection with the Lilly Agreement, the Company recognized revenue of $2.3&nbsp;million and $1.4&nbsp;million for the
year ended December&nbsp;31, 2019 and the three months ended March&nbsp;31, 2020, respectively, and had deferred revenue of $18.9&nbsp;million and $18.3&nbsp;million as of December&nbsp;31, 2019 and March&nbsp;31, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A reconciliation of the closing balance of deferred revenue related to the Lilly Agreement, is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Upfront payment received in 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue recognized in 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue recognized in the first quarter of 2020 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Balance at March 31, 2020 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrently with the execution of the Lilly Agreement, the Company issued a convertible promissory note to Lilly (see
Note&nbsp;6 for additional discussion). In connection with the Series&nbsp;C financing in November 2019, all outstanding principal and interest accrued under the note converted into 4,576,342 shares of Series&nbsp;C convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Agreements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2016 and 2017, the Company
entered into agreements with pharmaceutical companies under which the Company was contracted to perform certain research and development activities, as defined in work plans. All work under the agreements was completed in early 2018 with the Company
recognizing revenue totaling $0.4&nbsp;million for the year ended December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Property and Equipment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depreciation expense related to property and equipment was $0.4&nbsp;million, $0.3&nbsp;million and $0.1&nbsp;million
for the years ended December&nbsp;31, 2018 and 2019 and the three months ended March 31, 2020, respectively. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Debt </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s debt consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Term loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loans payable, net of issuance costs and discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Term loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued end of term fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loans payable, net of issuance costs and discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total loans payable, net of issuance costs and discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Term Loan </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2017, the
Company entered into an amendment (the LSA Amendment) to the Amended and Restated Loan and Security Agreement (as amended, the Loan Agreement) with Silicon Valley Bank (SVB). Pursuant to the LSA Amendment, SVB agreed to make loans of up to
$7.0&nbsp;million, comprising (i)&nbsp;a $5.0&nbsp;million term loan, funded at the closing date (the Term C Loan), and (ii)&nbsp;subject to the achievement of a specified milestone relating to the Company&#146;s research, an additional term loan
totaling up to $2.0&nbsp;million (the Term D Loan), of which $4.1&nbsp;million was used to repay the Company&#146;s existing loan with SVB, in addition to the final payments totaling $0.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Term C Loan matures on June&nbsp;1, 2021 and bears interest at an adjustable annual rate of the
prime rate per the Wall Street Journal or successor publication plus <FONT STYLE="white-space:nowrap">one-fifth</FONT> of one percent (0.20%). The LSA Amendment provided an extension of the interest only period through June&nbsp;1, 2019, upon the
Term D Loan advance. Beginning July&nbsp;1, 2019, the Company was required to repay the principal amount in 36 equal monthly installments, in addition to the monthly interest payment. In addition, a final payment of 6.5% of the funded amount, or
$0.3&nbsp;million, is due on the maturity date. The final payment fee was accrued as interest expense over the term of the loan and recorded in long-term debt, net of current portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, the Company entered into a second amendment to the Loan Agreement (the LSA Second Amendment). Pursuant to the LSA Second Amendment, SVB
provided the Term D Loan of $2.0&nbsp;million, upon the Company&#146;s receipt of $3.0&nbsp;million in convertible note financing. In addition, a final payment of 6.5% of the funded amount, or $0.1&nbsp;million, is due on the maturity date. The
Company accounted for the financing prospectively as a debt modification. As of December&nbsp;31, 2018 and 2019 and March&nbsp;31, 2020, the interest rate applicable to borrowings under the Term D Loan was 5.7%, 5.0% and 3.5%, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Amounts borrowed under the Loan Agreement are collateralized by substantially all of the Company&#146;s assets, excluding certain intellectual property,
which shall remain unencumbered throughout the term of the Loan Agreement. Under the Loan Agreement, the Company is subject to certain customary nonfinancial covenants, events of defaults and material adverse change provisions. At December&nbsp;31,
2019 and March 31, 2020, the Company was in compliance with all covenants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In conjunction with the Term A and Term B Loans, the Company issued
warrants to SVB to purchase up to 16,474 shares of Series A convertible preferred stock at an exercise price of $2.2615 per share, exercisable at any time following the issuance. The warrants have a term of ten years. In conjunction with the Term C
Loan entered into in June 2017, the Company issued warrants to SVB to purchase up to 19,918 shares of common stock at an exercise price of $0.25 per share, exercisable at any time following the issuance. The warrants have a term of seven years. The
Company estimated the fair value of the warrants granted using the Black-Scholes option-pricing model and recorded the fair value as debt discounts and are being amortized to interest expense using the effective interest method over the term of the
loans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Future minimum principal and interest payments and the final payment due under the Loan Agreement are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest and final payment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Term Loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Convertible Notes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2018 and 2019, the Company issued convertible promissory notes (collectively, the Notes) in the aggregate principal amount of $3.0&nbsp;million and
$4.5&nbsp;million, respectively (the 2018 Notes and 2019 Notes, respectively). The 2018 Notes and the 2019 Notes accrued interest at 8% and 10% per annum, respectively, and automatically converted into preferred equity from the next financing round
at 85% and 80%, respectively, of the per share price paid by the investors in a qualified financing of at least $10&nbsp;million. The 2018 Notes and 2019 Notes provided for optional conversion upon certain other events. Upon change of control, as
defined in the agreement, the Company was required to immediately repay 200% of the outstanding principal plus any unpaid accrued interest on the original principal. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrently with the execution of the Lilly Agreement, the Company issued a convertible promissory note to Lilly (the Lilly Note) and received cash
proceeds of $15.0&nbsp;million. The Lilly Note accrued simple interest of 8.0% per annum and, if not converted, would have matured in October 2020. All unpaid principal and interest were due at maturity. In the event of a qualified financing or
initial public offering of at least $30&nbsp;million, unpaid interest and principal were to convert into equity securities at the lesser of (i) 80% of the per share cash price paid by the investors in the qualified financing, or (ii)&nbsp;the
quotient resulting from dividing $150&nbsp;million by the number of the Company&#146;s outstanding equity securities immediately prior to the qualified financing. If there had not been a qualified financing, an initial public offering or change of
control prior to the maturity date then Lilly could have converted all unpaid interest and principal into the Company&#146;s Series B convertible preferred stock at a conversion price equal to $2.8269 per share or if applicable, convert into the
class or series of equity securities issued and sold by the Company in an equity financing, other than a qualified financing, with rights senior to the Series B convertible preferred stock at a conversion price equal to the price paid per equity
security by the investors participating in such equity financing. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Notes represent share settled debt that were accounted for at amortized cost
by accreting the Notes to their redemption value over the life of the debt using the effective interest method. In connection with the Series C financing in November 2019, all outstanding principal and interest accrued under the Notes converted into
6,893,036 shares of Series C convertible preferred stock. The Company recorded $0.2&nbsp;million, $6.9&nbsp;million and $0.2 million in interest expense for the years ended December&nbsp;31, 2018 and 2019 and three months ended March&nbsp;31, 2019,
respectively, for the stated interest rate and the discount at which the Notes converted. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Lease Agreements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company adopted ASC 842,
<I>Leases</I>, as of January&nbsp;1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with the Company&#146;s historic accounting under ASC 840, <I>Leases</I>. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with ASC 842, the Company determines if an arrangement is a finance lease, operating lease or short-term lease at inception, or as
applicable, and accounts for the arrangement under the relevant accounting literature. Currently, the Company is only party to a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> office space operating lease and short-term lease arrangements.
Under the relevant guidance, the Company recognizes operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (ROU) assets and liabilities based on the present
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
value of the future minimum lease payments over the lease term at the commencement date, using the Company&#146;s assumed incremental borrowing rate of 6%, and amortizes the ROU assets and
liabilities over the lease term. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company&#146;s short-term leases are not subject to recognition of an ROU asset or liability or straight-line lease
expense requirements. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2014, the Company entered into a lease agreement for office and laboratory space under a <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> operating lease with a term through November 2017 (the Lease). Under the terms of the Lease, the Company provided the landlord with a security deposit of $28,000 in the form of an unconditional and
irrevocable letter of credit. In July 2017, the Company entered into an amendment to the Lease to extend the Lease through December 2021 (the Lease Amendment). Under the terms of the Lease Amendment, the Company provided the landlord with an
additional security deposit of $28,000 in cash and the letter of credit was cancelled. On January&nbsp;1, 2019, the Company recognized an initial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and
lease liability of $0.8&nbsp;million and $1.1&nbsp;million, respectively, related to the Lease and the Lease Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s ROU
assets and liabilities related to the Lease and the First Lease Amendment are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">ROU assets (included in other assets)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current portion of lease liabilities (included in accounts payable and other liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liabilities, long term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Supplemental cash flow information related to operating leases was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months<BR>Ended<BR>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash paid included in operating cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Maturities of lease liabilities due under this lease agreement are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less current portion of lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liability, long term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Rent expense under the lease agreement totaled $0.3&nbsp;million, $0.3 million and $0.1 million for the
years ended December&nbsp;31, 2018 and 2019 and the three months ended March&nbsp;31, 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019 and March
31, 2020, the weighted-average remaining term of the Company&#146;s operating leases was 2.0 years and 1.75 years, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable
that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding for which any liabilities have been accrued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2019 and March
31, 2020, the Company has $6.1 million and $8.4&nbsp;million, respectively, of outstanding non-cancellable purchase commitments with two contract manufacturing organizations for the manufacture of materials used in its preclinical and planned
clinical trials. Approximately $8.2&nbsp;million of the purchase commitments are expected to be paid within the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners
and other parties with respect to certain matters including, but not limited to, losses arising out of breech of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into
indemnification agreements with officers and members of its board of managers and directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as
directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of
such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities
related to such obligations in its financial statements as of December&nbsp;31, 2018 and 2019 and March 31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Stockholders&#146; Equity (Deficit)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April&nbsp;1, 2019, Avidity
LLC, a Delaware limited liability company, was converted into Avidity Biosciences, Inc., a Delaware corporation. The entire membership interests of Avidity LLC were converted into securities of Avidity Biosciences, Inc. as follows: (i)&nbsp;each
outstanding common unit of Avidity LLC was converted into one share of Avidity Biosciences, Inc.&#146;s common stock; (ii)&nbsp;each outstanding Series A preferred unit of Avidity LLC converted into one share of Avidity Biosciences, Inc.&#146;s
Series A convertible preferred stock; and (iii)&nbsp;each outstanding Series B preferred unit of Avidity Biosciences LLC converted into one share of Avidity Biosciences, Inc.&#146;s Series B convertible preferred stock. All the property, rights,
privileges, powers and franchises of Avidity LLC vested in Avidity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Biosciences, Inc., and all debts, liabilities and duties Avidity LLC became debts, liabilities and duties of Avidity Biosciences, Inc. All references to the former member&#146;s equity accounts
in Avidity LLC have been adjusted to reflect the equivalent number of Avidity Biosciences, Inc. shares of common stock. Upon completion of the conversion, the Company reclassified an accumulated deficit of $44.1&nbsp;million from predecessor deficit
to additional paid in capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Convertible Preferred Stock/Units </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In November 2019, the Company issued 17,915,525 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for net
proceeds of $72.6&nbsp;million, net of issuance costs of $4.1&nbsp;million. In addition, all outstanding principal and accrued interest under the Notes and the Lilly Note were automatically converted into 6,893,036 shares of Series C convertible
preferred stock, at a stated discount pursuant to the original terms of the notes at issuance. In January 2020, the Company issued an additional 537,232 shares of Series C convertible preferred stock, for cash, at a price of $4.2812 per share, for
net proceeds of $2.2 million, net of issuance costs of $100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018, preferred units consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Unit<BR>Original<BR>Issue Price<BR>and<BR>Conversion<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,366,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,350,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.2615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,462,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,108,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.8269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,828,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,458,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, preferred stock consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Original<BR>Issue Price<BR>and<BR>Conversion<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,366,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,350,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.2615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,108,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,108,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.8269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,579,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,808,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.2812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,054,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,267,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of March 31, 2020, preferred stock consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Original<BR>Issue Price<BR>and<BR>Conversion<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,366,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,350,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.2615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,108,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,108,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.8269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,579,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,345,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.2812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,054,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,804,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of the preferred stock have the following rights and preferences: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Voting Rights </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of preferred stock are entitled to
vote, together with the holders of common stock, on all matters submitted to the stockholders for a vote and are entitled to the number of votes equal to the number of whole shares of common stock into which such holders of preferred stock could
convert on the record date of for determination of stockholders entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Dividends </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company cannot declare and pay any common stock dividends without first declaring and paying dividends, as defined in the terms of the amended and
restated certificate of incorporation, to the preferred stockholders. The holders of preferred stock are entitled to receive, when, as and if declared by the Board of Directors, noncumulative dividends at the rate of 8.0% of the applicable original
issue price of such preferred stock (Original Issue Price), subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred stock. No dividends have been
declared as of March&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Liquidation Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or Deemed Liquidation Event (as defined below), each
holder of preferred stock is entitled to receive, prior and in preference to any distributions to the common stockholders, an amount equal to the greater of (i)&nbsp;the Original Issue Price per share, plus any declared but unpaid dividends thereon
or (ii)&nbsp;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. In the event that the assets available for distribution to the holders of preferred stock
are insufficient to pay such holders the full amounts to which they are entitled, the assets available for distribution will be distributed on a pro rata basis among the holders of the preferred stock in proportion to the respective amounts that
would otherwise be payable in respect of such stock. After payments have been made in full to the holders of preferred stock, then, to the extent available, the remaining amounts would be distributed among the holders of the common stock, pro rata
based on the number of shares held by each holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Conversion Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares of preferred stock are convertible into an equal number of shares of common stock, at the option of the holder, subject to certain
anti-dilution adjustments. Each share of preferred stock is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
automatically converted into common stock, (i)&nbsp;at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the preferred stock, or
(ii)&nbsp;immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock for the account of the Company
in which the per share price is at least $4.2816 and&nbsp;the aggregate gross proceeds, net of underwriting discounts and commissions, to the Company is at least $40.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Presentation of Convertible Preferred Stock/Units </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company&#146;s Preferred stock/units have been classified as temporary equity in the accompanying balance sheet in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is
based upon certain change in control events outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company. The Company has determined not to adjust the carrying values of the convertible preferred
stock/units to the liquidation preferences of such shares/units because the occurrence of any such change of control event is not probable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2018 and 2019 and the three months ended March&nbsp;31, 2020, the Company issued 655,072, 310,140
and 222,872 common units/shares, respectively, for proceeds of $0.2&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million, respectively, upon early exercise of shares options granted under the 2013 Equity Incentive Plan. The early exercise liability
of $0.1&nbsp;million at each of December&nbsp;31, 2018 and 2019, and March&nbsp;31, 2020 was included in accrued liabilities on the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2013, the Company
adopted the 2013 Equity Incentive Plan (the Plan). The&nbsp;Plan provided for the issuance of incentive units to employees and nonemployees of the Company and <FONT STYLE="white-space:nowrap">non-statutory</FONT> unit options, restricted unit
awards, unit appreciation rights, and unit bonuses to directors, employees, and consultants of the Company. Under the Plan, 4,486,934 units were initially reserved for issuance. Upon the conversion of the Company to a C corporation, the Plan
continued on the same terms and conditions. In 2019, the number of shares reserved under the Plan was increased to 10,065,722 shares. At December&nbsp;31, 2019 and March 31, 2020, 3,377,646 shares and 1,715,553 shares, respectively, remain available
for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The options that are granted from the Plan are exercisable at various dates and will expire no more than ten years
from their date of grant. The exercise price of each option shall be determined by the board of directors. For holders of more than 10% of the Company&#146;s total combined voting power of all classes of stock, incentive stock options may not be
granted at less than 110% of the fair market value of the Company&#146;s common stock at the date of grant and for a term not to exceed five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Stock option activity for employee and nonemployee awards and related information is as follows : </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Grant<BR>Date<BR>(fair&nbsp;value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding and Exercisable at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">631,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,201,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(312,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding and Exercisable at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,515,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(222,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(93,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding at March 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,091,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,292,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant date fair value of options granted during the years ended December 2018 and 2019 and the
three months ended March&nbsp;31, 2020 was $0.14, $1.64 and $1.71, respectively. The total fair value of options that vested during the years ended December&nbsp;31, 2018 and 2019 and the three months ended March&nbsp;31, 2020 was $0.1&nbsp;million,
$0.4&nbsp;million, and $4,000, respectively. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019 and March 31, 2020, 410,779 and 298,893, respectively, of the stock
options exercised were unvested and subject to repurchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock option/units grants were as
follows: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4%&nbsp;&#150;&nbsp;2.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4%&nbsp;&#150;2.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83.0&nbsp;&#150;&nbsp;84.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84.0&nbsp;&#150;88.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#150;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Risk-Free Interest Rate.</I>&nbsp;The Company bases the risk-free interest rate assumption on the U.S.
Treasury&#146;s rates for U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with maturities similar to those of the expected term of the award being valued. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Expected Volatility.</I>&nbsp;Since the Company is not yet a public company and does not have a trading history for its common stock, the expected
volatility assumption is based on volatilities of a peer group </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process
until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Expected
Term.</I>&nbsp;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which
is an average of the contractual term of the option and its vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Expected dividend yield.</I>&nbsp;The Company bases the expected
dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The allocation of
stock-based compensation expense was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019 and March 31, 2020, the unrecognized compensation cost related to outstanding time-based
options was $4.8&nbsp;million and $7.6 million, respectively, which is expected to be recognized over a weighted-average period of 3.7 years and 3.6 years, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Common Stock Reserved for Future Issuance </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Common
stock reserved for future issuance consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock options/units issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Equity awards available for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding preferred and common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
operated as a nontaxable partnership until its conversion on March&nbsp;31, 2019. The Company had deferred tax assets in existence on March&nbsp;31, 2019 when the Company became a taxable entity. Deferred tax assets were not recognized due to the
uncertainty that such assets will be realized. The Company retained the valuation allowance on the deferred tax assets at December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the period April&nbsp;1, 2019 to December&nbsp;31, 2019, the Company recorded no provision for income taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A reconciliation of the Company&#146;s effective tax rate and federal statutory tax rate is summarized
as follows:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax expense (benefit) at statutory rates</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State income tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Book income (loss) for <FONT STYLE="white-space:nowrap">pre-conversion</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Realized gain on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Reserve for uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax recognized upon conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, significant components of the Company&#146;s deferred income taxes are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has established a full valuation allowance of $7.8&nbsp;million against its net deferred tax assets due to
the uncertainty surrounding the realization of such assets that preclude it from determining that is more likely than not that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such
time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. Management&#146;s assessment at December&nbsp;31, 2019 considered the generation of
<FONT STYLE="white-space:nowrap">pre-tax</FONT> book losses in its first year, the inability to carryback its operating losses, the lack of feasible <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, the limited existing taxable
temporary differences, and the subjective nature of forecasting future taxable income into the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company had
federal net operating loss (NOL) carryforwards of approximately $15.3&nbsp;million, before consideration of limitations under Section&nbsp;382 of the IRC, as further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
described below. The net loss generated in 2019 may be carried forward indefinitely but federal NOLs generated in tax years beginning after December&nbsp;31, 2020 will only be available to offset
up to 80% of future taxable income. Additionally, at December&nbsp;31, 2019, the Company had state NOL carryforwards of approximately $15.0&nbsp;million which may be used to offset future taxable income and will begin to expire in 2039. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company had federal and state tax credit carryforwards of approximately $0.3&nbsp;million. The Company has not performed
a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2039, if unused, and the state credits carry forward indefinitely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to IRC Section&nbsp;382 and IRC Section&nbsp;383, the Company&#146;s ability to use NOL and R&amp;D tax credit carryforwards (tax attribute
carryforwards) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50&nbsp;percentage points (by value) within a three-year testing period. The Company has not completed an ownership
change analysis pursuant to IRC Section&nbsp;382. If ownership changes within the meaning of IRC Section&nbsp;382 have occurred, the amount of pre-change tax attribute carryforwards available to offset future taxable income and income taxes in
future years may be significantly restricted. Further, deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC Section&nbsp;382. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At December&nbsp;31, 2019, the Company has an unrecognized tax benefit balance of $0.2&nbsp;million related to federal and state tax credits that, if
recognized, would impact the Company&#146;s income tax benefit and effective tax rate if the Company&#146;s deferred tax assets were not subject to a full valuation allowance. However, due to the existence of the full valuation allowance, future
changes in unrecognized tax benefits will not impact the Company&#146;s effective tax rate. The Company does not foresee material changes to its liability for uncertain tax benefits within the next 12&nbsp;months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The
Company has no accruals for interest or penalties in the accompanying balance sheets and has not recognized interest or penalties in the accompanying statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is subject to taxation in the United States and California. Due to the net operating loss carryforwards, the Company&#146;s tax years since
inception are subject to examination by these taxing authorities. The Company has not been, nor is it currently, under examination by any taxing authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10.
COVID-19 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the
Company&#146;s operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and its impact on the Company&#146;s preclinical studies and clinical trials, employees and vendors, all of
which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company&#146;s financial condition or results of operations is uncertain. A prolonged outbreak could have a material adverse impact on the
financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Avidity Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(information
as of March 31, 2020 and thereafter and for the three months ended </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>March&nbsp;31, 2019 and 2020 is unaudited) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
its product candidates and raise additional capital. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (the &#147;CARES Act&#148;) was signed into law on
March&nbsp;27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#146;s social security payments, net operating loss utilization and carryback periods, modifications to
the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. At this point, the Company does not believe that the CARES Act will have a material impact on its income tax provision
for 2020. The Company continues to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows. The Company currently does not expect to apply for loans or grants under the CARES Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent
events occurring between the end of the most recent fiscal year and through April 3, 2020 for the financial statements as of and for the years ended December 31, 2018 and 2019 and through May 5, 2020 for the interim financial statements as of and
for the three months ended March 31, 2020. The Company has concluded that no subsequent events have occurred that require disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g897644g14h12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>SVB Leerink</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Credit Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Wells Fargo Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, all dealers that effect transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments
or subscriptions. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table indicates the expenses to be incurred in connection with the offering described
in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and
the Nasdaq Global Market listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;paid&nbsp;or<BR>to be paid</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a
corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly
violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the Registrant shall
be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of
Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the General
Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership,
joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or
proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation,
no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court
determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem
proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective immediately prior
to the closing of this offering, provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by
reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she
reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of
incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a
director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or
by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with
such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such
expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in
connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with
each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a
director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims
based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In any underwriting agreement we enter into in connection with the sale of
common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Set
forth below is information regarding unregistered securities issued by us since January&nbsp;1, 2017. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the
SEC, under which exemption from registration was claimed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Issuances of Securities </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From December 2016 to October 2017 we issued an aggregate of 8,108,471 Series B preferred units to investors at a
purchase price of $2.8269 per unit, for aggregate consideration of approximately $21.3&nbsp;million, including the conversion of previously outstanding convertible promissory notes at a discounted price of $2.2615 per unit. Each outstanding Series B
preferred unit was converted into one share of our Series B convertible preferred stock in connection with the Conversion described below. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In June 2017, we issued to a lender a warrant to purchase 19,918 common units at an exercise price of $0.25 per unit in
connection with our entry into a loan and security agreement. The warrant was converted into a warrant to purchase 19,918 shares of our common stock at an exercise price of $0.25 per share in connection with the Conversion described below.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In July 2018, we issued and sold to certain investors an aggregate principal amount of $3.0&nbsp;million in convertible
promissory notes (the 2018 Notes). The 2018 Notes, including accrued interest thereon, were automatically converted into shares of our Series C convertible preferred stock in November 2019 in connection with our Series C convertible preferred stock
financing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In February 2019, we issued and sold to certain investors an aggregate principal amount of $4.5&nbsp;million in
convertible promissory notes (the 2019 Notes). The 2019 Notes, including accrued interest thereon, were automatically converted into shares of our Series C convertible preferred stock in November 2019 in connection with our Series C convertible
preferred stock financing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In April 2019, Avidity Biosciences, LLC (formerly known as Avidity NanoMedicines LLC) (Avidity LLC), a Delaware limited
liability company, converted into Avidity Biosciences, Inc. (the Conversion). As a result, all 6,159,933 common units, 4,350,299 Series A preferred units and 8,108,471 Series B preferred units of Avidity LLC outstanding at the time of the Conversion
were converted into 6,159,933 shares of common stock, 4,350,299 shares of Series A convertible preferred stock and 8,108,471 shares of Series B convertible preferred stock, respectively, of Avidity Biosciences, Inc. The Conversion was effected in
accordance with the terms of the Agreement and Plan of Conversion and did not constitute a sale for purposes of the Securities Act. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In April 2019, we entered into a convertible note purchase agreement with an investor, pursuant to which we issued and
sold a convertible promissory note in the principal amount of $15.0&nbsp;million (the April 2019 Note). The April 2019 Note, including accrued interest thereon, was automatically converted into shares of our Series C convertible preferred stock in
November 2019 in connection with our Series C convertible preferred stock financing. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In November 2019 and January 2020 we issued an aggregate of 25,345,793 shares of our Series C convertible preferred stock
to investors at a purchase price of $4.2812 per unit, for aggregate consideration of approximately $102.8&nbsp;million, including the conversion of the 2018 Notes, the 2019 Notes and the April 2019 Note at a discounted purchase price of $3.639,
$3.425 and $3.425, respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No underwriters were involved in the foregoing issuances of securities. The securities described
in this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated
thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All holders of securities described above represented to us in connection with their purchase or
issuance that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
bear the risks of the investment and could hold the securities for an indefinite period of time. The holders received written disclosures that the securities had not been registered under the
Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Grants of Stock Options </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">From January 2017 through April&nbsp;30, 2020, we granted stock options to purchase an aggregate of 6,407,946 shares of
our common stock at a weighted-average exercise price of $0.49 per share, to certain of our employees, consultants and directors in connection with services provided to us by such persons. 1,325,839 of these options have been exercised and 104,594
have been cancelled through April&nbsp;30, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The stock options and common stock issuable upon exercise of such options as
described in this section (b)&nbsp;of Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by
Rule&nbsp;701 promulgated under the Securities Act or the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation&nbsp;D promulgated thereunder relative to transactions by an issuer not involving any public offering. All
recipients either received adequate information about us or had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All of the
foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities
had not been registered and the applicable restrictions on transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Exhibits.</B>&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit Index attached to this registration statement, which is incorporated
by reference herein. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><B>Financial Statement Schedules.</B>&nbsp;&nbsp;&nbsp;&nbsp;Schedules not listed above have been omitted because the
information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17.
Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned hereby undertakes that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Registration Rights Agreement, dated November&nbsp;8, 2019, by and among the Registrant and certain of its stockholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Participation Rights Letter Agreement, dated November&nbsp;8, 2019, by and among RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant issued to Silicon Valley Bank, dated August&nbsp;7, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant issued to Silicon Valley Bank, dated June&nbsp;9, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Avidity Biosciences, Inc. 2013 Amended and Restated Equity Incentive Plan, including form of stock option grant notice and stock option agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Avidity Biosciences, Inc. 2020 Incentive Award Plan, including form of stock option grant notice and stock option agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Letter Agreement, dated September&nbsp;19, 2019, by and between Sarah Boyce and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Letter Agreement, dated January&nbsp;17, 2020, by and between Joseph Baroldi and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Employment Agreement, dated October&nbsp;2, 2013, by and between Arthur A. Levin, Ph.D. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman Agreement, dated October&nbsp;28, 2019, by and between Troy Wilson, Ph.D., J.D. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Release Agreement dated December&nbsp;19, 2019, by and between P. Kent Hawryluk and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for Directors and Officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research Collaboration and License Agreement, dated April&nbsp;17, 2019, by and between Eli Lilly and Company and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement, dated August&nbsp;7, 2015, as amended, by and between Silicon Valley Bank and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement, dated March&nbsp;31, 2014, as amended, by and between <FONT STYLE="white-space:nowrap">ARE-10933</FONT> North Torrey Pines, LLC and Registrant</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of BDO USA, LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Previously submitted. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit have been omitted for confidentiality purposes. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">AVIDITY BIOSCIENCES, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sarah Boyce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, the undersigned officers and directors of Avidity Biosciences, Inc., hereby severally constitute and appoint Sarah Boyce and John W. Wallen III,
Ph.D., J.D., and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution
and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for
the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or
necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held
on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Sarah Boyce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">President, Chief Executive Officer and Director (principal executive officer)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Joseph Baroldi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Chief Operating Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(principal financial and accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Troy Wilson, Ph.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Carsten Boess</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Todd Brady</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Noreen Henig, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Edward Kaye, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Michael Martin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Roderick Wong, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g897644g01z61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g01z61.jpg
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M 0$! 0$! 0'_P  1" !P /0# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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M5SI'/5ZJO-[(;>"WMXK6WABAMH(D@AMXHTC@B@C01QPQQ* B1(@"*BJ%50%
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MG">O0#'P'S% .@R23\3\C4+],;3J-Q:]H<UK"8Y"RQHQLA#:]%FJLC'BC2V
M(9Y][/:0Y2!'O:U2@"!"VM1D[>>*NZ-#NMO:U>Z?=!R!*\MK.^3ZU:2NQ@N
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M<C!Z(#WQV+GQ/PP!Y$C)S9SO2OQUCW:&K,$W)AUG@FQ* 7(,=LVHYT,Z+&4
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M>;MU ;SZ?CU^OYS5%."5\LX^'UUKE>KKLW)-W;7T5Z?>J2OFR#.,GQ_)-@+
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MIAE6[FNY"K*4=8[6W;#3705[?UC9W0MYZ7N#3Q>68ECG!*364RE9(I% YL2
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MTGO64E9+H )$"T5ME>>>;=J]#/[>EYUK_O&Z/_O?NT5YHOQ4&-]ZW[UTP_\
M\BPKU<X)_P"K3;O^_K7_ )[4ZMJYU[7:M5Q>J7V6_P G'JAESZ:P^CS_ &K\
MNLL(^&7V&B/O0Y_Y3Y!![%2:'\"QAEB\4Z-$02^-HD<YKIX_-E&3CP\:JQP/
M?V%?7TN^L?\ DT]5\4'NZ_Z/8FT?AV3GOS1?&:%/=!PKC>-D>]$FA7',<0&
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M]:2J+E@X_H[C4)L.NG69/42RH\\XYO5+>XY)#'IS]K.YF]>XF9KE.W<G?+5
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M@$"8=^,7)>69%91JF17;CZ!^.LI8A\FR,*@QRV:F1/\ ?B5)&3&QI\[A$L"
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MPC:EIA5K;Y5L),JK9L(M;BV CK4QNFJ/C+FN<?QZ>(OZJOG=\40T\7PNC?\
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M *:[6_YYIW]X2NO.+7^K'?G_ $MK/]SEK^?MS?JO)*I,=3^JNS^W^W*?5.M
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;G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g897644g05r92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g05r92.jpg
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M:?A_$U.;KC42M16*?4:G6F*A'>9<:AIJS+4B&3\7?L*,J6P:SNTAMQ8]#BC
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M2G]3L&_G2P,CS/6]P>?ZOO$S946# !@ P 8 , & # !@ P 8 , & # !@ P
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M%&;3=U!8FAX+;](5#9&TY0BGLQ !C4*=F_$- G<35Y0/QIJ8!7X>! L9@ P
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M)MK*63:-4^NKK&4M(DG8SL=\KG:V=\K6RMREQ#T28%!"$V]-U&?1EL_\-&\
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MF2GX42IT^5-BZ6^8D:;&?E1M!:4+U\=IQ3K.@M24*UB$Z*U)2=C,B/+<U!T
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M[#87OYA<)V)*FTR#3&D4NG$=,2FG.K.>2U2%MJ;C(=/;KGR$?HX, & '4O\
M^0GKZ)<?X,[ A6P^H_ >;7.@, W]<=_0=5OU-9_W&LTG.&KK&9'!+T^)BD''
M;B&?Q\E$5:I3SONP^0@L*QYXBX](YY3;=4KLW3ZR)O,6Z.M\,=:F!:2IE F?
MM!6!)FXU:AZ1KS4;GI%H! *#(:B._P!TKGQW._C;N[\Q(O=&.4<LXITY$YA
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M !QHPHT*1/HM.6$"P6 # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M8-#Y,8L[_I]C#&Z:5-B8*GM/K/ZVGXGUB>L"!!/&OT.L'T]8GWDR[ "=L &
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M..YH<6M[0&!H[ !]?@M/^_\ ?/*BJ[SXXVN\'^!\:Z>*O*/J4:9-&]Z[?8U
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M^S^^:M%5HGQP);X/J'QK>O%6[&*E 63OFRMF=@,! 96'C#KX9M,=N7[W\(P
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M.*QT4,_'I<ZTB2YNBD\:US.JYW>(2H6FG'1UV<&L294:$'M/KY_?GVYBS.!
M@GC7Z'6#Z>L3[R9=@!.V # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , .I?\ \A/7T2X_P9V!"MA]1^ \VN= 8!OZX[^@ZK?J:S_N-9I.
M<-76,R."7I\3$')^ M&AM%BMQTE7)N5R*,V#NT&"/SKF%RDG58M$S I7JD3@
M@J*6VV\5DF2,YCDK PM!45"TL1 BDS0B1ITY!9=!DTCM;+,K9)21VZR*_>+>
M/LFCD63)%DFD#)'$B]T;V1"J?75 T)EKT['Z2M30D/<%"<I2Z.:D04[>@)$-
M6L/%HE,489O0<"HBN;>FZC/HRV?^&C> $WX , & # !@ P 8 , & # !@ P
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M!0X&-C,U(!JC#1)&](1L!  &=S,^4[B6,"!!/&OT.L'T]8GWDR[ "=L & #
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M^B7'^#.P(5L/J/P'FUSH# -_7'?T'5;]36?]QK-)SAJZQF1P2]/B8F;*"P8
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M:7<]\AC2OE4A:42IQ>4"<MN2GGNJP)34WN*U("Q^)]F9BQ6! 8 , & # !@
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9O73KK&HZ?L_$0:[D96VE;;\!KTS8%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g897644g14h12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g14h12.jpg
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M 0$!             @,!" 4&"0<$"O_$ $<1  $# P(#! <& @8)!0$   $
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M;][G$8+CXGY#N"W+XF?@#/\ ]+W7ZEA,W;^Q]_9YJ'_K.L_\'85Q%T_T\?\
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M*Y:M2\EE&2X&,\M5%;!T(D1J94_F3M=;%Z%&(74]='-@ (9P9!LC#.->.*?
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M\^QG@/\ >ZGNQU.Y9"$3(1-,A4TTRE(0A"@4A"% "E(0I0 I2E*  4H
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M&VB=K!)):[M3<D-XL=9(T-],M=8YCS$XEK.WII6RT=8QC(ZNGF8UH;6>Y/\
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M%$I@:N+98G+0WO\ 4IVJR*B9_H=,Q3@  ;IFB'$MK6ZZU(UA!:VN:T8Z#%-
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M[?K.J]5VK2%KEN5RF;SEKVT5$UX%37U(;EL$#-SRY+>VF+3' P\\AW:UW>-
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MBC1[]W%M]K[*V+(3*M)@[@LQ6;NG]'K,#7G,V,,FX2;R4\JF$FDZ;((%2ST
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M#XM=@[>+2"T]XR 1!E9> >[(+<L'JUHR++P=E=+JQ&QVS5<*TE LQ*K(R4T
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M _S@/MA%YPB81>         ]@  Z  ?Q  ?3"+SA%X  #KT  ZCU'H'3J/\
M&/\ &.$7G")A$PB81,(F$3"+QT !$0  $?J/0.H]/IU'ZCTPB\X1,(F$7@
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I$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g897644g14p88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g14p88.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MV &4 P$1  (1 0,1 ?_$ !X  0 !!0$! 0$            (!08'"0H$ P(!
M_\0 21   00" @ $ P(*!@@#"0  !0(#! 8!!P ("1$2$Q05%B$X%Q@U5W5W
MEK2UMC9V>+>XU2(C,3=!=+/3)"9S)2<Y4519>9+7_\0 '0$!  (" P$!
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M[I@^<:NINP?D$W^B"7[D]SZ,5OJ.K]S3_-/7H;^\=[5WD*X]N?+A>8JKU_\
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MO]SFV?U9WS^5BO/W;I;^2NDW[/XS_#JE;Q5^I*KW/-\VY<E?/F>O-UDO2_\
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MJ[W%M,>QCCN'U&%8MI)HY6X?5<D*BFEQ.)K)>1FCJ(M8Q31O&I-%'(-5XS:
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MQR/X;_U%K6[8^'W3=3=;MR[)T+XH>_-O[DIE&+'=<ZQQ^ <GF[6B(EO, !B
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MAI8J*3$86L'*MBER&1N# P8;4L?;5#S3.<UO*.#Y'&X<\AKV1ZG?%K#*T#,
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M*QKP[#ZHN?+*]KVT=M4O8P,(8YS@&P.#W,CN0XN;^$8&N:_$%SZ];U/7"UG
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MDLT-/VU4N@B>R)]3.]CI7X4]'5R2O?'1536NU38T\C<]4!Q#1KZH+@2&ZSB
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MJYEDO^S]:WD:9A)1 6(R#A#J5/B3E/DV9^)LN'B/#>8R\\T5K]R6_P#O WZ
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M->NE%JK!^NA(?63MM7.P=MCGE$TR3]9#:QVC1WPM=P/@36E'72%Z'2V4DW(
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MH!,ACE"R$JLM#1;<>588F#MACX+RBZ#,AMV-/9R^%=$/3Q84NLB(@C;=UYO
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M8<=MV7.FR(\.(R]*?9:7"E1'V'4=F;$V>$G5N?.?H,DC5)L"8E^NF]=,# <
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MC*>&LUD!R!?KUZ\Y -7$#CX-W/\ 5]5R+$TQJM5R%OW?:(<;9&K:H98&&[5
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M(@O6FR=AW&Q8V^]-:&CY0AIMD2:-1Z83CC88W"'*D :GY:%9G%&L7ZM7\?/
M[FUA>XDVK/V&S4P?7REBM<#9UX?41L(X'97,DWYN-O!Y;[0>(4N(,)@="BP(
MOOYCPV&H[2I4J5/E+0TC",.2I\YZ3.G2G?+W),V;)D3);ZG)$I]Y]QQQ559>
MOA$X1.$3A$X1.$3A$X1.$3A$X1.$3A%C;;0BS'**2'U+$A\IDA6YDD;",NUV
M>?KPVRB"-KK(X^T]&4'(V6LQ2P.!.5,'LMRY[*9!05'6Z3B2-O7KDH.S+KS<
MU]E]RP;KG13I6UO7O8H@M%C S3;^NZ99T4:5."PXF TF"HXJGNGALIFOD:_7
MW:;A^UV2P,/UZ'8+#8ILO($#3%^'AM]'3X.%@+W@-SN=VSFR'.=F[XR<BI=\
MA65OV;ZJP+4Y3<U]1IE]AY$2S)(MBR,9"LYDCU$!2G)85^4CR2P9P,/-P%8R
MMP$1PKVTNE#?=\?7+ISZ%%&H==<VHF).;5#$1;]%LI^&)!/GAEG'VRN*:&O5
M24^994LQ@;7!LB;KO""&!!>XU05-;M@>*,NML!G+7MLWVYK$=;\ =FP%4#;V
MN#D3M-[[-O1L\&S.RF6TTTPTVRRVVRRRVAIIII"6VFFFTX0VVVVC&$(;0C&$
MH0G&$I3C"4XQC&,<JKK]\(G")PBHMA?L,81+?JHP09.M^QF&-.FI=>&2D_$-
M8E(?,005DDPUIB9?7&4@-+0[*2RR]EAEQR0T10UC:1L.W+2V>O\ &ME-D4*[
MSUB56;,(V>-U$I*^K8,&NV:MW*3 #1Q3]FN.MBJ%(.#+EKK(2%<@+IX6.^F[
M7 RR-QGPWC>.@]-[;2JVN=XL;B_3?<;<1;A:^P*:8D.) #8@8$+'!1 ]K#$
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4PB<(G")PB<(G")PB<(G")PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g897644g18y97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g18y97.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MT $O P$1  (1 0,1 ?_$ !\  0 " @,  P$            '"04( 00& @,*
M"__$ $<0   & @$! P8("P<% 0$   (#! 4&!P !"!$)$A,4&2%3EM4*%1<B
M,3(V=Q88(SA!6'67M+73)#,T-4)1824Y4E2X)D3_Q  < 0$  @,! 0$
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M.Z&#]/S3!+-C#_I%K/9ILR8_26U&+UX W,DJ'S1CLCG,C!\&K89654=M"HE
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M;.\Z&'Z>H-MRQ3H6NGIZZZZSP:B@KZ0D5=%5TI&\5%--"1VZQC5UM'B^$XB
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M*.5L8TCB>7L&K7OO>6?#J1\]SO+:C5"=A/%LC3S6O)24LVV6GA>3UNC87?\
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M2]LRE.[OR-EX746]1EG=@GL\>E"&5NH +2WY$D8_65^EL MN._;?KV;^9O\
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M(E2-QB^PIR!#4*S)(VN3 G1%*%#RWKFXI2D.J5@-B#P(.W=OZUJEV/+^RO\
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M<*PZ#$9)63XI188(VM<U]:YS6REQ(+8]$&Y:!=U["Q"L@A;,7!T\4 ;8WE)
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M4_",J8J*;V>P3K@+=KQ$&PAP0U75%(W<\6',C3G)"@$W1=L6N2)*K7$%+#'
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H(EP7>,+OH3_%"+1?<UW-ZV+O;T&V)CF$WMM'45!S@ZUK[+[_ (+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g897644g20b40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g20b40.jpg
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M@L"V%S\@EIDJPY_-4JQ1\D2UU9&.-@>VP;_8"VX6SRN=U[9<9_7Q\2H<L[V
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MT;2-MM^W+P;?#EX6L1M!M;/QY;#L.W9SWR%CN/)(OF,!A$M=65QC;G*(E')
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M6U-?YNMJMZ"LQLTE3+3]C"3@RT:_"EFMK,:_Z/!NM;6M](WM?CLO'OTL;_\
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M^H)=5S&ZERR^L;7UK/V?9S\"KD_2QO\ _8HS_P!]UO\ ENM$?NF/\B_](?\
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M5E!V]1>=TWMF*RD[;I?.(?:-4]:V:LX2B)1$HBKSTM7I$USL0"YS&\4*PXK
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MG^2#<??]^S^I4^_*V^UN._J_4J;3$>!2QLRDH"DLM0U-QY8%ARQ2K  U(28
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M@##>P@BN&]KU:JK_ %O"_9 ?&#]]$5=O*R#!?D\])BUAAO>\8B^JUA6O>_\
MO%AW\+7K8W4D[XNC'G55\-K5I/KC.\KIYZ/H/C>&+!94^EX]K1!^3O""'-FD
M-<0K!M^:R-^C>UO_ %:'^NHZ=<7W#T<]*U/NBFQUD_UJTV_1^@^(K6+O"_9
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MOS&SBW*9S>8(Y B-&K3. C4B8P2]$"Q2-:(9(!"5I"[*%=BTRF][G$ LJ4V
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M<@3@S/T4V]12_A42PW#D"<&9^BFWJ*7\*B6&X<@4))T663,)(446 HL#NL"
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MQ$S0@E;J@ECD]DV89;D6 M@$[#*%-QUUL_!QC9<[\@/N\0/$K;;=^=MN5_\
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H*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g897644g20k45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g20k45.jpg
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MI*\J3=8IP8"3FBJ!ET^GH\''\672/J)!NPSF#/RC8>GHF7F]IX ?,=1W&?\
M .$XL%&E<ELQ]S#_ )HFES4$G]E_")$YV/%DPXE9QK%Z&].F RX'Z?3N_ETC
M[VQ.],&FGG;WJM5>Q;X,I^ C5EK2771&]6N#"01HHK;JH;=IE;IRU<H-D6)=
M%P=:)<UV_62-F6G9;8,NGT]/@X9>'/H'%"PO8YJ,%2:V-IF9+9&Z<;L+HW3M
MT',$"P@B1<W])#LR=V$UB8%]%N"8VI8DQXP_JR;$(2K;+VVS/CQ1P,NG?O\
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M5C9B09=3WW\'#=QSON'%BPO8QI@*DSL;34V2R/T\BPN#=/W,<R0)B91%6^Y
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M;N/ R1]>G_$GY2$Z=5/NO=;OP$T]^7E=X&(GO@ X . #@ X . #@ X . #@
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MP < ' !P < ' !P < ' !P < ' !P @2N_>AW#^ G6[\P^U? ">^ #@ X .
M#@ X . #@!4;OU^CC'27M<O;TBTQ=9-:"V@]=I-'C!IMP8 ,U(F[,=K4.RX^
MJ\HRWA"50(]JRFJ//X0W9UH J(+2$EM+9M+;>VW?;.W@S&,3PJP-5"K+V)&
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MD(R&G_!3) ^9\&2'/2(<GX6?$E0I'N7E^YE1GX[GLNM+0D Y_@ X . #@ X
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M@ X . #@! W8#^I]9_CSI;^>Q7 DMOF5\AB>>! < ' !P < ' !P < ' !P
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M_LT_(%_!AV9_)NX\#)'UZ?\ $GY2$Z=5/NO=;OP$T]^7E=X&(GO@ X . #@
MX . #@ X . #@ X . $#=@/ZGUG^/.EOY[%<"2V^97R&)YX$!P < ' !P <
M' !P < ' !P < ' !P < ' !P < ' !P < ' !P @2N_>AW#^ G6[\P^U? "
M>^ #@ X . #@ X . #@!C.\EFQ=V:Q ]>+'JC76Z-KU-W;.P0VZZ)I/5LG<!
MLS2S75W?XRD+L5,CCB*956&;SDZG+3I$I#4./+@PE2/B4>L&4&16/6O;9E?C
MK%^JXB7QA;5[(;IV'M.[;]U5V%UK)&]0_'_03$W?^FINH)-QW_4X_9J5V*-4
MYF6*&M'@JS=@I\QYP:E@7 44BJAAPZ"*D20E1$1$1&1^Z5L.^7N;?(8S%\#
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M<"2V^97R&)YX$!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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MP)+;YE?(8GG@0' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M ^&H#;"L%ZP38+"U/9^;+]Y&3+CMY?8]$^^;]4>TGU]>6H[0V ?]'5_PD?\
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M$WQ$'UM &\>3;\-N!/MNK?H]5QOD\H0/7\. #@ X . #@ X . #@ X . #@
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M@YQ-\1!];0!O'DV_#;@3[;JWZ/5<;Y/*$#U_#@ X . #@ X . #@ X . #@
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M?[K1W6ZX=O7+FUH&]2KDYK]%?<M2)53MU7R/1:%&DA5-_6H&&^.Q*57RN%_
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M_:E)_2&D#0VY?<>0 R/^(S^T4ZU?ON\_E5>^:VTO?!SB;XB#ZV@#>/)M^&W
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MHGNP=(WQK>Z6>=[V=KF,ROY96@!8E\,AQ4R;\)\&/CRY[\:*]L'M,:2N]O\
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M@5(!V ;K*IT6GPY%I*00P?YJ,D[_ -H&VFXTV5E9 A$G2\N,+3[@2A;*O?\
M&UC07BJBTJI5>34L/NQZ9"DSWVV)%14^MF*TMYQ+27*8TV;AH09();B$FJQ&
MI)9CF\-<K/1]BG$-$PW!H>,6)M>JD&D1'I<*BHBM2)\EN,RN0MBO/O)92XXD
MW%-L.K)-S2A1E8[P>3'[A7:3\+"O^<@<ZCHQ[O\ "OC5K\AP;(T\? ]I!\GI
M/YQD?S_N>@H\:A>?QG??UZM_BF*_R<_G1-)W<!BKQ4[^6V-N:!OAAT?>4#'Y
ME\;<7ES_ +.OLK^Y*-^:M$Y4/1#\(V&?CYWJF>/2/E)? ECO[4I/Z0T@:&W+
M[CR &1_Q&?VBG6K]]WG\JKWS6VE[X.<3?$0?6T ;QY-OPVX$^VZM^CU7&^3R
MA ]?PX . %"_)#VDOW3WK(6W/K4-43MI@W"HUYB!=X)DB S$/37F)CST4$=K
MA!<AMIK_ .S*04:;0XKVG6GDX]C/?M&V%:?C+$[-%J;\R/%7#F25.05LMR->
M.A*D))<B/);))FKW5VC,R*Q&D\QI_3EI!K&C+ 4G%-"BTV94&JG382&:LU*>
MA\W,=4AU2FXDN$\:TI3_ $9E(2DC.ZDJ(K#6VLGG:[;V@S0#<_7779F7KFW3
M;F$;AU39+<>44G42[:]=8*H>VS(<?@)"WPO*;:B.PI&"<8<\J4N*S)A2[$^U
MYP9_M3$_WY2OW,*5>W0TG_[!P)GM_LVO^'OFZ!DF\;7EG[$]P^S,#3&S:5I@
M'6)=*MEB5/HM?NXPZB>!9ANQ&TR3^P;- S$=]^ZF0UD;[Y7_ $>6Y#7LJPOH
M&DK1'AS!N&'*U3)U:?E(FQ(Q-SY$%U@VY"EI6>K'IT5S7+5(TGSNJ6=TG<K;
MBT&<H[&NDW'C.%J]2L+Q(#E*J4XWJ3#JK$LGH:6E-I)<RLSF>;5KJ):38UCR
MU5IL=]A?E=Q=,50V$]O@7M+7];KVW*N.KVQ#5V;1$FZG9*3P$ #7)E@'162/
MUUA)(O>TRW$DRY$-GWS>%.H896K&$@%H1;$^,,'1BL]LH4CP(C!(FS"2.9(S
MVH[;<R>T/2_*3 ;ER$N2$0DR9"8J7,,8?>PW[Q0!@7^D+?=:TU^/T#\N[]RP
M')W[JJUY/N>L:>*<\M/X/L+^63/J2LC4-Y< >:HS]_1Y_O/;I_ :3^85(Y7[
ME$]RU$\?H]73A<CD5]W^*?(]SUU21;[Z1-^R7K;^(MU_EH;SIW)S]^,2^+87
MSIP;,Y;/<U@;QY5/F#(U1N6R'G6-B[Z.S^USLC^'-,_F8ARN/*,]Y\->,IOS
M5L7=Y$W='CKQ)2OG[XE;Z1K_ %5U$_>&\_\ +:DYQ')O_O\ %_Q5#_+JP[%R
MW_L;1K\?BW\WAP:O?+2B@ V9/HY7]:]N_P!WZ,_S.V^5CY2']U@_XRN_DT@7
MRY$'V1I*^)PC^7B49%?)OY(K?T*,:>%U;65;V"G98VZSYSM@-DQ&1>:M*K,>
M.W$2.C/X?Q+P<?4\I[*<MY8:PWC/MK]-<:,-&L3'[-8=E5233CICL)M!1V&G
MN=[*1)4HUFXM.KJ<PDDVO?6.^PAN[3WIRJ6AZ3AF/3Z#!K15YBJO.JF2Y$8X
MYT]R A"6R8;7K\YV8LUFJVKJ)MM,8?H'GPVE V/:]C(Z^4!R9:J1K^DOC56Z
MQ8C1(U /;,.Q)S+V('O7'R+NRYL>0TM.&V6Q<5;65*?=PG:GM<Z3WS5'[QC?
M[T5\]NSB/O%HGX5G_P"X&:KQD^0*T]] .W2UHUW7]?/:U+U =$9 &")=HHU9
MX9^2XY(41CL+8<BK"I2C#7MI<2^K*O9RC'KJ'2?H]BX!D4=F+4I%134V9CBS
MD,-LFT<5<=)$GFUJ)1+)^YWL9&G?<63T"Z9JAIAAXDDU"B0Z*JA2::PVF'*?
MDID)GM3'%*6;R$&@VSBD1$FY&2SO:PPY?2'_ -OF@OP@+?SH3YN7DZ^\&(/'
M#/S)H5BY:_=A@WR:D^M'QKU<L0*6#;3^CP?L#W[^+XG^2QG*C\HKW_P_XG>^
M>NCT>Y%/<;C'RFC^JHXH;](1^^!JO^&RL?FAMOG?>3QW'U;REE>JZ0-0<M'X
M2\.^0T'U_B(8'N;[%0!N#?1[ON@;5_B2LWY8:FY3GE#]V5*\F8GK6L#TRY%W
MP9XA\NJA^C^&QGBYH46^#@ X . $3;>W/4='A1EIOD&Y8J,LI\M,VFKTJR78
M52651)$I%@O#-2'F#%=J*%1\QR-ND"W*[7E.MS;,2"B</$6@"K72GMMMCM,<
MVW,M.D!]$U57)T%S4>T:_:3EJK&S!4RPW$2M L^0IU;JMN^'#5^OV?ZWZI/W
MW7\EJVMA6+#F<'6^2"3*UN.\N'7IMQV&1B_W @. %$/*1_9I^0+^##LS^3=Q
MX&2/KT_XD_*0[EK#[A&O/X0JE^3(_G(T?WVI?C&%\Y:'"8C[GJ]XFJGS%\?S
MU.>EX\*!(>HOVL:P_$.E?S(,YQU8]Z:IXNF_-G1S>&>Z/#_CNE?/XX_H6=J/
MNP]COP&V_P#E[8N>=^%.ZG#7C^C^L8P]I=(?<!CGR/Q-ZEFC^<ASTA'A^)^Z
MH?>EZU_C]IS\Q*YSK^+>Y7$WD_6?5TD=RT=?"#@3RRPQZ[@C>Y[X_<G[9_P[
M;@_D0YRAF N[?"/E'1OG[ ]>=+WP5:1_(C$_J:8/YY'/1,>*@MAT/^^QU+_B
M*T]_/@+G4L>]Q&+O)RL_,'QL;0_\*NCCRVPSZWB#=1\F/W"NTGX6%?\ .0.4
MGT8]W^%?&K7Y#@]3]/'P/:0?)Z3^<9'\_P"YZ"CQJ%Y_&=]_7JW^*8K_ "<_
MG1-)W<!BKQ4[^6V-N:!OAAT?>4#'YE\;<7ES_LZ^RO[DHWYJT3E0]$/PC89^
M/G>J9X](^4E\"6._M2D_I#2!H;<ON/( 9'_$9_:*=:OWW>?RJO?-;:7O@YQ-
M\1!];0!O'DV_#;@3[;JWZ/5<;Y/*$#U_%=MD;<V;1[C5*V*T\-M V]VU5-J9
MU6S(0-<HHQ0[1?I;I44_59SHN&R/IIZ"TXU+(NOS$#\^Y:9F..1 G+>9^C^(
MG"O2S<\+ F6,-'KQM]I2R :(62=CP'L.N)2TT61"')FI4TEMW+N(4?"5.9;]
MC/L>VH(&)#SH?<'L/XG:V_\ 4IG-R:">[^/XKJ?YI K)RM_@=F^/Z%^?=&D_
MR[@\JAF-\%?W]0OX6;(_R8WFFM._< _XUIOY;@L[R1OAAB^3U<_-L#/CYF]Y
M;9Z_]3JY=M-7DSKZUSMV5"N23H)<=$YP).J=^(2Q^528\EO#$B6*'O.>C>%Y
M5&1C"L8RK&= :%Z%2,0XMDP:U 8J,1%$F24L2"4:"?;ET]M#EDJ2>LE#KB2S
MM91Y"XO*BQ9B/!NCF%5<+U>51:B[BJF0ERX9H2\J*]3ZP\ZP9N(66HMR.RI5
MBO=LL[7OJL3O(WWA)% AJ=V2V))*UQR>\#G.21>7AKI2$L<07'S@9A.%2H+B
MXSOMI5_T:LX3Z9^WEI^U?H_[UJ9__%[_ 'P\^^WYIB_[0*]]TC_1QF&\,/<O
MM!O_ +76FD;EW/;]AU2)H^W6&*$/NP'8<<W N.O(40FUB-!C.)DL0R9",A67
M,I]U,>3E.<JQG&HM-6"\+8?PG$G46BPZ=+778<9;\<G"6IAR%45K:/6<46JI
M;3:C*U[H3F+(\EO2?C_&6D6HTK%&*:G6J<UA*I36XDU;2FD2V:I1&6WTDAI"
MB<0U(?;([VU75%;,K65^D+?=:TU^/T#\N[]SK/)W[JJUY/N>L:>.]\M/X/L+
M^63/J2LC4-Y< >:HS]_1Y_O/;I_ :3^85(Y7[E$]RU$\?H]73A<CD5]W^*?(
M]SUU21;[Z1-^R7K;^(MU_EH;SIW)S]^,2^+87SIP;,Y;/<U@;QY5/F#(U1N6
MR'G6-B[Z.S^USLC^'-,_F8ARN/*,]Y\->,IOS5L7=Y$W='CKQ)2OG[XE;Z1K
M_5743]X;S_RVI.<1R;_[_%_Q5#_+JP[%RW_L;1K\?BW\WAP:O?+2B@ V9/HY
M7]:]N_W?HS_,[;Y6/E(?W6#_ (RN_DT@7RY$'V1I*^)PC^7B4<9](P_[W=4_
M_+FW?_4]?<^O)P^P\6?;-'_-5 ?#EN^^.CK[2Q-^?H@UKN67%%!M-_1T?^YG
M:G_S/J?_ -*O?*J\H[[-PI]JU;\] 'H1R(_>K2%XPP[\VJXKS](?_;YH+\("
MW\Z$^=BY.OO!B#QPS\R:'2N6OW88-\FI/K1\:]7+$"E@VT_H\'[ ]^_B^)_D
ML9RH_**]_P##_B=[YZZ/1[D4]QN,?*:/ZJCBAOTA'[X&J_X;*Q^:&V^=]Y/'
M<?5O*65ZKI U!RT?A+P[Y#0?7^(A@>YOL5 &X-]'N^Z!M7^)*S?EAJ;E.>4/
MW94KR9B>M:P/3+D7?!GB'RZJ'Z/X;&>+FA1;X. #@ X 4\[I=3'>W^NZU0V=
MNW74*JY<46S).HYD/L&L?5VP5W(\T-BF +LS([Y_]8JW*^:(;"6P.$-KA$?@
M<1%A)'8]A'_,CRX'EU(2SJOKWJC31(X?H%88"6:WC042_6"(\]"D;#+@8RH[
M=VNHH:N#6C>PRF''%G[VZ#;M!S&6HQ(G(A0X,6, SO\ JZ"X%T":N! < *(>
M4C^S3\@7\&'9G\F[CP,D?7I_Q)^4AW+6'W"->?PA5+\F1_.1H_OM2_&,+YRT
M.$Q'W/5[Q-5/F+X_GJ<]+QX4"0]1?M8UA^(=*_F09SCJQ[TU3Q=-^;.CF\,]
MT>'_ !W2OG\<?T+.U'W8>QWX#;?_ "]L7/._"G=3AKQ_1_6,8>TND/N QSY'
MXF]2S1_.0YZ0CP_$_=4/O2]:_P ?M.?F)7.=?Q;W*XF\GZSZNDCN6CKX0<">
M66&/7<$;W/?'[D_;/^';<'\B'.4,P%W;X1\HZ-\_8'KSI>^"K2/Y$8G]33!_
M/(YZ)CQ4%L.A_P!]CJ7_ !%:>_GP%SJ6/>XC%WDY6?F#XV-H?^%71QY;89];
MQ!NH^3'[A7:3\+"O^<@<I/HQ[O\ "OC5K\AP>I^GCX'M(/D])_.,C^?]ST%'
MC4+S^,[[^O5O\4Q7^3G\Z)I.[@,5>*G?RVQMS0-\,.C[R@8_,OC;B\N?]G7V
M5_<E&_-6B<J'HA^$;#/Q\[U3/'I'RDO@2QW]J4G](:0-#;E]QY #(_XC/[13
MK5^^[S^55[YK;2]\'.)OB(/K: -X\FWX;<"?;=6_1ZKC:P\KVS+_ *AZ+[<O
MFL;:;HUS$D]:L#+-7)K@XP/:)[,J0T@B),:]'6,3!\J3"D91G&7(TAYE6?8<
M5C-3]$U+I]8QW1X%4B,3H3K534[%DH)QEPVJ7,<;-:#R5J.)2XF^Q:4JVD0]
M$>437JSAK1'B:L4"I2Z358KU"3'GPG39DLID5^F1WR;=3[I/.L.N-+M]<A:D
MGD9C3H)]]^Z)F97YY/LYN.9,JIAT_7WWKH4RL68>!FJT[/C9P[C"7U@[$:&Y
MRK"L?#D'\>GM9PK%PE:-L!J-!GA6C%S:C61)B(22C-"T662;$XFRS/462DDL
MD+MK(29>::-.>EY"74EI"Q,9.MDVHUU!:U)(G&W=9I2B,VG+MDDW&S2LVU.-
M&K4<6E63;Q.]R^U6W>\NJJ#L[?FS+U3# ?9#I2M66RS28B:Z+US9R@]R1$?5
MEM:X9"'&EL*SCU0\RA6/MQS7&EK!>%*/@6K5"EX?I<":R]32:E1HJ&GFR=J4
M5IPDK25R);:U(46]*C(;NY.>E'2'B72UAZCU_&->J]+DQJZJ1 G3G'XSJH]$
MGR&5+;5D9M/--N(/<M!&,N7G0^X/8?Q.UM_ZE,YJ'03W?Q_%=3_-(%D>5O\
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M)C#<QE9?B*DR</H]Q["MJ^V/D]Z3'X:<_=@K[[2"F6,^V//R,BM]2\>^=_\
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MA1)6&(_P,WUBYP[Z>\YWOVQ\GO28_#3G[L&ICY$%,(B/MCS\[_\ 1>/N/?\
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MW%F8'.]_GHA-\PP.B""L60)-Y8Q9]+U2:\2$2ZGB<()8F[MKI ."EM?'V('
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MX)9$<'& @9U9:9BC;.O$?)1Q#$)X.(GR-:,4&#/8BDG7[YL.B"6XJUDDM/\
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MHJ_'U_=CI7^*W/\ U-QVUM(7?1.^Y0_HPCVO.ACO!I7WQ5/IXQQ^1OHAU(U
MGHMG6VDZY4\[4\C_ %<T[L', C9GLVC6EXD7/-LJ4_X\Y+]B :R,@9DO1/AY
MZ,QD9CRV<Y5E3MJZ0B_Z3S<MG]%"RRME_5>&7@&9<GK0R>O? 5+.Z3,[R:KF
M=R//^T,\\\[YY[1D=_HK/'WZ>G^S)2_3_E\VNGI_[OK/QVU=(7?/.^Y0OHHP
M]KSH8[PJ5]\53Z>/S^BK\?7]V.E?XK<_]3<=M;2%WT3ON4/Z,'M>=#'>#2OO
MBJ?3QCB[\]$.I&J]G>.(-K_2=<K(S<G?.H:MV;$AD;,\BWT CIC=EDFUHBJ:
M<E.M0Y!RM R*WH*XDWWP]I*926EO-N1VU=(/?/-^XPMV[[%V= S3R>=#"M<S
MP%2S/5-1GV35;F=RS/\ M#/:>V^T9'L^*SQ]Y_7UDI>?_$M<\_\ S/R>VMI"
M[YYWW*%]%&'M>=#'>%2OOBJ?3Q^?T5?CZQ^KK'2O\5N?^I^.VMI"[Z)WW*']
M&#VO.ACO!I7WQ5/IXQQ=PNB'4C7W;[QAZ_INDZX!IV[]\[MJVU@44C9G8MT
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MFJ;#VE]G[#WC'!2.AW48GY7.P&B)^D:U)U)4^DW7_9==I*R%EP,%WJV[;W&
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M<1]F5%E,M2(TF.ZAZ/(CO(2XR^P\VI3;K+S:DN-.MJ4AQ"DK0K*<XSF 'NX
M0_N,_I. $' -Z?4B35K 4@26!NP1 \S5U3ZV5%EQILJT8A30HJ/7K D#-AV$
MS\'"$6!P$IF?'*R!F')L9[ O;?;KUZF)>0M#J$.-K2XVXE*VW$*PM"T+QA2%
MH4G.4J2I.<*2I.<X5C.,XSG&>0 \N $.;1LFC6TU4+N!ZAS84RR-G*RW>!@T
MN!'6JADX$F'8,SBL.8$K1>L6"2);$G"$D9('V68*@C9B#<N$PY-C/8%[;[=>
MOIMO$Q\@ X 0ML>V:'^;4,)M250)TW%K39:"JY#Q10<"O-.E/P8)X:8*Q)(B
MJVX.3D2Q8$BN:,.9++G#0KKDYN8PB;'GELV^<1<BMGMN1?K+]0FGD"0X 1#>
MRVJ'[-3H%^$5$X0K5H"%ZR4.# YY[7EZ,QBXBH&O;E1IDFAE;$PX<KU8MCJA
M*21":Y5AY%PB:CP)BPB]O!;,_DOZ-^7G$O<"0X 0[<K'H]&QZ "ORZ,K9(E_
MYYK.1:Q0YTL#*V=!*I,N4^P%82VPEEM,;!L##A"2,0[88#)B#&CS(;,UM,V.
MU[9"+D65[7W<1,7($AP B(Z<TI+VK3A%GQ2)&W*U%+R=>S#X> Y9 >;- 1"L
M ^DV8E!SD>:.A([63E? %6CA"NML3"0YT-[E_,V.U]W7K<1<KVOGP^3S_C$N
M\@2' "'2-BT?+W  $F%T9W=5?%%QU1FF!0[%O'#[!#'%+'7JC9)\+$I+Y,7"
M#&+)60!-4UT2R&+&1_P&1\E4V.U]PBY;+]?V_MZ1,7($AP B)H[I0CN)V+_U
M(<WC7:Z_6(Y":('Q[XU5BZ1]L*5FOV*=!9)$PN?A0U@L8&OD9D0>[@*1.PXK
MSHUU<V.U]PB^Z_FZY7L8EWD"0X 0Z)L&EC>VRKXJ+5Y.WQE??I,JV8K"6;!,
MK8J=%L!2D";\^*:18!M<*F(1:P5,*=(LULL38DF1T A)PI4V,L^/7^7$1K%L
MOYMU_DN)BY D>B3*C0F'94R0Q$C,I]MZ1)=;88:1ZXQ[3KSJD-MI]<XQ[2E8
MQZYQCU]<\ (HKIW2AK:5I?KN*0[N.*$:KEF*,"($&^$JK63$QI [YT_!C&+)
M4JS9B!*"[B!,)@ %HDDQCRH9M4V-R;'UZ]2S$7(\K[-PE[D"0X 0[1+!I>QW
M>ZFZ'$J^;\8B"XEPM$"KI#GKN&I\TN"#2,VE\5!D;!K54)OG08TF/(G08(A)
M(CHTF*],<:?FQA>^_C;TYV\_7,A,7( ?BE)0E2UJPE*<94I2LX2E*4X]<J5G
M/IC&,8QG.<YSC&,8]<\ (EUX9TY8K-?K#KN%647 W(".; /CJM]7[%<F0T25
M7ZH>)EY0D81O=<C0AT\'4+<S)-UQZ,,(#*\7=:'RV&),C+KUSZ-H@C(]^SKZ
M/Q"6^0)#@ X . #@ X . #@ X . $=[(V& H =A1,BIDW89*0E2##T#YMD/'
M):FX[+%=!SYT#!R5"S(;FR(;;Z?6.WE.<Y6ZTVXM?Y1!G;SY%U^45] 5RW;Q
M/"+C87X,6CPB,I6,C2QV!-*PF1*D#X=>S B"9#+,8](BVD->G9--VQK8[$MV
MKR Z? (&9TC+9?P;[<?.5K=)EL/A:"*^9\?DX'EL,]MB,LR,6X&#!X4:/#B8
M<<>*$P8@P9 B-I9BP1\!AN+#AQF48PAJ/&C--LLMIQA*&T)2G&,8QS$9;!UF
MZW.)48D%AMMDC:K*Z5$4.LKE? N6VU#ZT<M$< T06R_&&)DCZ^0=D%9^$0(#
M#*WI#GK[MMP77KO ^O7<*@Z:II[<DB==+RDW&JZ3,UX6VHX<BRBRGT/$XSH:
M<J>JUA&0LLTN.VIXH+NVM3\2_:@19+OKB0/:#Y7MU([ENO<OU9Y':^9X%[JQ
M];]!WW;N%S+>9%>B%"AC840<.BQX(\?%CPH,*(RW'B0X<5I#$:+%CM)0TQ'C
ML-H999:2EMIM"4(2E*<8QB,Q&6U=KC=7B794D62*%90HO.KP^/")NQ3<X,RW
M+F!F9@H:8EK,-BLS#S($:+*68R%"GGZN"/S!,F!B2Z]>I<3(09VZ]?VGN(S$
M#:]K-HWG-B[ V @<W220TS$R$'GR+\@FM1-MX..9FA8XX-(%U=,FT!FKY4B<
M!6PZL?=IEN&6@.'8M%AF]LBVWV]<\\CSV&5RVY8VN=SV&7G._26XMERL>[,M
MMS6VVV6VVFFT---(2VTTVE*&VVT)PE#;:$XPE"$)QA*4IQA*4XQC&,8QC',1
MF(AV-MT/3(1B- S%+6&$['%LP4S65,,'9<!LW@20;@O/F&BK%45(M\0&S P8
MLPF&N%5&BAN3%@KDBOUW=?-Q,A!G;P]?Q[R*USMD*_:.UG*V8!AW'9,0@^&D
M1I@\2%GVET_@S"3(=@/2Y%@'37'+&&>BL2Q,6UI(Q'=P4 O#&;7!W-ZMA+O8
M9,[9%Y\M]MW#]1[+7,AB1:Q$9]/GW;;^;I+([V(SO%S$9B*=F;5$:\BQF_?U
MZ4<F3AD/$([:8=6$AXY9)/Y>9MAIR(5>K@,G-$OUX.4?$28Q.VS@U?;4TZ05
M(C217_E>_@X[?0(,[>'KMX%NOLN(DU1K)F] P>P+\\5,KL(]HXU&F$5QX]J@
M'6!9P*=LH(<O$,&:0(E*IUSJ 4J2U[;V HJ=.@DX(RL1PDF=KD7'T&7#]1[2
MW;S."*Y$9_SOZ-V1EOW[!;'F(R$';)W=7J4B:+@R@\NRPCHJO%(9VP,4L;75
MGZP;M 0L;/F1DZ# %'8X*6!JY=<.4"-7EV-47",2:T76*DBZ[;[K%T]'#,09
MV_7?*W3L\WAR'0-/Z?A&FZGMJXO&IUM)U^)*)9FSWUB[M@I4((");;'5"34I
M-5L!FJX&Q[;20LWZLM'Q,%<A5D=K==-M#,RRX?J_CL/;X+F0@B(\\\]QG?;_
M  R,MF701BV'(&0A#9VXF:5*BU\,+9-6F<4&#'(1 XQ5H@R*<A3W A:07F"C
M4:,S8S$%=-J,TB/9K1>_O0ZH1.B9,E"U217Z]?"? LQ!G;+?^V_'+<=ND=5U
MMJ<I/)N7?8[J2;LO-:-@!#B2PIY@S!==+OV:PU]Q;,8":*3?J]/,ZZCRC]$"
M7NI_I!K:(%C.S<Q!GPRVW_87[=MCMF6V"3F9\<_/Q,NMCN9$6PK,\@9" =S[
M7FT=8P2$AS5SR.9J)!=YT*& 1%(!'3"1#%FLV<@V[M*$@396LBY$:8'R3&"H
M5WF5D-9A).9)%?KYMWA+]5QBH[<=_P A_LOYL[$8XS6.HY^"\R^;&0.('I1&
M,8KT0?(L;$6!EZ/B=.(D11=;$F*LD?DR[,,U^>?N(S51V42^IUB6X0D/-C/<
M7ZOE]&96OO BWGQN6W?T'Y\MUS%D>0,A63?>[<4P-)!U+&2IR?/54C9@07C1
M7]=3C(=^6,FRI#@"TCH-D=B8>)U<;8AK0\U-@L!6/F5C-U:KV:2+Y+^'^'&W
M[3*#/<7&Q]%^N6X]FW(_#2&K"<%,JQ['#RTV@98W':LN9:+%8(Z1"JP%@LF$
M9.6$N5<=G3'3Y1@';LD)^N#AZVUVKDR(1Y-HLPSX=<^@BZ-FVQ'T%"2XE;/+
M/H(N)]-B.]A9[D#(5,[";KDA!:*A0E2")*SO6BHDK;6B.%S*-8!L8;GY3 :9
M@2XQ.^S8LXJ_6*DHJ *V$O7I=9%%A1R4T2%9$6\]UCL>\N/@XGF,5'N+?<KE
MQX%T]&7I':-,ZMD"%3+9>J^X/O#5C,X&1W[B<N\<8,8B?(8,Z+8R\Y4ZUJGP
MUFYU=L%L&L7.JU6V/ZZ;5""#,Q'X,^OG,_-MV%E<K@DN-[WW^ ND[]!GG;(6
M+Y R%2=V;[<"6*%K.E3"(ZU+,-,FC:*^*-1HT5JH$K;@.*C&+%7HLXO*2FOR
MIL)^8-?+TI5[=HQ.39J8?>JF1%E<]ELO3;]OGM?(ROBI5LO3LRR,]_F\.[/9
MV#K11AHC7P*QR*Z\"-%(L;&1DV8^3R*8 MD:^)5&*N)BMVO#(AR2,K6RR(>!
M>+9K953BW"83F0,R78/;UZWX]()(K=>FW\[9BRW(&0IYN?9%BM8XS0J$U'6P
M?DQ H&RB5T6Y#=@,R6B0F\4J' N",T^%:*NYEL\0JEOD1HU^I@T^.JYJ(1:.
MD:?D16VY6V[2,N!\?/N/:6R^)G<LOU'?B6>5]]CVE^*3=,:@CT00(-6%AN1L
M)X(B&8ELDB4^".S-1 >("QWQDI[$Q+#L"$-;L9;YI<B(,0!%62UV;(6*1=@S
MOX-W7J17.UA)%;;MZ.N?AV\3/:)VY D5+VMM9RZ#CNO]80)ML(3X%K$SD0LS
M!2#:Q,_%:*BQDR:@#\YISIE):A7V[Z]MF;-J:Q3ZT7D#UBY4@A$DBWGEUZG;
M>5\QB9[BZ>B]MMO097VEMM;,3-K+6@K785F,VAJ28=P\X1))0AO#S\C$9M]Y
MJ+&8@B(L^?&'"LV8@""UV-;3<!5FGA8<^8IA@9WZ];]%\[97$D5BZ?-^K+AL
MVVN)'D2HT-M+TN0Q%:6_%BI=D/-L-JDS9+,*%'2MU24Y?ES)#$2*UC.7)$EY
MEAI*W7$(5 D4YVKMMK92+;J77@@M:7_0U6; S!62&,F9,:<_5K'4I)&(Q&+U
MP4XN4N+)V*#DD$T(PY5#5P O4BUUY5QR(K9GEL,OE(RXGT'MSMF66)G?(BON
M/]9'T=)'EE?IL9K[78F@B6X<9,>636Y,DSBK<%D<A^82S#<+R!XB*O(FN-'9
ML!DZ>%5F*'KY"T2"EA;#PYA.0GF)G<216+^%NNT2#P)#@ X . #@ X . #@
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M_7,OUW,K%?S8JOPR/;^P_-?9G>Q=!]PT_JV6":'W&TD+#)LD^.^50&,365Y
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MW5)CM0ED?EGQ'RE!Y\;&AAY=C;@)/S 8\:#E$GA Z%"8FYVMN$6*]]^P=VY
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M/MQG_EG'VXX 5]QHI^7:WYUDNDRZ4R=5T5\C7K,)8^LTM\1:!-KHTIR\5^:
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MQ_AQT(&,SSSO_+/]AF6T"(LC,LRV='XS\/1L%I.0,@X . #@ X . #@ X .
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M5V#;WY,^&7IOOR//.U[7X""3;;MZ-GR=!=%\[;!:CD#(. #@ X . #@ X .
F#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g897644g20v85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g20v85.jpg
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M  (1 0,1 ?_$ !X  0 " @,! 0$            '" 8)! 4* P$"_\0 3A
M  8"  ,!# @#! <&!P   0(#! 4&  <($1(3"105%Q@A,4%45I:T(C4W875V
MU-4*%E$C,C.!)"9"4F)QD1DE.'>2M4-D<I2BL;+_Q  > 0$   8# 0
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MN!BE,4IBE,4KO8*LV"S.!;0,0^E%2B *"V1,9%'J] N')NELV*/J.X53*/\
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MJXV!'3$4MB:XA;D0#VS5ZP0MK@HBS5V1;2\%.Q[65B9-H?K;O6#U$J[==,1
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MF>*VG8VQ)L?%:&YJ:06AA*@WJMB3;M9!WLQM9\ZO\V*RI*5&&XG>A>@7&/\
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M+J\@)W'OYC:5#*4K4A"BE2T!7)0TZ6B]V:NR2H)[3'H[C_#GQ[N9&0"0"02
M;@9P:A3%*8I3%*8I3%*8I3%*8I3%*_A11-%,ZJIR)))$,HHHH8I$TTR%$QSG
M.80*0A"@)C&,(%*4!$1  R1UUMAMQYYQ#++*%NNNNK2VVTVVDK<<<<60E"$)
M!4M:B$I2"20 34R4J6I*$)4M:U!*$)!4I2E'"4I2 2I2B0  "23@#-:9^*+=
M0;8N@,(1P8]+JAG#*$,41!.5>G,4LC.F+ZTW)DB-X[KYB5@B1<"HJO7*0>!?
MEC>4$GC7Q %MT]*4YP_T4N5;]/*0HAF]SW%I1=-2*1_$W,4RW&M6_FBV1VY
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MA92I3%*8I3%*8I3%*8I3%*_#&*0ICG,!2E 3&,80*4I2AS$QA'D    (B(B
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MMO1MVZ[M=!JU14<.7*R;=NW1(919==8Y4TD4DR )U%%5#%(0A0$QC& I0$1
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MN%C@*3R,6<,AF*E*"4E2BE (0DDD)!)40D$X2"HDG&,DDGG4% J !)Y=W>0
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2IBE,4KZ)?XA?\_\ ^1Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g897644g22y30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g22y30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X= +:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" Q-S4N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(U,# X-3 F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(# R+4%P<BTR,#(P(# P.C0R.C(X)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(# Q+4UA<F-H+3(P,C @,34Z,3(Z,C@F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA<G0F(WA!
M.R8C>$$[XH"B(#0@0TU92R!B;&%C:R!O8FIE8W1S(&-H86YG960@=&\@9W)A
M>7-C86QE+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA;"U";VQD
M350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @
M(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=)
M;6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @
M(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(P+3 T+3 R5# P.C0R.C,T*S U
M.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R,"TP-"TP,E0P,#HT,CHS-"LP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(P+3 T+3 R5# P.C0R.C,T
M*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R
M5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E
M871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW
M:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.FAE:6=H=#XQ,3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^
M"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:
M2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.
M02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K
M8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="
M9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%
M>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX
M.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!8T%%04%W15(F(WA!.T%!
M25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!
M2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C
M24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'
M13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4
M:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6
M=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U
M=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59
M;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1
M545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B
M2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD
M56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U4
M53504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(
M,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ
M3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.4M7,G)A:&,R
M.&1X1'!R3D9+;UHF(WA!.T0V<UEQ1#=%-'%I26)Z55AL5EI,0F]K2BM+47EX
M=%%E3D%A-'%J8U9E95=F;E!Z;$1:4$Q*<&MM;TYZ44=T=%!!635$-G9+,T%6
M2$PF(WA!.S$Y3TU,2G@T9W8X045D<S)%=%!J2C4Q.%%E-V8W.79*,55D6&U!
M=F@T=F=2,S=F9'9Y,S5O-U1V3W9M830Q4S%T3&IY+TY"8GHS57,F(WA!.T5L
M=U9L-'!'9UAG,65&4#)J57111VTR46YP;T-*26PP8DEA=DE:9T="04I)=F1,
M>#5V.$%0=&YC,U0S1VM093(W,UAP,FM347E)>7<F(WA!.VEE5U!L>5)7-FE.
M44]8.'=B-T]79FPX4D%Q5F)F;T153E9N:51C8D8W8F1,22]14&YF2E58.'<O
M32\V4E-Z4&PY+U9A4V)H1%-94$HF(WA!.T9(2D5L54I39S0K<5-Z4%)F:#=%
M:D(K56AW,WAF:F1L*V5Y8UA$=V0O9GDR+U@Q-VQY*V4O3TQ1*V]V;'E29W%/
M4U%L=T]4:$A+.%8F(WA!.V%.5T%$3'AA;W(T8D594'EU3R]Q*S5),6U5:2M$
M-R\Q2FAO+VY$>D1E5%A+6$]G5%=Y45=(,75.;45N-WE904@P>#A"*S)3449&
M5RLF(WA!.TAV6$E:3E!!059+.39B35=Q>5-*=4)(<'1#,DAM>GIF96%8<6PT
M*VQT8GI78V--.7!A;4M14$UI>E-#8T1L<U=E3TPT47!.2VIR:W F(WA!.UE-
M66M"9E Y5WI#1W%Y>6I+6$168F=59#EZ9GI!,E%L<C5Z+T%$070O4TXY-65K
M=5=E4C1$1D5R;V554V,K65!&>%-4,4)1=%%F064F(WA!.RM4;' X2C53<CAF
M:C5S239V3U!Q:&94-69R+U%M1VAE82].5B]F0F)N4TAT-%IB2#$T=55C<7(Y
M658U5D5:6G=T4%961EEC=6<R-VHF(WA!.TLX=41(16)3-B]:=#EZ8F@Q3U=5
M=#0P3T<K=E!F8C1P=#5*,5!83E,P3F)N5V]0479F5613;G!01#A)<%0T6&\R
M>'%+,$A4-E14<5DF(WA!.U)J2V\X;3=36DIZ:&-X579L.39B,V,Y,45&.4,R
M3G=46&M!-G!4+V=S;V-P1&98=%8O-G1J9CA!239,*W5+<E@Q5SEI84PQ-T)O
M-#4F(WA!.TI%:34K;VI536I"46%!,39N1EA*<70W2S!V;U=$4U)X>5!&>CE2
M1G%9,DMK,$IR,4=+<G9R,G$O.5=X=BM2,%@Y8U9D.64Q6"]Q,DXF(WA!.R]W
M06IO=C8T<7)7='IE>7E&6C=-,C9!5D1M4DAQ86IA:31Q;%AM+U9D5C V0WAB
M5&A74V4V4TM19E8U8F=C1#$U96Q5;W9I,4LK1UHF(WA!.T=N:$=24$8S9#E/
M3'%S<V]!8U!5.7A0,V-K;S%V>G8U:S S53<Y1C!.<'1-<RMF1S4O94QY16-!
M;$QC=4)4:5=A;&$W54]7-#E.0U4F(WA!.U(V=E5F,71'6%8U25-L-E!42#E6
M<&1A+VU&-6]U,W1R,C(P=WHV55I04FYM:&IL36)C6EIK959(8TME0599>G5"
M43%R5&9,6F%41TPF(WA!.T)0<2]S86]A-TI+<$-.=W5V=$\O,TEU>B]-4%8W
M>GER8V%Z6C993'DT:75X8DIB,C1L8T9F45-5;C=)8C=4*VY7;$LY2SE$0U=K
M:4TF(WA!.V=I5%%R.4Q/1W9L3$5::4YK1W1R-W(O678Q1'I(-3544F)#.',Y
M3T5T-U!,9%$S3G-)<$)W84M5=$4Q1RM,:5EO;E=V46QH=F=H:'@F(WA!.V-2
M0D\R>6-M9DU)06E.:VMI=FIT.6=0>D-%5'HU-3)H9VQ%+VQU86%:5$,V1E5L
M56-B9V,K2D-O.5-T4DAS4U%D,C<U3398151T4#@F(WA!.T0X5W='='I!1S1(
M<#,Y9GA8,W!N8F594$YS+VQN54QK,D)H,5<P=41(1D4X36Q:2751261&+V$K
M13 R-E5Q8W%/3$=*9U@V4T<K3V(F(WA!.TMC6DY624AU-DIL-6(Q6%9B,U4Y
M86AV0B]O.6YC96YA17=3445R5F=A1B]H:U@T4CA14%=V8FIL96)(1TU9:V12
M,W1M;GEY;$M14$DF(WA!.TAB66HK,SAE4V)85GAE4D]"0F%'-%5I<%E/:550
M:%)S>#-+55!R,G$O=T16<V(O:V1&+UA&6&98=%8O-G1J9CAJ;W8V-'%P6$]R
M86@F(WA!.V)7.&QX3G!R3$9%<%IZ-G-:;T(W031Q<2M8+RM/2%DO.%E5+U9I
M<5E9<3=&6%EQ-T9867$P55%U2$MJ;6])1%4S04Y#4E@S;TU6<'8F(WA!.T98
M67$W1EA9<3=&6%EQ-T9867%L*W1F-WHR+R]!1$8R,R]*-6-69&]V*S@Y>"]Z
M1C-0.$%Y96)&57=X5C)+=7A6,DMT37%S<%9G1U8F(WA!.VA2;$\T24]+=%)2
M4E)2<DA%:7AX<4M+:6="45!91$-484%+86AG:&=J16--87A2:7!#24%Q:7!Q
M9&AI4U1Z54%$:W9W2F1I<G-69&DF(WA!.W)S5F1I<G-64R]Z0B]W06-/*R\T
M=W8X07%X5E,P:3=T8EAY.5I46$UY45)#1D%:2E=#3%5J8F1I0FEQ3#%:9%-B
M4S=X9$QE3U!5:D0F(WA!.TE,2C5G5VE%,T4K;5A!24I8;%-U2W-!:C%8.#1T
M0SAT-FQQ2&U&3DIV<C%,:4E785=N<7)'<TQT=UES<$-->#5-=D56<C@X;FII
M1$DF(WA!.T%M9S!A;6,T=TIG3&PU<RMT3&TX;'19-5AH5&TX878X16Y*4U-!
M5'A.3VYH;%DU3G=.:%=%;'I687A!02]A4%!P=CA!3&9B0VQR,4PF(WA!.W)I
M5#9)-59&0GHW9F1I<F9Q6$YA96M+57)8;C-P5VY4>#)X5G(Q3')I1#9)-59.
M4GHW9F1I<F9Q6$YA96M+57)8;C-P5VY4>#)X5G(F(WA!.S%,<FE$-DDU5DY2
M>C=F9&ER6FMU8713245$-THU.60O;'1T:7)H2F,Q5W-105 R:GHV8B]!0S,R
M>%9R,4QR:50V23561D)Z-V9D:7(F(WA!.V9Q6%!-1#!H>$Y+='HV5C8W53=9
M<75I85IQ*W!'17 P;S-+=C1$1E5&<E@K.#EV+T%->&1T+WEE6$96;6QZ47=7
M9#%,3DES55-85GDF(WA!.UAK8VA603E:='E4<TU65$=/4T]73EI),D1X=4%Y
M3W!"5FQ)<4-#3V]/2W-..#EW+VTR.3EA;GE44'!-9&QW<&1R<5-Y;50Q2VYD
M0V<F(WA!.UE&94I',GAQ359:2F(S.3E.95AL<V)A2E1A=6]6:$UX-4DV.&Q9
M+W5X>&)X1R]Z3TMO<W1D5F%K8V1".6<X>G9V,RM$8F(U-'$T3F0F(WA!.U97
M<V-D1#ES.'IT=C(K1&9B-5EQ,7IV3THO9%(X<6EG.5)Q53<W.$U68C585F8W
M=4]L3W9-,7)4<#EJ<%A&5W5D-7A(-W%0;%4Q2'$F(WA!.TY3;F)F:&ER6F$V
M<3%)-#9$-T(U;F9F=CA',C-Z>%9W839Q=%DT-D@W6C5N8F9T.$<K,WEX5F]0
M955.66]W869$4U)T>EAV.$=+=&@F(WA!.W)Q<3%J:F]F=&YM9'0K,W=B-V9,
M1E=U9#5X4#=Q4&Q554AQ3E-N9F9H:7)F2S9R+T%(8V1+9&5:<E=N5#=(4W5+
M;U!8=5@V0W9E44$F(WA!.V(P2'%!86ET4$AB1EAM9C5X86M.4"]+>E,U>EEV
M955U3%AI55HQ36)52416:6QG:S9%-T$P27%$>')Y0E8V-V=63'1F+W="-%EV
M.$$F(WA!.VU-<W8K;WE,1E9(44=.<S%Z;S<W1W=91S%R6&4P:W%9858O:V\P
M9BMX=WDU*R\X04@T.31A8U<Q>#=V=39F<2M#8C1'-3)+=7A6,DLF(WA!.W5X
M5C)+=7A6,DMU>%8R2W5X5DPY82\S;G0O.$%M3'1V*U1Y-'%W>CAY3'1B5#AR
M+T%$2$\Q;S$V<5-Z:W=O>%$W6%91,TI(:F1A34(F(WA!.U%Q4U%D-DAP:%9L
M4&MM8S-(:WI18F=Q54TR;E=K;D$X<6IL06AO96)3='18=3=(,U!807%D67%L
M=&@O>#)D52\U-&8X;7II<5I9<3<F(WA!.T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<6PO;40O:F@S,R]'1B]W0E=+=D]V>E=U3&U$.')T34U'<5,V35=U3%%3
M86A#8F=&26Q$4$HF(WA!.WDK<7$X>$)25'-Q;C-O3G=64C%H1W8X07EU-U5%
M3C=.245S1G5"85-8:T%62&-*2"LW=%%I6$12.%)5,5IO=WAR.6]G2W%M=&Q"
M-3$F(WA!.VAS-VME6G)M,G5582LP,#9E8F-C5U9$8U%M4EI0:%5%:#EG=S9J
M<TU65&I89CE"=DQ05U8R4T9V<3$W-W=414%%*U!#5&E14&,T;FPF(WA!.S=T
M+S$O6G8X03 U3FE*9D$O:C-P,$-#2VIC2$$S3WA6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W!F<E@K.#EV.$$X>&1T+W=!;FQX5FDF(WA!.UAN-E<V:2],4'I'
M,7!D4U=.,%I*,&=U-&I)<GAU.3%X5F=945ID:60K04Q5-D$Y34MS9'1H2$PU
M=R],,FUR>C-I6$]K47I%=F5*0D@F(WA!.T])66535$I$8U)R9'E02WIC;E97
M<7<O=D9!0C5+=E@X0W!B668X9&Y64#A!;F@O>6)/2W!L:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G,F(WA!.U9D:7%8*UE0*T](9F8X65@O5FER>GHX>EIB-"]L
M.7!6<&$V4E!Q-6XT<UDT3$)D5$-M3TDX955-:V-Q1&MZ8D\Q2U4V:G)H5E@P
M:3(F(WA!.VEH+T\R.6MS-U=Z:G-$<'!T0E!&1$A(3C8Y<TQC=D0V:3A764I&
M3$A51E-!2U5B67%&5V0V+SA!-W=X9CAX;&PO=T)2:U="55ID,G,F(WA!.TXS
M87I7<W=R1D]J4G5"<V%-2T=H=WA.1S!3:4-+2U<K5W)Q6C=*<D\U4#A!<&1G
M,V]3-U5Q1C)69T]W3E!H.70X:G<X2DU2>39E-W F(WA!.SAU6'=A.%5I4G9Z
M0V(T5S$R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<&9R6"LX.78X03AX9'0O=T%N
M;'A6:69N964T:CAJ86Y(0G X,G F(WA!.TYC6'-S3#(X1G%,.75*=5=9<V)9
M<$MS9RM':'%P1SEC2W-8<V)0,'9/6#5E4U)A9&%7<E<R;5)1-FUK;'!$8EA&
M=$YD5S P<V-D14,F(WA!.T=*;6%+6#DR=%9(>&9:<4]3<C)407%7,D@O2%HQ
M5"]N:"]Y8D]+<&QI<G-69&ER<U9D:7)S5F1I<G-69&EQ;%!D,G1U544X>5)'
M43 F(WA!.VI$<T8U2'=&5'9H04I16D%C,5A!;$PO34@O2$1V=CA!:D,O-G-6
M959F;D9C6%-E4V9+,79A=D]*<FTW:%%X5S9M575O4W)";V98=# F(WA!.VPX
M06IQ-%II1F]#4FA6:V5I,WE.*V-'<W=F6&1*:VLK<4M'=&],5FLQ2E954F-2
M3F,K;49D83%O=G%(-69Y:%8K;"M7=D]M:#9B3W4F(WA!.W,K67HU9RMS-FQ9
M=F)T8U$K:UE):&12+T%/0E!):VME2%1#<D]I3'5R54UD4#).:C0Y.2]$07)'
M9&9N,6)39%9T8C)Y9U,T3BMF46XF(WA!.VI&441);TI&050Y<#!59CA"-S54
M<5I415%94C1I4#A!8VXY4BLY;VUE1U8Y+W=#4'@W;5%7.7I.8U)S67!)>7EK
M0FQ+=7),-&AL2D0F(WA!.T$O4$Q)>D5U5&-#<E5U-CE9*TY003%R5#4Y2S5*
M3%9,,VE0:6HU5DYD;7!4=#-X5G5L,UAR2'AP-$=T8690<%A&5W%8=D5F1DAY
M<6$F(WA!.S=.4VYB=FER6D8S5G%'3VXW1W@X92LO:&ER9TQU<3%-9% R.6HT
M.70O1$97<5AV12]&2'EQ2V).4VYF=FER9$QV;4XT*T<S3%DQ.38F(WA!.V(T
M<75I.69F,5-P+VPT9VHW-FLT<6=T82]W0C4W9CA!-6DW8B]K.'5+=E O04TS
M3'%E,B],1%8R=#5:27 S=C-J:DU,36I%=F1%54HF(WA!.U=E,2M';C)Q<U)4
M<7!'1E9$5&)W>&5D+TIT=$QD-EI&3TY'9U0V;F170FHQ559G8FU%:U9(5T%6
M<%=0,5%!9'8Y6E9L+VYV>34U<C$F(WA!.W4R=$DO3'9M2B],<S!,<S X>5%R
M4#9I:T%"4W)%9$XO=G=+:G105R]'<S9T5U-*<79%56]J3%)/2'=G+T<Q5TAC
M-U8X0FEQ86M89%<F(WA!.V]9-F9S8DAX-S<K1TMU074V<E5X,"]B,E!J,C,X
M359A<&4X5#A59DMO<',Q2V0K*TMT,'4V.5DK3E!!,7)4-3E+-'$Q4SDT:C1O
M*U8F(WA!.U186G%5-V0X5F))=39T47@P+UDR4&HS,SA-5F-"9#%7<&IP*S-S
M9DAT=C19<3!"93!.5VIR5#1A0G5T92LK2W1G6&16<5DV9G0W2'@F(WA!.S=B
M*T=+=DUV>FYV9%5T9C!&-F1Y,%!/95-V;TTV5G V9C)Q2&5L9'-Z3DE!8F18
M,FQ):F=O:V5P-F)3-W(Q:C0P.$17=%!N,')M1S<F(WA!.U)"-CEY+U%6-WEP
M>3E"<3 V5G!I<D)V4#)G4F$S-40P:4%3-EA"8W=01F-*3'$U:E=)4DEP.5AG
M-WAZ1E<S1S9J-E)H5EHU9EA33&8F(WA!.S@W=DU%554X3C%Q9#5:<%!/9S!X
M27!B5EEX16=4.4EE;TAK16]D4U8Y26<X4CA12VYK1EHU<B\K.$U8+T%$1U=8
M+U5:1FEQ631Q;&8F(WA!.VU$>3-P5W97.$9V<4M/.&1T3VQZ1C9C:E)K4U(Y
M3C!)4&9,8U=A5TUK>#9I;6I0<#1:44),;V)5-VI33E%6;&MT<G(Q,U0W2#%J
M-%HF(WA!.U9&9G-R4$=+.&9:,&5V9DLU4FA,;4M095!X*WAK65-(23,W+T%.
M9CEQ;75V,T9I94=S5S!K35DO-"]1=DM,-74P9DE+4&,P2B]L1T0F(WA!.V=K
M4#91.'5F>2]685!&<C9H4V-W6$5&>$-K,$5I>7=U2W!):$1+4C1G:F)&=$)"
M,T,O1DQS5F1I<G-69&ER<U9D:7%8-C$O=E!B+S@F(WA!.WAD="]Y95A&5TPK
M8TY(:C%N>4YQ,FUL<D9*-3=Q8C9Q*W!H4'%W;%<T3&9&>E-503A686A#:VI#
M<D=,4S(P97<O37IY8TI,<7IU.5,F(WA!.VTP5TLP:'193D]3-%)%:6AD+W)6
M=G%*949K43A'5D]+3CA,145$:T-O5C8O:7%7,D@O2%HQ5"]N:"]Y8D]+<&QI
M<G-69&ER<U9D:7(F(WA!.W-69&ER<U9D:7)Y<C@Y9BMM92\T>GDO.'DX>F1(
M+T4V<G10*T0K<SE$,&DY<W)M92M3,G5F6#E+5E%2-FAK-&=O4$5M;GA"<S%E
M2$HF(WA!.T=2;%)U:3=/2D,W>D(O>'<W-R]J0R\V<W9:4$IV>FQV64Q,>6HU
M4'5R:3AM=&]O8C)">$9#5"LX9%9"5&M%=3='6#14*S!J17(Q,C8F(WA!.S16
M96]7+VLW>3EB*UEB:GI$0F)01G$Q,5$S37%Z5&E/4FQ4,'=Z46,O4DQ"4&@U
M8TLT1EDY6BM8=DXR:S)%-3%8>D(K;&IC-FI94U(F(WA!.T-A13!H45A-64UC
M9$A88FM14E=P<#%*-C166G%6=7%T4U-/:"MW3T(R,S<O04(W-V9,07)G=#%6
M87E2,$@R>'=/*R]B-#ET=FYI<E@F(WA!.T,X-&XY-TAY<4M(,#)P5'9T>GA6
M=FID5B]V2395-F-$5W1/=C(K;&-663%R6&M+,S%,54Q#+VAU:G Q>EI41S1D
M<DY$1TIM3DM'44(F(WA!.S9&:'8X4C=';E1*:DQ-5T%2=C-I+VPS9FIU8UA,
M<$EZ;$=7-$U493(Q*SE-,3!V6#0S0FHQ;WE+05!G=4QA2G=A1'59+U)B<C<O
M,7DF(WA!.U!&-40W9C$O;V)E0UA36#-F<V%B+T8X6BM%-F9C:GA);6=0,U9N
M>'-F:CA"9E=/-"]:*W1O86PU:%1N-BML<V8U1&)T1$MO1F4U:VTF(WA!.V=9
M-V8U3T\S-"]:83AC=7-F;%@W2$1Z1$=I;S%W2C=C0VYR0U-X=5%"=CA!-SA(
M2TUB9"M2=SA+*TM/="])<DQB>E1P1C%Q4S968C8F(WA!.W)A>C9J26YQ>'=X
M<7I64F$X='<U1F1U;&$K,DIH2W)O,&=A:D=:8TEK3TQN4V(X8G)K1#9K9D1B
M:T]"<69':#4O=T%-:3-,;VA/2RLF(WA!.W$V=C1C5DLO<EIS5E%7=&8W>C(O
M+TU88F8X;FQX5C5Z*V-S:TUF-5=A<S@Y,4QA5S8V9S5M84AI6&128W0X2$5Z
M,FY+=CAO979S8TLF(WA!.W-P,$QY=C5C,5=(479.56M%:F%R*VHW45(S87HS
M369/34E*545Q979)2F%-,5(V<E-'=C=2-C1&4E!N6%%0375S,C%R1F]7=4YO
M8VLF(WA!.U1S.#AY2C9H:U5R4E9)<74Q979F=TEX5D9A96PO=T1P;E9Q>E)'
M<GA&2U)-2TE5*T94*S@S661Z,SA":7%A;&)Q<E5K:F]F<T1G9'0F(WA!.RLO
M>#<W9DQ&6$)B<7$Q:VIO4'1J9V0Y*S-X-V)F4$97=48U>% W,E!L5550<'13
M;F9B;FER9D<V<B]E4C!P,#1'=&%D9G0Y2S1Q,7<F(WA!.W9/22]E>#AQ;7 Y
M3G%5-V)C.%9B2S-65W!*2%$O64A!-V(Y+VHS,BM72W5#,U96<DI(469B2$$W
M-SEV:C(R*V5+=$),>6AR3$=45#0F(WA!.V%2='-A.2]J>%9S3&165W-K9$(Y
M<V-$=G8R*U!B8C4T<3AR+T%$>%=C9F]$,5A6=C,X=DAI<%=N.3,Q<7I:;390
M*THQ6&%F.$@Y6E F(WA!.V9Y-45X=G1C-'-O+V52.'%Q5%4Q;'!4-&@S>FUU
M>2]Q>64X9G!C+T9Z3$LY935F;TLY-45&=E%E<$%O2S X3C@S1&-X,U9F23)N
M*V(F(WA!.W9,1VLR=#ED,TYQ;'-G:U)R8C!#,TIO*TA)9E=)<'=R<E=Q4TE&
M9$1U<D$T<7I01E5S.'A":G X9D%G3CEB<W%%:6\O,W-I-U9'2V\F(WA!.S1R
M9%9A:VMD1#EG8T1T=C,K4&9B-5EQ-$QD5E=S:V1".7-C1'9V,BM08F(U-'$Q
M=W9/2B]E>#AQ:6@Y3G%5-S=C.%9B-#-69C=Y3VPF(WA!.T]N03%R5'(Y=G!8
M1E=U1C5X2#<R4&Q5,5!P=%-N8F)N:7)F1S9R+V52,' P-$=T861F=#E+-'$Q
M=W9/22]E>#AQ;7 Y3G%5-V)C.%8F(WA!.V)+,U97<$I(42]92$$W8CDO:C,R
M*U=+=4,S5E9R2DA19F)(03<W.79J,C(K94MO63981S$T3#EO-UDV9VDK;6PS
M-D@W=U)N<6Y,;GDF(WA!.V]F;FAV86U00DAI-'$S-S!4>'5U45!Q4CA.=5$T
M1W X84AN+T%!=TUL,%%N1F969%@X3TML9C%S,DMO3%=V.$%E93,O04]9=3(O
M-5 F(WA!.TQI<50V:C58<R]-=6<S5VPS:S!K3418.#!R1TI92D]2:FY9:%AJ
M=5ER:48Q2C9Q-DA&53DP:E1O.4TP<7DP,DM75V5+>&=I=&MM;F(F(WA!.VY+
M-GA)14133E%C;DE7<D=N6$956&EQ53)Q5'1R5W%E;DE%+W5/<3$O=T(Q+TU9
M<6U*:G5A=%-504@W231D3B]N=G1I<FA(8S%7<V\F(WA!.TE(,FAW-C<O040R
M,GA6<C W<FE2-G<U5D9$=S=F9FER9G S3F$K<4M5<%1H,W!3=EAX,WA6<C W
M<FE"-G<U5DY4=S=F9FER6FIU870F(WA!.U-504@W231D3B]N=G1I<FA(8S%7
M<V])2#)H=S8W+U!B8D97:$AD54Y:9U-2=#A(43$K94MT:4\U<71:45%0=$1H
M,3,K93(R2W9++WHF(WA!.W=36F8P0C9K9V5S.'1+3'AP+V0K-7I.,&8X5'%U
M,"\T4#9Y92]L>7-P=G1C-'5&<$EL9'$Q3EIA2'(R>FUU>2]Q>64X9G!C+T9Z
M3$LF(WA!.SEE0D=H6&]9,6(P1W%E;%143G<S3BM8+T%0:F@R4#A!>&A4.5=+
M<&AI<D=P=DQ8;4MA-S%74U18;4YR9#-6<F,V9&)M0D=&<6QT=UHF(WA!.V]X
M52]&>FM4;%A&56%D33AX5F5M=$%!+UE(,5=08F8O049T.7-64R]7-61C,'$R
M=')I8E=H>&QU-U-Z+T%.-'=W3%AD>6M#,4MC=4XF(WA!.V9504)/,65U1E5F
M*VDO36Y%:CE.:FQ555 Q5U!P=CA!-5=+="]O>GI&>7(K;6A3;$MF5EDK=$M6
M*S$T-S1&678U<C@R6$AL<3=T8E0F(WA!.U5.9C13>D0Q6'!:27A-5%-,079'
M:E5$97))=&560G@U1W4R1D1+4#!:-6DU5B]447!3;%!Q<V97;$LO83AD.$-7
M=C!8-6LT9V9P<V,F(WA!.W%M<"MQ>#E.=CAR0W):,'IZ1E8V83!!1#EG9E99
M.70O.6)F8D%R:'!N;4MQ5C%O140W62MQ>#<W+W=#='1T:7%53F4V,%!.2V58
M4G(F(WA!.V<K=4=X8E5'<EIO4#-9;5=&94IR>%!X13AU-#(X8TMP=BMJ4$U8
M34@Y3D1I2U98-G)(=E1R=GDW-$925VY7;7%1335V8B\V-')!8T8F(WA!.T5+
M>&-4,U!W:S%X5F)R6"LX.78O04UX9'0O>6581EAA3"]V4&-F.$%-6&,O.&YM
M>%9-3593;GI6<&US87!O1C%9-DYQ8F%.<54S<"LF(WA!.VAQ4WAI57AC6D9:
M=F=99TAK:6QF<'A646PX=39I,2]D6&%A;WEF5UA$96XV2VM+<7%&5F$Q1F1H
M:%9E9$4Q67,U+U-P+V5D9C-+*TXF(WA!.V8U<T-P8E,Y6'I,1F]V-EIR9$Q:
M;3E%6&]#=G!R344U13$T,$Q.5$-Q66I1=%<T1F8P<V%%9R\S2SEQ+S58=F=6
M=CA!46UR8W58-E8F(WA!.U R95 Y>78X=D@K8D97:F]7<F-!=C973D%39C=L
M93E0.'(R>%9+4$UL>F-A23)N;3<Q:W@O<&9524Y.9R]W0D<U5FUU0U-I+T-F
M:'(F(WA!.W<V.4U+<'=.13%936@O4W O9#E0,TLK3F8U<T-T3&]7<D%-4#!S
M9FE&4#=L9D5(*V(R>%9S84IQ=UI$*VQ4*S<V9G56.&$O>EEQ>%@F(WA!.WHY
M-4QG=61)3W!A=G)--E$V54=N5F]91F)C,$AX3#A:27%",'DS2&Q-3')Q-"MF
M5'AY5F9212M39$)%*VQP<D]L-GA+.$]Q24I#>G<F(WA!.TI1,#5+4W1#3G%S
M84AF8G!M1F<P,&-22FHO13-2:%1+3EIJ95!Y-612=2]Q3VQS5F%3;$]20S!*
M<#<U:TUL+VPO=T0T-&1J+T%-654F(WA!.R]6:7%967$W1EA9<6AD5VQV261,
M=DIR1S-&,V91=WE35VQQ>D)23$UI;&\P3$@W4$IW0EAT:7)Z86)Z0BMF3%0R
M<S%V-65S5F=M:&<F(WA!.TTQ<DDT-5)Z=35A5D1)2F1L5D8T.'A896YW-S%"
M5D9J6'9Z:6)1-VE6.41H:3%16$U1=%DQ16-I=&)M1C%F;78Q:$%$.5EJ0DHU
M-TDF(WA!.S0R<41I<398>DPK86)A<DQ',VME0U<R:EE,8C-B6&-13$PY86I1
M;F5P54-&;F8X03).9F)&5W12.#9F;6I:6%8Y26YL45AM;5<X=#8F(WA!.W-C
M,%1.-C-#0G!H8G-S23503#9O4TTP46(X=F)&57)I+TU$.#1O9$]3-S%$>655
M82]U3&1,5TM"2DIP3&5+6D=-<&YJ:EHS+T%(4E(F(WA!.U169W8R<4=N2&16
M-FQP8SDS4'!L<%!E>$-#.&QH:F4U9T9A2DMY075M+SA!2S%29U9%-'$Q=U1N
M>C1J;E-N2VTY4$-U2W0T<3=&578F(WA!.S%R+V5E,R\U:3=B+T%*4$QI<G1&
M+W="-3=J+VU,=68K5'I9<6U'2W5X5C)+=7A6,4)51VTT,D(W,$]+=7A6:C-N
M9GI&<E=G85A$96$F(WA!.U1O-S8S33@V=WE7<U1&6%985G5-;7EV54)W;V)W
M0G)I<D54*V-M=&I45G50.$1A,$QN,4-S:T)H3D%I>3)Y<S1+:&EA<&-S>3=B
M;$0F(WA!.S!&4T978F56.650;413=G(X,FTS1VUS:SAS471R,4]%;%E:0V=K
M04DK>3%+9S1Q;D]+=7A6,DMU241!9VEO3WA"-E5X5F)(2$A'9U,F(WA!.TY1
M:4QS<7%!05!K0FEQ0CAW9CA!2$1V=BM-3"]!2W-654Q+,#$R,'1)8EI*3%9K
M:%%)<DUS;%-"='91-'%R,#AW9GI7;B]!>68X,5DF(WA!.W$V;FU$*V$P+W=#
M0FLO-7%X5C%034@X,7 O=TUN+TY72W5P-6<O;710*T)K+W=#87-69%1Z0B].
M868X04%Y9C@Q67$V;FU$*V$P+S0F(WA!.T=4+VUR1EA5.'=F>E=N+T%Y9CA!
M3E=+=7 U9R]M=% K0FLO-7%X5C%034@X,7 O=TUN+TY72W5P-6<O;710.$%G
M6E K87-69%1Z0B\F(WA!.TYA9CA$2B]Z5FER<6594#5R5"]G6E X06UR1EA5
M.'=F>E=N+T%!36XO3E=+=7 U9R]M=% K0FLO-7%X5E1M=$Y:=51#<S<R=VEJ
M;6DF(WA!.VQB9W(X:C9B:#9#<$DW67$V1S Q;3)->7=08D=+4V%75F5A=GE(
M<4]8;V%%1'9I<7!4>D(O3F%F.$1*+WI6:7)Q95E0-7)4+T%)1U0F(WA!.R]M
M<D9853AW9GI7;B]!>68X,5EQ-FYM1"MA,"\T1U0O04IQ>%8Q4$U(.#%P+W=!
M1$HO>E9I<G%E65 U<E0O9UI0*V%S5F14>D(O3F$F(WA!.V8X1$HO=T$Q67$V
M;FU$*V$P+S1'5"]M<D9853AW9GI7;B]!>68X,5EQ-FYM1"MA,"]W0T)K+S5Q
M>%8Q4$U(.#%P+W=-;B].5TMU<#4F(WA!.V<O;710*T)K+W=#87-69%1Z0B].
M868X04%Y9C@Q67$V;FU$*V$P+S1'5"]M<D960SET3F1U-U-A,F53,59*:TM-
M>7)*54$W8E9/2W F(WA!.W9I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5E$R;S)C.3-B4$1$95175$UR3#9S06HU1&M+5B]E22]4,GE52D%'>4Q96DEM
M46\F(WA!.T5J,TI-,VQN5FHU6&92+S O9'9E=$5K839O=VHY5D=69U,V,%=P
M3S%0:EIV974Y6C5::5)S05)964U2:$5!>4UV37-C:B],,SAW634F(WA!.V]L
M6'IZ8VUY4C5$2D4P0RMO>5!B3$50,V]99D5*43!V4VQ4<T)L8F-Z5'DS<'0W
M<&5G869P,3EE=G%.,V%12D109E-6-7I-9V]:1S4F(WA!.TTU<3-5-S1&4C!S
M8D]T1FMA23$K,&Y%;C5F14='06DQ4R]1.4IV9$]T>D9D86Q.9G1Y3&-P4C))
M1S-X1C,R<"].;$=N=WEG2VQ)>5DF(WA!.WAI4C%99G)8-65E8S=M.#%E-S!N
M>EA*<&,Y.4UK=&TV<$Q+25%'0EI41SAX:5!W+T0X2T0S>DI:25,Q+TQJ.'DO
M4G,U8FYZ,4]L.'0F(WA!.W%9<C<P-&DX5'I!4VQ'54UY-TQ*27!/=S5"86)!
M-TMR3$1Y1"MB=C9:5V4O.#A5,"LR4S-32TM'3&LQ=SA32TI:2FQ927-F3FQ0
M=W$F(WA!.U="<E5M=4MV56-#=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W8O
M+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I
M;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C,Y0D$T-D8V
M-#@W-$5!,3$Y0S8R03="1$$P.3A!,#A#/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C,Y0D$T-D8V-#@W
M-$5!,3$Y0S8R03="1$$P.3A!,#A#/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y
M,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,X0D$T-D8V-#@W-$5!,3$Y0S8R
M03="1$$P.3A!,#A#/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C,X0D$T-D8V-#@W-$5!,3$Y0S8R
M03="1$$P.3A!,#A#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T
M4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,S9"030V1C8T.#<T14$Q,3E#-C)!-T)$03 Y
M.$$P.$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#0M,#)4,# Z-#(Z,3,K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C,Y0D$T-D8V-#@W-$5!,3$Y0S8R03="1$$P.3A!,#A#/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P
M+3 T+3 R5# P.C0R.C,T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R
M.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O
M9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%10
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @
M(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @
M(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S
M/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I
M>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$
M:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ
M:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI
M=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A
M9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \
M<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M
M93Y!<FEA;"U";VQD350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV
M97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S
M:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86QB9"YT=&8\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @
M(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A
M=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U
M<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C
M:SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ
M,# N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!2960\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0TU92R!996QL;W<\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D--64L@1W)E96X\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!#>6%N
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($)L=64\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0TU92R!-86=E;G1A/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3$U($T],3 P(%D].3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,30N.3DY.3DX/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T].3 @63TX-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXX-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3@P(%D].34@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C@P+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.34N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TU
M,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TS-2!9
M/3@U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XS-2XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU($T],"!9/3DP($L]
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-2XP,# P,#$\
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.3 N,# P,# P/"]X;7!'.GEE
M;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^
M,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3(P($T],"!9/3$P,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$Y+CDY.3DY.#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T],"!9/3$P,"!+/3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3$P,"!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STQ,#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N
M,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P,# R
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STY,"!-/3,P(%D].34@2STS,#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^.3 N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,S N
M,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS,"XP,# P,#(\
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3<U($T],"!9/3<U($L],#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STX,"!-/3$P(%D]-#4@2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXX,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C0U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STW,"!-/3$U(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIC>6%N/C<P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$T+CDY.3DY.#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,].#4@33TU,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P
M,"!-/3DU(%D]-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4N
M,# P,# Q/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P,"!-
M/3$P,"!9/3(U($L],C4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXR
M-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<U
M($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]
M,3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3,U($T],3 P
M(%D],S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,S4N,# P,# T/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,S4N,# P
M,# T/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,"!-/3$P
M,"!9/34P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,3 N,# P,# R/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-3 N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY-2!9
M/3(P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XY-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$Y+CDY.3DY.#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STR-2!-/3(U(%D]-# @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXR-2XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XR-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C,Y+CDY.3DY-CPO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STT,"!-/30U(%D]-3 @2STU
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\
M+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6%G96YT83XT-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C4N,# P,# Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/34P(%D]-C @2STR-3PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV,"XP,# P,#0\+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR
M-2XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/34U($T]-C @63TV-2!+/30P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU-2XP,# P,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XV,"XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C8U+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,Y
M+CDY.3DY-CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C4@33TT,"!9/38U($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,SDN.3DY.3DV/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],S @33TU,"!9/3<U($L],3 \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,P+C P,# P,CPO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^-S4N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 N,# P
M,# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STS-2!-/38P(%D].# @2STR-3PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,S4N,# P,# T/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR-2XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-C4@63TY,"!+/3,U/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV
M-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C,U+C P,# P
M-#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,]-# @33TW,"!9/3$P,"!+/34P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS.2XY.3DY.38\+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P
M,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/34P($T]-S @63TX,"!+/3<P/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C@P+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C<P+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,]-S8@33TQ-"!9/3 @2STR-CPO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E-03U0\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<V+C W.#0S
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C$T+C$Q-S8T.#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXR-2XX.#(S-34\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/30R($T],"!9/3@W($L],3(\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y34$]4/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA
M;CXT,2XY-C W.#4\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.#<N,#4X
M.#(S/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3(N,34V.#8S/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9
M/3 @2STW,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E-03U0\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'
M.G1I;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^-CDN.# S.3(U/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L
M;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA
M;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'
M.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S
M/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STP($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3 @63TP($L].3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^.#DN.3DY-# U/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @
M2STX,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXW.2XY.3@W.34\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3<P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C8Y+CDY
M.3<P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-C \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3DN.3DY,3 T/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STP($T],"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3 @33TP(%D],"!+/30P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C,Y+CDY.30P,3PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L],S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,CDN.3DX.# R/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9
M/3 @2STR,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXQ.2XY.3DW,#$\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/CDN
M.3DY,3 S/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N
M,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0N.3DX.# S/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"<FEG
M:'1S/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @
M(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,# @63TQ,# @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3<U(%D],3 P($L],#PO>&UP1SIS=V%T
M8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW-2XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3$P(%D].34@2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P
M,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,#(\
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,],3 P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,]-C @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXV,"XP,# P,#0\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C N,# S,#DY/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,#,P.3D\+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#
M;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C
M97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( 04"7@,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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MI'DJ<YDTH7]%N2H#!%<WS2^Z--1>7)';M-]UPMQB0YCDGPP3Z>21"4ISN".
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MPA<*/?J%XW*X'?YY@W'^S:B+RX$WY<0WY\]^OY_#T?+Z^'E]FWZ>M$7B%JV
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBU/\
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M\^*!NW=8W+8X!HC#2?+NR2_;JXK):'RTSYLQH')3:>DFF($U[%0LBL8#)D;
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M-\J\(;4.\3;5Q&<2XCS,GRZ*S7'&8M.;<'QZV12%0:!:<G ,D@Q*G1T11;*
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MGA\ H;U?X_$KW]?(-PZ,=21'9@CDM;[V*9*G4P^6LN2)%')F50G+8)"W9DQ
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M3$M1.0)-DC*D&B<A3Y 2XMD3@#U,9(A@^19=%;LAB[>M;K]]O>'&/MBFBD.
M(=L>(;>7D2/.-AL-O(/<MVJ!%8;4*)N2A<!,@2)D2<+MVY?NA82V26+07+UT
MQ[MZYZ.V7G=N&-<N&W.<PF$1$J+VZ(L(-.IO3:_+F]L8]0>#WER=IRLQ@U-[
M3EB!N*YRR4WV+*I?CQO2(W^\H63E"E46%*R))K=Q_36+]F]>;R6[A#&*2".H
M(Y;\QMR\_@L(^(C\EEZ_GETG_P";+"-%+/Q#V_H5=VBJE$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HBX#E:5?@)B[),W!NMO PV S&5 T7E
M)T=IT_!Z.N+O[W75=NW>N);:[W'[F.I)9NGL%NC=+;.)0*/*HP?:;M.MQF/[
M1:KP=X '%G>S,CXPTD EO%Q;$@';8D+6YFV,?B,K?,0G%+&WK9A+G-$PK599
MC$7-:YS1(&<!<UKG#?<-)&RZP>G?Q#X:ZZF8,1!I8BS,3(<ZQ#"V"S9RG)%U
MG'B^_)U+*XREH3WVKT3FM="R-$H5H5!$]H3,"2V:\)5!CVO=<WI>\S3T_>9]
MTSJE?*6;/[BD'W(A!%+%!)P3%S6L,,@86<3OWKSMR /Q%HOM(TU+V@5C6T.:
MS,G=TS0Q)=/J#N<7;-NW!<N0_:*+8B^46ZKY1/W41^S1CC(XBWM=5X ON]*(
ME$2B+4_X@7QB0C]2S_XXY5E9T/C\ L3^H\/B59C0O\1YOUR?_P!G:JJ_J/#X
ME69T/C\ M6OC/:ZI+I4G.,X'C#61/L-Y<R7"=XOA=KQ/I]<<5*4QGV0)+V6\
MQ9PSIC.<%@,4M D4,=YDBI)-(W0S 2VQ0-:N<KJRY19V $$EH('K._@ #N2?
M8/.0K7>&ZU2E=X>CR7'NH_!&?,Q2L,N.(9IP;A^%X9Q#8S0^(+P)[*6(PF'1
M%I=BQB0';/?J8.$/;GR7GM775W:[-^_[BM%5QW=OL1ZB2>7DZ\^GK\%JQP)A
M?7+=S=I,E&35NH"(97:\KX%@4&C,\UH1:;VF33U@MA/(->N2,M1V.9:>&7,S
MEJ8R++9C$X(EL1V82N.-<7ARQ>./61@2I%,>_I]>/7R#S*Q+=CT.^Y)#=N9Z
M <N0;UZC?F.8V79PRW"3Y+Q3D['%NZVV;F0,>S2$V[SU:?K[/:/*XVY,1+KM
M9BLBB$GO-MLR\#K[4<EL7?KB4+I&>1,C@*=S2RL8Y$'S+4SA#PO,E8TSAA'*
MS[ER*N$?QP[,SNHAUA//).[0AJ@#AK,OX_QSC+(4ZD3O+'6+JV[6 J:9J_3Q
M4M?US3C5D9D2<&QV2V8N5B[D1SY^'3EUV'_Q'T%ZFN.!:B6G59X?<SF.H6-3
M#!KQXCD"3PC""+!S=%W^%.5[3OJ-NH')?EZS/79=+;2%(B?4MQ!?AC.58=\3
MJ3*+ L]NTM("-CRY[==_6/(MUX%N[!O< 1XV@$> !N8IA&Z.WJ]*78H!\S;<
M-QHJH);NP[7  >-T '@ [&,8!M#MZ_1%W*(?/WW'8:(IV/RWYAQY[\>(?F>C
MX\-_;Z3\IR[[>7M1%KTUVH7+&R>!ZJ&!KMO5[&B=_P 5Y69A1&56)+A#-5I)
M&WDCJB3F(H<T,.R%9Q_-CI"F'W,RMDH&R:U[LOG'?5[,-O2&N]-VVP21W=-Y
M7-8R.VWCK?MO 8R[<CAD:2T=UD\;^T<;,T.8973UVEV[6[>3=I$$^&R6E-?T
M872OPEXZ=U##&PN-O2FK)JV/L.E:W[\K</FVX;,!O/NZ]>^1L)7[U?T4:RLH
MR;(F,<(RYRB=N%)V9:PI7)8CNIW]05D8%ER/H#NZIV&PI67;J-&VVMTAE2TO
M"V(W5=P;QOB[LD[5M19#.Z>TCE)L8,2RI/2CL2Q/CO/%2C,ZC";,EKNY)"^*
M&!N\)DF #=W2N+SV[$Y2P^>O4E='W(8Y@<1L_P"XP]VWB+MB=P&CEN1RYGFM
MU0EN[#M< !XW0 > #L8Q@&T.WK]$7<HA\_?<=AKZS7:U.Q^6_,.//?CQ#\ST
M?'AO[?2?E.7?;R]J(H MW8-[@"/&T CP -S%,(W1V]7I2[% /F;;AN-$02W=
MAVN  \;H / !V,8P#:';U^B+N40^?ON.PT13L?EOS#CSWX\0_,]'QX;^WTGY
M3EWV\O:B* +=V#>X CQM (\ #<Q3"-T=O5Z4NQ0#YFVX;C1$XW>OY0.IBB'D
M#H4+IC&#]/*T);>_J$O/N(T1!+=V':X #QN@ \ '8QC -H=O7Z(NY1#Y^^X[
M#1%.Q^6_,.//?CQ#\ST?'AO[?2?E.7?;R]J(H MW8-[@"/&T CP -S%,(W1V
M]7I2[% /F;;AN-$02W=AVN  \;H / !V,8P#:';U^B+N40^?ON.PT13L?EOS
M#CSWX\0_,]'QX;^WTGY3EWV\O:B* += 2;W $ *0#AP .9@+< X[_-Y&,0VP
M?F\! .AAHB 6[L&]P!'C: 1X &YBF$;H[>KTI=B@'S-MPW&B();NP[7  >-T
M '@ [&,8!M#MZ_1%W*(?/WW'8:(IV/RWYAQY[\>(?F>CX\-_;Z3\IR[[>7M1
M% %N[!O< 1XV@$> !N8IA&Z.WJ]*78H!\S;<-QHB"6[L.UP 'C= !X .QC&
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M40[% -R]:(@$/L #<$1 +0"/$O42&$3F_P"Z'E$.Q0#<O6B()#[" 7! 1"Z
M#Q+T$YMR&_[0>4 [& =S=:(IXFY;\QVY\N.P?F^CX\-^^W/\IOWW\OYM$4 0
M^P -P1$ M (\2]1(81.;_NAY1#L4 W+UHB"0^P@%P0$0N@ \2]!.;<AO^T'E
M .Q@'<W6B*>)N6_,=N?+CL'YOH^/#?OMS_*;]]_+^;1% $/L #<$1 +0"/$O
M42&$3F_[H>40[% -R]:(G _7\H/42B'E+T +ACB7]/(@A:$>X 4#!YA&B()#
M[" 7! 1"Z #Q+T$YMR&_[0>4 [& =S=:(IXFY;\QVY\N.P?F^CX\-^^W/\IO
MWW\OYM$6$=2Y#_BX9_ ;@B(81RB CQ+U$D&?Q.;_ +H>40[% -R]:V.'_M;%
M_P QI?WF):+5'\,ZB_D67_P^PNC1I8 3:G=.(%-Q,.>,0 !@#<2B.08\ &V]
M>P]=O7M7TGF_[%R_\KR']TF7P+I'^*],?\PX7_$JR_H"\3<M^8[<^7'8/S?1
M\>&_?;G^4W[[^7\VOEM?HNH A]@ ;@B(!: 1XEZB0PB<W_=#RB'8H!N7K1%)
M2F 3")Q, ]@$ #CYSF[AW\IBDZ^H@#W$:(O.B+4_X@7QB0C]2S_XXY5E9T/C
M\ L3^H\/B59C0O\ $>;]<G_]G:JJ_J/#XE69T/C\ M3'B[ZD=4&%M14<-AC(
M>IF%VX1@3'F0L01G$>"YOE["V4LPOFH57'<EQS438A.,Y@N=8HRX18K[@@C9
M)3"G5.J<1<XZX^_BE$6[19F@$<^'J=R7 $#;EMN1Y?45L(TEF>9_H7G(Q#.F
M?<XY(F33EZTIR]J,Q[*\!35?E%Z9EB8;C!CB512%*\6XZ97>\AL09D:V@S.P
M,Z<@HW9VOVE3C?*#R(W V]1!Y;^<$[GVKKQ>'[HTG4URCC&:85TT:&EK#B3/
M&B2Y-<[X&UDXSS5)\.ETW-)6G.J1I01;'Y'%&Z:D??%^FDWCB.4L(.[DZ75;
MY^&ZNX5X$LCB .KN8/(M(W!Z=3Y.6WARV7=$HL*41:T?$2_W]\,;_F78T_RV
MZJ:*1T=X?$+9=10E$2B+&^9+\*2XBRDKR26Z?'B/'<U6SL+!#W+X0]''')3)
M#)R6ORIE)&>TL.G]$(70O%(-H0N 40YF/J37[]*C7BBL3W;=>G#7L-:^">2U
M*R!D$['@L?#,Z01RL>"QT;G-<"TD+3:CGQM;3V=M9ASV8FMA\E9R;XN+O68^
MO3FFN21<'WQ*RNR1\99L\/#2TAP!77I\,_6=IHU"3&$Z4<B::(HGGJB'.[%%
M\NJFZ/N"_)MV(,+BY*U<N:D[&D41.6.,19U3PL<V^02"RL?TBVY85-]]2B$W
M?^TW_1?T3IRCDM58O3NEVX]\[3=Q,&$KUOV7%D965^"A:;NZ>O%:G9%#^YJ3
MUXG1/9NZ,N;\F=@_^D!C-:Y3#]GF<P<S<R<=8KX_4DT\,\F?DQ56:R^7)U&U
MXSC\A/C:LEF:2.Y>BFMQR[/C,L>^\;\#,NXA_+8P=[V5()8ZFQ=/GHQ):S)2
M] L0+)#@-ZXMLV2<2)8_/3*[06[1;":5-Q!*0/G7]DZFTP>/3UE^H\,WKIW-
M6W#)5(QR#,+GI^-TK& @1T<SWK>%@9'D8 0%]>]U:K<Z[S9A'_\ 3SO_ 'K!
MYH;#MR0.0#)]QL-A*U9%Q_F*%Y%4+&AN4+F.8M%LIW_'\L0W(_-V'EL'I%S$
MK-Z12A,(@%AZ:;KDQJP,44CE? :WF$U3B<Z^6K ^:GE*H!NX3)PNHY>GOM]Z
M6G*>*2$[C@MUG3TY008K#]UF@MPSDL:2R5OXX)6]W,S_ .S#S(Z?>:7,.XV<
M5E.NQKDI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(J:8B^
M5;J._B$4_86ZK'\+?S?JJC\3OR_HIP1\HK5#_*T7_N>*EW1GA\ H;U?X_$JH
M'B^Y/RE (MIS:87D74OB2"2W(^1?A3R!I1QX_9"RFW%C.#\@/F*F:XECN.\F
MKVZ)2+,5N$(I3<"-A:<&NW=;5;DWMZA;?+19F@<_P[\MN(@#KS/,CZ\B\?"
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M;+:MVP]+8(<VX\A'X7U%I[$6M2:;DFJN<[)WLBV_PVK<;;+:^#MR0M>R.=C
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MT78\C!"VXW'K9%SRYDML;20CE(TRA'(7 I4"<I5SZC6(FU6D>58 %]T3*FY
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M]1QZ%]H] HB>D(( ('+L($$!W#J%P>-L?J./0OM'H%$0;A  1$Y=@ XB.X=
MMCQN#]1!Z&]@]!HBGD7?;D&_+CMN&_+CSX[>WAYMN_'KVHBCTA! ! Y=A @@
M.X=0N#QMC]1QZ%]H] HB#<( "(G+L '$1W#H%L>-P?J(/0WL'H-$4\B[[<@W
MY<=MPWY<>?';V\/-MWX]>U$4>D(( ('+L($$!W#J%P>-L?J./0OM'H%$3TA.
MOG+T$ 'J'01.-L '](G*8@>TP"'<*(@W"  B)R[ !Q$=PZ!;'C<'ZB#T-[!Z
M#1%/(N^W(-^7';<-^7'GQV]O#S;=^/7M1%A'4O<(.G#4 ('+L.$<IB [AU"Y
M!7XML?J./0OM'H%;'#_VMB_YC2_O,2T6J/X9U%_(LO\ X?871HTKB!=3VG$Q
MA "ESSB 1$>P &0H\(B/Z #K7TGG/[%R_P#*\A_=)E\"Z1_BO3'_ ##A?\2K
M+;-JK^4CF[^<F4_XG?K\0>TC^/=7?S[(?_NY?:>0_P!NM_\ $2_]978GTO&*
M&G+!X"8 $,7PK<!$-_.RI"D_^8P"4OM$-@ZU]T=G?\":0_Y=Q/\ <XEWC'_[
M#4_X>+_H"SP!BF$0*8!$.X ("(>8Q>OL\Q#%^LHAW :[DN8O*B+4_P"(%\8D
M(_4L_P#CCE65G0^/P"Q/ZCP^)5F-"_Q'F_7)_P#V=JJK^H\/B59G0^/P"T@^
M/;%U#'E/&>:);IHT%9<P\S8D+')3/=2DHMI<S1]>BF$G=C,,'A#UJ]TILLUB
M@)71*X)6UC<)!,%#^N=4R)"MY(D9*+.SGR#G-Y^3?;IY=@3Y/+R]ZV9>#0YP
M5\T,PQ\QS#X#!HJ]2^:.2*/XVQ!E_"48L7%"].-^_:A>;)SD>77%B@Q0,K?D
M4P=HR\' MUCN$LV[I:*K]]^9)/K(<?ZC?]5M4HJKC4SB$=R#$)5 I@W \1*;
M1Q[B4H:#*EJ$KK'I&VJ6=Z;3K&U2C<$I%S:L4I3WT*M,KM%NB=/?M70*<I%@
M"&:+-,N/W3&;S%L86$CCAY$1NQQ=<)5.9#:C:1,61D:+1$DBDSLC<S1:U,)9
M8A-YZ3N5Z"IY*_)X=<8[#LNMWRG<\^?7JJ3:]L(X7B^?_#ERY&L18PCN5Y9X
MD>/4$JR<QP&*-.0I*A6:<]3"E6BD$T0-*>2/*14H:&F^I3N+DILW[S8W7;I#
M'1)C6B G8C?EMT]H6WKT9    A=@ @ &P= MCRMA]1!ZE]@]0HH0;9! 0$A=
MA X"&P=0N#RN!]1QZF]H]1HBGB7??B&_+EOL&_+CPY;^WAY=^_'IVHBCT9
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MP1+Q'F#BB4@?<H 'FWZ!M6LNX3#9+<9'$XR_Q<G?;:%6UOX]_%)NL3X89?\
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MM@.XW'0\PO(+9"[<2%#80$-@ -A GHP$/8($\@?_ +>G:I1/1D   "%V "
M;!T"V/*V'U$'J7V#U"B(-L@@("0NP@<!#8.H7!Y7 ^HX]3>T>HT1>0  "(@
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M@'H'8P[F#ZC#U-[1ZCO1$V#??8-]]]]@WWVX[_7Q\N_?;IVHB<2_O2] * =
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MAV"T CL'42&$3CV[W0\IO4 !Y=AHB"0P@(>D,&X70 =@Z"<P"0>W>T'E+ZA
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M;?\ \JF6;;[;_CD:8OS>.^^WOSWY>7;?MYM_FTW]1]WS39OI>XJ/QK/$'_\
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M]Q^NOS]2?C6>(/\ ^E3+.Q=_W9&F+N(^8/\ ;'S0Z@/SAZ;%[TW]1]WS\O\
MGLFP]+W'V_7E]2?C6>(/U_\ "IEG8VW[LC3%W ?*'^V/G!U$?FCTV-WIOZC[
MOGY/\MTV'I>X^SZ\GK5KM/F2LX9*8Y X9RTVN>FMX;7:PB8X^YY6QYE:Y)&N
MXBMW[SS;<L=JU:!J(G5F.A% X'*KNC;]TVP&R<-I4$#R'?\ J%8&BA*(J:8B
M^5;J._B$4_86ZK'\+?S?JJC\3OR_HIP1\HK5#_*T7_N>*EW1GA\ H;U?X_$J
MY545THB41*(E$6M?6EG+4AB[/6E"(X<0.]Z&SZ1-*>7)F['MV8H9HXJ]2NE7
M'D@AK](R-+B&/F^.Z=\E:A<SIW:TMCZU2MQ;:=[CJKC,1E<<?BLT @[^0? [
M?_\ 7"/;X%?8UU,.JS*40<,1X6P) YG&U<FPE-"3Z3YYL0-259C?,4)R<[L1
MH@.-9)>XJ4D,]ZDCK[_<!ON951D7!(:Q?(T@'<[\M_)ZO'X+E@Y@UU" @.A_
M&&P@<!#\<5OZA<'E<#XA.QQZF]H]1HHY><_T'S4_##KKWW_$@QCORY;_ (XK
M?ORX\.6_P"=^'EW[\>G:B<O.?Z#YJ/A@UU   &A_&&P 0 #\<5OZ!;'E;#XA
M.Q!ZE]@]0HG+SG^@^:#F#74(" Z'\8;"!P$/QQ6_J%P>5P/B$[''J;VCU&B<
MO.?Z#YK&V7]6^L+"./)#E":Z'X&,:C!FDSG[SZNFU>Y<GIZ;(VC,G2W,&)27
M1]VNR0MX1OD&VF]*<.0D ABD $[;G^G_ '620S!KJ 2B&A_& "4"@40UBM_E
M H&*4 __ "$Z  ', ;=@,8/6-%'+SG^@^:?#!KJ   -#^,-@ @ 'XXK?T"V/
M*V'Q"=B#U+[!ZA1.7G/]!\T',&NH0$!T/XPV$#@(?CBM_4+@\K@?$)V./4WM
M'J-$Y><_T'S4_##KKWW_ !(,8[\N6_XXK?ORX\.6_P  G?AY=^_'IVHG+SG^
M@^:CX8-=0  !H?QAL $  _'%;^@6QY6P^(3L0>I?8/4*)R\Y_H/F@Y@UU" @
M.A_&&P@<!#\<5OZA<'E<#XA.QQZF]H]1HG+SG^@^:GX8==>^_P")!C'?ERW_
M !Q6_?EQX<M_@$[\/+OWX].U$Y><_P!!\U'PP:Z@  #0_C#8 ( !^.*W] MC
MRMA\0G8@]2^P>H43EYS_ $'S3X8-=0  !H?QAL $  _'%;^@6QY6P^(3L0>I
M?8/4*)R\Y_H/FL?9;U6:QL+XJR;F*9Z'X ,/Q/CV;9*E8-.KMM7.HQJ$1URE
M4@*V(;F"TUM8X';6I4*1(=2G(I5>BM'OV@.-PI2 "0 3N2!T'E]JYRBS9KF7
MI$B^QH@QGZ%:GL+;(GUB-Y;G!38(>V8Y?@%'C<]"<I3!N.W4NXA11R\Y_I_W
M7L?#!KJ   -#^,-@ @ 'XXK?T"V/*V'Q"=B#U+[!ZA1.7G/]!\T',&NH0$!T
M/XPV$#@(?CBM_4+@\K@?$)V./4WM'J-$Y><_T'S4_##KKWW_ !(,8[\N6_XX
MK?ORX\.6_P  G?AY=^_'IVHG+SG^@^:CX8-=0  !H?QAL $  _'%;^@6QY6P
M^(3L0>I?8/4*)R\Y_H/FGPP:ZNO[A_&'40$?W8K?U$#C< 1__(3N!S&.'L,(
MCW&B<O.?Z#YH.8-=0@(#H?QAL(' 0_'%;^H7!Y7 ^(3L<>IO:/4:)R\Y_H/F
MI^&'77OO^)!C'?ERW_'%;]^7'ARW^ 3OP\N_?CT[43EYS_0?-<$RC,->&0L9
M9%Q^GT6XL:[\X@<KAUARO:OD2FRW79$P.+,G6W4Q,$63J+2&XN!2-@EVT:X6
MV)"7+9C 8.32L"K<J6BTO%:S!8+ >$O$,K)"T$@@%P;L#L=M]]BM?EJ7[2Q6
M2QS9>Z=?Q]RDV5S.-L;K5:2 2%H>TN##)Q%H() V!&^ZZ_,$\+3Q%L)3B&YG
M?,28.=V7$<KCN3W=I0ZA;UI:YM<!=T<K<&Y'<NXJ/:MJEJ1IO)DY[A#VR7;I
M#'*8H" ^GW^TFO<HW:8Q4T9M5+-8/-IC@PSPOB#RT0@N#2[<@$;[;;A?/&&[
M [V+S&*R;]25)FX[)4;[HFXZ9CI6U+45AT;7&TX-+Q&6AQ:0TG<@[;*TCIIU
MUZ:GU9=1\.T[XD:8CGA$V9=B[8\ZEB [H(]D)M22EF2NA;&(362.%EN=$Y%E
MNT8]NVH"X0ASE*!A^#M3]@5_4&H<SFX]24ZS,ID+-UE=^/FD?"V>0O$;I&V6
MAY;OL7!K0?,%[G9P#I[$\PM-:)97OX3$3MQ.)VW[P;[;]=AX+:YBB6:\L<8S
M@<!5:+\6.JB'11ACEYSLZOD2:TON,J*RE]U6T]S!%X]@EP]H;MNT>[<-;Y;"
M<PAN/OVFL2_ Z?PN%DF;9?BL;3H/L,88V3.JP,B,C6.<XL#RWB#2YQ .Q)ZK
M>UH1!7AA+BXQ1LC+@W8.X0!OMQ';?;IN59C#\[U'RB1.*',>G:'X@CMEFO*V
M^0Q[/*7*:QQ>RKT5NRS7F*QC2%G0IKR)2Y+S.PN2DMJ\BMI!0G%<"A/NUG.W
MDW]HV^)5C**%J?\ $"^,2$?J6?\ QQRK*SH?'X!8G]1X?$JS&A?XCS?KD_\
M[.U55_4>'Q*LSH?'X!7(JBNE$2B)1$HB41*(E$2B)1%53 4]Q;(\MZLX? ,4
M/..9-"LM1V]EB1.\;1QOX6YL_8ZC*9+D!#;(H.[/* (K'6",()&])$!WMLCS
M>L9K:V.&9W1<4G?8$].8'JV/S*M710E$2B)1$HBKEJIU$)]+6'7W,SCCZ49#
M8HN-]5(D$5>(.QJV=E1L[N[J'6^KGDHBK<KO+K[6FB<886I2XR&4SR3Q*,MC
M8(.ZAQ;BD#<[;@;^??X K$"7/N)<&:B,::5(AA9\A@9])),SK9DF;&*'0!)/
MLGN63IT]-SU=<UR)0]9;G+Y"IO(W>-L]A?(+QS*WQ4GN)2+5%@G,@G?IL/7L
M-@.7JY*]E%"41*(E$2B)1$HB41*(E$5'M2><L38]U"Z0X!/\/N,XE$OF<@=,
M<944)&!)$<'2M>#%B!&O<)5(EJ&RU2S(J/+KK"X>S,YU#[*RW'V.MR>^XN+8
MWN12 2#MYN?K'7X;^S?HKPT4)1$HB41*(E$2B*FF(OE6ZCOXA%/V%NJQ_"W\
MWZJH_$[\OZ*<$?**U0_RM%_[GBI=T9X? *&]7^/Q*N55%=*(E$2B)1$HB41*
M(E$2B)1%6/6+F;#^ ].N1\G9QC-N=P6/-'NLV.B,;9)W3(;\C.#I'XDP1UX_
M]FN;RL<FZRML7G UAK8$S>KE3XO:6)A<W9"4@$GEU_16"C3XFD\<8)*CMW+2
M20LC4^);5TULUVTF=D-A?8MW#6C'M&N$M*"E.:V<UL3 (D,8H@(E"^U1$HB4
M1*(E$2B)1$HBK5J^RY <(Z>)_.,H04<FP)8:*8ZD< .ECZYOEB/,4TCN(R,\
M@22F_98+\34*9O8&7VW$JRU^"Y7<2-;M>"VV*RD D@#JLEX9R.PYBP_BG+D6
M;'%EC.4L;0;(L=9GBR@3N[0QS:,-<E:6MU3M:QQ;$[FWH'.PD7V&YP7(;*NS
M=MI%BFP6W>.4'D2/,LE41*(E$2B)1$HB41*(J^:A,Y1G"K=CA+*H1+9JVYAR
MYC;!O!@9$SDP,*C+<Q9,?HGJ=KG)0F;6Z,$<9(A1WTPBN='B\K(B;FE79!P4
MH"D#?^A/]%Q;3#G>.93N90QG'<02##5G3E(V#%QHNO- +\?0(!B[>[QID9#8
MVDDECK O98K?93NT NJ$CM#&]SCME:CLV7-&4"$=-_+S\OOW5K**$HB41:G_
M ! OC$A'ZEG_ ,<<JRLZ'Q^ 6)_4>'Q*LQH7^(\WZY/_ .SM55?U'A\2K,Z'
MQ^ 5R*HKI1$HB41*(E$2B)1$HB41<.8X!$(W*IQ-F1EM()1DA3'U<V=B*5UV
MZ^J(LR68ZP7;R=0JO(THMS*GLH2%;TZ0MXA NJ2WKXFNB3?IZNBYC1$HB41*
M(E$6%,Z:><3ZD8W'8GEYC?'QFB<U8LC1P(]/\AXX=&B;1FTOMQZ0I)#C251"
M0%6,QG)4J;R&=#I4SB"1TMV <FYO5)2D';ZW_5?%)I8P@$_AV3U4:D#M-8"M
M='.+.4@R7E"2(43HZ+YVX%=5L=?YFY1I]=6"[DZ?I80YO[0Z+L?-,J=6."J(
MZRW2(+91OY/KZ]2L+1$HB41*(E$2B)1$HB41*(L.9"P#B?*LP@$ZGL94OTBQ
MDZ(7J(F_"B7M;':=&E_998PK)#$V9^;HG-KD9ED=8I9$RS9DD-N)REI0R2-D
M:WM.1<!-UF.B)1$HB41*(E$2B*FF(OE6ZCOXA%/V%NJQ_"W\WZJH_$[\OZ*<
M$?**U0_RM%_[GBI=T9X? *&]7^/Q*N55%=*(E$2B)1$HB41*(E$2B)1%C#+^
M%,1Z@(.YXUS9CB'92@KN2^"N-39A0/S<11?;US7[YMX+;-R\SO:9 YK[#<_M
M-U"]-?NN]=;5Z2\;T@$!(Y@['SA<TC,:8(9&X_#XHT((_%XHR-4:C;"U)R)&
MMD8&) G:V=H;4EH M)4#:W)4R)&GM@!+*>S;MD "E *(OMT1*(E$2B)1$HB4
M1*(L=Y3Q5!<T0Y5 \BM*QWCBEUCC_;!KD,EB#ZU2"'R%LE<5D4<ET-=X_+8M
M(8[)&9K>69^C;XU.[<N16;R59;$# 8B^S!(-$L8PF(XX@3&CC$(@<:9(?$(Z
MW!=]PL<;CC:F:&5J2C?N7E![*%N2)TQ+BF_?4W0M^D47KMXY[AB+E=$2B)1$
MHB41*(E$2B+ATV@$0R,W-#3-&6T^MS#,85/VE->4KDI4<OQU*6J:PMZ*= J2
M7;EUCE#&U.UE-?/=0JKJ0MA>E5H[EY/<)]?U6/L&Z<,1Z;VJ2L>'V211YFEL
MF=IB]-CSDC)<^0FDS^Z.3[('=K3Y#E\KM1Y0_OCPZ/3\2/%:[#T\+E#FYV52
MX_IP*2=^OZ ?HLY44)1$HBU/^(%\8D(_4L_^..596=#X_ +$_J/#XE68T+_$
M>;]<G_\ 9VJJOZCP^)5F=#X_ *Y%45THB41*(E$2B)1$HB41*(M;_BAZF,O:
M5M/D5R#AEWQ>PO[UF6%PA^=LJ.D79&])$7IJE"UR+$W?(<SQOBE'.53DTLZ-
ME+E/(4.B"I$H=TA'<TDO1] M*S0"=CO[.?Z G;;U+1!JKUA97U'XO2R*,NKX
MWO\ E?1UX7LL,Z-\DS+ILN2%^R7XFLXQ/+6KWE@^8,HM&,XE,FQFN(KLXQY?
MF$R<XD]>[&^?3.*$B;4B*P #MCT''YCR#=P>8&Y\HW Y^0+ASE:U4VF#).GR
M#YQR!I8U&-GBF:58'",".>>LWZ@V?!*&YA?)SU"YZBRYF%Z43O+>G_5#)65O
MF+C'%[<WQQ.A87F/*HO8>++FA I.PV.P<"T\]@-]R!Y-]G-!_KSY]3R5'K:U
M"9]P'J/PW;C&I6*:B]6/BB*\.2?$F)7RRLSO@C$^!]-NEN8ZR6_"*V32^/QY
ME01YR8Y'$HHY79$QM"B_E5ODI;9'-W/9O$X0.$[MV#-]R.1+G.X=^1]6^X\A
M&ZV,0_4WE+)_@4ZM'F=N$SA>J?3)I5U68$S5?<%=]AR3%\WX*Q%)F]-+'%P:
M75;>;)=*8\$,RB#DSO*FTG72JVH:'-19M)U9RJ !(T<B"YO@02//U'D5'(!J
MXNZ>;65LG^'SD^5ZD\-Q'P]\833.PS7+V:M4.%\1:KY)GG%D(LS14]RN;2U]
M9ET7Q%)\QY1RYC&"R]B3JXCC!"H5I&"_;1+S/KZ^O%3P[[!PX23RY;$C8[C;
M;J3L&DCS^19*RSXM&JJ$8LDCS"LMZ6LI0F#ZDY7B]JU=QQ@B<0A.H&#,FGN,
M9;OW\/Q[*FH*'X7?Y3 9R]OT G:)%J!37IJ6*76[%B%5* >+;:0,!\X/#OMS
MWZ[ G8$\^H^Z>9Y[ @G,$.\5G4I.]<.&\,-$;@[5C>>!I(!'!YO%8SC3)V2\
M?ZA-/R'+N0,U1QBEFH6_E5BNXSD#@X,8PJ,XHRO$62U 9?%YKD^Q+G!KOMY1
MPCA)WYC?<@[C<'D.FW/J.9W\@\^4M;>J/->$\[:W\B0-T:T;_IATE:(4F$(K
M-$[N[8_=%^K357/HEEZ?/48;7EBN/E^RBQ=!XHB66%]A6RBS+;2)8E!Y<;*T
M@ V&_0N=N?\ ZM!^)^"Q V>(;KV@N57B,R=7A?.:"/:BM>^F%J@L(PO*H),<
MB2;3'HXE&K/'$H1.@99FEIN=I:]M;7BJ_#$#$ML"V7;CT1Y6/:ZT1 4\((\W
M)IW)WV!.WF'GW/N6+\9>(;FO5LI#3.NSOB'*Y<T1GP]?<4VP'!)1BQRB4ASK
MEK(\MU5XS6*5F0IBJ5NV,\$83R,SV;Z!0S.+2N;[R"4)$LD;9%9M$+0!N01L
M2-CY0 -CY#S)']?,L3:9O$OU;XOTM:@4SZ1J0NF*HY)YC@%UR<T2+*;GE3'T
MJ\0[(N'\Y:GI _MDQM/2F":165T2MKUANTE:GMOCK&Q2UTDJ:'29F2M1"T'A
M\G(<7DV^X"/)U=L=CSW/D/EM?BO6OE[-$OQ#.RY?@>6#8P\7)+HOB\ZPS'GB
M#0#.^GK)6CEMF\F<W2+J9C-$+W?1/SI;RH@?VMY5,8FQ\W.<8N%CB@YEKKT4
M%NPY>5@<=_(>+;ERY>;V\RNQG142B)1$HB41*(E$2B)1$HB41*(E$5-,1?*M
MU'?Q"*?L+=5C^%OYOU51^)WY?T4X(^45JA_E:+_W/%2[HSP^ 4-ZO\?B5<JJ
M*Z41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7S'M.YJV9W2,C@1H>538O3M#K<
M2VEUML<[R2[;0.%Q%> ;*PB)4:TI.EN@-I06T-JX' XT1=1BQXZ&JIFBC;E&
M4(H=;Q[ =,LFT_9=,6*)P6*?%6;L4Z@LAL<>1'3EW;8^ZN.%&"+EB)"@G.[Y
M&;;5BS= Z4E@LO #N!U)W!\S-P 2.O0[^H [^7;9Q&_&,BD"E\LQ)FC',]?;
MNGV,SN(9XSE$DK.L0WLS:?\ 3M\-V:588T:K=I5'8 X"RR6,1*5W76TA<)];
M0QL&9M97-ID"E]>"KP<MQY>@/FWV&_KY]/-S')8#RUXZZ=AP_C#.1L6S?$\7
MC^J+"D8S$S@UH<L'GF$LOZ?,_P"46)IQL_-:%N0WLB791C!NC,F:TQ+1(8]I
M2VE,@51EZL2"X^OKR)P<]O."?(.8.W/?R>7P/GY*Y,@\5I!"LQZ8\13[!*R&
M!J/AF%98AGKUE>)(L<V5.;GAR;&V,X[R,Y-C=C3+DCA%A,TN$V96><L3VNMR
M-G38O:<F*%J,JLHX>1(Y[$@\N8V\I'4 ]![=]EMUHJI1$HB41*(E$2B)1$HB
M41*(E$2B)1$HBU/^(%\8D(_4L_\ CCE65G0^/P"Q/ZCP^)5F-"_Q'F_7)_\
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MPHI/.\E9(R;*G?+>280DQG*LF2R49#E4F?I;-+V.4801I>I X.%Z.Q)2M8F
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E)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g897644g32y50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g32y50.jpg
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M>+;6UQDC)S(SN"0H-$)25'%U@9135F%SH;74-E=B=)&3E['P_\0 ' $!  ,
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M]:IJ14&T+T>K]$;9<>2MI#YZ*E%\=P_THU[$;M$JD+H]J1X)Q#43A4O$:*U
M<J7HBW'68];G8:ZAM^'1GW&M(W_6+TEF.XT^Y$(G$(/VIKO&VPNYZZ5M+,]/
M3E,>Q%OGK8+M=\PC&$10'96%X?,YY\R;P4ZE4GQ@9V$L!)2BD2ZXMWI$5BF(
M'2*P;BA$>%).BS#:J+T./$T$H<=<>J".L@MKCMK5(8.8W^.-Z0TT3R/Q(-1&
M1CU3?2=@%R75(2<4TQ+]&C5.743=6ZS'9C49PF:LZU,>:1$EIIKQDU-*&_(5
M&<NATDJ(R+S>[<H3MHJ$!4K$UMKRS,[3E^K8:<(1D%.L92J3MF:)3':=K@IN
M-C+#%Q+.NJDFFXA$+NYM!PS"%;/$%EW;3LH/1YB:9(EQEQ$15Q:/+K25.OL.
M-2X\5:F>JB/L..QW7ER2-A7_ #)0PI*^O4A24H7T=6Z9\"4R'39J*D[/:J&)
M:?AA:(\26U(I\R>VF3U]1B2F&)D>.U"44I%HRW92%M%%;=2M;C?>EMZ^U=NE
M?%ULT58B6,YDE;NY^BF3!"V=2PR%51JQ0+%B:4M+B=BWK-K6H<)"==$2(];Q
MZL>X;.EN"G!&*U*@)*BRC54V3DP2NP77Q2CMRU2CNZ1-1$L.MK5*>ZMA)F;:
MG"<2I">W7TJ='J$U=:L4T\DT*44"JJT95HL]4UZG)I^4<^OJ"YC#K3<&-UTM
MPDDZAE3*T.*W$OO.VNP=$JV2I',]2)3;J\G(^L2349.2>2CVKE4/:VY8"-CW
M=B:*5,B9C6P'T4U"K@*?;PQ_2I<^K."\4OSY5,;HLPYD)##DIM9-M(:1+,BB
M*.0ZXB,HIAG_ .CT'E>E6/T?K-%5KR>E# $2D4^NOXHII4RJNS&(#[9OONR'
M:<2CJ+90V&7)K:J:23]8]=';*G_A],-G23=-[S]K5=GXVL2^;*8VF)9.CN&"
M2;EZ]9*,,E-FKNB2ZLNQ9.8=I!6A!\Q&*GGC]"&64>LT#/B+ND$U#&"\528[
MLIFAS5,LG/2X9H0A9.4Q2T5!DF7%I>7(B*;<ZZ.AM3Z2;6HFS2A1DE]*/1]!
MF,P).*J6W)?*DK:23CKK1M5UMMRCR526FG(K<2H(>9./,<>1%6IUI!O$MQ"3
MY@=U^W0MSN&/ARU5>]]"86J0M,2"KT0CTZ+&DF+LT0D 9C%RTQ4(LX/K/ PS
MV0G(%N!SRD>UZ-0"XEA/$9PH=0*D2O0Y[D1N(]9%W#GN]3!6IO3ZUEF8Z75Q
M9#S;;$A5B:<7<AR?]Q,$^M*G1?\ (Z?ZSH[-0>J$8E.GU":2P4FJMH>)KT>1
M*IK!];/AQ77I<1!*.0PWHJMT%MR@&S9VJ1%OG^E'.HZKS8HF"923Z&UJH-Z_
M,F65BB(DJ\B[<MF!;><Y:LWDG+:-=S"#]=)N?GJZ/L9H2:E8?G$1)DJ.W4F>
ME$)2I#)))TU'*;0A3APR(Y2FDJ=0RIM)J+IV^F/HQ=4E",8TI1J<A(+_ -T2
M=&HJ2B%*-2HY)*GONK0R53,RIZ'UH8<E(>6E!]UHVY:BVFY3]"F)"!KUH0S9
M?L*TR):SZM@=W*7QW18;(,^J<K>&8HUZ69UZ2=/WU?>+NA:,V*;@DJ[4?)MD
M>%/PS/B0H]09;?DQ54.GUN:\J.4=$)FHSWZ='(C4\M4AI<EI#:)"$HTUN&DV
MD$V:U=K2<=4FH5.91Y3T.%4$8JK&%J7&;F*FNU.31:3%K,Q1DB*TF%);A/N/
M.PG5N=4TTE92'%.DVGBI/>IM:AV%5E9',M9;QMSCW,Q!/P;SB[/L1I9W5+7G
MYIPWB54JM7BVMB^@"3]H-#PZTDS=-T'JAFZW,V:P3BIYR6TW192G83B67VS4
MPE?7KBHFICL)6ZDY4@XCB)!QXI//):6A2D$2DWXS_2GT?1F:?(>Q13T,51E<
MJ&\292V_1&Z@Y2ES)2T1U)I\(JBR]#*9/.-%4^TXA+IFVNU1_'\6O*CZ &@!
MH : &@!H : &@!H : &@!H : &@!H : &@!H : &@!H : &@#$RORI%(0C).
M",YQL&:&6[]7;DAB0UQ,%F<4U+,R6-/"!V9T7:0+]BF5L0M2MQ8@HF*/6>@X
MJ:^MIZ*YRG6G]&I>I5X.+$BJQZ%_Z5,TZ*=3]7];?JM'KB*-IFKK+'I:.ED/
MSDO_ % TE$=^(:Z%_E+728K Z,-G5+5!=,3BA-!]<^CZ/I&GZ*:IO5DWU.DG
M0ZS0_$*]A]Z.WN<M]CIC&U3G7:XAD14DRO0;XA4;6KB+G!E&.Q];3UP('(,O
M1#D.G/1%/?3$D!TG'4&SXC5R='QSV"L1,0XTQ<1C0DG32-E-0IZI<1-8MZJ<
MJ,0I/I%.9GD9&P],;9:L:>L4V:DD?TN-TI8+EU*=2V:C+-Z"BMJ*2JCU=%-J
M"L-?_L#%&J)P?0ZS)HZKIF1J:[)?)25]2VZ2%FGJ8\H!MN;UN>LDK*Y#@#5F
MW4*D3%7L&'LHP]\0GLIL'DGCA)O17E43M,@WNS)@Z4KR\=%N@?*)@V I'2B2
M)^9_M]B54F/&::IT@I42H3F94>LTIZ J/2G$-5)2IZ)9Q6E05K04A+KJ.K(]
M/-!&HNN/IDP,B#,G29-:A' J5'I,F!-PSB"+5TS,0,N2*&ENDNTU-0?156FG
M%0ELQW"=4DF\G%)2KGMNN[>O;C;YFNF0-"R+4DL/S-9B@D[S2KC4U)XEAJD/
M93*.6-FK4(-=EFIY<&Y*R^<N)MQ%)-+/T"4/,QQS\?$>$9.&X%$FR)].EG66
M)3O509L*64<XTMZ+9+D64_Z2RLF=(Y3:4L)=-<72-YEPBY>">DB%C>L8JI<.
MCUNFIPS*@1NOJU+J=.5,*;3HLXS6S/@1/09#1R2;* ZXN6N.EN?H)BRF#.M]
M>1'T@- #0 T - #0 T - #0 T - #0!C2PC![B<T4H;DVW"S%?3"8?Q'4%X9
M*1/SF*;505^L)NFA>:H#D !/H>)>8/$QN/DY"S0A6CU9'D1WO;7[C&:=)17T
MK9VU$/7_  $[D?G0R7U8#[SU331^D7\OL+65^;^I!X"=R/SH9+ZL!]YZ::/T
MB_E]@LK\W]2#P$[D?G0R7U8#[STTT?I%_+[!97YOZD'@)W(_.ADOJP'WGIIH
M_2+^7V"ROS?U(/ 3N1^=#)?5@/O/331^D7\OL%E?F_J0> G<C\Z&2^K ?>>F
MFC](OY?8+*_-_4A1F,:S;ZE5R1%VNBU]G ?NW)I]=D#!0S5?H^KL^K@LOP!M
MS#\#])\+I!^"'#RT49&=R+1+=>XDK[3O\!WIXT;2#1TP>HD<,WK9=H[;J (I
MKMG*1D5T5  0$2*I'.0P (")3#Y0T0M3:T.(4:5H4E:%%K2I)DI*B[R,B,N\
M5=;;>;<9=22VG4+;<0K-*VUI-*TJ+:2DF9'W&,1J')F7!9_@2F3N7,=SF&]L
MV082Y8CE'N&EE=PD56*];VMPB\6.LE'O0UM.N$<L8^-?3D?2FTM*QT>U3=-"
MG+Q+]>5TG0R;Q!-CTBI,5G$].?A5=I%:26'G94B&N$[54TTH!23DFEQQUN.Y
M.4RRZXLT+L8_-R.@:IK=P?2Y>)*)+PQ@.M1*IAJ0[A=2\:1J?"J;=3CX><KR
MJOZ"F$2V6&'YC-*1)DL,-I<;([F6\'DX\G3EXF;=?\]5R^+.JGN/I+9]<*);
MKE(RL/G1V@]B#VB'M649.DI1](29L(%M4:%6:-!O(=JN[Z9&:>IOF%/]R*6Q
M 9AT^@2:>2)>&YRFX<^)#::?H*5(=**]$I34XW)QK<D*F3Y4Z0AY:464P@VW
M-?\ 9"O2ZM*J59QA!K"W*=CFDMNU.D5*IO2(N+EMN1CJ$:HX@DTHF:2EEF&W
M3:/ I$1R*VIS23*=2ZSN:SR>V6JQ16,1&9QKJ$Q5=PF'\ZXWI[^(RG;\0T(V
M+(R4C7U<B&%[RW9<@),;JM,+S,LW:W1G'1SAA'1L0R:H X>J5D](E(E3W'G:
M%(-F7AVLT&IS&WJ5#K$_UJZTZB2\Y I$6GFY")E++*EP5N.)<==>6M6B@KP.
MA?$D"D-1F,6PD2J?C7#.+J'3'HV(:GAJC_X\P^P] C,UC$D^LH9JJI+DJ2AN
MJML,+:88BM-();I^GN]C=@:8PAJ]5LEP<=D2C;O[IN]HECF*8ZEJBI8K-;+O
M,-JC<JRWLD9(RT4E7KN^@7$K%S\3)H/6K&:CNKF; Q4ZM..HZZH_)E4Q]RFS
M\'PL'SXS,U#,PHT6'!95,A2E1G6V73DP6Y"6G8[S2FUN,.Z9+ZPN^<Z)9K5
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MG&J*%=Q[M)$)L>XQ[=H(#0 T - #0 T - #0 T - #0 T - #0 T - #0 T
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MDWQ5\S%"[:N'@+-UD+AH C.I^?#D_P"B&,]IH6M#]DG]RA0NVKAX"S-9BX:
M&@!H AZGR4^[Y13.K&4KY8F(BMIFWI&M2X2[1^-H9.LH9\>2$B:/013<08L)
M=9[" S>JKJNPC0DT3$;O$DRA.PN)_07#H(#0 T - #0 T - #0 T - #0 T
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M4OD@C&PE**W&?F)V%8M%7Z(2G67$MOGD+XT$!H : &@!H : &@!H : &@!H
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M820<-YN/D63<)V%Q/Z> R!:" T - #0 T - #0 T - #0 T - #0 T - #0
MT - #0 T 8O\2_@EL$?JJX(_9REZNWVT\1#FI7'ZC'?K48#,+L4^0XWZ9V#V
M:*U1[MGP(:HU'Q^A"9-S^)LWU;>W@G<K'9YD*S@R>G<081G,=1DQDQ.6+:;!
ME"#<M$65(B+9%8AL<1>RL2U"V6ZZ0;RV5JL6";/&%GE(BFM:]D-2,M&UL\SO
M8MULSU\"+*]C/>,LV@J&@").4@7L[?8ONC-5HN!E7"F&+ZA,)V">D*^BSK"U
M<D4['*1JT=6[,I)3T;%BX=0D"Z;Q,?-R":,>^LD W6/)(!*=9<2%MZ" T -
M#0 T - #0 T - #0 T - #0 T - #0 T - #0 T 2%@+SBM]?TPXA_NNX7T$
MGJ3P^IBO=! C+#/G2;EOS*I[*36JO9-\5?,Q0NVKAX"S=9"X: (SJ?GPY/\
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M4Y$J8J!&'PR#[H2@4SY#)QF_-;NZJ5D$Y=_FWW^ UR$SOUMMTCK$G4>OLQ>
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MT8V9:V$S-N6\IQ$ ,75U)@CE^6)7A5:P*R)H8S5 )_ZEQ5_]1?6@@- #0 T
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M%]UZ=5ZM((K'*JU6F./U"HR#S,G)4AS0(]!HFVR)!>PZZ8>F#0 T - #0 T
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MI1FZ3AM,L)=6@WWW$LNJ2VBYV18S)2VTK^?8WZ4<$]'<BAQ<6U?U8[B"0ZQ
M/T:3(;2EA3"'Y4MQAMQ,6(RN2PEQ]TR(C<TB(T-O+;ZSX]V"9;B3'+',N9W
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MV^885<N':F/H,[ATJZ6<*F!X8557LGDV8=&, N^;_/2>9,G/#% H%!6X2?-
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M,#G;%,(F,$'EJ.^KXE?X:C%*]UZS_P!78+U1'_\ I]! =UZS_P!78+U1'_\
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MV9.(UNYAH"*BW"$<\=IOW<>BLQ:(*),G3]))ZX:D,5!=VFFY53,L0IP .SZ
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MY7K&FT2L,%#3R3!XG(,4IF+8RB;)^B4Q4GS0CY!<K9XD4YRIN40(L0IS 4X
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M?V2F9]QT7N&NBT:K">&-OCY6CU'$LUA-UCA,SRA8S>N4\^RY,EK/Y9V\[/\
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M"S=9"X: (SJ?GPY/^B&,]IH6M#]DG]RA0NVKAX"S-9BX: &@!H : &@!H :
M&@!H : &@!H : &@!H : &@!H : &@!H : &@!H GW=3YOV2_P#=+#_SZ)U=
MOMIXBJ^R?N^9#!CK48C]:R\LR2Z%E*2+1'G"?H6KURW2YYN &/T:2I"<XP
M";AQ'@'$?(&M[%N+D W'>.P^G9GUH^]_I8MQ<B .\=A].S/K1][_ $L6XN1
M'>.P^G9GUH^]_I8MQ<B .\=A].S/K1][_2Q;BY$ =X[#Z=F?6C[W^EBW%R(
M[QV'T[,^M'WO]+%N+D0!WCL/IV9]:/O?Z6+<7(@#O'8?3LSZT?>_TL6XN1 '
M>.P^G9GUH^]_I8MQ<B .\=A].S/K1][_ $L6XN1 '>.P^G9GUH^]_I8MQ<B
M.\=A].S/K1][_2Q;BY$ =X[#Z=F?6C[W^EBW%R( [QV'T[,^M'WO]+%N+D0!
MWCL/IV9]:/O?Z6+<7(@#O'8?3LSZT?>_TL6XN1 '>.P^G9GUH^]_I8MQ<B .
M\=A].S/K1][_ $L6XN1 '>.P^G9GUH^]_I8MQ<B .\=A].S/K1][_2Q;BY$
M=X[#Z=F?6C[W^EBW%R( [QV'T[,^M'WO]+%N+D0!WCL/IV9]:/O?Z6+<7(@#
MO'8?3LSZT?>_TL6XN1 '>.P^G9GUH^]_I8MQ<B .\=A].S/K1][_ $L6XN1
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)+<7(!IZP ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g897644g33h06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g33h06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1] 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'R2^>7(X0DE-! 0      &,< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(V,#@P-#(< @4 .DUI8W)O<V]F="!7;W)D("T@.#DW-C0T+3 S($%V
M:61I='D@0G5S:6YE<W,@4V5C=&EO;B!2:61E<B  .$))300E       0]Z@F
MDVCD<IN]383 \,IW53A"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"
M24T$)@      #@             _@   .$))30/R       *  #_______\
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              *G   #
ME@         !                          $              Y8   *G
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   *G
M     %)G:'1L;VYG   #E@    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "IP    !29VAT;&]N9P
M Y8    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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M[_4C]BWVOZ\_M<RRWZT#U'-:[:00&[:MS6C[)^D9M?:UV0YMF=^CW6U?HO\
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MP>TC^?LK]_\ P?\ .^M^>%.M]APO^X]7^8W^Y+[#A0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%!$&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #9 28# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            <(!@D! @4$ PK_Q !2$   !@(! @($"0H#
M @H+ 0 ! @,$!08 !P@1$@D3%!48(187.%9VE):TU"(C)S$R.5EXTM=!4;<W
M0B0F-4-'4U=Q<G09)2DT-D5287>!L;/_Q  ; 0$  @,! 0
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MW$U"BQT\6[<;+PYRKMIERX[RA5-3C).#CQG*?,HCJ!@# & , 8 P!@# & ,
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M1("K"<  Y"" $"^'8!@X'\/RF-WF+QUU,4QQ*!14.6FQ('4$H="E$Y@$XE*
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M1=MO6 M!*FHU6 %@2.!0,4# !%'AT^7[!G#WR0*"/LY:D\GL#M)Y/P+B/)[
M_P ">5V@0/U 7H ?JZ8!<W & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MNU"'3.RGQ*HF]3, 7.XE'MD+HC?W7:8)WJ4QK,@DNF8H@9O' >";BE"*'CQ
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M5\BWH03L<\?2#TT,NS19.P.8Z6W:H,5ZTI.OFH*A3_7/H=[F7?H9G@2WPZ]
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M5_#LY(?;_C7_ 'DP![67(K^'9R0^W_&O^\F  Y9<BA']W9R0#_[C?^-?3_\
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MX[[QWY)/DN,FE&6TE%MQEMO8I5D"XT^K6TK5%B6S5Z&GR,V\K&3J#0LO'-Y
MK=&:AG#N(ETD0< FG)1;IQ'OB%*Y9KJMU4SF$&3X!!L!\H#8/T#IWWR1P#K
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M0(HNL8RBIRBH<>XPY!!G& 0; ?* V#] Z=]\D< ZP/R@;]] ZC]^D\ G3 &
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M?0.H_?I/ )TP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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B 8 P!@# & , 8!G5(_\ >7W_ )=+_P#U/D+SE]_\('__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g897644g36p25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g36p25.jpg
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M@_(B1=.5!F;R*U,$DDNZ3R2Z22:=U.$,044NGACA=13+?4YZRF?5M;KYY?\
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M)X=*(^K((B\. TC (@.4(8ND+I7&)><N)7-I^,FD'ZCT/_KU.: O#0"@% *
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M&.3BSGZ?]=2_O(^)G]#JTI_HU#+X<'"[;<3\AW,_@6UQO@VXNZN;X99=;+%
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M.4)".)#*#1YL,8$"K=@^D)1DP)-$)5+U1('":2S Y+&T:C34TB '#5^9^?\
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*][WO_P ;UD'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g897644g43p29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g43p29.jpg
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M87%T"#0V9':!L[46)$)#1'*QM&)SA):A5X*RP\0EP?_:  P# 0 "$0,1 #\
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MY$VJU;&W'-5_&(;/OSDJ3IL:!WLI4U7 ZA&1R[H=0K9.*F1U%>20SYV@@ G
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M:SP$.USJ]2M5Y(JP1712,\MC!E9E8L"9JM+T>Z5LXK1@:;K!QG >M=)I7NI
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MX/23C-RXQ:(K+N54D+**96334<+9XX\ELE,KVY:DIJ6BJNE"2E2*BEB"Q"C
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M%^Z.@4%ZEQ/NX']SIQ[^NM[1_OC@U=57^@OW1T"@O4N)]W _N=./?UUO:/\
M?'!JZJO]!?NCH%!>I<3[N!_<Z<>_KK>T?[XX-755_H+]T= H+U+B?=P/[G3C
MW]=;VC_?'!JZJO\ 07[HZ!07J7$^[@?W.G'OZZWM'^^.#5U5?Z"_='0*"]2X
MGW<#^YTX]_76]H_WQP:NJK_07[HZ!07J7$^[@?W.G'OZZWM'^^.#5U5?Z"_=
M'0*"]2XGW<#^YTX]_76]H_WQP:NJK_07[HZ!07J7$^[@?W.G'OZZWM'^^.#5
MU5?Z"_='0*"]2XGW<#^YTX]_76]H_P!\<&KJJ_T%^Z.@4%ZEQ/NX']SIQ[^N
MM[1_OC@U=57^@OW1T"@O4N)]W _N=./?UUO:/]\<&KJJ_P!!?NCH%!>I<3[N
M!_<Z<>_KK>T?[XX-755_H+]T= H+U+B?=P/[G3CW]=;VC_?'!JZJO]!?NCH%
M!>I<3[N!_<Z<>_KK>T?[XX-755_H+]T= H+U+B?=P/[G3CW]=;VC_?'!JZJO
M]!?NCH%!>I<3[N!_<Z<>_KK>T?[XX-755_H+]T= H+U+B?=P/[G3CW]=;VC_
M 'QP:NJK_07[HZ!07J7$^[@?W.G'OZZWM'^^.#5U5?Z"_='0*"]2XGW<#^YT
MX]_76]H_WQP:NJK_ $%^Z.@4%ZEQ/NX']SIQ[^NM[1_OC@U=57^@OW1T"@O4
MN)]W _N=./?UUO:/]\<&KJJ_T%^Z.@4%ZEQ/NX']SIQ[^NM[1_OC@U=57^@O
MW1T"@O4N)]W _N=./?UUO:/]\<&KJJ_T%^Z.@4%ZEQ/NX']SIQ[^NM[1_OC@
MU=57^@OW1T"@O4N)]W _N=./?UUO:/\ ?'!JZJO]!?NCH%!>I<3[N!_<Z<>_
MKK>T?[XX-755_H+]T= H+U+B?=P/[G3CW]=;VC_?'!JZJO\ 07[HZ!07J7$^
M[@?W.G'OZZWM'^^.#5U5?Z"_='0*"]2XGW<#^YTX]_76]H_WQP:NJK_07[HZ
M!07J7$^[@?W.G'OZZWM'^^.#5U5?Z"_=)H1#XDSYQS2+1QKYSS/G.;!!B'G/
M(\[Y'E^::X^5Y/E9>3Y7+Y/E9<G)RWY<&VUL;K+&QYLNQQ_=DS(KK'FK0?W*
MH_\ 02XJIRW%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12)XPS
M']KWPR0V72F(%(GNM<G%)&<C9%9A%X8JQ6? R;H6[59JN-AM5U&BCAJIFW46
M;-U<T;X9*()9WR3Q_?\ H_\ R>?#CI+0:'I'3Z_P:6CI#1Z;6TK;KND5M6K5
M4I?6MBIT0ZK8$L4.%=U# @,PP3\O]*_Y5GL;]#])](]$ZKH[PO;4]%Z_5]'Z
MAJ>C.BWI:_1:BS36M4S].5NU365L:V:M&*D%D4DJ,<^.?X5>IV]>Z<'_ #)J
MY[FOP]_.'@M]8=)_N:4/=>^Q?^;/#/ZJZ)_?T?'/\*O4[>O=.#_F33W-?A[^
M</!;ZPZ3_<T>Z]]B_P#-GAG]5=$_OZ/CG^%7J=O7NG!_S)I[FOP]_.'@M]8=
M)_N:/=>^Q?\ FSPS^JNB?W]'QS_"KU.WKW3@_P"9-/<U^'OYP\%OK#I/]S1[
MKWV+_P V>&?U5T3^_H^.?X5>IV]>Z<'_ #)I[FOP]_.'@M]8=)_N:/=>^Q?^
M;/#/ZJZ)_?T?'/\ "KU.WKW3@_YDT]S7X>_G#P6^L.D_W-'NO?8O_-GAG]5=
M$_OZ/CG^%7J=O7NG!_S)I[FOP]_.'@M]8=)_N:/=>^Q?^;/#/ZJZ)_?T?'/\
M*O4[>O=.#_F33W-?A[^</!;ZPZ3_ '-'NO?8O_-GAG]5=$_OZ/CG^%7J=O7N
MG!_S)I[FOP]_.'@M]8=)_N:/=>^Q?^;/#/ZJZ)_?T?'/\*O4[>O=.#_F33W-
M?A[^</!;ZPZ3_<T>Z]]B_P#-GAG]5=$_OZ/CG^%7J=O7NG!_S)I[FOP]_.'@
MM]8=)_N:/=>^Q?\ FSPS^JNB?W]-^N'KB/U;Q.0;&>:N+N'3-%UDP- BZ3=C
M)XR1Q\K+!B?%MW;Y-JHY1QLY9.&SMX/?-[WS:/%LDE\4?R;PO\#.G? CI4]$
M].Z=*[6K%VFU6G9[=#K:3@&W27O74;%1CLL1ZZ[:G&+*UW*6_<? /V0/!GV1
MNA5Z<\&M6]U"V&C5Z/4HE/2/1VH&2*-=IDMN%3N@XE3I;;1=6=U5K[7"WO75
M9W:*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(B
MD12(I$4B*1%(BD12(I$4B*1%(BD208?Q?Y?]=(F9%"+80,(EGEG&306Q=D75
MFC1R_=W;,FZCE>S9BS27>/'%TDLK(M&B*SEPIY**"2BN>&%X ,D 8R2 ,G Y
M\N9/(#^T^:3D@ D^8 DX&3@#/(#F?[IY;Q3:W$NZS9@]],-Q:FBQW8#78,@E
M8J,Q8@7B6N=AP.4$(QJO [ 6TY:BP,,VE%S0$M+':(Z<L8^ZUJTEGP(M,%G[
MSD&KH\])JL8(452S ,];J&LVOLR7K8,%R4+<0KG9@<6ENH.%OXU2M8+"X52R
MU6UL5JW5APJUVJ5+D*^TUA@-^3-Z_P!B[B(F4L-IS#?0%VV,!&^C1H'5;;!;
M;<(5W#-PPR4[('+P-J.:RF3:[8PY;9H,NY@&.N(R\M.4@<!($U7C'#UU ?@T
MI;*L;BUG]6_!0E4.\G:MA;AL ^]ALW.!B;5V7$CBOJ%(*BD"H?AD-K@/8#7@
M.U83BJ37PU._%9;(CN(';'%V)D^U&$#BL_CS.:Z,!QV L6$:#3.^LMM(&MF&
MBLS'FP@PV%=.WVJ([("]D3CTP!2F0/541N,0.3*X\PIKTQ6LNR$K<2Y+%=]9
M6L!2"00!8RCD =IL?.U,C&HMU:O<*UL4/2JU@('X5P-C,X90P)-2LV&)7>M2
MX#/@Y1)N+#=X<&DU$:X6RD09U.V4K=%-8['*IL$X_L8Z A.3-#!_#XT2,SB"
M#1$F1;E)Y$0F:L@8/&QE*Y.-QL_A=-46RSX4[-H%E8)!0%LYW, K$KR1F\D\
MCABNS:N]5PM>67B;LU6MC;8RUXYHI9T ;RG1<L"&&Y5,3)^)WB/48,Y+'M<F
M%GP::3VY+5+/4NQ6,F%1H%KSB#2B6<U.&%E0TI;S(E%M>['8!HEE#I .Q>"(
M;S@TI(1Y9X&GI!VEP053\)Q*RI8O26VJ!E-FYJRS%E)!;R0"!AM5J,;EK;*N
M^:A38&"K7J-N\DX<.4KM"IL895,MN#&RI1M7?TUX:P;B'1N4"=R[)G1&!AB\
M'B(8:\C\<$R&1/2NQFX+9\E>Q #SO7<2)91Q62S0W%'\N,QI,0=D; R(Q(1K
M70M[;F!JK0.0[$[F(4"O=6H9O+<;MJ!@H;*J5.)&MO?3+L5ENML-8*( 5568
MM8%M;:N:T.W<[(69<,P8 UP#XCN+%^WEA?T<HI.VT>M*>@9S5DV5(Q=U'=*0
MDG)X8+,A#;7"8K$MQ+SH*)),&Q1TY;QU^VC[.0W>!4,)#1IQM!<\VVAUL3#!
MK7"L01Y(%6PG. "P)QSD:ZG5$,W#YA=^PU/E=M-99 RGRR;38 0"<(=H;*R"
MF'%GQ#+6V1$XJ!#E9  A(<A$%XYJ':#,]LYO,9?MF(*3^(-RQLR/UZ+U^+@R
M,N2&3%K,;;!^!2J4=>)C#P!]CLFFH_!LS$*SD-NLK*UE5K;8Q !<N7VY79LW
M G)!$PVKU!-B(JLRJI7;5:&L#V6H;$RS"L5BO?AP_$VD*<,IEQ,M[\0(.<Q_
M6,IB49)/Y'*;1@1/6$.F(6/W0CD'U3MB:EB(9>1FG2B6<&F,_C$;<L"O,WNQ
M=;J-7EFF<@3C0J'@TLC6*S *NXH64MEGLK0 A1GRU0L-N0C\OQ=QE%^H5UK9
M%)9MJV!'"X6NJYRPW,>:/8JD'!LKYXW;!N^$=+/@PAZX72<KNQC!TNY0'O1*
M#A9PU25471%$E5R(Q)7//)1,>_76>LL,K-G2JBZ2F=ZK !B!R ) !()QGWR.
M1_O'(^<2\I)4$\R0"2 0,X]X'F/[CS'F,DZQ,S$)Q/8=K4#C*)V?8QF/Y&XQ
M'+EB5U<&>!F9205$8TS65235\Q\*2(V+&8.%K8-6ZCO%=XNW:)K+I[(C6-M1
M2S88X'GPJEF/^Y5)_P!W*:/8E2[K&"KN5<GS;G8(H_WL0/1D\Y^8#8D)E)N;
MQN/R484-ZX--8[.![97/SL=-O  64(#GV:F&".2]P,B"OU;MU5TV^+])NXS2
M=XJH)Y9'4(S*0+!N0_E#<5R/_P!RD?VX]$+8C,ZJP+5G:X!YJ2JO@_\ [64_
M[\>>5=GQ3Z-3P?YK2PLA9DHNBVLX@&QVZDE5:S<%K9RG TEHDFKL7-O/)1&H
MHOC L))=(S( K7/R<B;.ZTGB]W+R0<\\AZR%\@V>60V*_(5F\O;R4GWC(O&J
M.>7(QG&:[ 6PZUGA@IFS%C*GX/=Y3*/?$SV.[;U[*#(:,C9!S67'XT;F8N$R
M,4;AT[5B4=/,8P7DCB#2X:$EHX(V/$QPY(D1#-&CU5ZV48*N4%L%;Z-4Z DK
MY*L$+J0R;F4L%#J2I.T$X!)&#G$W6ZMR%5O+96<(P9+-BL$+;'"N%#$#)4 D
M\LRQZCDL4B*1%(BD12)\#._?[=MU?XM;'_SB9KU0\$O]%?!G_9_H;_EVFGBC
MX=?Z;>&'^U'3_P#S75RI:[!.JQ2(I$4B*1%(BD12(I$4B*1+[X<N(W8W#'L8
M?L/7A#R<\?-LY'''BBMP4N!75Q4<A339/*WE89<EU&+Y.UG@MY9-XS4QSQSP
M4ZGX9^!G0WAQT-=T/TQ3D'=9HM;6J^-=':K:0FITSD<B/Q;:F_!WUYKL!!!7
MO?L>>R%X0>QMX0T=/=!7\O)JZ1Z.M9O$NE=%N!LTFKK4_P#[J+U'%TUH6VH@
MAE;Z].&WB2USQ0:X8[!U\^\G/'S3.41=XJE<[#SMTK*+B"Z*=[>5AER9*C22
M6%F99G;%RVOCGBX;M_/'PT\"^F? ;IFWH?I>K(\JS0ZZM6\5Z1TF[":G3L??
M\RW4L>)I[<UOD;6?U<]C[V0?!_V2/!^CI[H&_D=M72'1]K+X[T5K=N7TFK1?
M][47J.%J:L65D'>B; UU&=YBD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1
M%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12)(,/XO\O^ND3)I(
M17#QT\6;8I9N184H1;X+XYY(9KLF*[E+%;%/-+/)+)1+&RF."B>=\+WMCGA>
M]LK0*,L ??('SF3.=JLP_P"RI/S F>9>J>/B;2N0:<%RR*1-!F5UV!&[B7"(
ME62@_>THW9I;5 UA%\BAQY@"AS.-[0';76"'\#LA)0S8.N%6AQME@\6-W[-&
MBK:R,Q(L/"!P<TK5;86; &6)K->5P R/D'WN-JU[NU(=4P:U%VW<,7O?34 A
M9CM0+:+=K!F*65X8<\V8UX]X^3+V$BX-=7X7)QZ,0M^\E6;<3(I7)Y3K^,C4
MGD@8Q<K%@D?2](P<J_4L?)[ 1%M')-KK-Z&+0\M*-#HRHR7\P9FPO-55'<X4
ML&)PA \D5Y(!L!#A9/'U+;16>954);"L[/6@\H*4"_A 3Y1LP"145*,W7"\<
M_GMB9P8E!<2%GLSUX*;/XJ2=2$6(C>P(EH+FCM*51P?)8A,'C2>;@?V6(7,0
M@,M#1XS,:J3E;\8".CI/(WA_,EC$-A22C7?]EBK*"E0Y8<[R<X7+ -=^$X9K
MSEZP-A+!5L33\]ZAD<BRX\\UKL"XRQ ;\M^<9TGU-M#847C\19'8C!]42^]S
MI2-SUL)OQ!#=:2#=,?A9G8C$>O! X+/70 =B\#9K+3(M()]%$12;5L@XL]4Z
M5;*ZV9B&>Q?)#)G@FP5,X0G>3Q"<'&P*CDG.(OUC56V*J!D2I_**V >,"MK@
MC6!36HX:CR<[RUB@# R<ROQB.6KE!,IK5!HS3.2H<0>(SUDNL[%PS;0#21LG
M#QZL?:KRL@I.SZ'P7'L5!;YX";V<KK,SAF+1V0:^+9&0Y_%4CR/,6K:T!CN.
MT;%.6P0#Z0&*[^.<\&L ;F!/$'F2Y:&*@J"[;VY+R) \X9D5JU%\>A\Y8 ='
M:K$Y1J^@9!Q%RUHA.VQ9\PUVD UI, :HR0,16(A6<,X[*9 B>U\H/6:K%5(B
MX9SQI'B2AE;<Z,+D<0[C<M">3C+YL5LJ3G:65=KYSC=E"1@1#7LVUA4-G .H
M<;\D5E:G4A@,;PKMNKP<G;APIR=N-,[K9;EM+KCHX1"6@9A.%2OX0=-U_@[9
M@O-]A.(2EYG##GG0Z^(6^9Y'D'F;'$^8X879.+7K6U&K;D@[QO7'OUG&Q_[-
MW/EYQCGYY<IN%V_"E>&=CY(.+1G>G+S[/)\KS'=R\QEQX#V"3]R538LTRCUF
MQ'O"6#9'!^[8#%B#D:Q<O,<+.%V8]P7*N&+953-%HL3(*M\$\WKG)6/)P!DX
M!) SR!. 2!YLD 9/OX'H$EP,DX&2 "<<R!D@$^? ).![V3Z3.NH$"JF6LC5$
M"U9"Q'/0[(ZH/:9F68@DX9/"(MJ4R1N^;CG[L:.=/6*2^#9TX8,EUTE%6J&2
M;)P5R=I()&3@D>8D>;(R<'^V-J[@VT;@" V!N )!(!\X!(!(\Q('HDI6)F*1
M*?WKIP)OK7+[64D>K,@!<]#2AF[='SRSX;%I>$E#P/AE9PVR:W--Q"@GX0PS
MS4'<\Y\FW<YM\6ZLM-IIL%BC+*'"_P!A9&4'S'.W=G'OXQD2&^E=16:F)"ED
M+8\Y".KE?[-VW!/O S4QEP(FAR)YTWW7@]DL\CLZ [*D)K6Z;S*2K[24UT7V
M&>$CQTV#H1TJ5E.O4281-14V*CP<PZCV(TAS(>40L'5J<?@L*C*:U%GXNS>$
M4DH=P"O@_BEB V1S!J#0$!OPV6L5UM9J\[^+PVL8 .NUB]>5_&50Q7:< B:>
M< \+=8QJW3$[?(:^*N))9XK(R+:1,BO$AJ7B'48"V3N99M8/Y#C5F,24<19)
MG=RU/J&5D;N1#!E? UCC=Y(Y@!?Q1C%%E&3A?+Y6;O*SS7'F)FQT"'9Y;<B2
MV=Q#9U%6HP 7(KYU;,IC(;/_ &0)M"QU&$#SG7TM".%1S#7VO]DP%@ SYT1N
M[;;%D>LY&L^5,D7[A_CF*7UUYE-NM9W=W8TIG=PULQP2<US82CJ>9=T<GD,%
M%L7 4 #F'][&-OFY\K0I5;*W7D*Z[:PO,Y%C5-G<23R-?(<_QCYL<[8J.2Q2
M(I$4B*1%(GP,[]_MVW5_BUL?_.)FO5#P2_T5\&?]G^AO^7::>*/AU_IMX8?[
M4=/_ /-=7*EKL$ZK%(BD12(I$4B*1%(BD12(I$M33&F-@[\V"%UKK4*H9D1E
M3RL\\O+2&!AB6:=GQTZ^LFI@.##L%,<W3K/'////-%FS1=/W31HOP'A+X2]$
M>"71&IZ:Z:U*Z?2:=<*HPU^IO8$U:72U$@W:BX@A$!  #66,E266+VCP.\#N
MGO#KI[1^#W@]HVU>NU;99CE=-H],I47:W6W!6&GTFG# V6$$DE*JDMOMJJL^
MN[A&X2H#PEZ[QBT9MB8EAO%F\GTX<(61(2<LV35LDFDGY2EQX 5=RZ2!B,%,
M\6J2Z[ERJY)/7SQQYY^R#[('2WL@=,'7ZXG3Z#3&ROHGHQ'+4Z'3NREBQP.+
MJK]B-J=00"[*J($IKJK3U:]BOV+>@_8MZ '1?1H&JZ3U@JNZ;Z9L0)?TEJJU
M8*%7+&C1:8V6+H]*&(K5WLL:S4776V;75T*?IT4B*1%(BD12(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1
M)!A_%_E_UTB9]GA@IAFFIABHFICEAGAGC;+#/#*U\<L,\<K7QRQRQO>V6-[7
MM>U[VO:]KU7EB8Z[AL0?M'C!]%(V]8D6ZC0@R=@Q;EH^:K-!C!5L\;+-<T7+
M=5B%#LU$5\,T\V@D8WRQNBP:X);!F&"&8$>;!(QS)Y<_22?[R?3-2B$$%5(/
MG!4$'D!S&.?( ?W #S 3HJ:ZU\KD^S5@D-5S)A;1PEDI& F>1"/65\_8"^RR
M8WN["V7_ .S6%N+J,;*_]D\QY?[ZSQ'Y>6_(Y'E'D?2.?(_VCG,<.OG^#3FN
MT^2O-<YVGES7//!Y9G>RAL0S<"7><5C>3L"XL\!NL@8S)P&=XCFPBSH2M=K=
M0<XL)9,Q=EV>2*MAS1LRMES9!)+#&YN8W-@\B,GF,DX//GS)//WR3,[$R#L7
M*\U.T94X R#CER '+W@!YA)!P$"O$7+9V(%NF[QUB^=H.![1=%T]QP23Q>.4
ME4<L%W6."*.&+A7'):V"26-L^1/&UL9(\Q(P,#F>0]']TR54^< \\\P//Z?[
M_P"V="\.B-\ J=XM'/-QIVH_CF'P(,\D ^6Q5P5>A,>:\@IVK@LMBHY86;K9
MXJJ6RSO;/*U\[FY^4WE<FYGRAZ#SY_[YC8GD^0ODG*^2/))Y$KRY'!(R.?.0
MD,U9KG7L5%0F&PN/ 8N&#_ 3(4U'(*87&9,1XYRB^<.<5WA58BS%#DR[THX>
M/C.3-NL5<O%T[*5E['=B[L68G))/OY)Y <A@DX   SR FJ55UH*T150#:% ]
M[ '//,Y &222<<R9+1*&1R##78J-,56;4@;.R0@HZ(DS#\@<DA1R8,$B!4R\
M(%'J[EZZ4LESIXJFQ8IM!;#!J+8,6;?#,SD%CD@!1R  "@     8 ]X<SDG)
M),RB+6"%! +,QR2Q+,<L26))))]. , 8  &45K-XI$4B*1%(BD12(I$4B*1%
M(BD12(I$\$)Y^QIA$UG$RF2^\94P6ELKD4F68I0\0NDR5/%WA51HFOF83S63
M;9N[HX*Y)X9*8X6SRPQO>^-OISHO_*0Z4Z+Z,Z.Z-3P7Z/N7H[0:/0K:W2.I
M1K5TFGKTXL91IR%+BL,5!(!. 3C,^.^FO\D?H'IGICI7IBSPPZ6ILZ5Z2UW2
M3TIT;I'2E]=JK=2U2L;P66LVE%8@%@ 2 3,4^)#@?;Y+NY0;\;J_[I[I;XI]
M'?66I_9IQON-/![XZ],?5>C_ &B/B0X'V^2[N4&_&Z>Z>Z6^*?1WUEJ?V:/<
M:>#WQUZ8^J]'^T1\2' ^WR7=R@WXW3W3W2WQ3Z.^LM3^S1[C3P>^.O3'U7H_
MVB/B0X'V^2[N4&_&Z>Z>Z6^*?1WUEJ?V:/<:>#WQUZ8^J]'^T1\2' ^WR7=R
M@WXW3W3W2WQ3Z.^LM3^S1[C3P>^.O3'U7H_VB/B0X'V^2[N4&_&Z>Z>Z6^*?
M1WUEJ?V:/<:>#WQUZ8^J]'^T1\2' ^WR7=R@WXW3W3W2WQ3Z.^LM3^S1[C3P
M>^.O3'U7H_VB/B0X'V^2[N4&_&Z>Z>Z6^*?1WUEJ?V:/<:>#WQUZ8^J]'^T1
M\2' ^WR7=R@WXW3W3W2WQ3Z.^LM3^S1[C3P>^.O3'U7H_P!HCXD.!]ODN[E!
MOQNGNGNEOBGT=]9:G]FCW&G@]\=>F/JO1_M$?$AP/M\EW<H-^-T]T]TM\4^C
MOK+4_LT>XT\'OCKTQ]5Z/]HGI'PJ<(^LN$R%N(W"4U3$A,JXN9;.RS=NF?DB
MR62EVC=2R/E)CPXW!3),<':J7;HY9+.U\W+]TZ=K?B_A[[(/3?L@=)KK>DV7
M3Z33*4Z/Z*T[N=)HD8#B,N[!NU%Q -VH<;V 6M0E2)6OT'[&7L6>#?L7=#OT
M=T*CZK6ZMQ9TGTUJDK&NZ0=2W"K8H-M.ETZL5HTM9X:$O:YLOMMM?:>NB3]+
MBD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4
MB*1%(BD12(I$4B*1%(BD12(I$D&'\7^7_72)8%5Y8BD12(I$4B*1%(BD12(I
M$4B*1%(BD12(I$4B*1%(BD12(I$K)3_A%/\ IY?[5ZL2O.%(BD12(I$4B*1%
M(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$
M4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$D&'\7^7_72)W%8$"5445R
M>S"V2N>:F5D]A3Y%.V6>5\KV322DN"26%KWO;%-/#!/#'DQPQQQM:UM.,_HJ
M["D_^M<W-*$DYMY\^5UP'S"S _N'*</1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>
MWO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*
M.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3
MTXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>
MS/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO
M[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[
MC@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TX
MS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/
MVC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R
M/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@
MIZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^
MBKL*.[C@IZ;>WO[R/1\!^>S/VC;"\3TXS^BKL*.[C@IZ;>WO[R/1\!^>S/VC
M;"\3TXS^BKL*.[C@IZ;>WO[R5YG"@UL\[<[E7[LLK?OG<XO?]U[_ ._?I%^^
MK'&?T5=A1W<@X2^FSMK?7G'H6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^
M=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?
M7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2
M^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ[
M"CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5
M.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RK
MOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH
M6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FS
MMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CN
MXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_
MHJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW.
M/$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^
M=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?
M7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2
M^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ[
M"CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5
M.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RK
MOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH
M6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FS
MMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CN
MXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_
MHJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW.
M/$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^
M=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?
M7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2
M^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ[
M"CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5
M.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RK
MOW./$5.,_HJ["CNXX2^FSMK?7CH6&^=RKOW./$5.,_HJ["CNXX2^FSMK?7DT
M(BPQKSCS3F19><\SY7.)?+'?)Y/G>3R.=&UO-_\ ?7\KS?D^7_H^7Y7DX\F#
M8S8R*^7HJJ7Y]J#/^^9"!<X+\_38[?-N8X_W2XJIRW*15XC--XC'Y5I+\SB8
M[8QW4:PV+1N6RZ2N-D1ALZ?R")BHC%P)>5&R0@2Q>'7N08,_:)1QJO([N;@D
MLR%I>!;D KC-8MRS*JBMB K%F(4 DA1D@EB%QN.)!XS3@D/NQ8U1"JSN;%YL
M@15+L0/*.U2 OE9V\YTT>)O23EP#;,I@Z(7.(!E^<C(?."8V.8R"1$(B(1V"
M681IR,U@\>2H08C>+#8[N*O43@8R*<-T7H@D@UR:+1G*@8)'-D!;:H8[!NS8
M I#93<,$'.",X\:HRH#D[@#R2PA=S%!Q"%Q42X*XL*$,K C*G$_)=YZRA\S3
M@,C.$ATANVB3MRKT0F;R,B$9X<*QJ&7D4Y81YU"(RK)Y %)!@K>0R$8X?D44
MVJ"62KMGBXPM-C)Q% *^4/QT#'8 S[4+!VVJ0254@#G[QFS7U(_#9B&PA/D.
M5'$8JFZP*47<P*KN89/+WQ,.>\6O#N/BT3FCC9@[*.3I/8JL0>M!$F(.#^.I
M6Y=SL2S 4P".2^:D83 E,':.;!-9RY029C\'CMXR0<;#37EF45G<FS>"5&WB
M8V9)('E9&.?]\T.KTX57-HVOQ-A"L2W"R;, *3Y.#GES][.1FT83LN&;#0(J
M1@F[S<ARBH4R%.@9##Y0%*I#QQ>[$S$I@*!2<2NJ(,"##6Q$0VQ>""HTHTR7
M8/FKA6-ZW3&X#!&05974C)&0R%E(R"#@G!!!Y@B2I:EF=I.02I5E9'! !PR.
M%8'# \P,@@CD09G=:22*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD3P9G7[9/7
MD*F\QAKC2LT?.(E*I#&5WJ,E!HHO%@)=X*5=))9L\LTDG&;3)9-//+++#'.V
M.65[VO>_TST7_DX=,]*=&='=))X2]&5)TCH=)KDJ?1ZIFK75Z>O4+6S!P&9!
M8%)  )!(&)\?=,_Y7'@[T-TQTKT/;X(],W6=%=):[HZRY-?HE2U]%J;=,UB*
MU995=JBRJ22 0"21F8K\=SK;L+G'>D#[E5[W,73?QIZ*^@ZOUYQONRO!KXF]
M-_6&A[N/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[N/CN=;=A
M<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[N/CN=;=A<X[T@?<J>YBZ;^
M-/17T'5^O'NRO!KXF]-_6&A[N/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!
MKXF]-_6&A[N/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[N/CN
M=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[N/CN=;=A<X[T@?<J>Y
MBZ;^-/17T'5^O'NRO!KXF]-_6&A[N/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'
MNRO!KXF]-_6&A[N/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[
MN/CN=;=A<X[T@?<J>YBZ;^-/17T'5^O'NRO!KXF]-_6&A[N>D/"SQ9:QXL82
MM*8(NL,-"%L6DLA!=9O>11ATK=3FJCG!#*Z;T4232S6%F&MKM75L%VREFY%F
M^9-?QCP[\ .G/ #I1=!TJBW:;4*;.C^D].K^)ZZM0.(*RX!KOI9@M^GL_"5Y
M1QOILJL?Z$]C7V3_  ;]E#H5NE.@['HU6F<5=)]#ZIJ_'^C;6+<,VJA*VZ;4
M*I?3:JO-5H#UG9?5=37L_71Y^CQ2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*
M1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B2##^+_+_K
MI$S NF[5$E$F!%(._5'/4V19=JF]0%N\VRN+8BLR56;I.TF*U\'*C55P@FXP
M2NEFLECG?/& 8R,C(R,@'!(SS //&?-G!Q)SG!P0#@X)&0#CSD9&0//C(_OG
MG]J7A;UV!<"YGPR[Y;%%XK>,)(O#1I??$7<RL5"#>OI84D]DY\/**.YI"WT*
M2># <IB^0@CKF)D&"EQCN1!CERS4.04OIQNW>8<%@I8.NWR"/(;?@E6R+&!Y
M[2./JTM:D/IKP2NSFQ-ZEE0UN7_" ^6FP85EVFM2.196L:%\-1S5)5WG$MV?
M >.TY1TEVEB^AXU:03.=N9G,MHRQYK<CE(FC.#)RK _(!10&\!; N+A@IJI'
MUPQQ@4E!#1[Q:/*ISPUVUX8[40*E:BP;27V[00P9,NQSE2JB5-,U1.V_;Q7W
M6Y0;G?>]K<(AALW;F!!%F$4;<$%C)R#A:5*2 ^F,V(29:ZFT9UQ%IS&Y$A*=
M@SLP,UU.9W.4V@W:LSV 5)CF4D7G;\ 83*@9&^'1UNFQB9..*ICG O U&%7*
M#>C6,C+M1 ;$1#FM4 )4(",,H+9+!LD'+:4LS8L(K=:U=6#66$5V.^!:]A(#
M;RK95B%Y(5Y8I1Y^SGCJH; 6TVB:2R',\DXQ9]&F+X;%WQ+3,XU)+W0H8@5'
MYI-YTYDX";RIFF^1S?GX>T\EVED3<O$)1KF#$\->?XV&(+ 6I:N3@\TVE%.#
MA6/(@ 2 ]'+M %K<@=N5!"EJ7J<A=PP'W*[#/-D\XW&;20G72D)F[^836<1*
M0; V677L[63B:$5Q=W#1$6.$1O7(Y]*Y 6%LA8.-%9!(F[DM+2QQT\)$%7XL
M(*'#!U=W#J%1&5*QR&[=^,Q):PA%!))"C 4  #!))-I*]EA=[$:RT\_)"YVH
M %J!=BH"JS,,N6)))"@ 7@.*C##?-V(),"K1)X1'*.ASQN^;ID!#]R*+,,UF
MRBJ>#P839NQI%KEE9=D_:N6;G!)P@JGC$01R((. >8QR(!!_N(((/O@@CE)P
M0PRI!&2,@@C(.".7O@@@CWB,&=^L3,ZV+QIF[7'X.FV;]LV:O'++%=+)VW:/
ME7B#)TNVME=9)L\6'$$6JZF&*3A5B\31RSS;+VPS@XS@X)(!]XD8R,^D9&?1
MD>F8R,XR,@ D>^ <X./0<''IP?1.S6)F*1%(FO'%-LV4:ATT1FT.^#['TYUI
MF+(9DVHAXV18["W- -?&E\&\@ET# Y/6X24$5QBAN81\0@23:+DB";));#.;
M3UK;:$;.W9:W(D<TJ=QYE<XRHSA6.,X!.)7U5K4TETQNWTJ,A3RLNKK/XSUK
MG:QQN=5!P20,S7UUQKJ02P:.2V.X2D^\UG(MFN9$TD, !!T&09]/&O1XRG$I
MCM&. SRF<89O!J;.:'F9>$"MI3R[ICCJ27@$IAI=^65MJBP5A2KDDD(<KN6L
ML,,<Y4$,:TQ^$5I7.MX>%==S<)K2VZM0 "XVML>U%;R<C#L&K%KY'"<3L.N.
M-ZP=R;%SJT0X$P)G@G,SPS:XK,1F=>G-Z1T8UA18U%P($_'K$](/$C\JDYF!
M-HY\/V3=L%W,>-MT T@.W%AW/S136<[0*F)<!F8'%ODJJN6V^AA!UV"WX)2M
M?)V6T8W%KU 0LBJRYI\IF:L+NY@E6$[VQ.,,X(X499O*%0)P5G V\^!- 3".
M[.G$4BDBA8N3%GAB=7'P6)S-G$AS".**.WA".Q5@_-O@\=3D8Q@;9RY,FF!U
M"U,X"'8=Q9$9E<J $RS*6);S L0 3M)&V;6:MAI7O2LEQQ% "VNB,@8EK,5J
MX0!?.54%BJ[@&#S/8%Q)O9EO^9:V?Q@U#H0&A((K%R\V@&Q807DYYW*NC3]V
MD1F(4$!P"DR) <#B(9+!0\9?CR9-!9RR>-6;/1Z-M*.&#N68,$>MPH"[@,*2
MV0,EV_% ('(@D[UZDO>U95D05J5+UV(68MM)!=57:20$'XS$$C((E?[BXJ-A
MQ+;YG5\-AC<>U:00HY"278D2E 4+(IRWG^A(]9V"E$C,ZYUJ7APX+M]\/;M;
M["&%I;L48E$69&/K* ,IGO5IT:H6,^27&51E)5-ES895#N')J!_$(6LER&Y[
M([M58EQJ1-HX;%6L1@K6"S3J"K,U=90"X@?A5+6 )E25WP6VN+V7P[AZUQLJ
M,6B[F72242\/*5Y#&'#&/B!&LTIPTV)(VP4)LB36>!HT;BS9VZ3B4[V";D<'
MP-'-;"YL2S$,%<UZ96OLK;<%55*88$DV;"@+%%P65CC<B!7VK84YF8MU;IIZ
M[%V%V9PY9"%"U;Q8P5;'RJL@SLLL9J]S5!S@2S-M<1YB,$]$&X6M&E]:;%$-
M)3*GY$>$,S'*/R&5ZICT/Z+Q5]M_6TARP*83TC\*%@D;V0X$O$0S3",/RA$:
M&.:54!A<'W!T)51DJNY5L9MSBJQ>6P *63=D^4 "1)=J60T&LKP[ '?(5G*,
M]2KL4W5-SXARP6S!VC:20#<>F9U+)RTV'TR'QX:3B&UIA"&;>-+DG;'(,$L-
M6%+N'A1)LX=DUFS^V1!=-@.:^?Y4FS/%-.RJT5J*A3:6(:M'.[ .2#G 'F&1
MRYDX\YDU-CN+-X4%+70;<XPN,')YDX//D!Z!+DJ*33X&=^_V[;J_Q:V/_G$S
M7JAX)?Z*^#/^S_0W_+M-/%'PZ_TV\,/]J.G_ /FNKE2UV"=5BD12(I$4B*1%
M(BD12(I$4B6UI+=NPN'W88;96M3.8H\)S\TX;J^<5$GA*V:>3\ ?8XJ)8D Y
M#%+"RZ&6>"R"R;=^Q7:$6C-XAU[PH\&.A_"_H?4]"]-:87Z6\;JW&%U&DU"@
MBK5Z2T@FG45%CM8 JZEZK5>FRRMNV>!?AIT_X!=/Z3PA\'M6=-K-,=MM3;FT
MNNTK,INT.NI#*+]+>% ="5='5+J7JU%55J?7APF\6&ON++7:<MBBF(J3",6C
M.=P=TXP6*10PX34RPMY=L4[OP9*Z#A8&:3232?((K(+)-";(@P:>>7A_X ]+
M^ '3#='=(*;]%J#99T5TI6A73Z_3*P!(&6%6IIW(NJTS,6J=E96LILJML]6O
M8O\ 9/Z!]E'H!.ENBF&FZ0TPJJZ:Z&LL#:KHO5NI(!.%-VCU!2QM'JU55O1'
M1UJU%5]%6TU=%GZ5%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD208?Q?Y?\ 72)EIMBJ3#%Q
MJ.2>"Q 6_8I9JWRLE@J[:*H)Y*7PQSSLGCFI:^=\<,LK8VOY..5^2UX%.&!/
MO$'YC)V&5('O@CYQ//.,\.'$7'L]<2<8MJJ+RG7VMH!JHE'8QL>=-P&R0T1U
MOMJ)7D$QE:&JA)&ZX62; !2>&Q56'F6HQP!*KJ25-^9'K@;C7T-O4\1E>Q[0
M61,H6>ML*G$(YJA5FWC((\G (/'KIM2IJ<<%'KKKJ*K99ML"5VIN=^$IRK6*
MR+PS@J?*RP*\@'"5MXF3USAM.:])&\.EIZ1R27C]W[M3D<R:DM=[,B<9&L8R
M@@#"016"J3(-'\BD?-K$)\ 9&#D@7&D2Q0"8'4U /PTV[E"JAJJ*KAZV8[N9
M??M)PPPA("Y&"N%TEQ-?%<,$=F9A==N<&NU$&T!53A[U7*L38 S,025:-B/"
M?Q*VD+)WLC>Q^1C%NB*<LR$[BV&+0E+$8?UJ5*#4XV+B@%>/7'BHK*(TU?CI
MLKA,6DF,/Y(+'.9291:9;44;3PZ0I\HKFM#M)#C.XLV<EE;&P;-JA2=H))I=
M3NS;>6!V;]MU@W@-6Q&T(I7 5U!5_*#$L,L0.;SA-XD.BEDF&]SB<V6S@HPH
M34VYM6[(K"8SK71L?D<7;J/V1EH!)S*7Z\V ^>3AK&7TD:I3YY)EU"ADD:$*
MAJ:-W.E=F'('"KR'9[BK<B,A%=,)D*=@4   QXIJ0G*]MYV DW6D%%KH5E&0
M<%WKL._;O'$+9)+"9I->&C<1S6V@VX>:@W6VM$2F1;" GYY))!)FN4CS;R#H
MM&7DK:102>,QJXXLGKB2'5@ T\[@3LLXYD^++9-W6JWU"R[*L*[E5"$55.W*
M[F"EB V1Q%7<5#@#..<W?2W-7IP+!Q:&:Q6=BPW<RJ;PBL5P>$S;58UDG&3B
M8!$N$;B"UE$G.M=?['$MH>YL3S3-I[&G$5E YZKLWB+FZQEJQ$PDJ-5DLX9;
M8@UYB?N_;+('(<LX4:2A)J'5QW?4TV/Q'K)?ER*(RG"4K@DL"%0UOM7!RK 9
M7)D::345(:Z[%V<R&XCJX/%U%FX (PW.+4WMD8*$G?RG[,N&3BE0!FAJ^Q1>
M9!SKZ4QF%&,=][SQ>:\/OV^W[-#;E)G'AHC81"1+3."(E2KL-#Q\&1A[9U#8
M>Z6" T+O&-/N4[#@.K..#3AP#62/QB4 VORW,7W>4PR8&EU6UE-@R:W6MAJ+
M\UD\;#'R0+"V^O)*HM>P;$.U1.IL+A?XK)GZ2#0W8$5BLFV'\&MT50.W=H"G
MT/8@WW$R2C;8/+V< Q4(LHZ^V_!7+8,2A]ABBH$LZ%X1PR'BYJY+].A0%&94
M_*JK(;(H#$H7Y%A6X)#9P0#D,P"W3:I^(0Z*SX\UUH*!3J2H5Q7S"FY,*4QY
M)(VLJ--WM+0630:,F4IL<<R"7R2=[!EI9[G*I-*1S5A(IL?*Q,$%SDEFWP2,
MC<.=  &(D,)#!D7(YRLU8YY+J/'-6UU=AM "JB*!M522J*&)VYR68$Y))P1S
MY8%VBMJT.]BSL]CL=[,,,[,JKNQ@*A5< *.7F]\V]44FBD2OMF2J-Q.-8.)*
M%=2A$R:!QH3%6 X>5(2:0FR2#8,(8LRSED(\]F[M9VJ]+OQPD4T:.2I(@Q9,
MEW26]:LS':=NT%BQ) 50.9. 3_9@ DDX ).)':ZHN6!;<0H0 $LS' 4 D#^W
MF0  22 )J\)XDP!2";<E\ T\,4CFN9AJZ%Q3$T191%O,I!LH3 W3WX19,8N<
M(PC"*7VLT%%\'0@P36<)FD+,$<LE$<K#4,KUH]A#6*[M@%MJHS@8.X!]W#R,
M$#S<_,95&I1J[FKI!6MZJU#$(':T5GF K% O& .5)SN&,YDV$XE()'B4DU]L
M:#,X--8/)!T*RCD(1=3^-%[*8::="KPLFWBD5*DD!C7B*@"A06ZAX5X$4(R%
M=HU(!QJIEWAJ'(5ZW+HZE]S^0PYV@[QN8 DT/@ASG"^^0)LNIK4M796*WK8)
MMK!L4YX)&PA$) &HK+#8I7+<B!N,!&>,S4)),8"BFO92YB)$$PQ&='&$()C%
M3TCGH&!"X(@+CDF("\2!%_+!I DXR>)A(^W6(,Y8]"F19L</RVEL&6:Q0P8Y
MW%P<*A<OEE!(&T@ #)(&T$$$ZKK*CA5K<H5 &T5D;FL6L5@*Y&27!//"C(8J
M01),OQ@Z,?M&SDK%IR12M#1^[6F"L-:N5;:?"WPF '=%L;E+Y)1)*P=X?#LE
MKISC C'W##"'I27X-%/<#37#.&08<U'RL#BMY!J\WXW, G\0!@2^W)&3K*"
M2KGR!<!L&>",NMV,_B>264'\)E?Q-V 8I?C-UH^!Y.9K C@U/,D9 E1)05\/
MW,11PQWFJV)Q1NQ'/LI*TD3_ (>I4-6 F6T754Q;)OT_A%DM&%)-D:9P1M=<
MX!4@XPP-.0QR-I47*<@MCS'!W;<>.5$>76PYE2I7=N3%V"F =P8T,-I"GS'F
M-I;9Z"'(ALV&BRS&,78BA!\Z#2C<C#"DG<6DVMY08A15ABR9KDQ#=U'I#'B3
M%@_"/G@Y5%ND]#$'#!=NX4@<-6Y!;)(5MRL3N6Q0X.>1.0P)!YYY$9EE&2U
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MJ99X8X7Y,KYXVM>]H%(# GS @G^[,G8$JP'G((']^.4\I L>XD-.0Z&E-?Q
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M(:HH2@1@V=C8\K'HCP__  Y;5@>QSGGD6/; M%/A'S_/_1E;8<JMJ/GG._\
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M'/!OM88+\B,8 4#&&!    SN;.,9)).3SFRZ>E2&">4#G<2S$G*$$EB2Q&Q
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M[DF&&!R\/%1B=.922A$D$,1KI!\9AX@5*<,QJ!('(8P]T '1'1_80@1R%Q$
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MU45DE'V*B2J2F.6"B>>..>&>-\<K6RM>U<RO0_2[JKIT7TBZ.H9'70ZEE96
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M4KD60Y8^G*?CV5KN!:O\;%B[ ZL#M\D.& 7=@[CA@H!,RFJ%A(2JQMI"V_B
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M"SP*5R&"S <;:PNTJ9C&,*E\9) Y'+E2&4%;+9,G;>3N1K]D]<;-IK%R1M8
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M; ;"*[;$M9 HSO1*T3R\YV@U(^T $L,%MI(-1D_V?PI^JY52VG(6F+>2+R(
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MO_2]/:G_ %C[+^9'ME\C]I_+CUQ_[N?O?^EZ>U/^L?9?S(]LOD?M/Y<>N/\
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M]?\ @CUH_H-]YOT]3VM^6^S_ )D>/_)?K_P1ZT?T&^\WZ>I[6_+?9_S(\?\
MDOU_X(]:/Z#?>;]/4]K?EOL_YD>/_)?K_P $>M']!OO-^GJ>UORWV?\ ,CQ_
MY+]?^"/6C^@WWF_3U/:WY;[/^9'C_P E^O\ P1ZT?T&^\WZ>I[6_+?9_S(\?
M^2_7_@CUH_H-]YOT]3VM^6^S_F1X_P#)?K_P1ZT?T&^\WZ>I[6_+?9_S(\?^
M2_7_ ((]:/Z#?>;]/4]K?EOL_P"9'C_R7Z_\$>M']!OO-^GJ>UORWV?\R/'_
M )+]?^"/6C^@WWF_3U/:WY;[/^9'C_R7Z_\ !'K1_0;[S?IZGM;\M]G_ #(\
M?^2_7_@CUH_H-]YOT]3VM^6^S_F1X_\ )?K_ ,$>M']!OO-^GJ>UORWV?\R/
M'_DOU_X(]:/Z#?>;]/4]K?EOL_YD>/\ R7Z_\$>M']!OO-^GJ>UORWV?\R/'
M_DOU_P""/6C^@WWF_3U/:WY;[/\ F1X_\E^O_!'K1_0;[S?IZGM;\M]G_,CQ
M_P"2_7_@CUH_H-]YOT]3VM^6^S_F1X_\E^O_  1ZT?T&^\WZ>I[6_+?9_P R
M/'_DOU_X(]:/Z#?>;]/4]K?EOL_YD>/_ "7Z_P#!'K1_0;[S?IZGM;\M]G_,
MCQ_Y+]?^"/6C^@WWF_3U/:WY;[/^9'C_ ,E^O_!'K1_0;[S?IZGM;\M]G_,C
MQ_Y+]?\ @CUH_H-]YOT]3VM^6^S_ )D>/_)?K_P1ZT?T&^\WZ>I[6_+?9_S(
M\?\ DOU_X(]:/Z#?>;]/4]K?EOL_YD>/_)?K_P $>M']!OO-^GJ>UORWV?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g897644g45w62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g45w62.jpg
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M9,HHQ&9O,;V965[KDP;7M=2^'<[]KVV6C[V6$V[5XK5L)DRZ<;9LR( F70A
M=&!A0XF480B10P_TF301'9JUQH/5FYY>Q]^;E7>O;$D6V:^W)$SCI%DP9ILL
M1'C0=[;,.@P#%%(65E&##X5,G"IR#KYU?9I1$HB410F\CN='(/6>[]BP2*.8
MSA'HT;P8BL'D72>NL6^0YDYOW9UDOC=;+NJZE^WOC;\/1;]U>1[^;L5]KOWO
MMVQK-C6>V1L^<$&6;%L]D6((9@08GVXA>"\Y3W8D9J#F7R<_;$[+S<>##=##
M(;\EH,,$TR0<37'$K,F6<BMS! .BL8UIZ4;#5VAJ'OND<KB( ^]9Q>4X0C&2
M-FQ"[6.DP(IJ:)(_=8UNJ[(OW3LFDC]WL<&K14SZ?NY/1[3N]8-I31:9JT+&
MLN>F2QN0PQYN1@1XQ8P5#&F)$=DM!.2*#F7TTJ]T66EXKZ9<2#!>ZF RGPPY
MU 3@*G-S#4L? /(GFLT::T,L]:SG88=S#H68V2.DVAYGKN5I;.F,.DHB0:T#
MH/@48LTBFO-C/]9R5><+ W0Y2&.9R+6E!M^ =OA/<K(H*TK[>;#SH=9(I@OU
MQC9?9(E->J3G&"QN02'%GI, A!)F$)0%4S,)4ZXY(RXLU%C864D,,A8E&2;R
M6GATV5EUXS84(^YQ*6,?.YXE3#21GYJZ:>W,-'/59&S/9>_L=6ZTDNMAI![)
M7D>G3?8(R=Z0G8DXVF*''>=3^'/5H\$?/W0&/,]G"(W%3(H UV H:(G&,/CT
MO>'VJ]SI/K.-/MK]%7NX_2F=S/5(*1;'!&(Y)WA><-\1LB$X@9(I%Q4]DXB!
M%Y*&20:M1DED4$81N02%F/:M1:!DH]P%-6XVS5' AS^2O-144"/);R\;/]9E
M_=FU9L/@-U*P[.=9^*DRX0>089ZR23WM.L>-PSJ"N,S'7\@LO*M+FL+MV\O\
M-8[=@FDXEK_&?361RR"H2K)Q/(I&A,(UI*7^0DUL0JJBM(2P[O9+O8N);!9B
M&A;>8DY>"&0PX;*N;#Z*H&%>;'Z^.:M.?!7W+[[T> V WU.;W!K(3M)VI'DF
MNN",YC3.=.5)8H\2C*;>)KDL#J^9W,>]^Z\4F&5WF#591&V2>-\J)0Z"J]-R
MB,QI)9Q(Y$"CZ#<80-KK&RX\4D@&$*L$"I=91^X0P2&#%RHM$@_SRQ:LE23!
M-RJEF\;XJ%1?<./@C2I5L'-"2SD([P'&FXTBS?KB""K)L128E$FJRJC!XH/>
MLWR;9WBDOFS=MG6.%T%TL\R+%[1&Q8-J?A#Q[V!LF4AH5"H_QXT3D;D\@>8,
M! S$E"8<'87>.U/P)6=E"#%@AVW]]RZ13MX\[5FV=9T_:TY!L^S)2//3TP7B
M!*R[#$C13"A/C1,A@Q.1"AOB.T,8XG +J[:MNR;NV9,VS;MH2ME65)"$9J?G
M8H@RTN(\>%+03%B.P;ODQ&A0FUSOB-'.L;-"=D.UC.-I3:&33EWQ3DS$7/@^
MN("'@4-DL/D<^)R.%:SDP@TP)G-W;!96;XR":&H-<&@!76?DP6!!(VR[HL*Q
M^@B7#OC!A3D>+=NU8<*SP]T[$=*O#95L.79-Q#&/_8&2T2''=7-#>UV8KX^#
MNM[F4S'LR5E[[W>BS-LNA,LJ"RT83HD^Z-.Q;.A-EFBAB&)/0(TJVF>-#>S.
M%*77R2V(E$2B*Q?*'],_(GV%[;^ )!7>W7XS7=Z]LCQ"77R5_P#B)?7LE>/P
M>=7.)[3#MNV[3'MOS[;M;=MT_P >GHZ?_FI(J#0-B@^RWTR<IV3FIE&E-%*T
M72MU5Y+];^H4/^'AU1GVKZTM+\_.=XB*=6[G%ZP>IK+[C 5>U@+N4HB41<T#
M=\9!DMT[.)/1^"[Y'8TU[DYR5<8YI=K)"6-NYV36PPPZ<;6QR[7&W;VMT9]M
M:I'+.LBSIJ0L>;F)9L2999LAD12^*',I*01]D-B!K:@ .H!E#A54)%M7FMRS
MK7O+9LE/O@2,:W+8WV7;"EW,B95HS+COAB07O?1Q+FY3CD$U9DE;XO8N/V?_
M !@]GZWQ*>KQ'NJ<H-Z>L&]UEU*KZ/\ R-7 ZE/?IM9]5K];B2B)1$HB41*(
ME$2B)1$HB410(\EO+QL_UF7]V;5FP^ W4K#LYUGXJ3+A!Y!AGK))/>TZQXW#
M.H*XS,=?R"R\JTN:CQY,[A?:3Y3<7!\8CFF0SWD 0<Z\F.PY)']9/MI&Q J;
MZX:"X#'7DHY$:%EZ8A9&7&R-B4; ;WN(D& )LEK)\8+AA<D*H%0<^&OR.CH5
MFN0Y 2#[)]QCQ4<RU,G*M<!T6K ;%]A8@B"P283ADLJV/PGDWJD))B20Z2JO
M9D,GNBM^!->0\$.D>*<6;29_F_*HS'-KPK\*\V%".?/C3*SDKPSA/(^2")L_
M,J1*9@H"M!&)YA'09A5ZT:[XX_\ (6-IR' BEBX.1\'-M #6JL64>-F) --)
M@C@X'OGJ+](J TV_(CYJF>.' J!<;8[L6*QR?[(+!YT/C(1N\L>6BDL" XO-
MMD;':IWF$.4"FR)UW+=LS%%[(.[,%UX8E%H<HUS9@%7A4A-:9O/Z%,,VU8:<
MSL+6[!HQZ+Y?AXX<0[>/+*_3T2/26/XNF]^VO?IZ;WOX[WM:]^F]K5L[<;Y2
M;M?>M7P.TUH;TFC_ -$+\9L8=@^S_FBQ#A]9EJ9<0HW'1/*OC>[%  HQVIOO
M3^"CH>*8LW&>&>Q(SV^&:S9!-3+'+N:?;8Y97MEW/#IM?M,>CV%>.R;*D;M7
MHCR5F6?)QGW=MIKXTK)2TO%<UUG1\IKHD*&Q[FG(94$D');4?9%(T[DWDO%:
MU^K@REJV];5I2L.^EUGPY:T+4GIR78]MMRF2]D&9CQ(;7-WV)DN:T$;X^A&6
MZO2"[2W1T=MG_GVU^G^YVGY]/3^7XO\ U_B_.H[U-(OF^%K]/XLK=-[W\65[
M='3CVG1;^%NC\5K?[_XOSHB7QZ>G\65NF][^+*]NCIQ[3HMT?E;_ !6M^[+\
M7YT16,Y0X_\ 9IY$WZ<O(9MR_1TWZ/)^?MT='Y='BZ>C^-[W_.]=[=?C-=WK
MVR/$)=?)7_XB7U[)7C\'G5SC*DC4'BZ5.J\>G6&N;]MEXX#$+>+*]NCICHRW
M3;^%[=KTVO;\KWRO;QY7J,ZU?6EI?GYSO$13KW<XO6#U-9?<8"KV^-K]/CRM
MTVRMXLK^+MK6MTV\?BO;H_#>WY7O?H_.]8"[E.U_/\67CMG;^]?_ !WZ;WM_
MXX_EA?\ PV\5O%1$[6W\<OW_ .*_[\K9?Q_=T=%OX8WOC;Q7HBYK^X?*YM+V
MC3?XF)U)=8WJ>RNK9'NL)05WGXRWAZ\M;O\ ,+>G[%SCT\ .+]^G*W1K]7\K
MWM:__68YEX[6_/\ N]'^5\K?E>]>$=U3E!O3U@WNLNI<O1_Y&K@=2GOTVL^>
MU_\ -E^?3_>O_O=OT?Y?X>C_ '?P_E6OUN).U_/\67CO:_\ >O\ NROGT6_A
M:_3VM[?OQM;'\K6HB_JB)1$HB41*(E$2B)1$HB@1Y+>7C9_K,O[LVK-A\!NI
M6'9SK/Q4F7"#R##/622>]IUCQN&=05QF8Z_D%EY5I<U$CSR$2E7E%PG?-(+L
M>>@W.TXVS*+0:%;(<1>*QUMM#41AVMM230K9<:C),&A*P\8DX0%L>)2<,/+A
MV\B:#[C <K(,RY"E'::89NG3]>VB\K?*I<GV4/1B[6,3@Z%BL'UJ*<O+:TVD
MO%@!@U)MM/GYH=.G_%/9^I\4?NEZ$3.O0?(+1)E-5@B%-/YB_9A L>(,QT^S
MHZ0?<>BAJI7Y=,8G (Z3E\YDH*'Q4-@@H6D4E*L@H4=BZ=H,&GVLD16;M$,G
M;]TU8-$\U;*.GKILT;XJ.%TD\RXKPX3M?5VS%CS77.QH-/7$8R&82)&&RL')
ME =SC+(@%N5Q#/GMV.!9E@JY&J..YX/4D'&3;)3[.O9,E#H41/,_]AHR_EQX
MB?$ND:V=N-\I-VOO6KX'::T/Z37(A?C\.P?U18BU2N*/ZH^-GM]T[_42.5[2
MO;Q5O-V?MGPZ947.YUR@W$[978\;D5T:ZC?4WR41*(K%\H?TS\B?87MOX D%
M=[=?C-=WKVR/$)=?)7_XB7U[)7C\'G5SBZDC4'BZ5>JO)?K?U"A_P\.J,ZU?
M6EI?GYSO$13KW<XO6#U-9?<8"KVL!=RE$2B+FN[A\KFTO:--_B8G4EUC>I[*
MZMD>ZPE!7>?C+>'KRUN_S"WJ.Q<?L_\ C![/UOB4]7A'=4Y0;T]8-[K+J7+T
M?^1JX'4I[]-K/JM?K<241*(E$2B)1$HB41*(E$2B*!'DMY>-G^LR_NS:LV'P
M&ZE8=G.L_%29<(/(,,]9))[VG6/&X9U!7&9CK^067E6ES4-O9%8\SE/,+L<H
M[*)1V3D16SW$L;JG]EQ"#YQ]"/[+TMDO)! N6SF(.Y(3&8O,FC49"@VQ)"0=
MEVC>T6;%THD52+D,SLV:G/7GS4U8Z:47U<H8H$DO93N)SO\ L_A!B01B 1(V
MI-RLZ@@&9!&"4]V3F/%A14MF@B68!KW;R H]2U#!)U(IZ;;@8C.3$"@;5YG*
MR _9..<YJ9\WLKFSYA6F*E WAIV,;]UA)=3S)T591R4* %GSD+B$5?8*QN2A
MY6.QR92<))8R6'JE ;)$P!DL>.QV0"%'P0Z((BG[MHJ5 :&JL9I3@UIW0P6=
M@(>=VRY'3P'#8T]5>[*.!9"%!0>3SR=#F$>FT#[S)PT4)SO:&PY;("KZ2$C9
M5Y+2 50FG$&PF-CB$DY]?-T>06"7,ZUL>P9L<;=/1;CAQ$M;IO?*_1:2:1MX
M\LKWRRO_ !OE>][W\=[WOXZV=N-\I-VOO6KX'::T-Z37(A?C\.P?U18BU2^*
M/ZH^-GM]T[_42.5[2O;Q5O-V?MGPZ947.YUR@W$[978\;D5T:ZC?4WR41*(K
M%\H?TS\B?87MOX D%=[=?C-=WKVR/$)=?)7_ .(E]>R5X_!YU<XNI(U!XNE7
MJKR7ZW]0H?\ #PZHSK5]:6E^?G.\1%.O=SB]8/4UE]Q@*O:P%W*41*(N:[N'
MRN;2]HTW^)B=276-ZGLKJV1[K"4%=Y^,MX>O+6[_ #"WJ.Q<?L_^,'L_6^)3
MU>$=U3E!O3U@WNLNI<O1_P"1JX'4I[]-K/JM?K<241*(E$2B)1$HB41*(E$2
MB*!'DMY>-G^LR_NS:LV'P&ZE8=G.L_%29<(/(,,]9))[VG6/&X9U!7&9CK^0
M67E6ES4/'9(VLZ><@^$R4"D4ZCY_&:8?<I(/JZ?[&UL .N-T\?6;,]MYQ".1
MNAPX"+KLW!".9I[.$[#BY\>;-C(@R$[1[T&DC+D.?-F]O/FP.;V4YU5>T)-Q
M^P[(7JV*R)[R,E.]B8^"ILV<4F3T3QVA;J+,Y >NO( SJ2LU I%\SD@DH[CC
M),QCL"Q8 DBQ-MXUL%X )0Y-<*#::T'U[5*<3)C0H]Z7,$&(D4,:KOB),F[0
M8#Q[)LGDJY>/7KI1)LT:MTL,E5W"ZJ:22>.6:F>.-KWL7%?G''09G,@B',BB
MJPI5!L42&D6CY4:X=L6Q-JW?IM5E<V:SD:\9D&Z3BR:BS)VV=IXY(+I*9D4+
M_,_]AHR_EQXB?$ND:V=N-\I-VOO6KX'::T/Z37(A?C\.P?U18BU2N*/ZH^-G
MM]T[_42.5[2O;Q5O-V?MGPZ947.YUR@W$[978\;D5T:ZC?4WR41*(K%\H?TS
M\B?87MOX D%=[=?C-=WKVR/$)=?)7_XB7U[)7C\'G5SBZDC4'BZ5>JO)?K?U
M"A_P\.J,ZU?6EI?GYSO$13KW<XO6#U-9?<8"KVL!=RE$2B+FN[A\KFTO:--_
MB8G4EUC>I[*ZMD>ZPE!7>?C+>'KRUN_S"WJ.Q<?L_P#C![/UOB4]7A'=4Y0;
MT]8-[K+J7+T?^1JX'4I[]-K/JM?K<241*(E$2B)1$HB41*(E$2B*!'DMY>-G
M^LR_NS:LV'P&ZE8=G.L_%29<(/(,,]9))[VG6/&X9U!7&9CK^067E6ES48G+
M-CH#8?*KBS%IU+.10/=FM)J FFKM?:LA5R4>V>%*RF,.STD.2(KKZ3#1VO=:
MD(N,7VW(HY-=?F(J(?C!,@>.'TYUBR,ER%:'0<_T--?;JJJ7Y.J/D>R(<4&E
MFDNL+.,8FLJV'F!3<#+'\3,[67;.47KO4TH>P9QJI&2+FI4V:;<U&KO,#.1D
M$0:;$PB3V-8D&8_'1KZ#3#0=%:K/;D7I,9R(U!)M2ECA*-MCQ"&F4#(K-[@X
M9E8'.(WL$%BXL,)A"BXET;BP]F=:"S@(H]"."#,:="OET";4N*QYXX\"H9QZ
M%;*#)[(V1,FNQ@,"C;PI<^2U],D&$$E.QYZF0<S?6A.+R1S)#,PVM+OO R->
M@D^\QM%(/8>H-!O'1HJUS=&;W>5=9*P[YG6MCV#-CC;IZ+<<.(EK=-[Y7Z+2
M32-O'EE>^65_XWRO>][^.][W\=;.W&^4F[7WK5\#M-:&])KD0OQ^'8/ZHL1:
MI?%']4?&SV^Z=_J)'*]I7MXJWF[/VSX=,J+G<ZY0;B=LKL>-R*Z-=1OJ;Y*(
ME$5B^4/Z9^1/L+VW\ 2"N]NOQFN[U[9'B$NODK_\1+Z]DKQ^#SJYQ=21J#Q=
M*O57DOUOZA0_X>'5&=:OK2TOS\YWB(IU[N<7K!ZFLON,!5[6 NY2B)1%S7=P
M^5S:7M&F_P 3$ZDNL;U/975LCW6$H*[S\9;P]>6MW^86]1V+C]G_ ,8/9^M\
M2GJ\([JG*#>GK!O=9=2Y>C_R-7 ZE/?IM9]5K];B2B)1$HB41*(E$2B)1$HB
M410(\EO+QL_UF7]V;5FP^ W4K#LYUGXJ3+A!Y!AGK))/>TZQXW#.H*XS,=?R
M"R\JTN:@ Y+2'7@;LPNE$9O!./>RS1..ZC$Q !--.2 WLZ)/"$N<6$[5B6PP
M'"G9S]A)H3(D_MPAV^Y+PZ%"1:*J)X7"7-^_7 N8)R30N J<QH,PP(J*UU>2
MRDV/GI*8]DKA3YKR@TE'=M:RB&N81(^/,L($ >U3:SE;8<^C;N%)6F,7;RZQ
MD).<EOL><=GC,+B.6S;XB7A,FFY*E#3,:'&O-T_6!TX%2K+KH-4%G+E9)NV;
MI*+N'"ZF"*""".%U%5EE5+XII)))XY9J*9Y8X888WRRO;&U[T7%>6,D( [D0
M2"' YE06HW0)IBB;(AF.7>L&Q1FB^P:+K9-%78QZS(MDW%D\UV+ML[2QS;KI
M*9D4,7,_]AHR_EQXB?$ND:V=N-\I-VOO6KX'::T/Z37(A?C\.P?U18BU2N*/
MZH^-GM]T[_42.5[2O;Q5O-V?MGPZ947.YUR@W$[978\;D5T:ZC?4WR41*(K%
M\H?TS\B?87MOX D%=[=?C-=WKVR/$)=?)7_XB7U[)7C\'G5SBZDC4'BZ5>JO
M)?K?U"A_P\.J,ZU?6EI?GYSO$13KW<XO6#U-9?<8"KVL!=RE$2B+FN[A\KFT
MO:--_B8G4EUC>I[*ZMD>ZPE!7>?C+>'KRUN_S"WJ.Q<?L_\ C![/UOB4]7A'
M=4Y0;T]8-[K+J7+T?^1JX'4I[]-K/JM?K<241*(E$2B)1$HB41*(E$2B*!'D
MMY>-G^LR_NS:LV'P&ZE8=G.L_%29<(/(,,]9))[VG6/&X9U!7&9CK^067E6E
MS4%_+S4TCF79$--['7UKL^:!M:S#BY>+B7&K.0VSM>$7I+:EV\QV/%IT'/9<
M?./973@ AWU20D;@IR5SEF)=BGDCBS1R*((ES!^R1ASXU%<V:F<@X4QH#4T4
MCFR>,IF>\DM5[]'[9.Q9AK\8+&E80Q;'\K&T0K^6D4T@Y0=-PD>$-)9>69B=
MDM97!-AY2./@(VRC+B#$V+HT_+C7"E/K_P!<V;GS@T5U-_:<%\@M.; TN<DL
MGB078@/*/&#</5$)FTQ:SMLX?CK)2 0>!OQ!YHW5 R4,6$/AYR-$BP9TEBD_
MR4P*@P(.A8X<=N!4 T&-V:&>2^3;,%[+!P6/$TY&W'@GMQ\&E>R-@(NR+^(X
M!LB)PE-=KRUPJ0:HB&K**LH=#V8S!G&LWA0JUK]= 'R6&_,ZUL>P9L<;6Z+8
M\<.(EK6_A:TDTC:UO'X_R_C6SMQOE)NU]ZU? [36AO2:Y$+\?AV#^J+$6J7Q
M1_5'QL]ONG?ZB1RO:5[>*MYNS]L^'3*BYW.N4&XG;*['C<BNC74;ZF^2B)1%
M8OE#^F?D3["]M_ $@KO;K\9KN]>V1XA+KY*__$2^O9*\?@\ZN<74D:@\71(F
M,@,Q3AX1DL=(+BCH+0K,H()-NT^T,7[.&-5FSI'NN"B?=$5<<<\>WPSQZ;6Z
M<;V\512;IL]-V;85][0D8[Y:<DY2VYB5F(>3EP8\+?WPXC<H.;E-< 15I%1B
M"IS;*>^%=.RHD-Q:]E@6<YKAG!$A H16HP6LU"#1^%;50VY&9+*!NPES)DFK
M(+R8\][=]*L7S8\O<20(NP=OMZ!5^G=+$;9%M9Q?)FFWR31R3\(PMU;=#=%A
M-=>JT2'1&-(R97$%P!'[OS@KI!:UHFC3-Q*5 I]C-KR:K<%J0E??)1%S7=P^
M5S:7M&F_Q,3J2ZQO4]E=6R/=82@KO/QEO#UY:W?YA;T?8OU;(=CYXS+WM?*R
M.NG2M\;>*^5DY$?SO:U[^*U[VMT6Z:\'[J[LB_UZWD5R)[*IIR92 :>VBEQ]
M'\TW&K@G18CC_P#MFU@<<[*MOW+:J*L:UWI]/2'W_'\EV1Q.:+[5O%\<1O?2
MDB382%O$;'U<[&.]]?,3<<ACF-^\6[BZ;KNOBW_B3L7_ ,9M3_[DI_L6P/YQ
MP*?NT:OWV4V4^:G#@,M;SV#0V<M&BP]K,HM'Y2V8.5,%7#) ^*:%46BZJ5K)
MJ+-TW>*2F:=K89YX998VMC>U>@;%M)ELV/95L0H3X$.U;-DK1AP8C@Y\)D[+
M0IED-[F_9<]C8H:XMP)!(P7?P8@C0848 M$6&R( <2 ]H< :85 -"JMKLU<2
MB)1$HB41*(E$2B)1% CR6\O&S_69?W9M6;#X#=2L.SG6?BI,N$'D&&>LDD][
M3K'C<,Z@KC,QU_(++RK2YI1$HBI.<S4'KN*&9I),#B@0"@BX(8QN+R69F>Y+
MNF[+#)G&X@)-R$A;!9REDYR8C'&#%IBX(O\ -L.:.W:!%:[27)[1_(R\BQTY
M-,I?C&!T=+E%;QN6 $,A$L<R4<"+#%Y."#)&AKHS"YE'5W@C-ZB.DL2DD>)9
M-# 9\S1*I!&=1C<S_P!AHR_EQXB?$ND:V=N-\I-VOO6KX'::T-Z37(A?C\.P
M?U18BU2N*/ZH^-GM]T[_ %$CE>TKV\5;S=G[9\.F5%SN=<H-Q.V5V/&Y%=&-
MVZ08M7+UUGW-LS;K.G"EL,U+IH-T\E5<[)I8YJ9]HGAEEVB>&>>71VN&.65[
M6O&^IOE:W7>]=4;8)&@^O9>VDI*.WOB=:MQIMGF*5MBSSR;/<R8QDDB]Q2(,
M5\F66?VO%N[;N+H605P4N17:HBL7RA_3/R)]A>V_@"05WMU^,UW>O;(\0EU\
ME?\ XB7U[)7C\'G5SBZDC4'BZ%^TOT02?^7;#X';U$UNM\5MT#JZW_X9A3E6
M=Q0LSL_9_<("UHF/^VL_^*;_ /.PJ-F!_;P?Q8?\;5\LW.-8^*W%JE+6STHB
MYKNX?*YM+VC3?XF)U)=8WJ>RNK9'NL)05WGXRWAZ\M;O\PMYSL9'[/#C=[,W
M_P#KTAKP9NM\>[W?FW=R@*7'< Y&;@]2.[[.+7EJ'1=FMKKCE^GW1OLAUO\
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MZ0B@;DD$@C*)U+83KTJOI%8OE#^F?D3["]M_ $@KO;K\9KN]>V1XA+KY*_\
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MP +R4GSUTS91Z&D5G@8WI_C#-MG1PVW[HQ)M7K&'X9X3AH3 M;W[5,_WB/\
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M13;FWM7,S<>5&QU)X,M<KIE\?'9Y_9W;1H6%XV[F\;+VPO@!H#6@-:T -:
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M$3OYFWIA*>L!;ZNE!H&P(G?S-O3"4]8"WU=*#0-@1._F;>F$IZP%OJZ4&@;
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@TLHX<+9WM:U\U5ELLU%,[VM:W;9Y97Z+6MT^*JHO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g897644g47w24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g47w24.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MC976>SV^Y5D-RGU!9]6VP%D#ZZIK:&XMEMES@G+G%C::*AB9'(/-))G",/\
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M=C&<X\OD\GEQ_P ^$7#GPD_!&B?A2SZWYW'>PDANA:VH?'HDY&FJ\&PM,(F
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M8);1^1'7TZN>;LGS)4EJTE HA?.SRPI2ZF(YI@[!75I-RI\>S/@%)(',K#G
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M/_YG_P#X6A__ -%@Y.?_ /$__LL^JY>VW'0W0VR6UM"Y;-9;,;C5F2+O3 8
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MJI<NR=D;Q1D#:=N;M$9.X9*L_P"%KO\ D_JK_P"7Y=_H?ST/G.K_ /P33?\
MZHNG_P 06QM5?_<T_P#YF3_VB?"UW_)_57_R_+O]#^/.=7_^":;_ /5%T_\
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MC1LR3T0;:JL4M=6JRB62DN<0 3D#@,#=S="Z# 8K&(JBNWC$< QQNZ5U6=(
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ME%-R0;-&^2LJGW"-PI:6:FGVFLI9&B2H+0=E[JF)S>9)/7,N,<$=,#1D-+I
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M-^U'QU^:2FHR52*"1S:&/33SXQO330/$Y(1O$[P-W/PXCVCX9/LQO%M>&%7
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MXS5C&/IPN9.I/&[!'B388.R<XUE>>&_/:#[,X &.WL)RM-]@NE?;:Q.\L,[
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M(YQIVY5'_,QQ;4D<=NB@EN_+TF7/F956R"("&0&39V2[FBZTKYY*9G+B5H<
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MVXL?RN;$I7OB_( RD3 0)NV:5I&(@PGHXN$^$<!1SQ\4LX;F'G&T&[6_?@]
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MGE+Z5C:R./SRHDMC &4PJ(F-?RCP'Q-BA*2VZNDHJ6 5F)H7O=(XOEPX$DL
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M]Q_@5T<X5$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$69>H/N&B_\
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M!ZCX*:UU[OH)\S8Q]2,>0[B>L^*-X#J'@IER%*<(G")PB<(G")PBXTT;X.,
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MGUEO:=D1R&*G&3KXVQO=@Z!,2KIRV9[).D'SG"6%U$D],Z[^[6X,'CG@3QZ
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MAX*9<A2G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(J@[
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D&CE-%PX1T7UTPKJDNLGKOC17?&TAK1O#0#T@ )DGB2>U?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g897644g49a97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g49a97.jpg
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M63K>#?1-1O+Q/JGH]^(/NB^_UG_O7&UDZW@WT34;R\3ZIZ/?B#[HOO\ 6?\
MO7&UDZW@WT34;R\3ZIZ/?B#[HOO]9_[UQM9.MX-]$U&\O$^J>CWX@^Z+[_6?
M^]<;63K>#?1-1O+Q/JGH]^(/NB^_UG_O7&UDZW@WT34;R\3ZIZ/?B#[HOO\
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MWO"VJ$/Z> N]XW8<\\FA<#:86R.(6M(J0=H'(HZ[<FI%R$;9Y(X)7)KV!\J
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M90G2'J#T^]:$$DI2K3$#,UWAT8<6'O[Q9YD%YM55<*BU4]?32W*EC?+443)
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M_*7GO#6KZ$O'*K!J"E\J;':RG0H>C N%H2)ZG?<8'O\ "(EI?5BF.HM![]^
M#>S)"P=_<$&@Z#K6<>@FCA>V:XT]5?ZAIUMOI%75=YWC@6TM9+)01 9W-@I(
MF@8 &  )%) 2#(UTQ'3.YTO^ZXE@[FA9F;FQM9TA2!I;T+6@(UX2$3<D(1)"
M0^K7<4F3%E$EZ[M:UW !K7JU_EG5P4\%+$V"F@AIX6##(8(V0Q,')L<;6L:.
MP +8#6M #0&@<   !] -R^[+E*81,(F$3")A$PB818:Y&>SW>_U-6?\ @A\S
M)GSM_4WS"AW _0^2J*9O*A6@>SU]CZGOHIS^9<RS3E_,=W?M"N9\H[_,J73Z
M6E.9'@I:WJ'=&:U.!:MJ2%Z-5.:4:0X*AO3%"-(T8H6E;&F)+V>3H9AH0[-+
MUOQAK62K8\6F%Q<.TJ@X6W@.MX_5ZP"D\N@5S2&H )+6>8H77C]!&ZOYLG-Y
M$/C-6S/ C ;8#+.C<6L,RQ/%%HT>S5TYCD3FN*P_(?B!.=X[\YSC?GD>T[^B
M4O:UVW&([-N/4+U>L6BCXC;K1DLCJ)DYNL7!2Y'QN=&U@;(-.T-U*ST*UO@,
M:D3>[!?H(K?61%8RTU"YI6R<BK=?&3"AH."<9X;]76''AV$CIZ.&1G*V<\2)
M$^R_BIQHEDHL)HMN32:@:>D$BM1@2JD3%93X\5['G!VGK,D7-C(M3-<N7J%#
M^@)5LK,I+3.!03VEM-T)$06)XGZE2%PH3"+7#S5I"F#)YQFO,RI*S'=9'+CC
M6P$6\."Q@5G$L6Y:-#ME*GFVO<H+:MHCCDFV\#II)M,:81LGI#$'93DXQDXY
M="V/84)A$PB81,(F$3")A$PB8185G?("M*YF;/ Y,Z+PR1[8USXA;F9D=Y&N
M, E5)DR5!IKCZ-R=AKW;1B]0W%%(1E"3,[B:H.3A"G\HY*\Z;:/V&ZTMFN%1
M.*^LHYJR&"EI*JOF(CDCCCA]WHHJBI,]3K320-;"6&.EG=(^,"/::\M5#%(V
M)Y.NYI< UKGG<0 -5@<[+LDC=C#221NSQO\ %:QI#_+ J+EIA(OY0/5FNS36
MK5H0OZ3?@P>Y#-!EAUOQC ;%48]^'9?> 6];RC^TE]KMUFT/N;F' %7I!4TU
M@IM_!WNY-==BT#>0ZVQ.W%NXXSCMYG_E4TF.M,YL3?KJY?)C_($^*=_27UR.
MTHO 4@_Y1ME7Q +HYZ+%_6'XVS\UT3[,[N\ 3D\*0B#K>AAT 8=;Q^&Z:U^^
MOTBMUEB.YU/H]:Q4U&J>(_$[TZH87#> ]EHA/!P .Y-2J?\ /,R(=+86:QZ?
M[R7(SVB,<.A>PKCC6RPT"J:!DUI+0#"/1]G2IYEB+0@;\6NG&E*@B()P^/O'
MTTL>(+UO>]:#H._#DLT$L,CFRW;\1TCF:00_2&Y55RB!&_X;>]\=K8,[\1T+
M!DG 4BDA.#)KS$;\S/=(/]@G9CN8%F1G8V6/(BVU@9VMC;BO^$@9V](V(BN[
M6M:Z:5$200#NUK6OY2]>K6M?)K.KI:.DH86T]%2T]' WY8*6"*GA;N ^&.)K
M&#< -S1N "O:UK!AK6M')H#1]@ %RF;"R3")A$PB81,(F$3")A$PB81,(L-<
MC/9[O?ZFK/\ P0^9DSYV_J;YA0[@?H?)5%,WE0K0/9Z^Q]3WT4Y_,N99IR_F
M.[OVA7,^4=_F5+62M!D@CC^P$N:]D.>V1U:"GEK,Z+FT&.2$]$!S;C?5TEZ
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MFT7J+C417/2^IANM5"\34=G@:]NCUJD&=1\5-*->Y5D>3BX7!KG-<<TU-2X
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MA%#'FE_:.-?^L[C5^-]813.PB81,(NORJ4L,)CKM*I,X$M;$R)!K7!:=XMZ
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MR&1OD:MD(XJ\KQN[>QNPQ%M+FZ-VJ2\L:TKJ,I2!K$XDI1.(D3CI&$_;:O\
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:6,D\DP91H! $(.VS8.#0F3S/W*PUF:A?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g897644g55g31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g55g31.jpg
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M((FS2E201P3NCS+:W#1<]5 B(<AC)&F1'\_"LX9MOJ"DYZ#.:N"OC<.W7KD
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M>$F&,@>6.>"9C9(IHGMDBDC<GEKV/:JM<UR?-%151>ND5E=5=&5T8 JRD,K
M]B",@@^L5M]^U<O5U*=*4Z4ITI3I2G2E.E*=*4Z4K3ON-W9_UC#AJ^>0<&$6
M VZ6-RL<;.3YE%#E5JHKA1X$B)='Y]$TT[%D:JC1JO7\.V,?+-](H:1F9(,C
M(15Z,XSV=FRN>ZJIP?3(KC.)=0D$BV$;%8PBR3D="[-DJA_L*H#$=F+#/S16
MJ?74UR5.E*=*4Z4ITI3I2HOL=KE./J K4;2] SM"'*(/-8V,JLC4H\J(( (>
M*-LA!AYYD\(@((D,YAA,L< T$LKVM6R26.%#)*X1!@%F/3+$!0/$EB0% !))
M  )-9(HI)G$<2,[D$A5]0&22>P4#J6)  ZDU! NX/A6RJC+L#D?-E58%7G[D
MLN$F5S8J[4Z,W'T,_M^S[\CS]97'9E!HHGE#7PD]27 .=&L'6$7=L5+"9"H5
M&)!_!D<Q(<=SF13'TZAP5.#TK,;*Z#!#!(&9G0 @?.C02..^!B,B3)P"AW E
M>M02@[P^W^ZR;=H9N@LS33:_98T-NDCD!/,/PQKAKRP@!@0N;ZDA#<%=2VKT
M:)6U-I727;ZLN:0.'$FHV;1\TRA%,DL0WC!+0G#D 9.P##[NP5EW[22!E?3+
MU93$(3(XCBE/+.Y0LHR@). ')#(%[LRL$W#!.5%[F..R-?R!B7FC0WF.-&%I
M(/K(.?\ #R&;C"AY4)M,_P##+,D5-6T>@#BL+@U8ZP1ZQD3%QP%#+)<+V$R3
M19&Z(@+Z0/-!MTN"R8_!5' 9CA1T)."*M\PGY4,H!*R [_1(Y)%P]N%?/=F=
M#M4>D>H )!KN9_N8X=N),35';:@I==MZO#&@Y2>SB.,&.Y"H@[[,54EB R:I
MEFN!S&PTI,9:"WD[%BJI"952+JJ7ULQB4RHDDJQ$1E@2#,@>-<C*DL#A2#AR
M"%)-4>PNE$K")WBB:8&4+@%8'*2, 2&PI'I#&5_"Q7?B[D>"B!-"</R=ER1L
ML6 %;N&*E)E0FUN)\]5LK!X()"+]EE?#$TP$U#%9P&6@\X(\DA,,D3:B]M"'
M(N(R(RH;#9.7<QKM ZON<% 4# L,#K5#87@* V\@,@)7( &%4.VXDX0JA#,'
M*D*02,59N5U><W&?K=3D[<2]S]O'++7V@+W.'(0<B8,EGA[8Y89Q3!R RQIX
MXB!2X)QB(HIXI(VYXY$E021L'1LX93D'!(/T@@@@]0000"*UY(WB=HY%*.N-
MRGN,@$>P@@@@CH001T-9Z6-DT<D,B*K)6/C>C7OC<K'M5KD:^-S7L7PJ^'L<
MU[5^;7(J(J7]ZL!P<^KK4/P?'N/XRH$S.(IFTM0ZQLK>>)QME:&GVUP4\VTM
M;6WN3+"XM[,\F1TA)]F>67+X9&Z;VXHF,Q10QP)LB7:NYF/5F)9CEF9F+,S$
M]RQ)]N *RS32SOS)6W-A5!PJ@*HPJJJA550.P4 >RO)+Z4_AGCBCRF>Y7KZ"
M=O(&LY#$J+[1EW^ELYBZIF9OB8JZ$&SN#*NN"'E $44:L!#A%CA2$=D4+GQN
M]N\E>N:I-=7&DO<K\'6FG/-;VR6]K&J2FZMU,C/' DLCL)'W-+([.6RQ) (^
M2O\ *,X.X<@TZRXFCT]SKFI:Y#:WE_+?ZC</);+I]ZZ6Z0SW<EM;PHT,7+CM
MX8DC";4"J2#ZC\.\/\><,95N>XUHI\Y1V$D-J15+?Z2Y!983CQH02'!H+>U9
M7/)\-<4VO06,F1K))V22,8YOEVM:SJ.M79N-3N%N9X]T*R^;VT,AC5CM5VMX
M8C*%[(9=Y49"D D5]$\*<*:#PCIHT_AZR?3[*9EN7M?/=0NX5G=%$DD27UU<
MBW,F 9!!RUD8!G#, 1;/4/73UV@3C*PP:PKR9@S0YF3C%#O='-#-&OECV/:J
M*BHOVI]CD56N16JJ+:Z)*C1R*KHX*LK#*L#W!!_GQJ^.1XG62-BCH0RLIP5(
M[$'^<]CTKTJXTULFVQM3>D,;&=(V42Q8Q$;'\<'(Z":2-J?)C"4:PID:>4B;
M.D7E?1Y7SC4[065Y+ I)C!#QYZGEN-RJ3XE>J$_A;=V!G%>FZ9>&^LH;A@!(
M04E &!S$.UB!X!L!@/ -CPJ>=:%2%.E*=*4Z4ITI3I2L+H[=M#265LK$D4,=
M7Q1N\HV2>1[81V/5/"HQ\\D;7JGS1JJJ?/QUK7EQYK:S7&,F-,J#V+L0B ^P
MNRY]F:M=MBLQ\!_P'ZZTU//+M#)SSYWDE$R+)++(OE55?L:U/L9&QJ(R.-J(
MR-C6L8U&M1$\\EEDGD>65B\CG+,>Y/J]0 '0 8      %13,6)9CDG^?JKI]
M8ZI3I2G2E/*+]BHO2E.E*U8[F;3E:L?QVO%,7Q-_++RD^@KYR5%J+OD</AK=
M&<:T>F>XD,1^?,N(32O9M2Q:F70U^=:24.1\)*W;M1 >9S_F#D!C^$L1N8A,
M\?<\P+T&T$["XP0362/;Z6[MTS@9(7(#$?0>OLS6JKN=NZG,;[AK&[B&R!.U
MUSC8XZ"*FXT-O]#0'<RZ2HVI&O:.77E1EU/& F7/IS^/J.N'&^.O;C:4N99$
M*ROW/-[-X[B2/!6-9,L3,JJPMT:(1YW##3F16$SDG"+$SDDM?LC(8CPR<Y.!
MZ((]?B3D9)Z#!/45>7</0\Z[*ZQ%WQM7;^MS4O%=L[=Y:FUP&1TA*G<R]N%_
M<XX(P34!UU7R18<54O+>?SVC!N8X:<PBT#KM=3.MAK1^O:M;()5E,3/S5Y3M
M&SH,6]XH<YC),0G:W=T*Y8!28VVE:M4H 0V"=W0XR/F. >W4!BIQX^H]JI_C
MGA_N(U6]P,VC39\<\990SE2SAJ=5O>3] 9;4T^RXHL,A6V$6:[B1[NNT!=?'
MR#!GG;#0<B9[.THTH]AD/19!U(N66:U6.79RY9I%@&Y(85"L$N!*5YEIMV!C
M$6Y:0N[$%9.A8U9D .-K-TZ@#O@Y[KZ\9Q@Y['Q.P_;IM>?9'66=[@,EHXKJ
MST=J[+Z+X+&P5R4M;25IAS;2LR1$L>:#BM")JVG9/:;53"'+$FQMXE%,FU[I
M+7T6MG3:$7>F9=VXLPZ-(!O. "Q"QXR/DU.15KA>A0C&!GJ>^3Z_9[NW;PJD
MM!PGRG0,Y ,I!^9;_-S=QX99>9 YLW1FCT7 ,/$-8T8#(DWG)]?+6"!\UF_7
MN@KP+_,Z?09RGO:"$PFN*KZDW.L\+<K<+='%JPWFVC"+<FY8YD5(#NS;#:A*
M.B.RL5!#,MP9>GS0=O?:,!\GJ<#U>PCQZ5#<MQYW-!0W')NZ/TN)#XU[>&%T
M.8O-GR'KR3M=1ZGN-L*]T4M-SG-1/T0N3=Q%8ZQW(]'S RSB(KLX/9M*IK(V
M;(\EF2L4863FW6&D$<,>V-DM 1Z5L'"%_.!&86M]I!?&'44RFX* #E@,X4>"
MC\7MG=C!7/<]ZV3X^,W55S7G:6WL[R>@=@>8#[N6\N32X2A9-GQ0=QF>2%96
M-H32FCE7/+F;H13+(XRRH* RPD+0..J!"CY9;9;=W9X4?FP*,E$QB.<3 -Z(
M8'; [8 "LX&,EF:U]H4G('5<#([X(8#MTZ*:VT6VJD^VSKT_6:,G_MDZT?.K
M;\X@^UC^]6+(]8^L5]-M*Q_R98@N7\S2QW?^R1>@N;8]KB ^Z6,_^:F1ZQ]8
MKM,EBD3S')'(GYV/:]/_ %57K*KH_P UU;]%@?V$U6N3JZE.E*M[BC3%!VT>
M>GD=)7V/O*,QRJJ"&1Q/G]47GSZ8R6QOCDC3Y+,L4B>E?<5\_H5[)'<"T8DP
MS;M@/:.0*SY7U!\$,.Q8ANGI$[5M(0VPG*MG ]1'7ZB,Y^NMDNNQK>ITI3I2
MG2E.E*=*4Z4ITI3I2M/.XW!GK81;JO@D(!D%@"NTC:KWA3#>8Q39$1%5!9X7
M1C/D\>B":&/UN_T2Q$Z_AV_CY9L9&"N'9X,G <-U9!GIO5LL!W8,<#T23QG$
MNGR&1;^-2T918Y\=2C+D(Y'XC+A2>RE1GYU:I==37)4Z4ITI3I2G2E.E*J?F
M+BYO*^;IZJ#0%96\R^SRG(&4T(X UO'6:?'V;+*KE/IC)(1[>ME\3"F@/)$?
M+#.KX"QIXXI6Z]S!YPBKO,;QRQS1N &VR1MN7<IZ,IZ@KD9SD$$ ULVMQYM(
MS%!(DD4D,B%BI:.5=K!6&2K>(;!QZC6KNB[>]+H.>.WR71W[]('Q_2:C4\@;
M*Q.RM$7R=)7[&OUN.S(W'M+"TJ*KX[W\E#?#V;H% KZ\L6M,M[:[MIR'Z,EF
M[W=D7<N(4D>:1C&AG*RB2*,0J,[8)BC@@!55@I9G;-2"7L:V=]RTY9F>.."$
M+)(( T31RR&=^FZ>$.FW.XLI8*J+68=V;V(39YLWS!8T5C\;SA7!FOQ-);L'
MX_YYTHNOU64(#/L%A*N*S0P2&T.MB4-\4,Z@V5)9"1MB6[X-(ZQW+(<W:J>4
MC8ANY!+)&0QP65QE).F!T9&'2K!J:G >U5UQ:L5YSK\O:(8XY 0,A&CPKQ'=
MVRKJ234!@[;> >,^3KBVJ^>*#&;A^4I\18T5[H\W];_BGIN$*#CQV4O*HZ_
M*)B43*T?(\.@>$',)85[99(2:IS_ #A\RLX;AF6[2*8QK$4:1-WFZ6B0<ME+
M D8C6??@8902"HK-Y]>3P(K6;RQ"5IE=(Y-GG#7;S\Q&",!UD> IDY#=PU9Q
MO!7#7'U94"Z#GG+U$-=>]JEE"5?6>6IOB2.VJEH9:(/U&WL+47:58 ]E/Z'N
MDKP[!I(3#1WQR27>:VL(4/=QH%;3R"[1IDV*H4'5Q_2J Q]0((R.]OG=U,6V
M6<C934$PBR-CSYW+GHA_HF)4?C%<'![8^M[$<9E\G;963D@&>MN \[D,2NGQ
M>8MD$J*[7.V 5#:36YTI^CL+"4<0*$K+6.'/%AKH[.D:!>O*M9J+I,4<;1F9
M2K!(HN9%&V$$G-",6):0L0 #&T1 4,F'RYN;6)I)$D$!!0O+-RY9%RQC$1=0
MHVQJN22)%F4EMK94!1N+PYQQ)Q+QW08&74W>R?2.M')>WY!9!CV65L=:15XR
MGGVIT%/31FLJ*,,RTLR0J@((6:P+DB=.^2MH#;PI"9'EV;O3<DG#,6"C<S$*
M@.U 68A0 2<9J+NIQ<SO,(UB#[?00# VJ%R<*H+-C<Y"J"Q) &<59_6>M>G2
ME:P=U?;4)W/XC/XTK6$8[ZAUX.G;8CU$=U\3##7V566 HDA];[4DPUF^0<OX
MA[1YX6>X*1&]S6]1PIQ*W#%]<7BVBWG/LWM>6TQAV%I(I4DW".3< T0#)M!9
M6.'4CKY]Y1N HO*#I%EI4FI2:7YGJ<.H"=+9;OF*D%Q;RPF-IH-K/'<%HY>8
MP1T&Z*120-FH8FP0Q0,559#%'$Q7*BN5L;$8U7*B(BKX1/*HB(J_8B=<RS%F
M9CW9BQ]Y.37?HH1509PBJHSWPH &<8&<#KT%<O5M75VP #;0T:NKAIC#C)F0
M"BCL62::5Z^&L8U/\JJOAK6HKG*C6JJ622)$C22,$1 69F. H'<D_P Y[#K5
M\<;RNL<:,\CL%1%&2Q/8 ?M/8#J>@KTIXUR3\3CJFBG>V0Z-DI=B^-?5&IYD
MCIYXXW)X1T8Z.8+'(B)[C(&R*B*]4Z\XU*[%[>2SJ"$)"1@]]B#:I(\"V"Q'
M@6QX5Z=IEF;&RAMV(+@%Y".HYCDLP!\0N=H/B%SXU/.M&M^G2E.E*=*4Z4IT
MI5=\EW^7JLU8!Z.X'KEL!7M#A_*G-GGA>V8=T 4*/(EC83%$DLB,;#&B^))8
M_*+U5M*N-6@FM8(RV],<P](XW!#(7<]  P4[<[B =H-:-]>6MK$?.9ECW [%
M^=(Y'4;4&6(!QDX 'BP[UHB9MW>5: &U$^Z4MRJJI_O,3D1OZ/XYWZ4^[K+I
M_DW3"OJFH,6(!:"R4* ?5YQ.K%AX'%NN.N&.<CD)]?.2+> 8\'F.2?\ NT(Q
M[^8?=4%M.2&"W-+GK#1AU]UI6VDE!4>[ *;;,I8(2[9U?$B(00VN&(@F+5KW
M>S'*QSU1'?/J+?A#AJT9$\QCFE8-M-U++,TFP L>6[\H[003MB'?K6@^I:E,
MKR"5ECC*[S$BJJ;R0H+ ;O2(.,L>HZ5C;'8 AV])0VFA9!=:5;)*&L+/>AEN
MM.*TVT0"!\BO(^ $<P@KT(OM1*CW>$\=34>G:5;LB16-A S;MBQVMO&6VC+;
M0L8)P#DX[ ]:U#+=RJ\AEGD2/;O8R.P7<=J9)8XR>@K&1:_-%+J4AOJZ=<24
MX+7(PICUSI;*8'1.'MD154.9**SK[962^%^!,'G_ )$C57<5H@'"% (CMD"X
M 0[%?#8^;Z#*V#X$&L3)*>665SS1F/.27&\QY7Q/IJ5]X(KEH]/G=)&Z;/7M
M5<LC&JS)OJP\<MXXUW706]/*3'!(^05MG5DC60*$,C<2"1 5$CH98WNJKQRC
MT62084D ANC*&4D=<;E(9<]P01T-4=)(SAU9#E@,@C)1BK 'QVL"IQV((/6I
M)&67%_I11$7^]S2,_P"BY.M>6PL9P1-96DP/<2V\,@/O#H<U<L\R?,FE7]&1
MU_8161@T-R/X]%A.]$\?*96D(OC[O,S9%\?J5.HFYX3X>NL\S2[:,GQMM]K@
M^L"V>)?H*D>L&MF/4[Z/&+F1L>$F),^PEPQ_7GQSGK6>$VQ;%1I@L,[?DGKA
M5T$GZ7*CO<8]?T(D:?I3KF+[R<6,@+:?>W%L_4B.X5;B(GP4,HBD0=LLQE(Z
MG![5(PZ_,N!/"CC\:,E&]Y!W*3[!M'[YC77M=9^&CS>B;QY4>9$CF3[?/I3R
MK9/")Y58G/\ 2GCU>//7GVK\-:MHN7N[??;YP+NW)EMSDX&YMJO$2>@$R1EC
MT7-3EMJ%K=](I,/^2?T9/6<#)#8\2A8#UUEW.:U%<Y4:UJ*KG.5$1$3YJJJO
MR1$3YJJ_).N?) !)(  R23@ >LD] *W:A%KNJP%SH0F.L9VJJ*Z-R1BM5/DO
M\<J.63PO_@F.8Y/LD3J&N=;MX24A!G<9&1Z,8(_M'JW^J,'P:L33*O0>D?J'
MU_P!J#&;>^*5R131!1K_ ((T3?5X_P!]E]V1%_2QS/G]B)U#3:S?2Y"NL*GP
MC4 _[3;F^HBL)F<]L+[A^\_\*CL]E8%>?B3BY_/VI*1*]O\ YKGJU$_0B>.H
M]YYY"3)-*^?QG8_J)Q5A9F[L3[R:Z76*K:=*4Z4KZ:YS%]37.:Y/L5JJBI_6
MGA>J@D=02#ZP<4R1V.*R@U]<B*GL69C43YHQTSI8_E_XN99(_P#U?T=;$=Y=
MQ?T=Q*HZ=-Y9>G]ELK^KKXU<'<=F/TG/[<UE2>7(LP$MAJBJP>MCDBA>:7.R
MO7W9G>B-B2+YA?(]?*I&V%'*C7.54:USDV9>*5TV'GZG+;1VP9$::9A!Z3'"
MJ&^86;P&W/0GH 2+S=",;I2H7H-Q.WJ?U?0 *VMX.(J]1<#W<1+(8@X9)@QI
MW-9*=/-"^)KQ/#EC*'@BD?,^6"1Z(Y(D]*HLGH]%X5FM]1F6[1]JQJ3&CD R
MNRD9B(.V1$4EBR$]=O3YV)&T*R,'!P "5!QEL@@XZG( R<@^KVBMN.O0:DJ=
M*4Z4ITI3I2G2E.E*=*4Z4KXDCCFCDBEC9+%*QT<L4C6OCDC>U6OCD8Y%:]CV
MJK7-<BM<U5145%5.J@D$$$@@@@@X((Z@@CJ"#U!':J$!@58 @C!! ((/<$'H
M0?4:UIW7;G56LD]CC28J,R172/J24D?3RO7RJ_#21I(17>IRJOMMC)&;\F0P
MC1I\NDL>(I8@L=XIG0=.<N!,!X;@2%DQZR5<]2S,:YB_X;AF+2V3B!SDF%@3
M"Q_LD9:+W .O8!5%:LZ7 ;#(O>E[1&BP-7PA\<?Q5:]//Y*M/&649%<GA4C?
M(R9$5$?&U?*)U%M?VEV!R)T=B,\LG;(/7F-L-T]8!'J)KE+K3KRS)\X@=%'_
M ,0#?$?5B1<KU]1(;U@5#NMNM*G2E.E*=*4Z4K4/G+ACD/D796Q.4T1>=!N,
M-A:Z.R&MGU#(YL1OKV^T&7+.&%L["N&WE;IZJ1QHE)<B/=B$$MQ'CS00DQ]U
M;332,8W*!HHEW!MO]%*[O&2 Q43+(OI!&'R6&!!%25G=0P1*)4#E9IFVE=V>
M= J)( 2H8PM&PVET/RV5.02*WX^XI[A,CS>).387^GS>?H'#3\@;?6SS5FOD
M=@N+\T,!+1UNO/FFEK[:EV=T(>1B*(F2XM;<LZ1BFL/T6&&WO([H$L\B*F#-
M+)TD^2MT *+(V2&25P3$GI,Q)]++YYKFQDM2 J1N\F1##$ T0YT[E@[1@ ,K
MQ*5$S *BJ!Z/HWGS%P8;R7;ZFT L*:O??]O/+W#<+S1)99X+OD63,K5WDLD,
M;E<#5149,1+&.4M6DL:.BM]Q.MJYM3.9"&5=]G<VV2"2&GY>UCCP78<COUZ>
M-:EM=K D:,K'9>VUT<$8*0A]R8/BQ8$'MTZ^%4GD>RL_.[4$\OD"P)Q=%J+&
MRS(-<=:5.GJ,L_!4V3S^06W@55+KLU)725@;IY7RDY@6K&,?*;'.]VK%IACE
M#&9C&LA:,!F618^2D21[P<D)M*C/4QA0<MDUMR:J'B*B%>:R!7+*K1M)SC*\
MFTGHSYR<# <MCIBK.V7%7)]E"P5=%-HX#-IA["!9+H^)E$RCY\I>1Y]*M4:B
M5T4M7B*^*C "K)F?!FT(@P,! FFL'U&>6WG88WE\RQ,,L<($NUG+[3Z.5B78
MH&,%  ")#MP17-NO7EA"(I01L'IE[-X!'N7TB&F;>Q;YRN2Q!C7?M?UOU&TZ
M4ITI3I2N2*&6>5D,$4DTTKD9'%$QTDLCU^QK(V(YSW+]S6HJK]R=4)"@EB !
MU))  'K)/054 L0J@LQ.  "23Z@!U)]U7-DN!]SI'13'")FJU_I<XJX:YA;F
M+]OL5350QTB(J*U"T"B>B_DS*J*G4/=Z[8VV51S<R#ILA.5!_M2GT /#T.81
MXK4W9Z!?W.UI$%K$>I:8$/C^S$/3)]C[![:V_P 'Q=E\!#ZZV!QEM+'[9-T<
MC'FR-5$]<0Z-1(PAG.^:PP(CGM1B$3$.8UZ<C?:I=7YQ(VR('*PID(/46\78
M#Q;H.NT+DBNRT_2K73US$I>8C#3R8+GUA<=$7/X*]3^$6P#5C]1U25.E*=*4
MZ4ITI3I2H_J[IV<S5[>LA0B2IJS#HH%\^F6:"%[X62*WPY(ED1GNN:OEL?J<
MGS3K8M81<7,$!;:)940MXA68!B/;C.T'H3@'I6O=S^;6UQ<!=QABDD"^!*J2
M ?83C)\!DUYB75W::&S*M[DR8ZP,D62:>9WE?M7TQ1,3PR&")OAD,$3610QH
MUD;&M1$Z]+A@BMXUAA18XT& JCZR3W9CW9CDD]22:\LGGEN97FF=I)'))9C[
M>@4=E4=E48 '0"L5UEK%6HG=+PKR#RTM 3Q_85E98TW'?.V;B--MC:@D:\Y$
MQ0-#F"0R00R9HHA[(9TAQ4;HY@X49-!&0_\ (2.O[6:XVF%E5E@NXPQ9E(>:
M-5C(*@D889)[@=1FI/3[J&W$@F#$//9R8"A@4@E9Y 02.ZGH.N3T.*IO0=G^
MQMM';0-,&FPPNEY3OL?7F;C62V%2[:<$XG(UC_BY'RV$:KRE3WVE.'6QG@C>
M5'=M;.>1+!'KOITC2-Z0,0DN'C!EE++S;2&->I]+^L(\A&X@$AQEB<;4>IQ+
M&"01,R6R2L(H]K"*\FD8$=%_J[(@(49^9T K  ]K'/4.LLKWZPH ;>YL:2YM
M>01^1]:ZZ/%KNVFGXKO<D=EF4D=2=%I]^%!>2Z,FQ<9$'5064XKK *G'2U;"
M[$K/N0,S([3">3<0MBEN\9BV!3S)EWERV<*&(W*HJXZA9\L( [*HD58#!&%7
M=?O<1RB3=N#1PDKL VY;:#@N:^ >T_E^D)M"_JW-Z<&TN>$]!K\_+RCK<TWD
MP?&\%IQUI<S<W %(86"VLY$BAY K2)4+ T<<(HEC"$\6&**T:?<*6.$D#-:O
M(AN)8^>(K0P/&SA&*A9L3 X*OT! QTJ=2MG"C=)&RK=I$XMXI/-^;=<Z.1%+
M@$F',+ 89"25)R2<I'VD\P3XW8P:C7D:?<S\?\-9G)7 ?)&CK5")RML99<@!
MH3<T&AKC8+0&.EHG&Z3,V<NXK:UP>B^IXK,XB.\:?<&.022F27D6T<;B>0;3
M&Q:8>FCJP8!%W.C&4#Y3;DD6G4K82Q&./EPB>Z>5# C9610L!]%XV!4EW(CD
M7E,<IN*K6YG 63VF&XDR&4Y (J2=3306D!KZ4RR/!8'+>69-*/\ %VKE(E+%
MI)Z\>Q0=@]5"?$2/2""TT( \<E:1RQ6\<<Q4R*&!*EF&"[%1ENI(0J&QA000
M@"@"HN\DBEN99(0PC8J1N"J20BASM7H 7#%<DL1@L2Q)K6SO[V7<#F>(;]O#
M--%64<=*2=O^2G7]6!;4-&Z5!):G*5KBFVJVYK9$^+NXX6/K0Y&LJ%?93J=4
M>D>3ZRX=N=8MSK<YEG,RII^F"WEDAN)P"XFNY0ABY,>/0@+$2N,S8B7ES>%>
M6W5..['A:]3A"T2WM!:23:WQ U];07-G9EN6]MIEN9!<>=3 _*W813!$P%L3
M.YEML#]'7MNX30\24#>5*EMQBW5T\O'')*:&M*OI@*JR(IWT&DK5+6WDD"(!
MG;47+HGSN%@0<_U(@I3\WE*L.&H]5N1I<@CNV<)JNDM:R"U+3Q+*9[=S'R-L
MJ2+S[<G868L@ZN@TO(-JW'MWPQ9)Q/;+=:4(&;0.(5O[>6^:"VG>U-CJ,'-\
MZ9X'A<6MYM9VC3ESYQ',_I)?:4XX .O<]S$2-SC)&^6J6K7N9$CO'A%8C6^J
M1J?DOE7U*B(UJ)\)^4NS31M<.G69Y=I<6T5^L0)S&)I)8S 23DHDD#L@/X#H
M&+%<GZHLKN2YM$,GSU+([=N9MQAL>T$!L="P)Z=A#>O-:V*=*5I'W2]V4? &
MTXVS8L^44<U&;#DF+0%20VH_&[=/19.;\$8(S!6F:B:2WN-"&-*PJ.:HQ&@C
M]CWGPN3I=#T'X5MKR9A/E<V]F85!0WG(EN ;@D'; !''$Q!!$ES$2< ULP0<
MU78Y\53 R-^TL-WJ7H!GH,L*[W)_=?8YG*<T:'#\<':(+BT/7@"ZJQO<P+G+
M+78^JIK:V#DITOQM413!B723M.KPWRV3JPZ"!@H\P%D3;9:"DT^G17-XL+7S
M6[M D4S31V]Q))'$PDY30"1VCP5=@$#H26(=%HD )C#.!OVDJ V0K$@=<;02
M1CQQG/7!%=<WN[$QA.X9OLS;Q_56OU62SX=6'7-G779[C3C+;U_%ZE,T%H/?
MZK3S[.XAS]V*VIK3I*<L%]</&'#:6E5X?:Y6U-I-&>9;P7$S2,^!;S7E[;/>
MXY2&*"$6\9EC8NZB16#L6,:7>;[@I1@<HK'.?FL\BE_FC:H"C())&>Y[5A>2
M.].7+3\C9W.\<EV.LQM-:V57,5H,Y8YJT(S6TQ>*U099M'<2H&;3'[029:EY
MD=NC!"!KH7/V#H@I,EGPX)Q9S37BI!<21I(%BE2:,3V]Q<P,JRH"RR+;L!)L
M,9+ QM*F7!+;=L+/A6(S@$, 59@1D=B%[XQZLCK4DT7>7GLNFH+M^/-?!29]
M>5*D.Y8=F9X;S9\,YDW4;O+#A0V\EB"T4:JN@ZN\-%CK+0RI(]+H!R:R<_%%
MP[+/R%CO+<R2^8R-'MF!CM]1F6&UG9C&$8LSQL\2L7C60=V5U6T6Y.,.N3L)
M&#T60X5L]CG(R.XS[#4RS/<;-<\KY+B.]XPU6)OM<-!)7EZ:TS8M;,4936E^
M&'4V"67U5IITKZY@]@%F[.SN:^V(>*ZGF!!-M8;?B]+):27=K=0W:1R,FV%)
M<Y1TC;?N4&'TF+(9E2-XP&Y@=UC+S<E2R.' ..@(['!SGYO^M@$>-6!W:9*:
MFXA'/+)8\EVNIH4@A15BC;(%;N<KY7(BO>GH1/#6M:GS_*>GCKS/RIZ8]GPI
M%/*X,C:K:)RUZJH:"[8DL>Y&W& ,>TU':G'LM5).295&/ >BY[^/;V5NI@7O
M&QN,D&<X>2',YZ2%\*K$^)[:L1S7QN9Z58YKORFN:J*B_-%\]>PZ)Z&D:04]
M KIU@5*^B5(MHB"I&,$'J".H/7O4K"<11$=,1IC'Z(K>?"W9-_F@#S/F6GO#
M$2(B-2>0:1T:3HB(C465B,?(C41J2K(C41J(B>I:9<O=6<4LG63TD<XQN9"5
MW=.F6&"< #<2  ,5,0N7C5CWZ@_0<9^G]M2_J0K)3I2G2E.E*=*4Z4ITI3I2
MG2E.E*_'-:YKFN:CFN16N:Y$5KFJGA6N1?**BHJHJ*GA4^2].W:G?O5=7O$O
M'NA5\AV9!@(?Y52JQ'U4ZO7[9'J Z"*>1?M5Q,4R*OS<B]2,&K:A;X"7+LH_
M EQ*N/5Z89@/T2OLJ-N-(TZYR9+6,,?PXLPMGUGEE0Q]K!O;52VW;#13JYU)
MI;2O5?*I%8BC6D:+_BM? ZLD:W[D5RRN1/M]:_;*Q<33KTGMHI/;&[1'WX82
M@GW8'NJ'FX6MVR8+F6+V2(LH]PVF(@>TEC[ZKJQ[:-J,KG5]G064:?R6J06$
M0[_[.81XZ?VM?G^CY]2,?$EDW])%/$?T4=?K#AO[E1TO"]\N>5-;RCVL\;'Z
M"C+_ 'ZA9O"/)X7E7YB8AB>?#PCZLOU>/O2.$UTZ?J=$U?T=;B:UIC]KD*?4
MZ2)CZ2FWZB:T7T+54SFU+#UI)$^?H#[OU5&">/=V(J_$8[3,1OVO;26,L:?_
M &L0[XU_J?UM+J%BWS;RU]QGB![9^:6!_5TK5?3=03YUE=#VB"1A]:J1^O\
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M1LUDL;@;/,[NZL^X;DS0<9Y"K.V6HYF/R@L&6LPJ@S172Y<=MP!-9S@5-3/
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M/WL.RVDT0NAPQV8S7'X \O()LOP&IMJ^Z&T][7VU)5"5.@KAS@R,Q4P:*IT
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M=JL'C;N@%WNXS^%M>-MA@;#39N#0U!6I,SK0K!3,\'L!:VI-!LR*W16+,P?
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M.UTLE6^ DHAQ4D+$5R"$,(:DA#6N2&2!4(>QCH.NMX=O+=(WM'*QS/*9$9L
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M2>N[B.2 E:I1-3;M3[6GU<,7J3[_ )U;ZY47Q]BI\OO5%ZUI.'M.?.Q98?\
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MHV.*)C8XV-3[&L8Q$:UJ?<C41$_-U'DEB2Q))ZDDDDGUDGJ:D0 H 4  =
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M5L%9(Q53\RRM3]/6)N)+ 9VQW+'PPD8'UM*"!]!/LK*O#&H-\Z2U0>V20GZ
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MR598[2\<R1R$)%,QR\;'HJNW=T8X4$^DI(.2O06UQ%SO1\O[#G?'5-):U)?
MO)[.+[TNQD#>->6;\GG=:EE4M&EDEC!031CBJPQL1'Q \SO1[:L<O&UVH.<^
MPXJ]>E5ITI3I2G2E.E*=*537<)Q?5\R\,<B\<6F/P^Z_"7,6@E7G>1Y+(;'3
M7R"R/HS;BPI!BKZIBK+-!CV6N?;!?5\@[2*@T$YD)D,SP]JLFB:SIVIQWM[I
MXM;F*2:YTX1-=K;!AYPD4<[I;RF2+?&8K@FW<,5F22,LC<QQGH%OQ1POK6AW
M&F:3J_G]A<16]EK9G33'O.6QM);F:UCDO+=8+CES"XL@MY"R![:6*8)*FOO
M..Q?:KQB!QQE;G0\IZV1T1V]Y6V9SR]%O-+$$-61V5M:2J0>;7TE2#79C*5C
MR)XZ/)4]-5,M+*88BQ,BN-/*$>(M6GO8K2W@@3=%8:?9KR=-TZW+O(8K>-0
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MD6MCGK$.N@B(FEAA@DF,FAC9-+-%'$YR/?+&UJO3%.K/!,BC+-%(JC(&69&
M&3@#)(ZD@5FMF1+FW>0@(D\3.2"0$612Q( )( !Z $GU&M/-%Q-S&ZKY2=)7
M3:B/64O/5-QS3M("$DXVT&C#T!&>U3HY-# )H$W4)4E!-:R2!W6.A?2U%8(#
M4W^WM^HY[>YVW'3?S$O%@7('(D</LD.7"OS02A;H\0*HJA7E:I1+FTW6V&$9
MB:S>=B&(G2,H'C'R9*<DC?MZK*0S$LZ0J,MI^)>2+O+;;"750?H;:67D/1E<
MCB6(];+R78W=%!F<:*D27#"\S+59O7Z:DDIQGA5%,7C*^QH7B!VPL45SV\S1
MRQ,I=CSG,P8+SV= D8QNS&521T*C"J8@R85@*LCN8$DBF1@B@0H("I80!&,D
MI)V8D#211N'.682LKY*$UCRN$N6-/N1:W9B4M]GZ#6U@XNPUU/1[BIU68I^-
M]E75&AO,D?8@)^$:FW-13WDBP1-DTXIM_6"Q5)(S1K6M;B24+*$=$D4"25$F
M62-890KO&67T]SJKD #F NJA",7B[MHX=T1='>-B8HW>)XW:>)FC255/R>%=
MT&?Z,A&.X'-G<LY/ELEN#!QE;F_@,SH;#V J+XZD$(PX_'^CK"LY8OC7V<X1
M>F2U5)GS:@*Y@S1Q -TRNE;3-F@SW$=P1$L03;&Y.%)0&(02*8S^(78JJ%0P
M1BK[?0S6M;2VPYQE:3=)&N2^'(F,R,)%_*!!N=U=D,B@IN]+!K@SC_<6O+]5
MM*3C>VI!7:/AT\">SIL3#94.6IA:NOVU*;MH=E)HZ9E:"VV^)S^? OJK6E0Q
M /(*JKLPZ+"T,K7"RK"RC?;$%EB#(BA1*AE$I=0J[LI&'60C;N*N36P)XEM6
MA>=7/+NE8*\I5Y'+-$PB,6QRS;<2.4:(9(PRA3OIU*U#4Z4JS,_V[\H\D CW
M&<YPY1[>PH6S-:?QZ)D7V&OC(]AT;3X=AF] QM;7>R^0(@2,1Q$QDOY9,<:+
M%'S<1:7IDCPW.A:7Q"[;3R]1>\$=F5W F,V=S;DRR;@'5R^U47HI/7)/P?KN
MO0PRZ?Q=Q!P8D1<M+HD>EM+J*N$VK.NJ6%Z!%!M9HFB$6]I7W%P%VUSW ]H/
M<!7<.[F6M[P^[+F,\FLAK!.,Q:?A&5FOFMK .L;5V3B>/A11*-?BEGO[ N5P
MM=30G'$CEPP/$GE.'^,.'I=8L1+P;PCHT:RF5]3>;7 ;-88WE,L>S47=IQLQ
M;QH \DQC161F#KR7%ODVXRM^'=4>'RG>4?B65X%MX]"BM>$&&I-=31VXMYS-
MH:0Q69YNZ]GF)B@M%FFDCE5#&]!=MO%6IX8XBS6 V.WL-U=U,<CI3C/;<)20
M3)&L&6HI?A1#)Z"A:U1:V:Q8A#F*]!QJJM0"EK9OB;5K36]8N=0LK"*P@E(
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M95MBS1OK;/6\,:A[K#%U]^5#4$I0W!U7)-:VE,<+L><VBVPM$DPW*NHQ=!9
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MSHE:YA]W(EA,U[?FU[!W,CKX9&N_*;+"''*UWA4?^2WQ#7.LW]T"K3<I#W2
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M=S'YY;64YY%O>YE"M%/=03>+<:\ :'Q=Q1HG$D%[K&@"UOYKSB&PTJX$$7$
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MO</&JO>I)TI3I2G2E.E*=*4Z4K5CO*_U#3?_ "_XA_\ >GD.O.?*K_[GS?\
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M54Z/Q!H,8G:36M*1;6^32[DOJ%HHM]2D.(]/G)E BO7/1+5]L['H$-!8WK%
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MTT2:A=+:6TKV9N$ND2:4D0&6.)9@K,C[%9Q74O*+PM8#58DU!+F]TNTU>X,
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MK!';2S&*WM^254R-'B63F[W5@H*J"K?/?^4'PQJFM<)7FIGB.:RT?14M+AM
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M*&!99[0LH()4-<1[21W&<'&>^#CM6TX=E76#SHP#PCI*PU];9,$*@)?7V,<
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M]YH--CJ;?G\6Z@/'\@7%73<0: S09."NVTUL=;1"D7:,LI[#$#/H:4[;L^.
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MU\5W6"V<81OP\LP_Q8C"D@)]B::'WHW^U+(STO6*==CNA(8HS+N7.T[21D9
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M&[L%/\W$?TO7=4O?4[)R=M/*Z<,*&E-_![3BZ_7G>/,(OUDG+2U"5/X0+IU
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MNV_O/Y-&W?-O<?W <G\ W''_ .%G(MB/JM0F8#>(>+CLC1YJBK6P!FV(()I
MD8Q\\Q(([A/AD<4TK>X?X]EU?B7@K2WL-#X;X>TOB"'4/---B:TM?.G#QM>W
MD]U<2EG2*21%<O&H1VW[L(5B.,?)#!PYP-Y4M>35^*^..,]?X-N=&^$M;G34
M=0\PB,<T>F:;9V%I $BEGBBE>)8YG:2)#'RP9!)1',/:]D>)^)/H\;I. +[2
M=N5#:5&Y[S./L7C;?3:#4[>UXES%9D.0^2,8#'/>ZL;,:2+0$:N$L,QL26!
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MBC(Z$@XP?'W8_7]/; [^DO\ ![^F;XK^7'?>SP9SU4A?."IYNXPCR-B9&S_
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MH[#CWAZQL+F76=-UG5H;.ZE/GFF:I>Z:[QRR0NH*22JLTD<Q&XK&JILF>Y6
MJTK$)J-O&C&>.:8(V=\4KQ'!((\0"0V.PQ62Y%ON4K1O>EJPN9N2LXW@_4U1
M6"H<]=#@TT$DE>*48-:Q2 D%V-5)%$V(>H0L>NAEF+*F'*EF;[>SKM[Q%<+Y
M6-3BXJU^P'"&I6[Z+9V-VD-JA:"*26.Y5H7DGMF4!4MN:D"LTDCI(6 6^=KA
MCJLBW4\?FDB-"B/A =BE@PP2R$#HF0N220<UZ<8:V+OL3C[VP<QQ]UEL_;&N
MC8V-CB[&I$,)<R-J(UC%FF>K6-1&M14:B(B=?06D7,MYI.EW<Y!FNM.LKF8J
MH53+/;12R%5'1078D*.@'05/PL7BB=OG/&C''09903T]YJ4]2-9*=*4Z4ITI
M3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*
M=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2M8N[[NJX[[..#-7S5R'.V>*JB2MR>8A)
MC'M=QM#X9UHLI4J]LCFRFRPRDV)K8)V4]('9W,\,L $D;E4)P,_R:_SU>?>=
M>1.Y/EO:<T<I6[K?8;:UD/+5GN,KZD&-J#U.>I!9))5!HJ&NC'JZH3W)'QB#
M,>1,05).3,K 3DD^NIEVF=T/(W9_SADN;.-RE<?23J%H\[.1+!4;;'G2P_7V
M1NTC1Z."LX(8Y125AFDJ;<6LNQ(U.K1G(JH)!S_.*_T*>W?G_CGN>X?QG-7%
MMJEGE-C6M);!,L3;2@MH/XFYS%^-%)(@5[0V#9@+ ='R0O?$PL*<JO*#+G5F
M!R,U=G2JU^.:US7-<U'-<BM<UR(K7-5/"M<B^45%15145/"I\EZ4K7;D'M#[
M6.5O??R+VZ\+Z\LCUK):7'&^3FO$<_SZWPWS*N.Y&D?Y\ND'/B>J_-7>43I5
M" >XS6D>V^A,^C[U1*V.?XVUW%5RDBS17/&?)6PK"1I_GZ)P@M'8ZFD!DC5?
M,;0ZF")JHGF-?GY538O?&/<?Y_GMBH%_<K.>>._"]N7TFG=5@1!?#J_/<EEL
MY:S[/1\XX75BW>1HX6JB-8^9F>F\,1/4-*U$9TJFT^#'Q]O?^33\!OIQ>*/X
MVCYG[2NYNM&_)B"WN4/P>D,C8OY+'PY.BP]0Q[F(C?>FUDDGN+ZIG2_E2.4]
M/U@]O^/\?V>JG\.WZ2CB_P#BN<?HO=/JAXOF1?=OW(X&T1T;?Y4X>4H0^0K"
M=)$\NC')O B(T\-E;ZO/A5<MG&W/?J#T]?B/HS[\>JOU?IK.TQ63Y+N$XF[C
M.!YK2">LN:CF#ALB2H(A(C=$8(\>FL+JW.%=$Y\<\9&;'D>Q7M494^W#<6\%
MU!-;7,,=Q;W$;PSP3(LD4T4BE)(Y(W!5T=2596!!!((JUBK JRDAA@A@,$'H
M<CQ%;?<'=_?89R:F7PG#?<'Q2T@MU=GL?B2C)\#;F$3NC#JZ.BS.T S5H98$
MRNC&$K0@9C22'MCCADF?X=;:VMM8VT%G9P16UK;1)#;V\*+'%#%& J(B* %5
M0.@ ]IZDFJKL4!4PJ@850,  =  *WC<YK&N>]R-:U%<YSE1K6M:GE7.5?"(B
M(BJJJJ(B)Y7K.2 "20 !DD]  .Y)\ *OK3=G>CPU=3!BFYGDE>.]1>2XL'E*
MXP$[>(KT\L@BJ<$V^(*>^<$R>(D.20FH:+Z8BOB_:@'*?%Y:/*OPK=M%'-I^
MO? >HWC:3#Q%=:*XX8O9I))+8Q"]>1B\,KK)$S26PCPLG,VHDA6*^%;5\!H[
M@P2-RA</ ?-7))0KO)Z@D$'*8[Y['&VM)1TN:J@J+.5%704E;$L%=3TH M75
M@0*]\BPA@!10"C1+(]\BQPQ,:KWO<J>IRJOI=I9VEA;0V=C:V]E:6Z[(+6TA
MCM[>%,EMD4$*I'&N23M10,DG&2:DT1(U"(JHBC"JBA54>H*  ![A77JLSFZ&
M:Y(HZ"EII]%937.@FJZL&OEO+<EK6$6EO()!$^RL2&-:R8TQ9B96M:U\CD1$
MZQVVGV%DUT]G96EH]]</=WKVUM# UY=2 ![FZ:)%-Q.X #S2EY&  +&J+'&A
M<HB(78LY554NQ[L^ -S'Q)R3ZZJNFJN!^.^3Q,KF,CBLKR=M:.UT",SF1 K+
M0^@KB8VV)AMK75L,4(DA[HV_#2EL>:6UTS!YE@FEBYRUM^#=#XABT[3],TG3
MN(=6L[F] L=+AM[B:R@=1/++<P6Z*D33;1RVE!FE!8(Q1F761;."X$<<44=Q
M*C/\G$%8QJ?2)95  +8Z9RQZX.,C \35_ 7+^ O-1D.,,Q!EN0KNS9J:ZXQ>
M=#?I;;.7%@#*;? #L-%L)(;)#B@2299IHY"92V)"01*JZ?#4/!?%&B7FHZ7P
M]IZ:;KEW<#48+K2;&(ZA<V%U/"TM[ @ECG9+@2RPR2,[JTC2C9([&K;9;*ZA
M>2*WC$<SL)%>)!S&1F!+J,AL-D@G)ZD]"35HA\5\95^>$R(7'N)&RP%G!=AY
MV++TK:4:Z&D;,/<0UOP7PC+6&9K98[)(OC62HCTG1R(O70Q<.</PV,>EQ:'I
M$>G0W"7<5BNG6@M([J-@T=TMORN4+E&4,MP%YP8 A\C-; M[=46,01"-6#JG
M+3:''4.%Q@,#V;&?;7?FP.$(ATXT^,RDP^VD;-LAY<]420ZV6.-(62Z6)XBL
MO9&1(V-K[-I3FL1&(J-\)UG?1=&=-0C?2=->/5F#ZJC6-LRZFX 4-?J8B+Q@
MH"@W D(7 '3I5QAA(D!BC(E_I047$O3'RG3T^G3TL].E=3+ZFML+W5XFMR^C
MH(./4S]=&:?GEI\I;#6=:\D.+%'-?\+;!5 X[0;%HL,$580L(GH7RWQBT[48
M)[S4M)@T^_LDT3S* 336)M=-N4N+<R1+I,P/+N8K5$$,XC1%MY-L6.U6QR*S
MR0K'(@@Y8RR;(V#*2!$>S!0-K8 "G %3GJ8K-3I2G2E.E*=*4Z4ITI3I2G2E
M.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4I
MTI3I2G2E.E*=*5$]7@L-NX0Q]QB\GLAZ^668"#5YRGT4(,T[&QS3!Q6X9C!I
M9F,8R62%K'R,8UKU5&HB*5"OX/' '_S&\/?_ '9XK_\ A.E*?P>. /\ YC>'
MO_NSQ7_\)TI4\RV,Q^' FJL5D\UCZPDMYY%=EJ*KSX$YTD,(\ALP=2*(/*6^
M 8>!Y+XW3.A@AC<]61,:U2I+TI3I2G2E.E*=*4Z4ITI72L:RMN YZZVKPK2O
M*8L9(%B) :&0Q?M9.*3'+!*Q?O;(QR?HZ4K7,KLP[22]A0<@N[;.$Q=OE[RO
MTM'J:OC?*TUV%?5)49U7:N/J*P*8LNO-AA,#D.<3\.5#%/$C98V/:JF!ZA]5
M;'G/FC",>.(A\[!2'P NDCA:;,V)ZQB.FE:Z*)"'HV%9)&NCC1_J>U6HJ=8Y
MBRPRLD0F<1N4A+*@E8*2L1=@542'";F!5<Y((%#G!P,G!P,XR?5D]!GMFO#9
M-G18NL 9V^;#E?)<GR;>$6;LRVE'9;C-C6$VB>RRKQ([*C%KZ8!X;WVOUDR<
MBS:LGPZ&AFHA0?R -5L])@@'!&J<2:9Q"VK)&_DIU>SN-7L(YGORL\,8N+..
M"TAY1-R)U>2X4G8)8I1S(N0$J1*OF4MS'<<['P5*C31AC)Z0&4557 +;\E_#
M*G)%U\YU>RR_,&\[?LTVR'IN\2[X_P!%4V0<KW19*<6TDBYDD@D54<YY=;6L
MM3VLB<UH!K&M:URN\=;QA;:IIW%&L\$V G2T\J=WHE];3Q,Q73'CN"O%;*V0
M29+>W%U.%0CDR@ 9S6Y>)+'=364>X)JCPR*P)(BPQ%T1GN2JAF _!('L')R!
MQ/D]1R?WO"754>76<=\)8"PPM<RSN1:RJN:?B<Z2GM1@A#(!3;*GDJH8Z^4N
M(KX=A!L2,5II+9;];X:TS4>(?*Y'=6TTEOH?".B3:/ MQ=1V]M=VO#=PUK<I
M%%*D<MQ:&W00-*).6LDJX(F<-2:VBDN-75U)6"TA:%=S!5=+4[& ! +)C"Y!
MQN88ZG.$QH&/3G/LMVG)+"W6.PX R,85[9DZ"26ZY1K)*H',,FG'F<V2T9&\
M1)XRO 9#YF$V[97S+,_2TN#2_CAY)]5U\2&?5."M,$5Y<27S-=\16YM8M/#.
MC$&X ,0<28B<L'N@Q;<;8EB\\TJ6?):6RBVNQD)>X4J(\D$Y8=,Y]$YRW?-5
M]A,%59[A/MWY:J1;8/D:3NQK,^^]99W/OC98[::86PH( '%J +2'L#C)/%B#
MCC+G(,E(=(AQ230FBZ+;V/"7 G$MM%=1:\_E*M[%KP7%V'CTV;5M1CGLD@YG
M)CLYA$LDT8B"R/)*SDB:0-AAA1+2QNE#"<ZBL?,#OD1--("@&=H0XR0!U)8D
M^D0>G>QZ8KF+?MO]!79SGYO<)Z<'8&!\HV7(C,DRS%?EQ,K64+)<L5QD=3,)
M%):1!*GP<TTEDBQ_5Z+BO1J$G%.M"\O8+'C3X[_^QYI8N(KC75TP7$?P;'IM
MO:!M-EX?EL]\<F]&^2=S<9009L?F&[GW2*EZ+WY$L+EIQ'N'+$:I\D;<J"#N
M!]$^ETVUD>6RP\GS_NM'"E5R=JV<N59=;A]#%R?B.>A'2%U\=;6\47>?)?2V
M^&'C63X$F94&GKH'2*"])!9"-CB:6+3.-=8OU6WXAU(<3VLMOH]\O$.D<9QY
ME@6"WX;N[*0VEUHZ*2()&^2DMT+<DYB9[KHK%>S286XD\Y0K#)YQ%> DC:MN
M\9*-",X4G.0.B_-+6?RD)+8W_?R*=H=)EZQVF[=GRVM527&B#@"ASA4Y@UY6
MTT\)_P""IBQH-H"095^&AD;--$5"V06?H.(HGGO/+1%+>W^G0-J/ Q:YMK.Z
MOHEB6P=Y([R"T=)_@V4KR[Z2!CRT;<RRJ&C?9N 2^M N\8,EB2RHS@+L)(=5
M.>6V,.1T .3D9!M7L0MQWVO+F>J<WCHZ6OGRQB;3BFXW)/%%[83A%1R T%)M
M)'QT]V,.V,C0.I&QQ$DR-C-BC8-6K)TGD;ND-QQ-8VUAI0M('TV7X6X;NM8D
MX;O)W@D5H;*TU9B+6\C0*]Z;4*LCL!*JK';[MG1V&ZZ18X@H,9YMLTQMG8J0
M0B2GT7  +E<9) ( "Y]%^O=*G*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*
M=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3
MI2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E?GI;ZO5Z4]2IZ5=X3U*U%
M\HGG[?'GY^//CSU3 SG SC&<=<=\9[XSX4KS>X:E(V/?9SN5J3#[Z7C&KG X
M_;96!I(^2$NW545K#2AOG^$%0V(LF&9Z0.D]F9\3'MC\-3PCA9GU3RQ<82:C
M+->-P];O#H@N)Y9$TR*\\W6Y2TB+\J/G+)(K$(6V,54A>E0-J3+K-X9"S^;I
MB$,Q(B#[0P09P,@D'IV.*](NO>*GJ_%1%5%5$547RBJGS1?"IY3\R^%5/E]R
MJGW]/W=J5^]*5^>$\^?">4141?'S1%\*J>?M\*J(JI]_A/S=/Y_GZA2GA/*.
M\)Y1%1%\)Y1%\>41?M1%\)Y3[_"=,#OCJ.Q]6>]*_>E*_$1&IX:B-1/L1$1$
63[_L3Y?;\^@ '0# ]0I7[TI3I2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g897644g63w26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g63w26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5@N:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DQI;F4\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @($QI;F4N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(R.3,W-#@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(# R+4%P<BTR,#(P(# P.C0T.C,Y)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(# Q+4UA<F-H+3(P,C @,34Z,30Z,SDF(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[
M)B-X03OB@*(@,B!#35E+(&)L86-K(&]B:F5C=',@8VAA;F=E9"!T;R!G<F%Y
M<V-A;&4N)B-X03LF(WA!.^* HB Q(&AA:7)L:6YE(')U;&5S(&-H86YG960@
M=&\@,"XR-2XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L
M9$U4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S8S=S(V+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M(')R-C V,C$S)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P,BU!<'(M
M,C R," P,3HS-SHS,R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P,BU!
M<'(M,C R," P-#HS-SHS,R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86PM0F]L9$U4)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--
M64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \
M9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^,T0\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A
M1&%T93XR,#(P+3 T+3 R5# Q.C,W.C0W+3 W.C P/"]X;7 Z365T861A=&%$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP-"TP,E0P,3HS
M-SHT-RTP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#(P+3 T+3 R5# Q.C,W.C0V+3 W.C P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z
M=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,C \
M+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF
M;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W
M44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!
M14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)
M44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"
M04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X
M9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9B\X04%%46=!94%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!
M445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"
M9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I
M4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH
M9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP
M2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$
M0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z
M2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD
M1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2
M;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV
M+V%!07=$05%!0T5135)!1#A!.4=A2F]M:U,V4EIY>3)C5'E017 F(WA!.V1Y
M;TI*239N0W%.+W<O;V8O3$1$+W=!04U#=2]W+V]F+TQ$1"]W04%-5F0O:"]1
M+RM71T@O9T)I<5(V;')(-6(V6G%8-DUV-7)/,W8F(WA!.W=%4#%D,2M,.34Y
M;G14,U!G3GIT:%9.5C O>6\Q-C%I<U9O,39I.#-T4G=-;U%C9FE+9F%!*TYD
M-F1X9U98+W<O;V8O04-W=R]W1$$F(WA!.T1&6&8T9C!0+VQH:"]W0T%'2W4O
M=R]O9B],1$0O=T%!359D+V@O42\K5T=(+V=":7)V.$%$*V@O.'--4"]!1$98
M9C1F,% X0359668F(WA!.RM!1TMU+W<O;V8X07EW=R\X04U69"]H+U$O.$%L
M:&@O-$%9<3<O1"MH+SA!3$1$+T%-04U69"]H+U$O*U='2"]!24%9<3<O1"MH
M+S@F(WA!.W--4"]!04%X5C,K2#E$+S59668K04=+=2]W05 V2"]Y=W<O.$%-
M5F0O:"]1+W=$;&AH+S1!67$W+T0K:"]W1$Q$1"]W07A6,RM(.40F(WA!.R]W
M0U='2"]G0FER=CA0-D@O=T%S35 X07=!>%8S*T@Y1"\U65EF.$%G0FER=CA0
M-D@O>7=W+SA!041&6&8T9C!0+VQH:"\T05EQ-R\F(WA!.T%!+V]F+TQ$1"]W
M07A6,RM(.40O04]71T@O9T)I<G8X4#9(+T%-<TU0+T%$1EAF-&8P4"]!2EE9
M9BM!1TMU+W<O;V8O04-W=R]W1$$F(WA!.T1&549R96EA4D9P1C5,1EIX2DEK
M5$9(0V=%141Q34MO,WDO+T%-8T]X+S1W<"MR07%967$W1EA9<7AV5V9Y-CAN
M-C%Q<F%R<59I6C<F(WA!.S5H1U!6.5=64E-+=D=I<39R,%EQ9'1X561Z:7%:
M>B\X<$A9+SAW9#,O=T%N8F)&57AX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8F(WA!.S)+=7A6,DMU>%9A.&E2<GEC.%9Q0E4K2DY"9TIP541R;78V5&]D
M;70U<6LO,64R85))5FLT3SE:2D121G!'<D@T:G--2W!0<&XU;BLF(WA!.U%D
M541'>#%Q,VQ#>4I$53AK-5-34V5K<7!Z5F5D6$Y0:')I<5!V=D]N;$MW:'5P
M8G)73%)&<VTT6%E%>4\X5&5O<U9(4D-Z2U))-G$F(WA!.V1T:6-684AN5'EO
M8D)D44=Q44Y:=&1#=SE93E5#-EHK06EA;39T>3AF;C!X5E)J+T%$03AM4UA)
M=&\Y5V=E8WI#,T5A;&E3-6)G1',F(WA!.U!S8VIX-2]:<C-X5D54*V-02SA&
M9E8Q3T)E3C<K:D=02V]&-7A$;45K9$=65%9V1'9I<2\O1G9L4W)$.4Y71E59
M4G50<DU/>G-307 F(WA!.RM,66MQ4E0R>%93,'IZ<C52,5-/0U-X,6DP;49Z
M23!6=79Q;W)V27 T;%92:7)%,3=5>%9/<U93+W=!=V8X8T\K+S1W=BMR1EAE
M6"\F(WA!.T%0:F@R4#A!>&A4.5=+<&AI<58V3#5P.'9A,C!Y85AF4EA-,75A
M6$9U0U9M:5 X07A:0S174E Y:W5+<'!I<G-64S9F+VQ)-T@O;40F(WA!.W4O
M.$%K-V)9<6U/2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M;TQ66'-6:%0V-4DP8UIB67%#86UN96=B2V-X:4(F(WA!.S9K1DPO3F0U-5IG
M,$]*+TU%<%A46&YT4VI%4VMM94]66G)E;VE(3W9Q4G)T,S9D.'1J>5-W:GDY
M1BM213!-,&5J6%5)4C)S-V%5<E F(WA!.V-X;59R931I1G%!>FQ3-5-A1D%#
M<"ME>'E3<3)R9550>5%H939V9%1M=#5'=$I*+S!I2'8U<%0V;'I/0DM*-#%L
M6FEF6&M8-U$R86XF(WA!.V9&5E)F3%@U3DAY-WA->51A5$IQ2&\K<3DS8WES
M3#EL83)61V-Y3DES:6@R-#AJ=%AL,W)I<G)+=R]*<4A6-#5B3S=#86UL,'-C
M5'@F(WA!.UAD,DI!,W%$:D5#<B]W0SAV<2]S+W=">GEX5DAA;%DO;&)E6$YZ
M8U@X>7E-3EEI3GEJ>EA!:EA5,&I72TUM34U%1E510W1/2G!I<50F(WA!.S9V
M.$%L.2M49"]Y35=Q=S)%-'5X3&-45S)O<4I#-V]95VA*9#,T8S%5<CA.1S(R
M4%A&5BMJ9590>6=U9%(P:E9F3"MQ4C)X:'9:<&\F(WA!.TQ71S<R=6)H-45:
M;&%/8W1)4TAH4V=7;%%"-UEQ.5)W2VPO;40O:F@S,R]'1B\Q67$W>2\O=T%C
M3W@O-'=P*W)&57=X5C5V*U-K1F@F(WA!.RMI<C97,U$O0DXV8TID63!D26EI
M-TUI32]",C1G>6=%2U<S0VI#5F5K649E9F5A=E!F;F)3=DUZ-F)P=FQQ6%5.
M3E0P2UAY2DMY+W8F(WA!.TXR,U55,V(T0E-V13%:='-+<W%K;6MB>EAA>$<S
M:U-.3$\V2S-$1U!G.5I,6%I11TPW9C53:D%Q8C1Q-T9867$W1EA9<3=&6%EQ
M-T8F(WA!.UA9<3=&5W!'2V]Z2W!C<4-1:3!Q>$A98VE"=C=N1E5&<%=Q='%+
M4U Y5&YT56I:;RM5-6A02C!D;S5&2'!34R]96D-$5V<X2S58:GDF(WA!.V-1
M-55G1DA:66PR2W5X5D$V>&1A5F(R;V)5-45J=#)D44,O9'$Q03(S*V9T;$]E
M8TEX.5HR4DEJ<6=F3C$U-5IH,%I(.'=3.&1.:W4F(WA!.TQ9;W=%:E9N:FU7
M83-P-DE,9C-K83 W2' S>31*65 U96DO26EA1V%04G)Q14DW5V1T2U9N=5EZ
M2S%V8U)#,4%:>7!C<$Y#9T)5+U F(WA!.UDT5E9T5SAO9FMH0SDQ939N3F)Y
M3F%35"]P15!F>E-N,4QM8T-55'AR2WI%*W9)=C)H<S%/*TMQ:2M7=GEA4&PS
M:5IK;3!M5%504CDF(WA!.U8W=35L65@W2S%S<4TU:V%26D9$='@U2&%V3'98
M1EA75F@K5%5/<GAY,F0R13%.3'!9-&YI=3=S4T)V54A'2498+S-L.5@Y;BLU
M-5DF(WA!.W%J3&I49GEY;&QV<GE7931M175S2D)F;%HW-E-)-FQ#=S123VES
M52M&:49P5&E.:#)!>%9+9%@O04,K+TIU+S5'3%998D-C6%EL=4HF(WA!.W)B
M559%:&0P34Q1:W4W.$]A<58K1VIB8DAR:7$O4G9+;C516$]O-E)Q=FPO5DDW
M67<S<S P1G)$9#=83G<X:4UY=$A/5VM*1'=P44PF(WA!.U-O03ES5F5O-$93
M+WI"+WAW-S<O04EW=BMR1EAE6"\K3TA9+SA952]6:7%+=E,T<S5Y:S8R>FE.
M=4YY-$1,1V%(-'E#44-&-C=N1E@F(WA!.VEF;'949DM-9C5C*V%J2'%&-V5A
M9D)D3&0S25@P-U8O5E9&:U<Q:TM.8W%F:4E7551+6"]!2G=D<TMS."]*-4Q"
M=DDQ;F0R9&I*<# F(WA!.V0P,&IM,6MK-3 T>4UG3D)&8DEU>2]S>$PW,4\K
M0E=B67%L,"]W1'EK9&HO04UW9#,O>61T<U942$9867$W1EA9<3=&6%EQ-T98
M67$F(WA!.S=&6%EQ;#-M4S9U-U!Y-W%T,UIM;#-B,F,X='5107@Y4DEM6E!H
M24YF:4A427I*15-1<GHS.&UV32]M6%9R,U5R8E9*;6QT;V]98FDF(WA!.TU'
M1DEU33EY5VMN,U96<E8R2G R-UIH84Q*23-F969V3$-$,5!-.6TW1EA9<7@O
M>FQD959B97AH4&U&9W-,4VHP2T)Y+TEB;6Y!1G$F(WA!.U4K,2]7;5EU<D=)
M>$AI8VU-9T]R=DUL.353:CAU,C!U<U-"3D9L;'1'=&UJ16A5>4I+:S%Q1D5)
M3%4U>')19$0P-S5K=W%H6$IK=W8F(WA!.WDY1BM213!-,&5J6%5)4C)S-V%5
M<E!C>&U6<F4T:49Q07IL4S53849!0W K97AY4W$R<F554'E1:&4V=F14;70U
M1W1*2B\P:4AV-7 F(WA!.U0V;'I/0DM*-#%L6FEF6&M8-U$R86YF1E929DQ8
M-4Y(>3=X37E4851*<4AO*W$Y,V-Y<TPY;&$R5D=C>4Y)<VEH,C0X:G18;#-R
M:7(F(WA!.W)+=R]*<4A6-#5B3S=#86UL,'-C5'A89#)*03-Q1&I%0W(O-WDK
M<BMZ+V,X<U92.71&*U=%1W%386I&9#AR>517:$,T3GAC>4LR<6LF(WA!.U-)
M<65K5UI34GEF:CA0154R*WIS<6LR<B]L.2M49"]Y35=Q=S)%-'5X3&-45S)O
M<4I#-V]95VA*9#,T8S%5<CA.1S(R4%A&5BMJ958F(WA!.U!Y9W5D4C!J5F9,
M*W%2,GAH=EIP;TQ71S<R=6)H-45:;&%/8W1)4TAH4V=7;%%"-UEQ.5)W2VPO
M;40O:F@S,R]!0FAF.5=+=3AV.$$F(WA!.R](1'-F*TU+9G%X5D$K9EI9669*
M3W5Y>E-E;$5L:F-&-4M/94E%6C-O:%9V=7A6-70U274U-V(X=2]-;'9:3SDY
M<4U)5T=387=F:DHF(WA!.S9S:UAP.#!K355,8V=W3R]'=GDV-%5-*R],15AV
M*T-R03-G;5=C;5EL3&=30C!(<E!X44Q,>61656)+<%IQ3%%C:F=3>6Y&575N
M+S4F(WA!.U-/>"\U9S=V+VLW8EEQ;4]+=7A6,DMU>%8R2W)9-5EP5C52=7)Q
M0U%3<$)&4C%',D%%2&MQ-T-Q,E=226\S:VM01D5"6C)064%62G<F(WA!.T4P
M<5%A6C4V.'4S,&-R3&520C0U1U%225AD,E5-47)"94-S959+-T$P>DAX-G%%
M:'I9:59O-SE.=$E33%A4<GDT<#--46=(+T%%.'0F(WA!.T-F=4=794PS06XW
M4'9P:S Q>C5J:U%M2WAT;T1V>#EE-%IM.7%R2$=2+W<K3GI04690.$%9<D8Y
M8FLQ9E)F2RMP6%AM3C=985)&2C8F(WA!.WIX5T5B5'I/8G$U-4UV-SAX24%S
M:V=P-V9,9D@T6GAG94EI<C9E6C@R23)2;C59-C%O=6\V2$I$<'1V2F)Y5TUI
M=U@T;%5,>G521W8F(WA!.TXQ;WI61%4W,"M75#!C9V-9<%EN6FU'6E1*,DMS
M2R]--U5F23%R85=-9FUS>7%K<G4Q;SA+=5=Q9UAM2V]$<U%W>D8Q56-:044P
M1W4F(WA!.W%/,6)59DIG.&XV9&-A:7AI.'9Z;7AK<U)X;39Q.&,Y;W1)=UA(
M>%)P<V5V43EC>4E647)K;&E8;#9,.&E*;UIO.4=U;U%J=%HR,' F(WA!.U=E
M-6I-<E<Y>$5,54)N2VQY:S!+0494.#EJ:S%6=%<X;V9K:$,Y,64V;DYB>4YA
M4U0O<$509GI3;C%,;6-#551X<DMZ12MV278R:',F(WA!.S%/*TMQ:2M7=GEA
M4&PS:5IK;3!M5%504CE6-W4U;%E8-TLQ<W%--6MA4EI&1'1X-4AA=DQV6$98
M5U9H*U153W)X>3)D,D4Q3DQP630F(WA!.VYI=3=S4T)V54A'2498+S-L.5@Y
M;BLU-5EQ:68P5BM5,'5S6&QH.6-6<C9854I,-CET4')T>#98,3(S6#%P:DEN
M<65K0W%K;&Q064@F(WA!.RM86E9+9&$X:69K=F5W9E=9.5=H<VDP-S-5;'A:
M-F=':VLT=VA:;S%Q.&@S:5E6.4UC=6YJ=7%J3D4X:B]L5F0V=G!6.35B,4)%
M;70F(WA!.VYK,5),2S!U>$HV-&UE3GI*2D9)6DI!;V5*3VQ/;$0P1D98<&5"
M578X=V8X8T\K+S1W=BMR1EAE6"\X06IH,E O1T90,5EQ:EHT25HF(WA!.S18
M9VYJ5U='5E-K:U1G37)+=V]66E1S46-694LK5V)N569-=FMZ>DEM<6%2<%57
M:6DP;&MI8U=K9&I&.6%J:D1P2T0V<S-+3VI%<3<F(WA!.TMJ1&IU1G)S5EIZ
M*U1L=3A(-60V5W-I=TQ+,W)02W1S62]41'1/-5EC678S4T5(67%M=U!H,'=+
M:"].;FPW.'I,-U@R=71%,7%'>C F(WA!.V]F5FA&86QN4G%*>DUP86E/0U-Z
M<3-8-&=V2'AW<7E74F)S96$W5FYK:F$R3FYD96Q'<UI$<695=&$X;DQK3CE#
M:D%Q8C1Q-T963S0F(WA!.V0P=#584VY.55ER>39607%+,'E-:E%+;&):>E!.
M85%43T%(:VI2,D,Y2W-O2G!81T)U24M!<%A.+V%#4C=.<"]2=5=58TMG9S%E
M=D@F(WA!.V=32TTS=VY98C=:0V533CA.,%9*63%O9FU!45A-,6M#,3=->$Q2
M5W1U05<Y47,U;'%Z1D54>"M).3AW=$YN;VU033DS>G1H13E%.$,F(WA!.RM9
M<F]69#1.3VI0-TM!,T4Q4#A!5V)H1W O,DPO4$TS,6YU:CEV-"LQ;7!8;FQE
M>G9,4V5#.&YU3' U,&1056UL66A3>6MC:$5N0T<F(WA!.V]R=%)-:DQ!2D%G
M:VXX9DIA4V8X=F9*9BM(4F93=$\X,&QW+W!G4$59<4Q%>D%-4&EB;'I"0CES
M;S!7;CA/>BM.;4U25$UC>FUB<U8F(WA!.U-R>E1P5VQA<F]6,5EA=$A,3' X
M,T0Q-#1&:V51.%I&9&5+=VAN4'A+3V=Y1U-)36%02E-L;C5E-D1P96LV33,Q
M2T-E,W5,<&QL,48F(WA!.V)H2FM9,TIJ6#%#;VU#+T15.58K2$MD3$%29U!C
M>&IY6E)M4WED:7)Z8C@V3'(X=$QA,C!P+U!.>F-7.%)E65=*=&QK66QQ25I/
M6$(F(WA!.U@W8V-R>5EH4&UT5VYS;#,U25AY1F\X;#-/4C5B94=W;# U-51)
M<G5S05,U=%-1;T5H64-&6%E5-D$Q,G)K-&EH459*;R],,S5,-E F(WA!.TA0
M1$AD,E9R55<X5GEG=GHV:D=W;&EE14Y36&YY:65&4&9T,WE3<4(X;2]K;G%&
M-FMH;70W-F5F-GI++T<O;&Y7451C-VE:-75-<DLF(WA!.U)65V5R-U97;S-'
M2W14-D8K4TYV<&$V9DYE451753AL>&1O,S$V931*:W1R571++W%R23=C;V]*
M0W=Q,5)7;S-/2V]L.4<O2T138G$F(WA!.W@Q4#8R;'908VE7.# K-VIV<FLX
M-$Q8.3E*2$<V4T5F5C!0>&5L6&A8.6Y&5E-#>B]+5%8Y9&XQ1TM71V963#)+
M-&UU2E!6;55"5V<F(WA!.RMQ5&QW4W%2=7-+37!5,%I2>4Y"=FEQ5%$K569Y
M875R,C-U<DQ6>&%7,FYU=#-08DQE3D9$2V(T3$Y'6DAL26-H=U%E2W8P3D0Q
M>%8F(WA!.T8V3G!(-5-E54YB='17<V1C:'0P.4)D4'1,3#8R:S!++U=M5GA*
M*S-*5U0P>#A43GAP.49&6&]L:G$R;%@W4W)96&M&,C!"0WII0U(F(WA!.TI#
M:DAO2#1%.%0X.$-Q4&U$+VIH,S,O1T8O,5EQ-WDO+W=!8T]X+S1W<"MR1E5:
M8W=M93-L:$5J=VU61U0Q66E!-CAH5&MP24Y#3S(F(WA!.TMV179+5#9H0C5$
M.#17,3)5=5E,:$IH.61T>F)3<$1).%!%;U5T+VDY3F9T3$EW,TAJ:%%Z4#A!
M2E=W*W$K54]3=6MS8S%X3U9L16LF(WA!.W-K:$M3=6I#8C%12T]R3'A*2%AQ
M9#8T;$Q0<T-P9% O04UP2%DO.$%-2&0O.&YB8D95>'A6,DMO5%8W;4<R,'DU
M;FUL14UC8V)%=68F(WA!.VQ11&]E<#)Y<DY-4F=35%-*2%IH9FQN>E1Q9#%Q
M0FIT9%!E-U%7,%52269I<4]G4'A/>"M"43-4<%AB87943EAO.5A/8S9%8DA#
M1W$F(WA!.T5I4VU$,D8W8V%S<U8V,W)-5U@Q=E1$;%96:7AO3U<T545&82]4
M;'-S6FQK;S=S:4XR.45T<FTR.#18>5(S8TLR2E%C8E-*074Q6#0F(WA!.V]&
M04%5>&M.>5!F-F1J9VI+3V57-#1E-S4O8VE).51,<S)B83=&6%EQ-T9867$W
M1EA9<3=&6%EQ>&YZ=BM82&Q0>G1$85$K67):-VTF(WA!.T]Y6C-T=VMS:U9$
M24%'<C9:5W8R4FEQ2W502F9L*S0P1%0Y0FMH:UA4.4Q32DQ$,#5P;W!9:$)%
M654T>E)S:V=0<$5O5'DS0DYE=4LF(WA!.W!43BM52#5F4S--;'DR;7-,:5-5
M6$)K5S1U1DEK06-,>'!*.$E8,6TT<4YH6$96-B]L4#5%4C!E3%0R:6Q31T\R
M5U-/961'.4M/1F(F(WA!.V9H5EA'>G=X<6MN.#1!-59X5D1V*U,S-6-/:WE(
M4S)P34I!5#E:=6%Q2FU,4SA0,VYW8RM61TDV:EDW67%J2B]Y<SAJ6$55154K
M;D<F(WA!.U)B5TXT;T-:<'=Y0U8U2DI31T1H=55J5'5887146#)'2V]Z4F9)
M=FQZ4G(T6#)N>%1X6$I6:$MZ6$YW-&UD,DQ03$UJ>4US<W)--7(F(WA!.TDT
M3&(Y8U93-79Y:SAG1WEN<WIP:#E#-6AH=#5H-C@Y4VQV14E9.2ME>$5904I(
M5V=R:7%82#AJ4$E,-FAE6$9X8GIZ,FPS=TDP,34F(WA!.S5"8GAU<%%S-FA3
M<FMV-E,Q-4UE-#9(1E=1954O2D=M95=*.51L<UIP-68P<$]B:5):,T1I3W)/
M+T)$44=N3U9J.%)*,S-/2W!J-6<F(WA!.R]W0T](9F8X65@O5FER=DPO=T1X
M=S=(+T%)=W K<D966%=,;')84V(R-58R:F%#0U-14TMN<7-V0D-A:4]O-455
M-E9X5C0Q-50P5F(F(WA!.S-Y4#5K;$]M5$QD3WAT3%51:31:;$M)3TQ'1E<K
M2DDU2V)+1V)J,50Y;D-H;C,U4S)T-5DK4W)45&)Q3V18<WI)9VMN=#-T47=:
M,F,F(WA!.V5N1DM%;%961%4K2D8X0EAR9U-Y;6)63DUG;CE#83=H:6XK12MK
M.&E++S=W.%4K16UV>$YS4$A&55!0+T%-<$A9+SA!34AD+SAN8F(F(WA!.T95
M>'A68DLO0TYM,G%"='E.0EAT53!.4'5W13!&67AQ9'A.<G5L4$A*0V)45&=Q
M;39M6E,W=$E!1SE/16-A,%9T;6M++TQX1T9L4&DF(WA!.S0Y>%5E=C=0,7-$
M=45F-54P>E1R5%-B85,P5&DX:U-I5GIY0EDO84Y19CA!2UDU4%(T;WAG3TAU
M5T%!0V%R8E%R8W9C9T@Q<$962% F(WA!.TII3TM%;%)X<GA&3U(W6FMI074K
M<DML<5=P5RML=7952CE616HY3V=O0D=726]E=E9Z9T50550S<E<V=FLP=7A6
M,DMU>%8R2W5X5C(F(WA!.TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMP9C5G+S0T9#DO=T%96"]6:7)V3"]!4'AW-T@O:D-N-G-65V5A3&948FIY
M,W$F(WA!.VM'<4MZ861,851,94MJ0D=-4FI04&EX2V=(:C!Q8U99;BM56CAS
M;3$Q8V58-V4U:G128W%0<DXP-DTQ=V]J0W!+<4QX9$9B:5<K3E$F(WA!.U=R
M5W9917%Z+T%R0R].2#56-D@U:S%X9%AV-VTT4UI"1W-58U!P244T5D0O04)E
M;5=0<4LS1G%K.49P.6M9<6YS;')';FUU,75!,&@F(WA!.VML<S=O37)34TUG
M<$IA:C19>7A29CEI0FEQ8C1Q:U8Q3F-A>#9I5W-N<#988G-23D]445A$;V%-
M:70O=G!#4&E0-U(R-D$Q>'!K>C4F(WA!.V94.2\W149'864P<W5I2S8O=D1,
M15=G04\U5C%Q;TI/,V5M4WAK;D@X141K:7)'3U-/>'0T-4)X:U-*1F1A,6]1
M;T)&4FQM345205 F(WA!.V-K8VQF2G!D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E,O>D(O>'<W-R]J0R\V<U9D
M-68F(WA!.R]W0T](62\X654O5FEQ3FYG9W5)6DE*-#%M9VQ5<$Q&24%Y37)#
M:%9L3WA"1TMT5S%R8E=T=DAB5W-+45<X4VA9;UEL0TEQ:F]&5F$F(WA!.T%$
M1E941EA9<6PP+R]+4C)0+TU(9"\X04HR,GA65#%+86$Y=78P4F%U54)54'%.
M=VAO66]M-E)Q9CDK4SE0.$%*5W V.&$P>DIK944F(WA!.V9(.&5A17EI9VAH
M9U-#2D931TY1:5)G555+0E%!1'=P;&]!07!+.59#9T)2441O0C!W<3=&6%EQ
M-T9867$X6CAT9FQZ*UI&;"MD5C4F(WA!.S5N=G)Z;C58;75,>5-',RMT3SE%
M;5)X15!14'=I:%EF3$98<S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8F(WA!.S)+<&8U9R\T-&0Y+WAH9CE72W4X=B\X04A$<V8K
M34MF<7A634U69&ER<U93:GI4-7$P:GEX<&8V5#%6,U,Q-6E/<V%L>E5G<U11
M9&PF(WA!.U9762],1E5U.'<K63E0,#=88E928U%'.49T8WA*03AI<GAK:VMT
M:6AL<69G6&E/4DHW9$UH3U9$8FUH1V%:<79L=7ET=E1/<U=K<S@F(WA!.VI'
M5S5N33A136MR535-4GDR-E5!-T-G-UEW:'=H55@O04EL.'5F.$%6,7,O*VMI
M3"]M<DIP9"]I6'DU+S%D8E O<$EI+W=#87-685 F(WA!.VUB>3)!4V16<W="
M=5-B:4PO;7)&5R\X045V;'HO<38R9B]34D8O>E9I<G8X4RM84"MR<EHO=T13
M4D8O>E9I<G8X4RM84"MR<EHO.$$F(WA!.U-21B]Z5FER=CA3*UA0.$%Q-C)F
M+U-21B]W03%9<3!033-L<S%P<71N='-F.4EI+S5Q>%9V+T5V;'HO<38R9B]!
M16M29C@Q67$W+T4F(WA!.W9L>B]!2W5T;B\P:U)F.$%.5TMU+W=!4RM84"MR
M<EHO.4I%6"].5TMQ;'9R;6DS37EW5S)O5S X-S$T4E)Z4G5X;TMM:7%35'-+
M-'$F(WA!.VIC5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%8*UE0*T](
M9F8X65@O0499<3=Y+R]!36-/>"\T=W K<D95=WA6,DMU>%9$86@F(WA!.W!M
M;F%J04QF54Q72S=G1'))27 P5U)1-D=Q=%)G4E59<6ME<&5:<D<Q.#DV4F]4
M,FMK;#=F5S%W66)P5#A%845'4F=Y.7=F<6]"4%DF(WA!.VQ2*S%I<DIC5F1I
M<G-663$K65!M87DX=BM8>F-8='$Y,V)8:W$R57--8FA(-'I+,TUR,5IJ>%4P
M5D%763=$1E56-4PX,'<K85!,='8F(WA!.W)53G4Y<DAC3DMG:6-H=C=M5F]U
M4W-.;59U1E%C5E1V1EA9<6AD579V<4=M6&0Y-DPS2#%71C5V46I+:#,Y3E,S
M1E,U5F%M;F,T<3@F(WA!.S4X=F9N3'!.+W=#8EED1&@P939H;3%6,6QK=6DV
M=$=(34M,4VUX<4%G<5 U2U S<&A6-FAG5C)+=7A6-7HU=R].6%1T13%H<E,W
M,'$F(WA!.V%35%1B9RMN2C8P83%*=&51:U9&-7-626YO9'9H1E=A9T=&5V(K
M6#E85%=D0S O5FMH93-454QE2S570U0W84-60315+TMU0E5F:7(F(WA!.W-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7%8*UE0*T](9F8X04=&+S%9<3=Y+W=$
M.&-/>"\T=W K<D95=WA6,DMU>%8R2W5O2V<P,T<F(WA!.W=096AX5C)+=7A6
M:DXS*UE8;#9Y,7$U,&TY.64Q:W1!:E0S53!:4S)66E$U4G9663!O=VEC:B]6
M4&AI<4U8>FXU3VU*4F1A<UA+:%HF(WA!.T-V,6E),$)8,490,G9!8W-654Y5
M."ME5CE/,'E854)E3&57.$4V5VMI,E)7-%E43V%+;$5/>'A62G)F.#9F24YZ
M35E,83=M;6U*26HF(WA!.VI3,VQ:,V(Y,$DQ4E%V26U6<FQ&454S4&AI<DEB
M6'IJ-6)N<S=A-F$K:716=3-L:6EI=6E,9553,C=&2F]M:FLT<TAJ8V-72%DO
M35DF(WA!.W%S6'HS-4Q:95,V-5EK96U:<6DT:BMW1S16-B]Z8F901E8Q>C5V
M.$%+;&YC:4,U,4<R='EY47E,2SAI2D=W=4$O<&-82C1K<VM,3G0F(WA!.RMY
M2SE+67%L5V@O;70U33%Q+U-X<TQQ4G)H,D-584HQ0W5Z>7AQ<D5I9TIA03 K
M82M/3DMY+T9867$P55)U<6<P3E)59#95+U9T:7(F(WA!.V5+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5DPO041"+WAW-S<O:D,O-G-646UL6# Y<G!T
M=&)3,D8Q-FM-86\O1D9)<4(R*TPF(WA!.T-Q3"]!174S+TQ"9"]W1$ET9CA!
M;7)!<G8P=3,O3$)D+W=$271F.$%M<D989G!D=BM70S<O=T-282\X04Y72W4O
M4S=F.'-&,R]W06DF(WA!.S$O-7%X5C,V6&(O;&=U+RM282\X,5EQ-SE,="]Y
M=UAF+TET9BMA<U9D*VPR+W=#5T,W+S5&<B]Z5FEQ4F%Z-68X=6%Z3&-Y-FQO
M=#4F(WA!.T\Y-&M59'=A=6Y*649M4U W16DP;W0Q2C X9EE95E-H9GDP.&=Q
M<FA03#DY1WIX4G=--E-3<3-#1F5+9T548F9#3T\S8C5N1E5D864F(WA!.U10
M2FQR0E!B>&588F=W6%8P;#E0131A4EAN:DI:5UE027=)<7@K13=(1E503BM8
M+T%*1FPQ1S8Q22M8<G1,-C@S;6YJ95=.9W=K.58F(WA!.UA4:$M/1$LY0W!7
M;$M#;E%9<6DU4$MN;%=3,'0W4CE%=E=G=#!N:6]8:S53>#-B:5,T5V0O5C54
M0U=243=E;U16:%A&54PO9U1Y8G@F(WA!.U-U:39G,#!B<DUL>5IP>DU*:V1P
M1FQ%:&TU8S%D>7=0:FEQ<'%8:S=Y>G%6,4I,93949E-X4U<V5WAH2EE!0T]#
M83(U.&A)2$Q.0F0F(WA!.TUH<50R4%AF1E9#=SAG951T3G9O-S-43D5V3%-:
M8FU/-VU+.&XY4F]625%.-FMJ54%E:C=D>#=N1E=99G!D=BM70S<O04]282]W
M1$XF(WA!.U="6&9P9'8K5T,W+T%/4F$O=T1.5TMU+U,W9CAS1C,O04UI,2]W
M0V%S5F0K;#(O-5E,=B]!2D9R+W=!,5EQ-SE,="]Y=UAF+T%#3%@F(WA!.R]M
M<D989G!D=BM70S<O-49R+WI6:7)V,'4S+TQ"9"\X:3$O-7%X5C,V6&(O04I9
M3'8O:U=V+TY72W4O4S=F.$%,0F0O.&DQ+S5Q>%8F(WA!.S,V6&(O;&=U+W=$
M:U=V.$%Z5FER=C!U,R],0F0O=T1)=&8X06UR1EAF<&1V*U=#-R]W0U)A+SA!
M3E=+=2]3-V8X<T8S+W=!:3$O-7$F(WA!.WA6,S988B]L9W4O*U)A+S@Q67$W
M.4QT+WEW6&8O271F*V%S5E%M<3,P.3%P='IB4E=&,39K,&));DI&07%2,RM,
M0W(O05 O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU
M;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-S(U
M1$(P.49"0S<T14$Q,4$U0C-&,S<U,$4X,#4X-S$\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-S(U1$(P
M.49"0S<T14$Q,4$U0C-&,S<U,$4X,#4X-S$\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P
M.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$
M97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-S$U1$(P.49"0S<T14$Q
M,4$U0C-&,S<U,$4X,#4X-S$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-S$U1$(P.49"0S<T14$Q
M,4$U0C-&,S<U,$4X,#4X-S$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS
M0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#IF.#$Y-CAA-BTX,CDY+30Y8V$M8F)C
M-2UC-#4T83(P-3<V.3$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#,M,C94,38Z,C@Z,#(M,#<Z,# \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(T+C$@*$UA8VEN=&]S:"D\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C0Q-#=D-C%B+68W9C@M-#EE,BUB8V9C+3)E-S0P
M.&,S-V0Y.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,"TP,RTR-E0Q-SHR-"TP-SHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@,C0N,2 H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W!O<W1S8W)I<'0@=&\@87!P;&EC871I;VXO
M=FYD+F%D;V)E+FEL;'5S=')A=&]R/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IC-# Q9&5B-BTT9#DX
M+31A,#(M8CDP,BUE-#=D9C@P-C!B8S0\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#,M,CA4,3DZ,# Z
M,C M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(T+C$@*$UA8VEN
M=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]P;W-T<V-R
M:7!T('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z-44W1CDX-#,R13<T14$Q,4)#1#)$035%0S W03E&038\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C M,#0M,#)4,# Z-#,Z,3 K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<R-41",#E&
M0D,W-$5!,3%!-4(S1C,W-3!%.# U.#<Q/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 T+3 R5# Q.C,W
M.C0W+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R
M871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F
M:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS
M=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N
M<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN
M<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @
M(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.
M4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXU,S@N,#4U
M-C8T/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XR-#@N.3 R.#,R
M/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T
M1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @
M(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;"U";VQD
M350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S
M=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1FEL94YA;64^87)I86QB9"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*
M(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA
M=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL
M;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G
M.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U
M<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X
M;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O
M=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ M0&& P$1  (1 0,1 ?_$ !X  0 " @,! 0$
M       '" 8)! 4* @,!_\0 0Q   00" @ "!@4+ @4#!0  !0,$!@<! @ (
M"1@1$A,4%=865E>5EA<S.%AR<YBRMK?2.7@*(2(C)#$R024U0F)W_\0 ' $!
M  ,! 0$! 0            $" P0%!@<(_\0 11$  0," P8"!P@! @0$!P
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MF$\^GV#Q#5/95#;_ /9/"FN-O1Z<8V].OI].N<8RBGBF,HB>'F&5T,EOTR-
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M]KC/_I#M+'GS%O%;#!_>V3PRLNRLSNR&01":T]V7?4K!ZNKF;;*D9F#60I+
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M/\P/)<QV$Y!K;"]^)ZJ>.?1KI3A$X1.$3A$X11_![2KNR%Y*W@DL#29>)&5
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MAFU?3&4/@46$"]2Y;0>P;NY"658LV."APWHR9HK.TL/2Q?1LCJJ\?XT5(OW
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M3V)=ANPYFGQ<81<Q&6R&/8H^<@C()4B^C!GIIU][5*9LB%.)"M+P3K7:U)8
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M] >W89D)'($IPG/,:7X\;6RM?/$/JU\>%^+\W3N6'B3U6E%J1M^)22559*
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M-5E5)2['E@^TSA\\K(:"HI3*69ODD>^EA8]XQ:O<7FYM?-8QRP.<6Q%N(W)
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M>X9'5%8#+ J U5LJ@<;=CPU:'SE*1MTK5-@[#':J#F0R.&%+3EH+ ^JTD@\
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MD->:T->%''(W7W?2XE-'=Q&7]N1R^AC"86%'NH6T=-V%0<_J =V6BL)VI&
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M(80[>AI:V&2=\KQ']UTA=A(:7"QP>MDUSM,FW#LXMX=.09RD0T&$UP,B0JR
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M3CVS'$G$ 3JNJK\&+5:E(-N .5LUUW7;J!6?6>56O+8*:FYA_;#QIJY:RXB
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M:>NNNN,8^G8QD;&1QL;''&UK(XV-#&,8P!K6,:T!K6M: &M       6X
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M*4.>_=Q2S,$3I]SBW;IV18XXIGM<^%DT[8W-$S[T+6N+2X7+22WD"18NMIB
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>/5]=;VGM?6T]G=C R]B3>VMN%^0'-5+BZU[9+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g897644g79k49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g79k49.jpg
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M  ,! 0$           <(!08) P0*"P(!_\0 8!   00" @ !!0H'"P8("PD
M!0,$!@<! @ ($0D2$Q8A%!4Q-SA6=Y6VU!@B,D%14G870EAA<9&6E[2WUPHC
M='B!UAHE,SE3<[/"&419DI.8H:*YP=4D)C17<H*)L?#_Q  = 0$  @(# 0$
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M$,<DTTLC@UD;'.)X:'H]I-H\3LGAKN>SEEU;'46Q=*^.&6Q/++8FCK5:M6M
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MC\_@HZM:\_-8EE*Z_HJ=Q^1IMJVY-2WHZU@S"*=^\US=R)[W:@C34%:N.O\
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M.YX2YF;)8/'[+5I<-/B:7T;=DP45**S$_(?2SYF066P2AKCCI"06AT>CCN^
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M)N-[/Q/YI^#73OS>.?UA6/\ [V\=([M']5OY)N-[/Q/YI^#73OS>.?UA6/\
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MB=7IUF26H87/+'BU8;7@DC#A#)*[ZI\CVWVQR61P&T.,\FM9^T&T45.Q",G
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MFOV;)\EO,=X\5#N1[CX+ (_)_2^AW3[%8Y/K_>^:CU/N_)9NG/BBJOZ.(/\
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M"-19H^333\1W:=JLEPH3A$X1.$3A$X10;V6^(>S_ -F5_P"TMN7C]-O>JO\
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M.MYK2UI,Y\"V^#/K'&046D+Z.)^.BV-%SNHYLME'?"*V^=5,)ZK_  =M2?\
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MFS=XHTPIA#=RBDMMIE337;!%!%ZG*(BY2OS%O0?,H,IDSIF%DF56'K%(@'D
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ML:.AEY;ULL':9MRXY=\UPN%-16>]<I"6BKN5:YVCP3W)J82:&B+%1O(2KO5
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M\DCH,,<-5FP$-9]@6?HVS49+!/YFU[0('XNSBYZNC-Q\L+7UYK0)=E'L94Q
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MOOUX6.OAF\OA_P ["W_U'J>_OAN_GT7^SI_ES:/^BJW_ #:^*OVV/\T=B/\
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M55_1Q!_LP+X?Z;OM.\2I;R'</!2/RJE.$3A%S[L+HPXMCLY);RG=K9WAR\,
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M)J;MULH[+-]]],;;(J[-U5V^RB6<YT4R@NLCG;7.4E5-/-WR55Y>$6B6D4+
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M#\GG->T4ZH\N6[;"Y&+LMO.-6;+23PQA!2"@5:NZ[+F&Z 9A&XCHH.C]D%;
MB3%]D(NU61CWH <TMF,M@=P3XI=IKPY?WGW\N/'C[!R5[N%5.$3A%'EN_%/9
M_P!'DU^S9/DMYCO'BH=R/<?!8!'Y/Z7T.Z?8K')]?[WS4>I]WY+-TY\455_1
MQ!_LP+X?Z;OM.\2I;R'</!2/RJE.$3A$X1.$3A$X10)VKG<]J[J_V/LRJP_K
M#9U=T-;TYKD#[@5*^_4ZB5?R$_$A7O6AXKD_? ^/'M?>Y''IGWI?<J7^<5UX
M_7:I U(!Y$@?BN=O3GM;VML2B)')H)&QO>YB$ON=P*)W4^L>J:3UG%<!X56L
M@8RI-S#J]:5Y*MF,]E%@5ONZAL;!M6W[G^$R>'AO4D[6*Q UY[O#73B=.)X:
M]VAZ^:]KJ>]\H'UQZ_U]2Y/HS$)0^A24D37.L.W$''-'^3LPD$G3RDR<5ZY6
M1PW2-:--_/7W](HANKKYNN^--2$-))WN9/JE27:UD]^[&JZR:];="(L+<SN
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MG=&B>T]M6!UHE77&T48(+K"9/"UEQ\Q<%IUW$)@&>2JM2FN))#:J!:$K34'
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2N?#'CKMKG&?#X.-!V#X!%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g897644g86v25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g86v25.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M-\(0D6_G_3N,5ZU\LN?;>86[HL.K*#]&YCS\;H[:C8UFJ6>R$PI,;6UHM'Z
M=@PYLBO+;)1UN)?BMR+EKX:6U>VXL.PJ[J1#M85':Q*TY?6K;2P=Z$1ATI<6
M,V^T[)18OF(YF R$5HD11)1L:?\ '/3MP\REG37VEH5EIZTU7I^RNVZ]8MY0
M4S"3+&6P-=/G2(K[$%4L/)S&6GCA*CX*2$ G [?O_H_6._\ A 31N=]:XSR3
MOUHZ60?D]%KG.WA_:.=C>?/&*N3#31Y2V':N]")HC%W8&W:T0F#"@F:Q)-"9
MF]L[]?#ZMJ=/Z]>GV-1=6^GXM8V(ULFQ1RELG;%&933P.-1&)2&TI,HYM*;!
MUIT"%EX$Y<B/C)=ZBUCX0QJFDU)I?3FLK"]?)R[@TI,ZIHX](<JOD176)%C+
MKR;D(U*5E2@/NQY$=T#E1G%XS/ZV]+=9XGZS\<T2B!+A?ZIU.O\ H5RU\DHP
M>DRK!?352JU<E4U3)ZX.B45J%7IY*87*D&[2!@)&,RW2>B26(\)S2:1TS47>
MDM9SY[\.OEU4C3J1+><].&/7LS)<D)O*/#1Y9)R6V@9:;6)(<ZI C72Y$XG4
M>)&N]1Z5\1O#"HJ(MG<5VH8>MEL=-U,6J<FW,JMKH#E5QF691T@-0GI#LF0^
MEA#82.+I2.N@ T6Q<^^(KRF^D.-"U4CI%3F]5[!T;SV;:M \'"5R7N7.!+)6
M5SCH.F#LE39:S-OMM5-X"DPQ.<5]!']*>;D,L8]AX<VT!NZ=2=6RPJ:>MU$P
ML1Q]SX7HK)XF0LJ[DP.[,514I@R.B3:=V^LBB19M+XVZ=N'M+QUJKRN=U%J6
M\T7+&P9B-+IS5M'&&2Y1W/"6XJ2)XD@UQPTE \2[/^7)#$+$^??0=9]&@KU:
M:8$L ^L4[J=WY:..&T#D0KP_0Y[8HI;:IL?/G+?J<PGN5"&2Y^H,Y]X?,T\/
MCI;1MSG-0Z>E:;D08DU^.Y*F54&U=885Q3@C/;5YJ'+ZC;:#+!K@XZ#?4;$7
M XN%NNW;:,UG UO$M["KB3&:^LU#;:?8F2D81JV.G>2-(L:[HO.J=<Y(ZC,=
MUY&G3)EWDR"(F]>@OOX!)[E0^,7#A/;^8-=7M-LIW,;GT$5503-G+U!J>])E
MS*.Y:%]'K  VV.=75S1ZJQ&C3,H?)0PQ%???B]$_X?R!HI]W#OJ.T6IBPYEI
M"KGI<@HK,Q0$0"<D5*V5(85Q$E,1Y9JP0N"I$8B)\7%\8X9ZMI]+6>D=5T Z
MBL+*KH;2YCUT0+"36@\;CCE0M@5[ ARQ8):^7,KF@E"XRX@@V9DW@/B1DO1O
M->(7KO\ PWT<5Y)'Y11WB<^A1.8<TND"Z$W#<..U-F'[L%,D@FV(LW\?3 UE
M<9S3*75M;=6I6LCPU:TW9WL#3][IMJW*VG(TW8':V<)R$TC!DH!'@OLM/\C#
MER<)"3ELB[(B9A>.;^MZ+2=OK+26N).FPTY4G(>IVJ"AM&;20LMH!==F6L24
M_%X-N\$!@5 N*$H\E5<Q]?[G>O*_%N>6OT!UKH?K3H_H0O11?'N?U/EG-J?<
M)-CLU:06DU<-$J_[- Y(>'IQ9$S:+-+BM"HK+2=;V[*8B/W)%% U7=6,73U1
M7:1K=/,3GKFPF6UG-AC&BR5:&4\<KS3XO'LC;,6*!*\:K[!(QLPM6VWA]I6E
ML=9:CNO$:\UI)J(^F::OT_15EFY.GP$DG7Q6Z]($1R,UN3TJPGN-C';$4WY.
M V><<^(U1(',.H]"/<>[,"-< NU;J7H7E\L/7)%_Y&+M#/Y0[H1&#!L<D;8Z
M"Y"W^HMEZP1)37AB))1 S0V))EM6$\-Y[EK5UT>YI9#&H(,F9IVU!Z2-?<.Q
M2X.US;AQA=C6"'][5F4TTV+JBRKO5, +++QOJ&:#4%U+TSJB'*T;:P:W6M [
M%A%<Z:CSQZC%T^TU.<8GTY-??QDU[[[IQT.0D?H-N.#H=]]XA^@\SJ_2N2$^
MH4+GLKU]S'A==ZA!HU LHSM40C89P>QHJXJX&F9,+FY&9&T(F7I,2%8HSK4C
M]G1\B9"(,Q\^!H%^NLY59<-5<^Q'1]I?2:LY]A%=I#:C@]&64]#8(#LFP+K!
M 4SC$BCYEP6S;4]1<>+\:ZH(%[IN1J"FI7/$N@TE"OVJBGGL:J:?G.19R5\>
MSE@;5&^Z'E7;=&VIK9"YY%DW6GA"5I/OJN2>G6NETSA7?.E4;GO5X_#^B=EH
M%2&6.H53IJW8;!0-^@PSBKZ;'5200BL6XR&J\M@*I>UH9FL/0'IVI'P_DA5Q
M)TV^T_63K&I*]K::PF.QIDNK1#)I[S!L) 8=EBV90V'I0$_MLI 2.(WT+GC%
M!<O[&JJ](ZQOJFEU$WI.[U135T>=65U\I-!(BK#;EK<2F*XWVPLY46O<"(JJ
MJ"Z!-$[E/>?H#HG#^?\ +Z[QS0./UWT-W+G_ )^Y_8+-#V1K],*WQ^;J1<B@
MWYZ030%B0'$Q(#OW&5SYD63)B$8D22/E6M Z>KKVQM)-RKY4^G:*PU#8QXQ]
M.1-:@"'&$T[ZM*^;B*;@[$C8& FV9BX&1XP:SN])TU!!TPD0-2ZUU;3:,I9D
M]KKPJN3<&[SM)#&Z)(2(TR2-LER%7G&S<;>;;-ER!N57GK_)O65;XG??B!<?
M]$0RXHJ.Z#R:]UJG\X[?6;FNNLV:M2^; N=AGTF8QB&\S-( ;,0AL"JYIZ6-
M61FOQ]M[^V@4]OI*3>0/#VXTX;+K+E=;0)4RRHY,))*Q9(63UB\*LDR8JVW(
MBMFKTE4%U&P$M^0T];ZETYXC0=*W'C+IG6K4J/)8N=.7$&KH]65]HL(9\!RB
MB4L4DE-RFB%UZ'/=:&/"Y.,*^Z8<9?HGOT#:NY4#AMLX5V[D!7KW[>ZY48Z8
M+J89ZR_P=CII<TLW2X]IF7RB-S1<"1.K^[;7!RC+"HZV$)0_I:=/8>'\B)16
M%[$OJ.X:I_@];9FK=EOC%^$G 981B:40*^>K;S@MR$B27.@2$A+NFR]+4>,<
M.PU;3Z2LM(ZKTU(U*MPFG95ZQ6QBG_ C#TF44NJ;L7;BH%V.P;T);*"QYH%!
M11$/=()X9\0]IGBGDF.4!]R]+]4]-#.\3*3/&TCD]&M5DF<BO!<?/A6.O";B
M+H=5:BBMMM1B<,JX.T! 2#1E]@K(7#?WM[X=*MWJXFGZ+3%5IAVA":V[.MI\
M2,%Q!9<;.-(=A.V$M3=W4FC91WS$@6&1)D4,>1TEXU"&E?#<)$35NO-0Z]CZ
MO=J7F*G3M38SG=-6LAEYJ?"C6;%/7"W'41;D-22CI$AG*E&$@U;.YW!/7O*>
MZ<KB=17*=Y6U^U=JH9JK]3(U^MG@5TI1#8ZQ@7U_J\@9.=B.;8DH='SI&E1)
M3&Y+<25]^(QQE_H^VH;4ZM!2U7RD2>S*JFY$F._"G-]2,^*=$76T-.0JCC8_
M' N*F/$R]0T?XE:=U;IYN_5PM/#\(V-/*K]0OPX$R):53W0G0S7S)L/$T2B:
M$P\:*VX"FC9\VP@:\_$NYC3+%TAR+RGLUQXYQ6]1^:=D]!U,"!(<VH5S7*'P
M20]QAZQ1K6?B5>:5@1K9/! )B1*Y#2F&"#<F N;OH/AG:38U:AVM+#N;N 5G
M2Z=EOR&[.PA(+AMN(21BB1SE TX41N1(#K(*H1-J+B!R%OX[4-7-O";T[JFS
MTQI6W"AU/K2NAPWJ*GM%<9:D,D!3@L9C5<[(9;LGXD)U(RFB@+PFRKL3\L].
M]DZ5\1/T!3[ =O-%\Y<!"5!$40J!QMCG)&+;Z>;DB[GT6XSWYUU:@WZ9J!;>
M6KJI9C7Z7&B0K=$"+>G#2&VM=+TM9X<Z>F1V(,[4FH'YBD\CER5DV4.8P+T*
MNA-BW!4Z\.I$M?-M%]],CAF^B ZWSFG]?:GO?&S659,EVU1H?1T.L1N,K.F
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M^_J0\PTZYK^*';O^".0J(GJ1=UV]?;]6>E'X!PJ9=+!SR'WOT;-N=3>J<>S
M878+Y,D@G+P.-%JI^JO1H+L.$V8'5XM*9??DH98;CM:EN1USH"93FOKQ#O\
MS$]F-DWVY%O\_P F_N]R9(/[EM(_G:])?UVVC'-?Q0_J)D\?YQ?7C]RVD?SM
M>DOZ[;1CFOXH?U$QQ_G%]>/W+:1_.UZ2_KMM&.:_BA_43''^<7UX_<MI'\[7
MI+^NVT8YK^*']1,<?YQ?7C]RVD?SM>DOZ[;1CFOXH?U$QQ_G%]>/W+:1_.UZ
M2_KMM&.:_BA_43''^<7UY@Z_Y0Y;:H,@G7^U>CB4&(<LM;D2&NU6]M+1NGV,
MK4K*/VF0TRO;@JQ!"@QYQ*-L.NPUNQG7HZVGG'-?Q0_JI[<<?YQ?7[OHS/\
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M&($T%N6Z06RPJ7G7Y\[#Z%V[<O1?8G;?ZDSH#PF;7Y-<M<2K!10D #Z9?:]
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M&;\8#<WW!IUQMY>Z=-%0D2Y6;/.)QC&,8QC&,8QC&,8RG?L+_1^8?]\+A_\
MSK%E8>I?T#_0N4E_)_I)^O+B91E6,8QC&<NN<>DNQGY7.-J/6$H4MP'IMKM
M>W\T 5"EQ*?3Z_9U:-\WMJ'!!"UDQ%PU0Q\@1$;MKSP0Y-GE8@F'IHY%K44W
MV[>J)V7==U7V^Q.VZ^B9;12V]OHJ]T1$VV]4]_?Z_DS<^6^M+1*C\G%]>D@J
MQ9H'.K3?.RKCP_LBRU-B<Y@WJG=/K7W5*>A5P\/T7_4X[.W6Q-K VRJZ>DH
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ML3%'VS##ED2S BPI=79)S.=W]%3U3]7I]G;]N=WMZHOHO=/I]?M[_3D3<_\
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M(C$Y;^B\N(A7T_F-KUM"]_).MZ^6][UK*Q'DBJI(*)MZ_+O^S*2+;;MOOO\
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MQX/- >P.BA<>)(0JJ+1O^)0W_2E+?U/A_P"_.=1]T?6?^>E_-]7_ ,#GG/W
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MI>UW_P"+%_W<?N>=;_IP>B_^UA_^YC^-]5^16G?ZC_\ O8^Y;J;_ $O:[_\
M%B_[N/W/.M_TX/1?_:P__<Q_&^J_(K3O]1__ 'L?<MU-_I>UW_XL7_=Q^YYU
MO^G!Z+_[6'_[F/XWU7Y%:=_J/_[V/N6ZF_TO:[_\6+_NX_<\ZW_3@]%_]K#_
M /<Q_&^J_(K3O]1__>Q]RW4W^E[7?_BQ?]W//'\@=99>2XOV]Z.VE/U?/3<F
MMJ7_ "IWK7R20'$8F_Y=_P OW8;N]:^>T;;<^EQ&!9ZBK["$[%8TQ35KKBMJ
M,R(+J2&N#H.$@*2JFS@BK9?S27-WIW05[26\:RF>(VJ[^.P+Z.55H<<H4E7H
M[K(*Z@(A;L&X+[>WHXV&_;/8=\4R;*2K>NL>C^X=AI]?LHBUO\[N<JG(J=A)
M@'E3 [5AC!JN.E$AD4AIB:Z,=D?B3%QVVY+:T:U\N4STI$7VKO\ )LB9>;&5
M97+N'G /V4W2+H/NUSY5TCGRB\>O]"YY(%Q+#^A6"&N(9K1'18:4@D0LQ7V)
MC<>5%6N%-8V_#<9W)EZ?9"IOW]%3T7(GE>0.CS4:1-]H^C9:$[^>D2D<SD(U
MO_UZ2[15ZUO_ /'6LA41?5$7YT1?TY($ZVNX.D"^\-Q7ZT5%SRM>2.G,-I:8
M]K^DF6D:^2&FM\U;;3K_ #_)*$4=*4Z^?_HUK62B(G9$V3W)D+S)54C557NJ
MJFZJOO557=<\G[IO4_Z;GI;_ /LYQ_<C&1L7XW_E3+E!H#XL.*&2BDXW)'#8
M,"0:*?BZ)EWX<5J.\4(Z@QH4+4X@XVJ7+_#AQ(OY#KGX\9AGZ&D,JS)8QE-.
MY5CL\'NW+.N\JYL.Z5&J='N]8+"I]X#TG[4BRS!3D9Y$PFQ-<>TVU"=7M#,%
MQ"M_)*W6M_+ZJQ4>)(J[;J/LW]-_E3W_ *<I7?=%1-]M_:B>N>?^%GV'_1%K
M?_Q#U7^[&-@_'7^I_P#UC<OQ?_,F1Q<_9W3^/6*GBNX>==U"!>6K0U6W:GTJ
M!T,X8- !L9V$"'@@U;C[7,-&BH$+'7)FQ6VE$U2_F\B&\UN>"*BJ);[;;[IQ
MV1=^^^Z]DV[Y')45-QVW^7?]&27P/C=N5>;%Z3[*U&&=<OPA@-#IP-W[ 7G]
M):4RZ.K9%V)]K5ILOT,15F3)/\I,:0RB&,TRS'TM4$2;( _@HN^_O7W_ #?I
MW^;8*+OR7U7V>[]__G+@91E>4[]A?Z/S#_OA</\ ^=8LK#U+^@?Z%RDOY/\
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MEL4*0_;*J,,R4-F,I"W-1]EMUS4O4DI[DZ?EC==66\\V+KK8 \_.JI+(LN]
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M\R[$",H?R$,55"D)W_Y4F4!GLB(@"7JIEEW\Y_-SC&,8QC&,IYXG_P!6M_\
M]OO:?^L965N?AK\P_P"RF4A^"GT_I7+AY1E6,8QC&:;0N?U'F5:AU*DAHH0)
M#<D2?QXZ=[=ESICNWYQ,A)7\WIQ&<^K;LJ7(6MU>_I;3M#+333<JJJNZ_O\
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M[/?O\N^^WU;Y0@>G?T5%^GMO]:I_=G@KOE/IH@+58,Z\T67,YU3_ #/1Z?\
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M#*%.3UQT)5O14V[;HJ[[;)O^S"+OLNVR>NZJFR=OGS;&/2'!)2):X_7:"\F
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ML<%=4W4)M[I&K<4557.NE;=G*<>;9;6+U9215%Y3=>A-H<%^8?21";)WDC2
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M)XU<<,U-TDV)TN2KR<)$1"-=R5$V55R0::;XHVVVV@@C8H "/%L5W%L>*)L
MJJJ@IL*+Z)F2@!Q(K9#8L6.&[+$'RQ7<"#&A[)E93;+,HF0W':;W-(26H\=I
M^;)^Y)>;890XZI+2-)I)PSX<S,^F* '(E+@ JJH ;JO$4555!39$555$[KE0
M@ \N("/,E,^(HG(UV12+9$Y$J(B*2[JNR;KVS1JKQGC]%VA5)Y1S6G*;)-F6
MU56BU>O;;+LM'F&2J-B!</:"33-IL[+<Y/RE(:L9YM+ND%R&I&0]/G2-_,39
M;^X*VO6D/.[@JMJH+S,OB*K+*J/HJM-]OO8[66H<1C;HQ8[.Q(:=)AIO8T1Q
M$). I\9$==1"]=G'._QRW]I_DW*Y)BKV&3S/G\@_1W"#U+./TRN.F*@\6D.R
MRCM7)N#53:^X2E/OR2"Q+\14R0\Z])VXXXM6X2;-1MYI)<I&I""DAM)#J-OH
M"(((\"'Q=0!1!%#0N*(B)LB9*Q8RFTXL=A7&5)635EM3:4UW)6B4>3:DJJI*
M"IR5=UW7,4_PCA\JMSJ;)XURF14">XVR54?YY47JV0W",EK%#W.!.!U"Y>XE
M@/G3L;;\5S;!DT6*-?1-)3'WJQLK$71D#/FB^&_!X93Z.CR;!HN+B.(8\FFF
MFUV)-VVP!?B@*)2L*&K9,K$C*T6W)I6&E;+8S<3D"AQ79QQPTW3L9F7X1*J[
M8BBTEIG49NG55N/I%5;TPBO"$,Z119K1*D(TTF'I&D4TBPS/JJ=)^5>FLM2A
M&H;[:'-6%DR%7=7WE7=Y=U=-5WDBHR%WY;[OBJB]_P!**JA\D7;+G09VVZ+6
MWWKMTPV^\$A,]MMOO)(A-?\ 1DB*&RIFTY9R[C&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
,8QC&,8QC&,8QG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g897644g91l87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g91l87.jpg
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M$"_<R_H6_9"MHK+#_);_  8C?.1+/N3!6I-\:^"%K."^/Z(2.549B@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% 8RS7[S66_-E/?PJZU+>*>*?4AW!?!?H5$2_<
MR_H6_9"M\H+#_);_  8C?.1+/N3!6I-\:^"%K."^/Z(2.549B@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% 8RS7[S66_-E/?PJZU+>*>*?4AW!?!?H5$2_<R_H6
M_9"M\H+#_);_  8C?.1+/N3!6I-\:^"%K."^/Z(2.549B@% * BQU=8 S+*M
M7^GS+^(G7)BE<AP3J^@8G?I.L*Q7C"6/^*$B/&+^6P$BF:FF22F9++2E<G<+
M'%T4%,#<B2JD"!%>G/$]B\.*<L^W\\N&[\R",=(6JL,#>QH:7]1/ZE@"Y &
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M7 /\8\ VH %QG>[E@&]M@W=^ \VX0NYX>#B%@A: #PYW.$>'-'< %Q@C;N6
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M!0"@% * 4!C+-?O-9;\V4]_"KK4MXIXI]2'<%\%^A41+]S+^A;]D*WR@L/\
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M% * XV#CP#CX>'A_G\M <B #X0 =AW#?XA^7^= * ;!X=N(^$?EV\%    \
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MVRXTLCH*^UU\*[X:V@JF24\\:[E<S:1J^)\;W9;K1/>% * 4 H!0"@% * 4
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MVCR;>0Y2,Z.,!93(QF.ZJPQ;>U-)=C>BN.%.EMM)LL"@=QX9;DW?DA*Q0@4
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MJF:*BHJ*BHN2IO0^]9$B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4!C+-?O-9;\V4]_"KK4MXIXI]2'<%\%^A41+]S+^
MA;]D*WR@L/\ );_!B-\Y$L^Y,%:DWQKX(6LX+X_HA(Y51F* IO:,(2I>,Y,J
M73/IOUB069:A7['>KVR;H^4IRC=B%\TZ/>4YI$W+*^JE.B;(^Z/&3CE$!5)6
MG"B9#D 9HCDP(39<A:&&3'@+%W\7)NS3+2FY4[$X;M_'=DO9VK<AH5B@% *
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M">-?Q0U-/*U\%3 ]$DAGCDB>B.:J&4:Q/6% * 4 H!0"@% * 4 H!0"@% *
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MU/B&V6VWPU<#$?74E5;:NXU#8E:]6-6AK([@]T[F2[1E124W\3*QZOA_-/\
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M_P#K5,OC1O3\]U7QZ'/L'J9+_9R5A)0'RG8<FQ(CQ\ ]%FR\ _F'_P#7NGM
M3A?L(O\ [V%;PQ?%=.+G#1<$7^44BIWTLR?2K'L=J=M_TQP.=_\ ;7(*;?\
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M_P 1.G^RJ:D:W<G:EX%I^D3\9&(Y%2K'J-)C93B3+LG/EC.6<[D7":60ZP6
ME^QZNXJUM7WE2(LTLM=:/<JHD#@MY+',F.ZC#E9!-688P>CYZ%K+[1XGQ/)4
M1ROK8&14L$5NPBE8^2M>]*?3&YJ*USD=J14:[P,2W.XVNU2U:4$U0C)(FO2U
MU,:U,3%57.F7WM]OB;"W3IE=[PCD1Z*C'-U*FGO)7:@9QE3-<I8W*5Y&E$5*
M@$S<^@?)6#Y'$4D&<1D]R=#$-TF<BRW5:M<'2^]Q*17J5ASLH5B?>0X&J3/,
M]GF#\:8+Q?66G&&+FUTTV&GW>##LU5BY:A6W>NM=>R\LI;[9+=1*LGO<WO<S
M)W5D5955%/41MJ4K&1\E[/\ &L&*JN?W"&Z2T4;*UCZN:>W3T<=53U3(YHW+
M2W2LD29S]:QNV.F5CDF9(Z*5DCY\:^YGU@4 H!0"@% * 4!C+-?O-9;\V4]_
M"KK4MXIXI]2'<%\%^A41+]S+^A;]D*WR@L/\EO\ !B-\Y$L^Y,%:DWQKX(6L
MX+X_HA(Y51F* @HE?)XZ-].K;A'#V7.4:U307';C/X.9AS &6M5>+8[CV</^
M-,@12=1:'Q^&/..FA5(FQHFJ:(W7-+0J$\E8M94@*B%KBWB<,]2KGDU%7)<U
M1,UWIZ$Z]# 4 H!0$:?)E_NUK4_J6:W_ .[*BA*\?R;]$)+*$"@% * 4 H!0
M"@% * U<U42RPK&<V@*"*Y)DDDDL2,N:2H=C#($Q:S3#UMQ):54_QF..C&WK
M><C-,O1+W!,J*(O3J#";"%:8PWJ<*TBNN=%7R5=MIJ:FJT29:VZ6^BE1$9FK
MV4]54Q3R,_&B(^.-S%<CFHJN8Y$X7'EP1MDNEIBH+U6UM;;U6G;;;'=[E Y7
MRJU(WU=%1STL,N<;E6*:9DC6*Q[FHR1BNSE"YNUSIO5.34US%J)2+!1&$32"
MS"!.!AH$DG]*E;9FRL:]8C&PZVP%R5.:C$^TY.!PG$&EV>'6T,M!(R.66BF<
M]FM'45?1W"-$U*W)\M%//&Q^;579O<C]*H[3I<BKU-MND%UADFIX+C V.18G
M-N5JN-IF5R-:_5'!<J6EFDCR<B;6-CHU<CF:M37(GL:TCT10'0R&*Q>7(;FN
M61MAD[9>%P7MTA9V]Z0WA<&UP7)').I3W!<'"[<L=PX#PK8IZJJHY$EI*FHI
M94RRDIYI()$RWID^)S7;EWIO-2LH*&XQ+!<**DKH%SSAK*:&IB7/<N<<['L7
M--RYH:X+]#^E52K.<6;#K%CYT/O$TQUP^Y23"KH)X\>Z!7XF>H8I$\+@"[I;
MC+KKKN-XW;W;]''C?%36)'->)[A$U,DBO$=->HM/R[.[0UK=/<B)W'%R^R[
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ML*T:MXMJ<06F%V[LT25;7*O<B*O<>"'7;I,-'9HS*RRP=Q"T($R2[(8F"'A
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M48<0;\IKI1D 'QED3[<_BS/Z-K;AFY$1-W/=WIDBY]_BF2$V]# 4 H!0"@%
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M%5.X:F8&5X-CSP^*)0R$L[2_DJ2D9S&YN9BZU$@>"59Y*4UL5'E+2U)Q1%Y
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M8^D8;K;V-,R+KVX5+4G9KK++FDE :G+;KK+11VDC: @![R@% * 4 H!0"@%
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MO89>=8ZN\'@S%&')RL-, ##;5RQK.56F7@%]X&A=< 7"(4,%WJJ\U4S30@4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4!C+-?O-9;\V4]_"KK4MXIXI]2'<%
M\%^A41+]S+^A;]D*WR@L/\EO\&(WSD2S[DP5J3?&O@A:S@OC^B$CE5&8H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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JPH#++BQ,MMY]MUNX"2!$5%U+N[D"O545-V_Q]2-,OW,OZ%OV0J\P/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g897644g93u47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g93u47.jpg
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M & , 8 P!@&OUY9_T]0'ZHAG\Y37/50>1_L_9'*.]</EEG/CY_4_IW^'FO\
M4>89PI//%Q+@\J]?=DS,@H8 P!@# & , JD\VW[-B[/K#ZG?ZPZ#P:K_ $B]
MF6MX,& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MS"JZ]4C8J3.:XZP]M3=<!SP^0N7TI-DE(/516*7$",@W0]NW<1]U+F;Q!J]
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MN4E588HYL&2S=Q))4H:#.=OW&?.;YV2(W^<?KAU],=/;1[%%J0J@G?L:F75
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M,_G*:YZJ#R/]G[(Y1WKA\LLY\?/ZG]._P\U_J/,,X4GGBXEP>5>ONR9F04,
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MVLZORI:"MXQV-HJ1.+1+G@%:-P=M0,JO81V+>R?E*&A"+$\NI*RD?X/ MS+
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M1];\G4HO[392+XA[*^'PX>2G_A94'\8Y5:-O^(>7RZ'^[\ Z]N=L!1LT4<0
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M;Y/^S.=_BI5WOIDG.^S"2M]1#*VRV45L]SU%]^:2, 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!B2]J+JGLO4<ZHN[H:+GU7V.%4!2N,%M%/4.VW*R+MF\
M:.D-TG@LR')-F9@";&KM2H,TP8%A;IJ_9MUTQJ;3FK&BI2.^#>GYP#E3?NI=
M]R=QY@S"C:SZ^V/,3BD)FO6JF(<6:DX*)KDI$5VR?-MJ+#Q[FR+G=MN#]AJ-
M4QI$<U!KF1YL5GM*222UJ]-O%.:E@KE?>7"U35-<T;7,.J.HX<#@%;0 &TCL
M0B$=:<,Q(42SXY^ BCIZ=UG#EPMNL\(D7BSDD5).79,F[=D';ERJ);;<W:V9
M!P8, 8 P!@# & , 8 P!@# & :_7EG_3U ?JB&?SE-<]5!Y'^S]D<H[UP^66
M<^/G]3^G?X>:_P!1YAG"D\\7$N#RKU]V3,R"A@# & , 8 P"J3S;?LV+L^L/
MJ=_K#H/!JO\ 2+V9:W@P8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M?WU\4GW8=O/[NX'X?RZ$;3'8/S1!NVL$ZBK$_%^M+)Y0MAWZQE25:]K>(ZQ
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M:LOW&693V[HR#QJI)A,C4QB\<NQ0"G"2ARIK8'H,]93(8=$8XO86JT*X5J1
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MD9;<P0XAW#!-)=%:/BP!)DQ(-PG*6YM\Y=C*LXZX5W-NNKCJ_P ;'HI67,!
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MK8\LX3V>-T1(L\N6'[#U$MU'Z"2;GG=OMOKR-G?O4NJ?P26P8, 8 P!@# &
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&3;O<S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g897644g96w97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897644g96w97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (@J^AQ0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #Y    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    + $, 80!N &\ ;@ @ #4 ,P S #4
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T#\@      "@  ________   X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      +V    "    !     !        ;G5L;     ,    (
M8F%S94YA;65415A4    !0!5 ', 90!R       &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "R     !29VAT;&]N9P  !=P    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M L@     4F=H=&QO;F<   7<     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M0T#QJKI_PG_HM7KV]?W'[.[% @;=X?SKNW;?^@I9V6'8Q?A6469#2TU"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT4:32K-/%&T<,DABCED#NI2-Y08DD;"M("BDL,5@LHSEE& "<D# )P"<^1/
M/KQ68Y)K:G%*C\&LRQ5U/FQM+0$:$9'J1107%?+<0)&WW2?-61D.-B^-GA[T
M?"U6-5'.\-5%6&FHZ?)=/8QWUF][&"7LTN86ND"C+%H YE4*.3E!CSQ6H="Q
M4.I8=U##</J,Y_*I!R96U8X*XJ;*,::NM*X^(QI3A)0C1BHRFA3?3&N&?!+(
MV=HA'\@I8E<@\W\J7V/_ $\X17-M.J-!<03+()#&T4L<BR")MDI0HQ#"-_!(
M5SL;PM@\5@$'!!!!S@@@YP<'&/0\'YURF6 %<T=]@<& PHP:O%>83"*TD\V5
M( P1W3O8DQA<SFPC#1JZ:>5R1Q,>]43F\LT,(0S2QQ"22.&,RR+&'FE8)%$A
M<C=)(Q"QQKEG8@*">*$@8R0,D 9.,D]@/F?(>=>9K  <L, @T2 ZQ0A:\*8F
M&(LY XVREJ&,][9B4%B<V4A8&/\ @C<U\OM:J*N&FA22*%YHDFFWF&)I$624
M1@-(8D)#2=,$%]@.T$%L BF0" 2 3G SR<=\#SQYXKM\ZUFG%*<4IQ2G%*<4
MIQ2M4"_6UZ<(.W0NB@M]#?=H'Z&LS8^;SE;97BN.L91H2)UL:X:>K97T<A3(
M]":\QD-1+$6,2Y"@R8(J2/VATJ>^?3K:X-U<QRI%(+>*6:&-V5F97N40VX,0
M4]53+N0Y4C>K*/67/L1[2V.DQ:WJ.G-IVGW%N]S;O?RPVEQ/"K*J/%9S.EVZ
MSEA[NX@*2@JZML=&;:Y%1?V5%_\ I_O_ &Y=UY.O/%*<4IQ2G%*<4IQ2M9M?
MZJ,#B^P#NMK2IU,VA#UG7F0A<&'6R!6!G88R%BG!RRVL,JUV?@>,NADFAAG&
M<:&T0<U2(_*LX_7XG^G^==D[U-9$.CFO&YO8&Q0YS4:7Z4,2ID)4+*]CC=9V
M"2.=<,'&9^;E-MI#29XJ\#/0E65B4(X:0?BL5ST_J,I=+#E'Y;$[/4SZ.B74
M'#9Z3'VO\-YU-1/D$M33!=8^NNH9K80Z4:')F7Y,U;7F&_"SXXX95*RVA[[R
M^=Z\/[')JKF6I WMIU[((Z?/UQ3K>IWI_7LYCS+B[KJ0.I?;U\QC3;"U$^.L
M>R<F.";Y!V*5E;#N&K"Q.-UX]#<6Y6_M*NCR>8ICLO8V5K;6T)Q@X\=Q!H'9
M%H\5966%J58_Q$X",(.7XYYBEB&E4J,+ZB*.+=9+KPW(Z>FTNKI,Y=_0Z"PP
M]$73Q:.WN:>,$JOL]>/8VUC73T1LQXV6$O\ _HSQ)!'E.+@8]6<<9_7E_F.]
M2BC[ESM]2]07HE;=Q"]T&."SD1$(#2*V1N2T.Q5UXV*PECA8M=FS1T4"6P<I
MLPK?;\#I2(58JW>*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6
MONQ]472V!U-[D-9I+BLM,N^F9I2V8?=66=SW\0""G5$EYJJK-FYNJ@,&,'D0
M@ZT@@B]SVSR1.AF1E[:>S6L7]M!=VMO%+'<B8VR&]LH[BX]W=DF$%K+<)<RL
MC(PVQQ,QXV@[ESYZ]]J=$T^ZGL[NYFBEM3"+EQ87\EM;^\*KPF>[BMGM8E=7
M!W23*HY#$%6QF[?U!]141G8]?9ZZ(<_J:+.$;L)E9<D%5 NLCKY*$L> >OE?
M<"&): -D)I4L(0I2&1'/&D\M3C%H.JSII\D=J6CU0W"V+F2%5E:U,@G5F:0"
M)TZ3D+-TV<+E PYJ1-[0:1 ^I1RW@6321;M?ITIF>%;L1F!U58R9D<31@M!U
M%0L%<JW%2.V[7Z_HNQ<OU/:Z(<3?[*KL;G.9]XQSY;"OJXR92YOK(AGUXKOC
M!.>/ 67!.8T(SZ2.;Z>7VQXM+OIM/N=4BMV>PM)8X;BX#(!')*5"+L+"1N70
M,R(RKO3<1N%2)M6T^#4;729;E4U"]BDGMK<K(3)'$&+MO"&-3A)"JNZL^Q]@
M;:<22CTU5HI[\>L4]9<S>D9RU^NJ+6J8EF,($;*@$MF&)';@_ >/\=K5/,K)
MI?F'B+?.,1'%'FMI;<0-)T\7$"W$6R6*4])G=!U!&[F)]T;9BE"2 88H%929
M,%S%<&<1=3-M.UM+OAEB'514=NF94031[9%Q+$7B8[E5RRL!(.<*D4XI3BE.
M*4XI3BE.*52G>= ;?9RA0*AO;I]3JZZX=-ES*Z/0T:CBGP,NJVKN()JS0N@<
M5].13E.B^8<F2:-Z/@16^6]K+.6\L;3I6=W=-;:A!<[["6!;RTZ:2J+J"WN5
M:"]*,X5[60J'1V<$% 1PG4LJX5CM<-E"NY>"-RA@5;&<$'R)/EBJ D@VM'3]
M84%O6;"MCN-!VD0108*8#'ZN[IV5S;"E.M*W/V8=0)=?4N2Q/" .:V*+Y$1)
M)9"1YO&,-5M+?0;.Y@U.!;J[U]GL]':+3-1N[80F>UFG@LKB*VBN^I]O-%#*
M %! W,SHW [U6,%7&6E.V/".RX)!94(7=G!8 _S(.5M\;VP726!%E76AVK*Z
M6Z]I"CA9X'D$:(#>D65F"I4$S&36 M5*R:PFC=\,RK-(R:5'^72KC3/:-[6=
MYX9YM1?V8T:U>>-T+27L.KO//$9%<!IDMR'F8'8Y+$,P/.624J<ABY@B4D'D
ML)"2,@CQ <M@X/.,U,_H.TDW&T<P7</MB#-<_*7*:(.'K,7.39ML60')HR)B
MH2+4>\1K28X*T.Q:2KSBCYZ])(I;/H^T'[6U4A-6-R\NI'3KOWR)-!CLGL N
MFQR6CM(LEQ'=@"0)!',)29I)GAW(=\2]1^),DOL;<!&$V#8"I/)W$C@ CDYQ
MWSG05=V" )??QM+JDBD91M%%UGOF)CN(@I6Z$D PG4Z4V<(DAPWE/%;5_412
M35 <<$\L44SV/AUB&*[_ &HVH[6%H(X]1R\BW*Q,+UX99-0OII(I)"G_ &%O
MN4M;1*C,J[6XD ;J;^=N _)!QXL$NY(SCT'&1WXKBGPVM@[5@D$Q]Y6UTFWU
MMS>36C,Y:9L$"[%L8WZ;&;.- M>#<6JDP*E(V%_T4L\\4SV00*Y*.UTK44]H
M5:/3+N"!M5U*YO&N193V,4-VDRF_TK4UZ>I0W-QO0^Z;2(V=E<JL>1R$;]48
M1@O5<G.PH%(/CC<8<,Q(\([<C& :X,AG/4"[79T+2V&A;F?ST.LN35N9U]M+
MUJ)#(#9O?&6DS_\ $>R<]+&5OB8\>-\9Z2Q/^W/3++VT.I645_/>"P]\B@NI
M?>&'^ZZ'&IBN"0^\_MR;(G/#RH")<J16(UN-Z!R^W< Q+$^&(<'C'[UOB/=A
MPV>U?O.XCL("UP%R^KTT5Z-A>U:.$UY[G5]/HS='8V67DT0SCTB=4EBS-E<C
MH#(22(:=9X'25XSQM[+2M;AN-'N6@OEO$TCVBM$F:;,%M>S7LL^GF^3K;3!)
M&=QRDBO(EMO0M#&4RL<@:)MKAA',N<Y"L6)3<"3P<\9R.%R/""/(V2W%]E:6
MK-INT1B(MQU09?%:K40V)L9]><CMG=9E6EG&U5<&JH7&=#8-$D=\,M37"O'E
M63$>FZM>:?:6\MM[01NFK^SLMY+J-^D\HE@E'[4N[ B66>W@C_>"59Q&Q*M;
M0QE&RV2,J@B8'?"6+N"<AO&5Y. OJ#C^Z,UG@\]V9"W/P2QZDE:(WOH$0XVQ
MG+L4J2H"H.OY2K&8MYA<Q$?TZ591$TI+5;&KWQJUJI+CLO:!!9J1?O[I)[80
MQRRSM)/[M)U%T4R3/(99&=0@@DD9I.%W,"*V"RC;D.=K7 !)R=IST\G.3D<
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MZ;MC%063<,-M8C*[APV",C@\4P/3MV^5<W-J4XI3BE.*4XI3BE.*4XI7%/!
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MRO=,Z#RJN5ZHL8?TT3F^Y7?H<Q6^U4C5%CCB8R.U[<,,;@!C&-H;' &09-[
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MDLH"?#NB/?@,Z@%V )4EG'A4L0[(P)5/%(2B]$N9 /%AQV'923M!(W !3R0
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M2G%*<4IQ2G%*<4K\221Q,=)*]D<;&JY\DCFL8QJ?=7.>Y4:UJ)^ZJJ(G]>9
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MW/P@G#FTX(0^PSTFAY'5M,$\5LU_:+-,TZ1HTR*&>VQUXS(2(DECSDQ2.LC
M.55@CD34]DO:>6TN;Y-"U)[6S2RDN)$MG9DBU$,;.<1*#-+;S%=OO,4<D$;M
M&DLB/)&&V!Z%]??I3]2VT-ZYZB[+(N=X"!:6\N2O,1OL5=34U,>M;8W0(VRS
M%$VPJ1S?C@>>%)..V6>")STFD2/G2TU'3[]2UE>VMV 0#T)XY""5#@%5;<#L
M96((X#*3@,N8VJ^SNO:&_3UG1M2TQL$CWRTEA4J)&A+*[+L9>JCQ!E8JSHZJ
M24;&X_)E4U.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M5&;C.Q&I*0$K137-E<OA$^F(E?['>^>+PK&S*^*)7$M9\KVL1LORL:QK9D%V
MT95),R1 J/\ &BC/"MP=H#-A"=H)RNTY)CRP*V63"OXCQPK,<<L.V<A26 R<
M8;([0X:P.IC"$;&Z-T<D_P!0#+\JI+&V9I*R_I265'H.3-[9G,,\M$5![0\>
M-1X9[Q1W"*2000NV12N58KMVX)52-R+E<QG,GB@B=@[0UD>%F&,8)+(0W/B#
M$\9/PEO%M?X#MED5=HLBOL1K*'YAW?=JJV2)71N?&YKG-7RZ)\D<C'*UWQS1
M220RHBNCD<B+XJ98GA;:X[\@X(!! /9@&! (RK ,I.& JQCD61=R_>.,@_=D
M$>A!(/D:[_.5;TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE1&\OGQNDKJQS%,<U6/(5RJ@[WS,&:C&1QSRO>V1ST?*V!\4;XGP(K
MR?,;)]M:A@)I@>F#D+CE@%+Y))50, 8!8,0RMPGB,6:?!,<9&\\;L_"2VW@8
M))!SDXP""N=_ C]/2.M7OG5JQ5TCEDDD>B.E,<\ADS6*GOG9.C((!6O>638I
M',Z99'2V/RRBR9[D0@+G=,OA '"Q@(5)!PI0EG<@1I"2H7&V':).$4'5.2,1
MGDD\E_&& ()8-X54$LS@$MG,A8I9,$$0T3(8(VQQL1?:UOG]U55<YRJJN>][
ME5SWN5SWO57/<KE55J69G)9B23W)_(#R '8 8 '  %6"J%&%  'D/S)]2>Y)
MY)Y-<O-:S3BE.*4XI3BE.*4XI3_Z_MQ2M7_6'Z7\=ZO.A]ATWK1JY9K05]AD
M;:TA/*"S6T"'(;0:&<  ZODL8J\B=_S@R3_"2/)-&YON<US:_4[+W^SE@5Q%
M-AFMKCQ![>;:R+*C*0P(5V4X.&5F5@RDJ?1>R^OO[.ZK'>F!;RSD4P:A82",
MQWUH727H.98I0NV>*"='50X>%=KJ":]>5]^"[TE;V9]N+7]:#6 FJZ$W.6*F
MZRI3!([?K8$BI[.RE]3D)*-:]<]J5[0'RYRQ*MTJ["+ZI7DJ+#\U>NBR1O<&
M*=(XWO;&Z@18PJHL*1K>1&-!&B1W;B64PQXA$LA=E(9DJ_G]MTNDLO>+&66:
M'2M8TR[F>Z9Y;@W<TSZ5=]:59)7N]+@:WLQ=3&2Y>VMT5)8W5'6V.JOPI>E.
ML*['!!AXJ9]#1=X8O1/;US3RMV6&[3O;J_RE);N.*)E>?UQ9V01===/=).<\
M)X[8 (9HE'B)[+Q-'$MS,EPX@OH;AY($D-T;@H+.XF+G+W5C'%$D4[$R!45$
M:-%4"R?_ &GW<<]Q)8V#641U#1;^PMX;^:---CL!,VJZ;;[$ 73-;FN)Y+JR
M4+;%YI9)HKB65V,X@_#1Z502L%-GB.<%1>G>E-G?E<_')<?X#55U1EDV2_%(
MIC>QZJZ=%I1"W%#,* KBGML?IF0IVE]F+*=%69MY6;2;@R&*+J/+I8"DL2#G
MWI%"2GO@L"64A1%M?]IFL64LDEK"(E>Q]J=/6$W=STHK?VEE>91&B-& =+E<
M-:@@H=BD)#(.I5K]:^BCJSJ[NDSO7./G@VMG9]E'6Q,%=6AOM@^Q;,6Q2BL"
M88EFGI\VX9D=1$GL+<@]8R<M0JL0))MIHEE9WCWT(D%P[WI9MRA&CO;@W+1N
M@3#]&3BW<D/'&63<0[9K=6]O-6UG1!H5Y#:O:I'H:PR8E,UO)HFGG3NK;LTA
M$?[0BV2WT9#1231I(JJR(4W&Y<5XBG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4K%6M0);0I&0Q$E8C_@(1J+)$KV.8Y$7RURL<UR
M^6M>QS7>V6&2*>.*:/M#/) V4)P<;ESPP!!Y\LY YP01E6#(65N4L*2C# 9'
MPMCD9!'UP03D9!\P0P#"NI(;.D.1R(L9C6^63-57Q'?-&V!7RRM:CI$F,A'^
M:2P@D:DIJ-(-%*=#8S6P:&YBQWCS@KV:+:=P"J3QMC9BHB<';&=D4D>Z%8!6
M2%\_Q^3>3Y&.2.^75?W@89?#R(Q61K#J+B"V@21B?',UK'20JYKOL]J*DD3V
MJYLD2JJL547W12M?!,V.:-[$JKB!H'P>5).&P1V)!!! (/&1QAE(=258$SXI
M5E7(X. 2N0>X'(P3D<X]0<J0&!%9?G"NM.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE0R_T#F/?7UKFR3L5WUDL:RR.B;'[$<,Q!OULEEE
ME@&=(LH[VR3I"-(I?N<-86MH& EFRJG'34[0&SGQG=D%557<+M880O(.G@20
MYYSDQQD$C.\C)*X_A&W!!+%4)R#EMJG>#MQ%'GG'*R<I$_+HGN2-J.8U#W1,
M<.DWQB*T?XY%>3-\JRF(C25B$E1/F*)[W-V(P53]\P!)P3T@Q#[07\890$7
M6/E-TBYVHG*"#?@L!TU/&,8DP"H;P\$'<S9)?XL*W=FLAC&1L;'&UK&,:UC&
M,:C6,8U$:UK6M1$:UJ(B-:B(B(B(B>$Y4DDDDDDDDDDY))Y))/))/<U8
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MO:D?M<DBN'D(BEE6TYB8AMS0M^\4,5&",$^8R02N"#D'PX<(R\)XPZC& X^
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MVO*'G(C8^%?/L>YB*SW2C_+^ADWAGW\)(R-_EJ5MWIONF3).I0G",J%@P(R
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M9H5N))LJ(T@9GZL)3XN4QKGLOJ3VUN][I=TUK>P2%DZ+2%K90':1TC622WV
MK)NE2-A&ZR*0I5CI]^'GZHNQ4]80(FH6FQ./(PFVJ+B<74B5W7%P3F,Y:S]?
M5^LOCHFL@K@)*^^.M+^S;>[4;7+;3Q@UE78V]:39^U6DS)9B1OMV2= '.7G
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M[O<^(=JQCBBQC B,?(@XS'2ROD\S>7D]],9IRI; 4!5"JJCL!YGZL6;L,X
M]7INF6NE6PM;0.(]S.Q=V=F=NYP?"@]$C5$SEMI=F9KPY$JPIQ2G%*<4IQ2G
M%*<4J#:PYSWPUT+B&MC5I!+QG$12>]%:V"*.:&"9C96.EC=&C_:L)Q-1.J+
MDRMLK&( -*P4D@H@<(5P<EF96925(5@=OQ1)<)\>T&%=.<B,9P/$Q&X'/&T
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MI "[E:#T5S-C($Y=I?$QZC2 !BP).20!DY&3XL;R7K*XK\#CH#+9[/T1_?\
MZJ[5M1<5FBL(J[L/-9JCN[FMH"\DR:>B Q,[!1)LB;/E)AHCGD3Y\BQ"+.)E
MNKPFRV.M7^\NKQJ_424,(8RP>-E>,AF5F.UU5SN)+N [EG+,VSHLBHDBATC5
MDC1\NJ(^2ZJ&) 5RS%@  23D5L#FOP@OP\LJX-P'I^@.^EI8J.9NA[![1TL=
MI"(6(;5GVT5[M3XS[FCD$^&@MI6H;2 E%U]9**#,@[(PU&^7!6ZF4@( 5<J=
MJ-N121@D(<;0V=H5 ,!5 SM''RSVX[]^W;/<XP">]6'GOPTO0[FCA[<+T_YN
MPOA=U!V0-I--=[+7Z4?7P?$UYHU_J-);VPM8?&.,/<9<4N'*W8@@8=O2&B!B
MPPYGU/4+IG:XO+B4NTC,&E;:3*H63" A%#H%1@J@%%5,;5  *H&  !@# &.!
MV[>F3CTR<=S6]/(-;5X5$<BM<B*U45%14145%3PJ*B_945/LJ+]E3CMVI5.0
MM7KS6I BK'E=(]/B\K_*KS?<C4]SW+]D@5S6.<Y45P$K))'O6O<O+]B-5L2Q
MYO;0<GSEC[\ #^,9( '$JD #JBJH#W&Y"]K:X/'?$;\8R3Z9 )/)0@Y.PU<G
M*"K6G%*<4IX1?W3SQ2OGI_$6RWI3*]73YN]L 3(ZUZZZYO#;E<E(M;LJ[K4S
M?;K39T+0C"QW-KHKVEH,WA28\^=%!A:JW%VVB-%%KQ@[#P.O7$MIKL#G3KJ6
MTD2RD]XMK2:97NK<WQGMWZ,39GNXCIUC&S[A+'*T;G9:J$^K>R][++[,36*7
M]FLT3ZI;+#=W*P36]K?_ +-]UF26:952STZY_:6K+$BJT=U'*T.)+V0MI_UE
M@/39DZB:N#]4FY#L<S87&HMAP._^P\8YEKG>L<QAK79%4XW8(DM)M!.W>RL]
MI2+9*QC A>M]H<"2=&51#R4,.N)+:1S#4I$=X%FA:W8PH[+HME=K%$H*F:5]
M1FDV;H6>>+3]0A(>..6%/6!+9+H0S^SMO)$94M[A;E%O2$F]H-1MYV:1XQTH
M$T* VXV72I;WNHZ3>(89V2Y6UL;->1[;;X#IGUY=V+=$J_(TTYW;9W8 AYP'
M88G3>7@BM=45II Z07L2CW>^N2:?0"7]AG=1@J\VW23:6\<MR-0U!KB0V>KS
M"-V2W1I8K:Y@DFN=7M[2Q>T,D<J&.4R7+O,HVRV\UG$)1T@T=:L7LDMC;C5?
M96UDEC"W9-I)=V<RPP>S5[>ZG'?-:W<$W5CECTJ**!E46]U#JMT8\S/'+[YO
M1OHMWK?3%T]J>S-L[L;8Z#,27%CN9:.KS,VE!/MK(G/V95#3U]57U14F<?4L
M+$CK@YHR8Y?K8&&J1SV>E73WVGVUT[PRO*K[I+<.(7*2O'NB$@#[3LR,J,GD
M # KY;[3V%EI>NZC8Z?[P+.WEC6$71!N%#P12.DI  +)([KD9!"C#,/$=F&/
M9(UKV.:]CD1S7L<CFN:O[*UR*J*B_P!%151>6)!!P001W!X(^ZJ $$ @@@\@
M@Y!'J".]=&TBDF"E;![/J8UB)%:]R-;(4'-&5!&Y55/$<LL+(Y%1?*1O=SI"
MRK(I;.PAD<CDA)%9&('F54E@/4"N<H)0@$;AAU!.,LC!E!^1*X/R)KJTA,,H
MWT\2K\<*-D%1R>URU\ZN>(GL7RYBC(CZ^5C_ .8R8.3WHGN;YWN497W'NV0_
MG]JH D.1P=YQ*I'A*R#'8XU@8%=H[+@IGSC;)3CN-G,9!Y!0UD"@@CFQ,-$%
M,9 1"7 PH>(AL)8S_D'*B;,QZ1D02(CX9F(DD3T]S'-=]^1656 #*K $, P!
M 92&5@#GE2 0>X(!'(J2KNA)1F0E60E6*DHZE'4D$95U)5E[,I((()%:?D_A
M]>CHO:1[V7HS*LO()XR@Q1)KBOS8!;7G2R$@9,"R&S8CB9; F<F"&L8)*3)(
M9],TPDN<BIET#2)G=Y+&(B1MTD:F1()"0P)DMT=8'!W'(:,@D*2"54B_B]J_
M:"&*.*/49/LAMBF>*"2[B " ".\DB>Z0J$4(5F#*N54@,0?45^)[U3L\3W%;
M]B97$AF9B[I K6!A(L5W2%14^3CR^@?+4WY,^0KXJ&%:<F*K;G3U>P6*PLF$
MTSK((K](^PUS::C[+0:8\R-)82RQ/;(4MY8XI999( DBJ7V2(\BB0E54YC1=
MR@U\<U^!(]8EGN4(6Y59H9W#2*\ZJF\X15=Y Z9:-Y"&#!FR77;*_P $>\[F
MK]1ZA\)I*0\KK1TF>U(NC(+FGKJ77/! "%J*R>(=E,?_ !1ER!+3XJ%H%?5U
MN=K'.K*^:T0./P'MK%&+B&5F"W&6BZ.X.QMUR4D+9P K[E 10AW8PK*0;7V5
MF5X)$@C(MS]J7"&,"=B%="I!<.0 S=5VEXR6D4J]?0FJ^/\ =?LG^_\ ]_=?
M]$7GA:]83C^GS-$7RG_R_P!O[_\ /]_Z<4'Y>7T_U[UYXK-.*4XI3BE.*5P%
M$1"#S%3.]L4$;Y7K_7PQ%7PU/ZN<OAK6I]W.5&HBJJ)S9$:1U11EF(4?4GS]
M .Y/D,FM68(K,>R@D_=^N*JL(5UU:-:0C)7%3.G-5BP/1@['/^2%)1#E7V.C
M?+%'-\;O#"QG*KHIPI8[J1_=X"4)4(H2,'<I+$##;9(NX(5F7<,F.0=UE#5J
M*9I,$?&Q9SA<A>V,K)CL2N[!)5U.""A%MHB(GA$\(GV1$_9$_MRCJTIQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4JGQFKM]S*6]5DS^67XQF_9T!9S9%1'+]E1
MZ2$1O(54<K7#!AHYBM(5>7K$:=IH0<75[RY[.D9 X]?"AV<\AY),$%2*JUS=
MWI?O!;<*.X9\D9^]ANS_ '43C#5<'**K2OPL<;E5RL8KG-1JJK6JJM1?*-55
M3RK47[HB_;S]_'GBE'11O<CGQL<Y$5J.<QKG(U?/E$54541?*^4\^/NO]UXI
M18HU]WF-B^YJ,=Y8U?<QOE6M=Y3[M:JJJ-7[)Y7PGWXI5,]N>H+HGH4:KE[D
M[/P_6\-Q\[J>+5W(57+81CS#BF$!"2N^>8428\6(XN.)1A%+A0J6))V>Z/-=
M6]NRK-*J,_P*<EFYQD*H)(SQG'<@=R*L[#1M3U-)9;&TDGBA.)9=T<<49QNV
MM+*\:!MOBV[LXYQBM<ROQ+O11 P4@+MV.]'F2)L9N8Q&]T(4#)5KG&-G.J,N
M4*+)4Q689%Z)--&951*_ZT:.6&2-L.36M,BR)+N--NW=N)7;N!/C#8*A0"TA
M;"QJ"[E4!87D'L)[47 #0Z7+(&ZFS8R2"0QD#;&8RZR/(S*L*(2\KLJ1JSLJ
MG9;I7NOK/U!8G^.^KK$VVS,=U94,K[;,WV5.$NZ:2)EB$32:>KJ;0:8666-%
M?($V-SE58I'^U529:W=O>1=:VD66/<5W*<C< "0?0C(R#@@\$ U1ZMH^H:)=
M"RU*W:WN#$LP1O.)G=%<<#*LT;A6'# ;E)4@FV_BB]_R?%'[_/GW^QOO\^%3
MS[O'GSX54\^?/A53DBJRO*1QI^S&)^W[-;_1RO3^G]'JKT_LY5<GW55XI1(V
M(JJC&(KG(]RHU/*O1$1'JOC[N1$1$<OW1$1//VXI7Z1$:B-:B-:B(B(B(B(B
M?LB(GV1$_HB<4KSQ2H]J,Q5Z^JCIKEDL@,=UF;WXX7L8KS<II*G55;)/?'*U
MXSK.F#:7"K/YXJS0(^-9$D:I5!B^D;IT0.N&B!MG3T8E7%G+.8H":SS5C25/
M5]14:"C(DJW1B78,7461G69\,P9TCKD6S!.JK<FNXK.3^O/Z^OWUVY/2CT_-
M?%WT];;S/MBGFZ.J=;/92:DG^(+K3C3Z"N@AB:;.'<6XDT!4<@Y<D&7R 9DY
M8F>#AXK'Z^E7EE,X'C\QGLG7$V!E=FJ6MH:\FV*4ZSE J0X00U/.5D;S2D&@
MB;,7*U9R7M6:=\DSY)'*5(.*4XI3BE.*4XI4=U5#'HJ4NN=[6D*WYP97(BI"
M;"BK"Y55KD1DGET$WZ7>8)941JJJ<EV5R;2X249V_!(!P6C;&X<8Y& R\CQ*
MM<+F$3Q,G&[XD)\G';R. >QQY$UA>OKV6VIE#-61+2ED2O,;-X^9[(T5!YI/
M")YD5K'CS.\JYQ(T[G+Y7G?5+98+CJ1X,-P.K&5^$%N653Z D,OEL=0.U<;&
M8RQ;'R)83TW#<$X[$_/'A;_$IJ><K:FUTELJYI[:IU@$EH\=2F5JE0(>X5'.
M8I+0UD^H<.CFN:LR1K'[FN;[O**G%*XQ[>I+:YXMI7$L822$]XYHTS6&!M>\
MP1SHY7(TD1D<CB8%5)8&QO=*QB-<J*5PLM:$V>2!EE4%DA.%66%A@<\XCS_9
M&$LD:2/D@<;\\;!5<C%)^9C8O?\ (U%4P#W&:I^TZ*],NCGDS-QT_P!&794,
M0$DU ?@L&>3$/66\FEKEEK)JJ29@P=Y837@S7P)#%9'SV#$0@N663B]O ZA7
MAB=1C"M&C*,'( !!&,DG'J2?.I"W=TCF1+F='))+K-(KDLH0DL&!)* *23DJ
M .P%4KK/0[Z +^R,O]!T#T+77,&LBN#;ZHJ:3%W NNBKXF0K-<9DBCL!36##
MQ6+*U2HHT/B;?()^9HI_(<VD:;< K+:1E6/B"%X@05VE"(F3,9'>,_9DY8KN
M)-3H-<U:V96BOI<K\/5"7 #%B^\"=)!U<L1U<=3;X-^P!18+_3QT0_J47I'K
MN"FP>4Q;2K'-UN,ME9#CR3IBK"0F8%ED_P"HJS"#""#:ZRD^C*9*LD#Q281"
MQ;S0;D>SLBM80Q]$ENK!+NE$JNP9_M93)*DI/*RABRG@[D+(WFO:BR/M9!(F
MI7$OO&%Z%U%B(P/''TXL0Q"*)X0OA> J$=>1LD"2+*,SU7'D1!:X;M36S5@(
MP<(P)MU%\0PCVNC"BA:R6&&$:1D$C V1P,C5D3V0HJ1JC;"YUA+IVD?3K%97
M)9G6/EF8DEF)!9F)YRS$D]ZJ;/V>DLHTACUC5&AC 5(WF.$10%5%VE55%  5
M0@   '%6O0PU$HD9E7:-O!WJYK+%A\-C'*Z-RM>C2!G+"]S'(K7(BN5KD5%\
M*B\JI)FD/PH@_NHH4?U_U\ZO8;9(?XI)#C&Z1MQ/Y ?B*X3Q9JXA3Q5]@ZR/
MF<OL<]@4\RM4KYHV(KW51ZM;(8L2+("8U+'V2QO)=#WCD65!$_+ !1R 9%4$
M(%)X$\0)6,$@2QGHY5@@?613&QD7X223Z(S8W;@.3%(<%\ F-QU,,"VW,!V,
M):-8O\DA6)(H[W-57,5$7Y1Y&JL98SD5%80.Y\:HJ->L<J/C;PDB9,GXD!QO
M . ?[K@\QN.Q1P#YC*X)[)('X^%L9VGS''B4CAUY&&7(YYP>*[_.5=*PN@S>
M=UE612:FAI=+2EM]I51?U8-Q6$M_[) %A 0+,G^DD3DYV@N+BUD$MM/-;R@$
M"6"5X9 ",$!XV5@"." >1WKG+#%,NR:*.5,YVR(KKGUPP(S\\9KO0# U['1!
MBC"->K7K"&/% CW,BB'8]T<+6-7V00PP(]R>&0Q11^YK(V(G,EGY9B<<98DX
MY)QD_,DX'))) )-; *G"@#/DH SQCL/D ,G@ <G KF:JR?=?'M_NB^6JG[^U
MJ_\ $B_\3_V7_*U/"JJ8(QZ@_@?]/EY^9QQ6!XCGN"._EZ8' //?(],>5<W,
M5O3BE.*4XI3BE.*5#=<:YD4 4;Y8_>Y"BI8E)8L,$/N>U_SBQRRCR-^.4J"1
M(W(R0-9G-?##*QUA81@L\A"G V(&V$,[X!&UR X.51ER"1+M!#,I$2[8X5 2
M <LQ&X8502#N4$@C!<'!P4R1M!!Y<F&Y@LI\T;63$O=&QJ-1/BAA7V+&U'00
M21HDK5@;&Y')&,*&.R22$>%W-;YP9!$IRJ#)/J[<Y/B8'((8D$9=Y'(#.PK-
MLF%+D8+<#Y*/( A2!G*@<X144$JHJ6\@U*IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*B.YO%H,V>7'(D1<[4""=Y\*TDE'-^5O_ *0T+9BD_HJPHB_9>3M-MO>K
MN.,C<BYDD'JB8\)^3L50_P#-46\FZ-N[ X8C8A_Q,#S_ .49;_RU&'9PVKZH
MT=8! 0^]L<IH)FQ"HY"Y+8ZG)8(,.C/:])X548.!(_:Y9(FN3];E59,MTD^K
M02NRB".Y@0%_@$,<REG;/\+'?(V?)L8P,5"N+>5-&OHH5<W,MC=[!'GJ-/);
MR"-4Q@[PQ5%QSD#!SS7I\_PH]3W_ .5>U?W\_P":[_?_ -XY]1&I^SGG<Z9^
M$/\ ^ _("OSS^P_;/_Z#7?PNO_RJPJOK?N"'-R#G8'N2;1.JM/"XIWYU]/\
MF1D8#<\2/(VR>B,KI()E49P@KG/E+GFL9HI(J]\"74-*:X!2]TD0=6V(4=$'
MIH7ZZL#&/C!'BW.  BA 5:06<.D>T*VA232O:)KHPWRLY%T$,LJPBS=&$IP(
M"KY3IQDEG=IV4B&M9.[^LO5#:]:WV/S-!VH7NG$T=Y#GJHVX_B3\A6W&%DM&
M #FM/;6.G'*'4M&(,^:":'WJ]CVI^>O]K%MJ&H^W&FW7L^ES/IR>SL$,TVGL
MRVJW@OM7=T<QLD8E$4MN6R Q1H^_%?1/8.RU>TTRX35(;V&5M0G95O!)O,1M
M;0*0)"S;"ZR <8W!L>M41?=%>IF;KI*R@Z0]5<&V9E*,/\U,=KXW/UT&N(+M
MK65[;VPAGKI,FA 3(QUJFH79@0R51WY9!85=%+8Z@;$QPV6K"ZZ4(#O-)N,J
MR$RN6$Y7:4SP-H)91M.P%?<[6!R%?.,<J>^>#CG^'CRP?7 -7IWWTSWWK^I#
ML6-B=SH>Q8<[D[0/._&6?JH:UFEH8C[(<&29]E"%\X4\1!C&M'?.,^)TBR1J
MU/G5EH7M:=0C::QU?IAICNEZVP'IN4.YVV#QA=IX\6TJ00*Q;RZA;LW1FNH4
M<MO$4LL:OX73Q*C#=X79>0?"Q'9CG4:V]+?J*7+LK*WTY=TP:!<%55S"$H;V
M) -3%HLB5<&-]AHK7_GH,6P^O>;#=1?%-G&5DM8XBSKPO<S:5?M:+%'IUWU_
M=41VY&)C)&92?M0"9EZH<D.&7I@$;F19ZWVJ@AA>:AQMVL+BYX:,Y1E(88*
M-M[E>2N.:VQMNC/5 %Z6A\S18/M4#7R8_'M)JZ>"U$O)+4,O.Q6\DD0T\4TE
M@..++$9+(Y9$C'6.>3V,\)XVVT7VJBU@N+'5T@]XN&+ RI$5V.NX-U%0@Y4
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M2:XVC6L/AD;T=&GV\ML'N<[_ %5MA7GRL\_;]/ULB-^_A?Z\R7@;D@[B.W2
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M273.3R5D&Z2U>4E6=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE13<?^25[_\
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M".6-(9(Y'MVW;DEC4QL-NU%Z<JX*[6W;!'EL%AN(P*^33QM  J2LG3MU;=&
MLO55G$:"1075W;?@1G/!\CEI*?O,;H-G)_ '>$F;W=U0B2RX9 P;X)$</+-
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M@&12W@R-PRS<&M(Z$G?=,QNU>1Q& M.Y8V9ZJ,V-L>62FUN):TBTN#:UE\3
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5S"I/JW_]CR2><G_VP,"I+R'4BO_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
